WorldWideScience

Sample records for radiopharmaceuticals annual technical

  1. Radiopharmaceuticals

    International Nuclear Information System (INIS)

    1981-01-01

    The catalogue offers a wide-spread product range which meets the requirements of the international trend of in vivo application of radiopharmaceuticals. It includes: (1) conditions of sale and delivery, (2) delivery schedule for radiopharmaceuticals, (3) technical information, (4) product specifications, and (5) the complete delivery programme

  2. Report on the Technical Meeting on Therapeutic Radiopharmaceuticals

    International Nuclear Information System (INIS)

    2009-01-01

    The purpose of the TM was to provide an experts' platform to facilitate exploring the current status and future directions on therapeutic radiopharmaceuticals. The invited talks and presentations in the TM were in the following topics: - Radionuclide Production; - Production and availability of alpha emitters and their radiopharmaceuticals; - Therapeutic radiopharmaceutical chemistry; - Targets and biological evaluation; - Medical physics and dosimetry; - Clinical applications including radioimmunotherapy and clinical needs; - Peptide receptor mediated therapy Panel discussions: - Radionuclide therapy using alpha emitters; - Regulatory challenges with therapeutic radiopharmaceuticals; - International activities in radionuclide therapy. he technical meeting generated a large interest among scientists and physicians working in the field of targeted therapy using radiopharmaceuticals. Participants from both developed and developing MS reported on recent developments on the research work and clinical studies going on in the field and provided their views on the future developments in this field. The unexpected high number of participants and the high number of presentations with exceptional quality underlines the great interest of scientists and professionals in therapeutic applications using radiolabelled drugs / biomolecules. The intensive discussions including panels specified the challenges in the future on developing novel agents and to finally use them for the benefit of patients. The IAEA can play as vital role in streamlining developments and to provide tools to overcome scientific, professional and regulatory challenges in the field of therapeutic radiopharmaceuticals

  3. Report on the Technical Meeting on Therapeutic Radiopharmaceuticals

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    2009-07-01

    The purpose of the TM was to provide an experts' platform to facilitate exploring the current status and future directions on therapeutic radiopharmaceuticals. The invited talks and presentations in the TM were in the following topics: - Radionuclide Production; - Production and availability of alpha emitters and their radiopharmaceuticals; - Therapeutic radiopharmaceutical chemistry; - Targets and biological evaluation; - Medical physics and dosimetry; - Clinical applications including radioimmunotherapy and clinical needs; - Peptide receptor mediated therapy Panel discussions: - Radionuclide therapy using alpha emitters; - Regulatory challenges with therapeutic radiopharmaceuticals; - International activities in radionuclide therapy. he technical meeting generated a large interest among scientists and physicians working in the field of targeted therapy using radiopharmaceuticals. Participants from both developed and developing MS reported on recent developments on the research work and clinical studies going on in the field and provided their views on the future developments in this field. The unexpected high number of participants and the high number of presentations with exceptional quality underlines the great interest of scientists and professionals in therapeutic applications using radiolabelled drugs / biomolecules. The intensive discussions including panels specified the challenges in the future on developing novel agents and to finally use them for the benefit of patients. The IAEA can play as vital role in streamlining developments and to provide tools to overcome scientific, professional and regulatory challenges in the field of therapeutic radiopharmaceuticals

  4. Institute of Bioinorganic and Radiopharmaceutical Chemistry. Annual report 2000

    International Nuclear Information System (INIS)

    Johannsen, B.; Seifert, S.

    2001-01-01

    In 2000 the Rossendorf research centre continued and further developed its basic and application-oriented research. Research at the Institute of Bioinorganic and Radiopharmaceutical Chemistry, one of five institutes in the Research Centre, was focused on radiotracers as molecular probes to make the human body biochemically transparent with regard to individual molecular reactions. In this respect the potential for diagnostic application depends on the quality and versatility of radiopharmaceutical chemistry, which is the main discipline in our Institute. Areas in which the Institute was particularly active were the design of new radiotracers, both radiometal-based and natural organic molecules, the elaboration of radiolabelling concepts and procedures and the chemical and pharmacological evaluation of new tracers. This was complemented by more clinically oriented activities in the Positron Emission Tomography Centre Rossendorf. With numerous contributions in the fields of radiopharmaceutical chemistry, tumour agents, tumour diagnosis and brain biochemistry this Annual Report will document the scientific progress made in 2000. (orig.)

  5. Radiopharmaceuticals

    International Nuclear Information System (INIS)

    Theobald, A.E.

    1989-01-01

    This book is a review of the latest developments in radiopharmaceuticals. It covers the development of radiopharmaceutical compounds, the theory and practice of their synthesis, and examples of their application. Also covers safe handling of radiopharmaceuticals, legislation affecting their use, radiation monitoring, radiochromatography, and computer techniques

  6. Radiopharmaceuticals

    International Nuclear Information System (INIS)

    Kristensen, K.

    1988-01-01

    Different forms of radiopharmaceuticals such as radioactive gases, aerosols and colloids used for diagnostic techniques and radiotherapy and methods of labelling them are discussed. Some reference is made to their documentation, handling and quality control. (U.K.)

  7. Radiopharmaceuticals

    International Nuclear Information System (INIS)

    Ganatra, R.D.

    1992-01-01

    Today there are an estimated ten million nuclear imaging procedures, performed each year, in just the United States, and the number is still growing. More than 30,000 therapy procedures are performed in the USA each year using radiopharmaceuticals. Moreover, while the numbers continue to grow, so also do the variety of the procedures being employed. A weakness of nuclear medicine is related also to one of its strengths. Unlike other types of imaging where only an instrument and the patient are required (e.g., with ultrasonics); nuclear medicine requires a radiopharmaceutical. At the same time, the variety of radiopharmaceuticals offers the ability to trace one or more particular functions of the human body. This provides nuclear medicine with great variety in detecting specific pathologies. Various nuclear medicine studies are possible because of the localization of radiopharmaceuticals in different organs

  8. Radiopharmaceuticals

    Energy Technology Data Exchange (ETDEWEB)

    Hunt, F C; Wilson, J G

    1980-03-13

    The claim describes a reducing metal complex of a compound in a suitable form for labelling with technetium-99m for radiopharmaceutical purposes, the compound being a complex derived from an indene heterocycle structure. The indene heterocycle structure is selected from the group consisting of iminodiacetic acid derivates of benzimidazole, benzthiazole and benzoxazole.

  9. Technical artifacts in chromatographic analysis of Tc-99m radiopharmaceuticals

    International Nuclear Information System (INIS)

    Kowalsky, R.J.; Creekmore, J.R.

    1982-01-01

    Technical artifacts produced during chromatographic analysis of technetium radiopharmaceuticals were investigated. Such artifacts are, we found, caused by improper spotting and drying techniques; these in turn produce spuriously high impurities in Tc-99m complexes of DTPA, MDP, PPi, and GH. The ITLC-SG/acetone system produces considerable streaking of Tc-complex if the applied spot is large and not dried before development. This results in activity in the solvent front portion of the chromatographic strip indicating falsely high levels of pertechnetate impurity. Proper drying of the applied spot eliminates the artifact. The ITLC-SG/saline system yields falsely high, hydrolyzed-reduced technetium impurities if the spot is allowed to enter the solvent during development. Correct spot placement and size eliminate this problem. Strips that are allowed to dry in room air for several minutes may indicate considerable pertechnetate impurity on the chromatogram; yet this may not actually be present in the radiopharmaceutical vial. Drying spots rapidly with hot air or in a nitrogen atmosphere before development eliminates this problem

  10. Institute of Bioinorganic and Radiopharmaceutical Chemistry. Annual report 1992

    International Nuclear Information System (INIS)

    Johannsen, B.

    1993-04-01

    The Institute of Bioinorganic and Radiopharmaceutical Chemistry of the Rossendorf Research Center (FZR) presents its 1992 anual report in order to in form on research activities in the first year of its existence. This volume contains 27 individual reports devoted to various aspects of radiotracers for nuclear medicine. (BBR)

  11. Institute of Bioinorganic and Radiopharmaceutical Chemistry. Annual report 2001

    International Nuclear Information System (INIS)

    Johannsen, B.; Seifert, S.

    2002-01-01

    In 2001 the Forschungszentrum Rossendorf e.V. continued and further developed its basic and application-oriented research. Research at the Institute of Bioinorganic and Radiopharmaceutical Chemistry, one of five institutes in the Research Centre, was focused on radiotracers as molecular probes to make the human body biochemically transparent with regard to individual molecular reactions. As illustrated by the large number of contributions in this report, the Institute is predominantly engaged in the coordination chemistry and radiopharmacology of technetium and rhenium. (orig.)

  12. Fabrication of sterile experimental radiopharmaceuticals: technical and regulatory requirements

    International Nuclear Information System (INIS)

    Briand, S.

    2008-03-01

    The radiopharmaceuticals devoted to the biomedical research were the object of the directive 2001/20/C.E. transposition that defined again the conditions of implementation of biomedical research using drugs at human use, whom authorization is delivered by A.f.s.s.a.p.s.. In an other hand the law 2006-686 of the 13. june 2006 ( called law T.S.N.) has modified the regulatory dispositions relative to the radiation protection norms. These new dispositions allow to the health facilities to realize their research projects without difficulties for experimental drugs supply. (N.C.)

  13. Forschungszentrum Rossendorf, Institute of Bioinorganic and Radiopharmaceutical Chemistry. Annual report 1995

    International Nuclear Information System (INIS)

    Johannsen, B.

    1996-02-01

    Research at the Institute of Bioinorganic and Radiopharmaceutical Chemistry of the Research Center Rossendorf is focused on radiotracers as molecular probes for diagnosis of disease. The research effort has two main components: -Positron emission tomography (PET) - technetium chemistry and radiopharmacology. The research activities of the Institute have been performed in three administratively classified groups. A PET tracer group is engaged in the chemistry and radiopharmacy of 11 C and 18 F compounds and in the setup of the PET center. A SPECT tracer group deals with the design, synthesis and chemical characterization of metal coordination compounds, primarily rhenium and technetium complexes. A biochemical group is working on SPECT and PET-relevant biochemical and biological projects. This includes the characterization and assessment of new compounds developed in the two synthetically oriented groups. The annual report presented here covers the research activities of the Institute of Bioinorganic and Radiopharmaceutical Chemistry in 1995. (orig.)

  14. Report of a Technical Meeting on ''Alpha emitting radionuclides and radiopharmaceuticals for therapy''

    International Nuclear Information System (INIS)

    2013-01-01

    Considering the high potential of α-emitters for future development of radionuclide therapy, the International Atomic Energy Agency (IAEA) organized a Technical Meeting on ‘Alpha Emitting Radionuclides and Radiopharmaceuticals for Therapy’, from June 24 to 28, 2013, at IAEA Headquarters in Vienna with the purpose of gathering eminent Experts in the field and discuss with them the status and future perspectives of the field. Sixteen Experts and two External Observers from ten different countries, and four IAEA Technical Officers attended this meeting. Outstanding lectures have been presented covering all relevant aspects of α-therapy, which were followed by extensive discussions and analysis. Selected arguments encompassed production methods and availability of alpha-emitting radionuclides, labelling chemistry of alpha-emittting radioelements, design and development of target-specific radiopharmaceuticals, physical principles of alpha-particle dosimetry and advanced dosimetric models, biological effects of alpha radiation at the cellular level, on-going preclinical and clinical studies with new radiopharmaceuticals, results of clinical trials on the use of radium-223 chloride solutions for the treatment of metastatic bone cancer. The broad scientific background of invited components of the Experts’ panel conferred a strong interdisciplinary trait to the overall discussion and stimulated a critical analysis of this emerging unexplored field. Results of this comprehensive overview on alpha therapy, including recommendations to the Agency on suitable initiatives that may help to promote and spread the knowledge to Members States on this emerging therapeutic modality, are summarized in the present Report

  15. Harvard-MIT research program in short-lived radiopharmaceuticals. Technical progress report, 1991

    Energy Technology Data Exchange (ETDEWEB)

    Adelstein, S.J.

    1991-12-31

    This report presents research on radiopharmaceuticals. The following topics are discussed: antibody labeling with positron-emitting radionuclides; antibody modification for radioimmune imaging; labeling antibodies; evaluation of technetium acetlyacetonates as potential cerebral blood flow agents; and studies in technetium chemistry. (CBS)

  16. Hospitable radiopharmaceuticals

    International Nuclear Information System (INIS)

    Gonzalez, M.B.

    1994-01-01

    Two types of hospitalary radiopharmaceutical was given in Nuclear Medicine: the centralized and hospitalary radiopharmaceuticals. The good practice in the use, instrumentation and quality control of radiopharmaceuticals are used in nuclear medicine for diagnostic and therapy diseases

  17. Forschungszentrum Rossendorf. Institute of Bioinorganic and Radiopharmaceutical Chemistry. Annual report 2002

    International Nuclear Information System (INIS)

    Johannsen, B.; Seifert, S.

    2003-01-01

    In 2002 the Institute of Bioinorganic and Radiopharmaceutical Chemistry, one of five institutes in the Forschungszentrum Rossendorf e.V., continued and further developed its basic and application-oriented research. Research was focused on radiotracers as molecular probes to make the human body biochemically transparent with regard to individual molecular reactions. While further pursuing and extending our chemical, biological and medical activities in the PET Centre and being engaged in the coordination chemistry and radiopharmacology of technetium, rhenium and other metals, new lines of activity have also been opened up recently. This involves bioactive substances as they are present in food. Such substances may cause a health risk or may exert effects not yet fully understood. New biotechnological procedures in food processing also give rise to new questions that can be addressed by PET. As illustrated by the majority of contributions in this report, the Institute is predominantly engaged in radiopharmaceutical chemistry of both radiometals and the PET nuclides carbon-11 and fluorine-18. The improvement of labelling methods continued to remain an area of considerable endeavour. The review article on radiochemistry with the short-lived positron emitters 11 C and 18 F is meant to emphasize this field of research and to help to classify our contribution to this area. As for the radiometals, our studies agree with the more and more demanding insight that the coordination has a not sufficiently predictable impact on the in vivo behaviour of the molecule into which the chelate unit is integrated. Therefore, attempts to better understand and adjust the in vivo behaviour of the radiotracers are being continued. In order to reflect on and identify trends and perspectives, the Institute organized on March 7-8, 2002, an international conference on advances and perspectives in radiotracer development. The Institute's chemically and radiopharmacologically oriented activities

  18. Lung radiopharmaceuticals

    International Nuclear Information System (INIS)

    Gonzalez, B.M.

    1994-01-01

    Indication or main clinical use of Lung radiopharmaceuticals is presented and clasification of radiopharmaceuticals as ventilation and perfusion studies. Perfusion radiopharmaceuticals, main controls for administration quality acceptance. Clearence after blood administration and main clinical applications. Ventilation radiopharmaceuticals, gases and aerosols, characteristics of a ideal radioaerosol, techniques of good inhalation procedure, clinical applications. Comparison of several radiopharmaceuticals reflering to retention time as 50% administered dose, percent administered dose at 6 hours post inhalation, blood activity at 30 and 60 minutes post inhalation, initial lung absorbed dose, cumulated activity.Kinetic description of two radiopharmaceuticals, 99mTcDTPA and 99mTc-PYP

  19. Forschungszentrum Rossendorf. Institute of Bioinorganic and Radiopharmaceutical Chemistry. Annual report 2002

    Energy Technology Data Exchange (ETDEWEB)

    Johannsen, B.; Seifert, S. (eds.)

    2003-01-01

    In 2002 the Institute of Bioinorganic and Radiopharmaceutical Chemistry, one of five institutes in the Forschungszentrum Rossendorf e.V., continued and further developed its basic and application-oriented research. Research was focused on radiotracers as molecular probes to make the human body biochemically transparent with regard to individual molecular reactions. While further pursuing and extending our chemical, biological and medical activities in the PET Centre and being engaged in the coordination chemistry and radiopharmacology of technetium, rhenium and other metals, new lines of activity have also been opened up recently. This involves bioactive substances as they are present in food. Such substances may cause a health risk or may exert effects not yet fully understood. New biotechnological procedures in food processing also give rise to new questions that can be addressed by PET. As illustrated by the majority of contributions in this report, the Institute is predominantly engaged in radiopharmaceutical chemistry of both radiometals and the PET nuclides carbon-11 and fluorine-18. The improvement of labelling methods continued to remain an area of considerable endeavour. The review article on radiochemistry with the short-lived positron emitters {sup 11}C and {sup 18}F is meant to emphasize this field of research and to help to classify our contribution to this area. As for the radiometals, our studies agree with the more and more demanding insight that the coordination has a not sufficiently predictable impact on the in vivo behaviour of the molecule into which the chelate unit is integrated. Therefore, attempts to better understand and adjust the in vivo behaviour of the radiotracers are being continued. In order to reflect on and identify trends and perspectives, the Institute organized on March 7-8, 2002, an international conference on advances and perspectives in radiotracer development. The Institute's chemically and radiopharmacologically

  20. 2003 Chemical Engineering Division annual technical report

    International Nuclear Information System (INIS)

    Lewis, D.; Graziano, D.; Miller, J. F.; Vandegrift, G.

    2004-01-01

    national importance. Included among them are: Advanced lithium-ion and lithium-polymer batteries for transportation and other applications, Fuel cells, including the use of an oxidative reformer with gasoline as the fuel supply, Production and storage technologies critical to the hydrogen economy, Stable nuclear waste forms suitable for storage in a geological repository, Threat attribution and training relative to radioactive dispersal devices (''dirty bombs''), and Aqueous and pyrochemical processes for the disposition of spent nuclear fuel. Other important programs are focused in superconductivity, catalysis, nanotechnology, and nuclear materials. During fiscal year 2003, CMT had an annual operating budget of approximately $36 million. Of that, more than 90% was from DOE and the remainder from other government agencies and private industry. Displayed below is an overview organization chart of the Division. A complete organization chart appears at the end of this report. In this annual report we present an overview of the technical programs together with representative highlights. The report is not intended to be comprehensive or encyclopedic, but to serve as an indication of the condition and status of the Division

  1. Center for Advanced Space Propulsion Second Annual Technical Symposium Proceedings

    Science.gov (United States)

    1990-01-01

    The proceedings for the Center for Advanced Space Propulsion Second Annual Technical Symposium are divided as follows: Chemical Propulsion, CFD; Space Propulsion; Electric Propulsion; Artificial Intelligence; Low-G Fluid Management; and Rocket Engine Materials.

  2. Career Technical Education Pathways Initiative Annual Report

    Science.gov (United States)

    California Community Colleges, Chancellor's Office, 2014

    2014-01-01

    California's education system--the largest in the United States--is an essential resource for ensuring strong economic growth in the state. The Career Technical Education Pathways Initiative (the Initiative) became law in 2005 with Senate Bills 70 and 1133 and provided more than $380 million over eight years to improve career technical education…

  3. Radiopharmaceuticals generalities

    International Nuclear Information System (INIS)

    Leon Cabana, A.S.

    1994-01-01

    Many applications in nuclear medicine used as diagnostic techniques, images methods with direct and indirect labelled compounds in organs. A brief description about scintillator counters or gamma counters SPECT(single photon emission computed tomography) and PECT (positron emission computed tomography), as well as therapeutic proceedings,radiopharmaceutical classification, labell steps,administration form in the body,physical form and the best radiopharmaceutical ideal classification. Two tables was used contain radiopharmaceuticals more used in diagnostic and more used in therapic uses. Tabs

  4. Engineering Technical Support Center Annual Report Fiscal ...

    Science.gov (United States)

    The United States Environmental Protection Agency (EPA or Agency) Office of Research and Development (ORD) created the Engineering Technical Support Center (ETSC) in 1987, one of several technical support centers created as part of the Technical Support Project (TSP). ETSC provides engineering expertise to Agency program and regional offices and remediation teams working at contaminated sites across the country. The ETSC is operated within ORD’s Land Remediation and Pollution Control Division (LRPCD) of the National Risk Management Research Laboratory (NRMRL) in Cincinnati, Ohio. The ETSC’s mission is to provide site-specific scientific and engineering technical support to Remedial Project Managers, On-Scene Coordinators, and other remediation personnel at contaminated sites. This allows local, regional, or national authorities to work more quickly, efficiently, and cost effectively, while also increasing the technical experience of the remediation team. Since its inception, the ETSC has supported countless projects across all EPA Regions in almost all states and territories. This report highlights significant projects the ETSC supported in fiscal year 2015 (FY15). These projects addressed an array of environmental scenarios, such as remote mining contamination, expansive landfill waste, cumulative impacts from multiple contamination sources, and persistent threats from abandoned industrial sites. Constructing and testing new and innovative treatment technol

  5. Career and Technical Education. 2016 Annual Report

    Science.gov (United States)

    Utah System of Higher Education, 2016

    2016-01-01

    Career and Technical Education (CTE) is a key ingredient to meet the needs of Utah's economy. Utah System of Higher Education (USHE) institutions offer CTE programs in all regions of the state, working closely with local business and industry leaders to develop and deliver programs specifically tailored to local workforce development needs. This…

  6. Career and Technical Education. 2015 Annual Report

    Science.gov (United States)

    Utah System of Higher Education, 2015

    2015-01-01

    Career and Technical Education (CTE) is a key ingredient to meet the needs of Utah's economy. Utah System of Higher Education (USHE) institutions offer CTE programs in all regions of the state, working closely with local business and industry leaders to develop and deliver programs specifically tailored to local workforce development needs. This…

  7. Inertial fusion research: Annual technical report, 1985

    International Nuclear Information System (INIS)

    Larsen, J.T.; Terry, N.C.

    1986-03-01

    This report describes the inertial confinement fusion (ICF) research activities undertaken at KMS Fusion (KMSF) during 1985. It is organized into three main technical sections; the first covers fusion experiments and theoretical physics, the second is devoted to progress in materials development and target fabrication, and the third describes laser technology research. These three individual sections have been cataloged separately

  8. 1981 inertial fusion research annual technical report

    International Nuclear Information System (INIS)

    Solomon, D.E.; Wei, J.L.; Greacen, N.T.

    1981-01-01

    This annual report consists of the following two topics: (1) target fabrication technology, and (2) fusion experiments. The first section is reported by the following seven areas: (1) characterization, (2) fuel shell technology, (3) polymer technology, (4) lithium foil development, (5) precision etch technology, (6) analytical instrumentation, and (7) target fabrication. The second area is reported by the following topics: (1) experiments, (2) plasma theory, (3) code development and simulation, and (4) lasers and optics

  9. Chemical Technology Division annual technical report 1997

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    1998-06-01

    The Chemical Technology (CMT) Division is a diverse technical organization with principal emphases in environmental management and development of advanced energy sources. The Division conducts research and development in three general areas: (1) development of advanced power sources for stationary and transportation applications and for consumer electronics, (2) management of high-level and low-level nuclear wastes and hazardous wastes, and (3) electrometallurgical treatment of spent nuclear fuel. The Division also performs basic research in catalytic chemistry involving molecular energy resources, mechanisms of ion transport in lithium battery electrolytes, and the chemistry of technology-relevant materials and electrified interfaces. In addition, the Division operates the Analytical Chemistry Laboratory, which conducts research in analytical chemistry and provides analytical services for programs at Argonne National Laboratory (ANL) and other organizations. Technical highlights of the Division`s activities during 1997 are presented.

  10. Chemical Technology Division annual technical report, 1996

    International Nuclear Information System (INIS)

    1997-06-01

    CMT is a diverse technical organization with principal emphases in environmental management and development of advanced energy sources. It conducts R ampersand D in 3 general areas: development of advanced power sources for stationary and transportation applications and for consumer electronics, management of high-level and low-level nuclear wastes and hazardous wastes, and electrometallurgical treatment of spent nuclear fuel. The Division also performs basic research in catalytic chemistry involving molecular energy resources, mechanisms of ion transport in lithium battery electrolytes, materials chemistry of electrified interfaces and molecular sieves, and the theory of materials properties. It also operates the Analytical Chemistry Laboratory, which conducts research in analytical chemistry and provides analytical services for programs at ANL and other organizations. Technical highlights of the Division's activities during 1996 are presented

  11. Chemical Technology Division annual technical report 1997

    International Nuclear Information System (INIS)

    1998-06-01

    The Chemical Technology (CMT) Division is a diverse technical organization with principal emphases in environmental management and development of advanced energy sources. The Division conducts research and development in three general areas: (1) development of advanced power sources for stationary and transportation applications and for consumer electronics, (2) management of high-level and low-level nuclear wastes and hazardous wastes, and (3) electrometallurgical treatment of spent nuclear fuel. The Division also performs basic research in catalytic chemistry involving molecular energy resources, mechanisms of ion transport in lithium battery electrolytes, and the chemistry of technology-relevant materials and electrified interfaces. In addition, the Division operates the Analytical Chemistry Laboratory, which conducts research in analytical chemistry and provides analytical services for programs at Argonne National Laboratory (ANL) and other organizations. Technical highlights of the Division's activities during 1997 are presented

  12. 1998 Chemical Technology Division Annual Technical Report.

    Energy Technology Data Exchange (ETDEWEB)

    Ackerman, J.P.; Einziger, R.E.; Gay, E.C.; Green, D.W.; Miller, J.F.

    1999-08-06

    The Chemical Technology (CMT) Division is a diverse technical organization with principal emphases in environmental management and development of advanced energy sources. The Division conducts research and development in three general areas: (1) development of advanced power sources for stationary and transportation applications and for consumer electronics, (2) management of high-level and low-level nuclear wastes and hazardous wastes, and (3) electrometallurgical treatment of spent nuclear fuel. The Division also performs basic research in catalytic chemistry involving molecular energy resources, mechanisms of ion transport in lithium battery electrolytes, and the chemistry of technology-relevant materials. In addition, the Division operates the Analytical Chemistry Laboratory, which conducts research in analytical chemistry and provides analytical services for programs at Argonne National Laboratory (ANL) and other organizations. Technical highlights of the Division's activities during 1998 are presented.

  13. Chemical Technology Division annual technical report, 1996

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    1997-06-01

    CMT is a diverse technical organization with principal emphases in environmental management and development of advanced energy sources. It conducts R&D in 3 general areas: development of advanced power sources for stationary and transportation applications and for consumer electronics, management of high-level and low-level nuclear wastes and hazardous wastes, and electrometallurgical treatment of spent nuclear fuel. The Division also performs basic research in catalytic chemistry involving molecular energy resources, mechanisms of ion transport in lithium battery electrolytes, materials chemistry of electrified interfaces and molecular sieves, and the theory of materials properties. It also operates the Analytical Chemistry Laboratory, which conducts research in analytical chemistry and provides analytical services for programs at ANL and other organizations. Technical highlights of the Division`s activities during 1996 are presented.

  14. Radiopharmaceutical development

    International Nuclear Information System (INIS)

    Zielinski, F.W.; Robinson, G.D. Jr.; MacDonald, N.S.

    1976-01-01

    Progress is reported in the following areas of research: compact cyclotron production of 123 I iodide for radiopharmaceutical synthesis; synthesis of 123 I-labeled compounds for myocardial imaging and evaluation of kidney and liver functions; 62 Cu: a short-lived, generator-produced, positron emitting radionuclide for radiopharmaceuticals; dry radioaerosols for lung airway imaging; and improved particulate agents for perfusion imaging

  15. Radiopharmaceutical licensing

    International Nuclear Information System (INIS)

    Mather, S.J.

    1992-01-01

    Recent health service legislation, and especially the loss of crown immunity has once again focussed attention on the arrangements for licensing of radiopharmaceuticals. The aim of the article is to describe in general terms the UK licensing system and in particular to provide guidance to those responsible for the supply of radiopharmaceuticals in hospitals. (author)

  16. New radiopharmaceuticals

    International Nuclear Information System (INIS)

    Payoux, P.; Esquerre, J.P.; Alonso, M.; Tafani, M.

    2008-01-01

    With the development of positron emission tomography, the significant increase in prescriptions of [ 18 F]F.D.G. has underlined the interest for molecular imaging in many pathologies. Facing the demand of 'new' radiopharmaceuticals (frequently clinically validated in the last century) for more and more specific diagnosis, the nuclear physician is confronted with a sparse offer of the radiopharmaceutical companies and a particularly complicated radiopharmaceutical legislation. This paper briefly reports on the radiopharmaceutical statutes encountered in France nowadays; it emphasizes that is essential to deeply modify the conditions to obtain a marketing authorization for radiopharmaceuticals if we want to propose to our patients the kind of right they have to expect from nuclear medicine. (authors)

  17. Chemical Technology Division annual technical report, 1985

    International Nuclear Information System (INIS)

    1986-04-01

    Highlights of the Chemical Technology (CMT) Division's activities during 1985 are presented. In this period, CMT conducted research and development in areas that include the following: (1) advanced batteries - mainly lithium-alloy/metal sulfide and sodium/sulfur; (2) advanced fuel cells with molten carbonate or solid oxide electrolytes; (3) corrosion-protective coatings for high-strength steel; (4) coal utilization, including the heat and seed recovery technology for coal-fired magnetohydrodynamics plants and the technology for fluidized-bed combustion; (5) methodologies for recovery of energy from municipal waste; (6) nuclear technology related to waste management, the recovery processes for discharged fuel and the uranium blanket in a sodium-cooled fast reactor, and proof of breeding in a light water breeder reactor; and (7) physical chemistry of selected materials in environments simulating those of fission and fusion energy systems. The Division also has a program in basic chemistry research in the areas of catalytic hydrogenation and catalytic oxidation; materials chemistry for associated and ordered solutions at high temperatures; interfacial processes of importance to corrosion science, surface science, and catalysis; the thermochemistry of zeolites and related silicates; and the geochemical processes responsible for trace-element migration within the earth's crust. The Division continued to be the major user of the technical support provided by the Analytical Chemistry Laboratory at ANL

  18. Chemical Technology Division annual technical report, 1994

    International Nuclear Information System (INIS)

    1995-06-01

    Highlights of the Chemical Technology (CMT) Division's activities during 1994 are presented. In this period, CMT conducted research and development in the following areas: (1) electrochemical technology, including advanced batteries and fuel cells; (2) technology for fluidized-bed combustion; (3) methods for treatment of hazardous waste and mixed hazardous/radioactive waste; (4) the reaction of nuclear waste glass and spent fuel under conditions expected for an unsaturated repository; (5) processes for separating and recovering transuranic elements from waste streams, concentrating radioactive waste streams with advanced evaporator technology, and producing 99 Mo from low-enriched uranium for medical applications; (6) electrometallurgical treatment of the many different types of spent nuclear fuel in storage at Department of Energy sites; and (8) physical chemistry of selected materials in environments simulating those of fission and fusion energy systems. The Division also conducts basic research in catalytic chemistry associated with molecular energy resources and novel ceramic precursors; materials chemistry of superconducting oxides, electrified metal/solution interfaces, molecular sieve structures, and impurities in scrap copper and steel; and the geochemical processes involved in mineral/fluid interfaces and water-rock interactions occurring in active hydrothermal systems. In addition, the Analytical Chemistry Laboratory in CMT provides a broad range of analytical chemistry support services to the technical programs at Argonne National Laboratory (ANL)

  19. Chemical Technology Division annual technical report, 1992

    Energy Technology Data Exchange (ETDEWEB)

    Battles, J.E.; Myles, K.M.; Laidler, J.J.; Green, D.W.

    1993-06-01

    In this period, CMT conducted research and development in the following areas: (1) electrochemical technology, including advanced batteries and fuel cells; (2) technology for fluidized-bed combustion and coal-fired magnetohydrodynamics; (3) methods for treatment of hazardous waste, mixed hazardous/radioactive waste, and municipal solid waste; (4) the reaction of nuclear waste glass and spent fuel under conditions expected for an unsaturated repository; (5) processes for separating and recovering transuranic elements from nuclear waste streams, treating water contaminated with volatile organics, and concentrating radioactive waste streams; (6) recovery processes for discharged fuel and the uranium blanket in the Integral Fast Reactor (EFR); (7) processes for removal of actinides in spent fuel from commercial water-cooled nuclear reactors and burnup in IFRs; and (8) physical chemistry of selected materials (corium; Fe-U-Zr, tritium in LiAlO{sub 2} in environments simulating those of fission and fusion energy systems. The Division also conducts basic research in catalytic chemistry associated with molecular energy resources and novel` ceramic precursors; materials chemistry of superconducting oxides, electrified metal/solution interfaces, and molecular sieve structures; and the geochemical processes involved in water-rock interactions occurring in active hydrothermal systems. In addition, the Analytical Chemistry Laboratory in CMT provides a broad range of analytical chemistry support services to the technical programs at Argonne National Laboratory (ANL).

  20. Chemical Technology Division, Annual technical report, 1991

    Energy Technology Data Exchange (ETDEWEB)

    1992-03-01

    Highlights of the Chemical Technology (CMT) Division's activities during 1991 are presented. In this period, CMT conducted research and development in the following areas: (1) electrochemical technology, including advanced batteries and fuel cells; (2) technology for fluidized-bed combustion and coal-fired magnetohydrodynamics; (3) methods for treatment of hazardous and mixed hazardous/radioactive waste; (4) the reaction of nuclear waste glass and spent fuel under conditions expected for an unsaturated repository; (5) processes for separating and recovering transuranic elements from nuclear waste streams; (6) recovery processes for discharged fuel and the uranium blanket in the Integral Fast Reactor (IFR); (7) processes for removal of actinides in spent fuel from commercial water-cooled nuclear reactors and burnup in IFRs; and (8) physical chemistry of selected materials in environments simulating those of fission and fusion energy systems. The Division also conducts basic research in catalytic chemistry associated with molecular energy resources; chemistry of superconducting oxides and other materials of interest with technological application; interfacial processes of importance to corrosion science, catalysis, and high-temperature superconductivity; and the geochemical processes involved in water-rock interactions occurring in active hydrothermal systems. In addition, the Analytical Chemistry Laboratory in CMT provides a broad range of analytical chemistry support services to the technical programs at Argonne National Laboratory (ANL).

  1. Chemical Technology Division, Annual technical report, 1991

    Energy Technology Data Exchange (ETDEWEB)

    1992-03-01

    Highlights of the Chemical Technology (CMT) Division`s activities during 1991 are presented. In this period, CMT conducted research and development in the following areas: (1) electrochemical technology, including advanced batteries and fuel cells; (2) technology for fluidized-bed combustion and coal-fired magnetohydrodynamics; (3) methods for treatment of hazardous and mixed hazardous/radioactive waste; (4) the reaction of nuclear waste glass and spent fuel under conditions expected for an unsaturated repository; (5) processes for separating and recovering transuranic elements from nuclear waste streams; (6) recovery processes for discharged fuel and the uranium blanket in the Integral Fast Reactor (IFR); (7) processes for removal of actinides in spent fuel from commercial water-cooled nuclear reactors and burnup in IFRs; and (8) physical chemistry of selected materials in environments simulating those of fission and fusion energy systems. The Division also conducts basic research in catalytic chemistry associated with molecular energy resources; chemistry of superconducting oxides and other materials of interest with technological application; interfacial processes of importance to corrosion science, catalysis, and high-temperature superconductivity; and the geochemical processes involved in water-rock interactions occurring in active hydrothermal systems. In addition, the Analytical Chemistry Laboratory in CMT provides a broad range of analytical chemistry support services to the technical programs at Argonne National Laboratory (ANL).

  2. Chemical Technology Division annual technical report, 1994

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    1995-06-01

    Highlights of the Chemical Technology (CMT) Division`s activities during 1994 are presented. In this period, CMT conducted research and development in the following areas: (1) electrochemical technology, including advanced batteries and fuel cells; (2) technology for fluidized-bed combustion; (3) methods for treatment of hazardous waste and mixed hazardous/radioactive waste; (4) the reaction of nuclear waste glass and spent fuel under conditions expected for an unsaturated repository; (5) processes for separating and recovering transuranic elements from waste streams, concentrating radioactive waste streams with advanced evaporator technology, and producing {sup 99}Mo from low-enriched uranium for medical applications; (6) electrometallurgical treatment of the many different types of spent nuclear fuel in storage at Department of Energy sites; and (8) physical chemistry of selected materials in environments simulating those of fission and fusion energy systems. The Division also conducts basic research in catalytic chemistry associated with molecular energy resources and novel ceramic precursors; materials chemistry of superconducting oxides, electrified metal/solution interfaces, molecular sieve structures, and impurities in scrap copper and steel; and the geochemical processes involved in mineral/fluid interfaces and water-rock interactions occurring in active hydrothermal systems. In addition, the Analytical Chemistry Laboratory in CMT provides a broad range of analytical chemistry support services to the technical programs at Argonne National Laboratory (ANL).

  3. Chemical Technology Division, Annual technical report, 1991

    International Nuclear Information System (INIS)

    1992-03-01

    Highlights of the Chemical Technology (CMT) Division's activities during 1991 are presented. In this period, CMT conducted research and development in the following areas: (1) electrochemical technology, including advanced batteries and fuel cells; (2) technology for fluidized-bed combustion and coal-fired magnetohydrodynamics; (3) methods for treatment of hazardous and mixed hazardous/radioactive waste; (4) the reaction of nuclear waste glass and spent fuel under conditions expected for an unsaturated repository; (5) processes for separating and recovering transuranic elements from nuclear waste streams; (6) recovery processes for discharged fuel and the uranium blanket in the Integral Fast Reactor (IFR); (7) processes for removal of actinides in spent fuel from commercial water-cooled nuclear reactors and burnup in IFRs; and (8) physical chemistry of selected materials in environments simulating those of fission and fusion energy systems. The Division also conducts basic research in catalytic chemistry associated with molecular energy resources; chemistry of superconducting oxides and other materials of interest with technological application; interfacial processes of importance to corrosion science, catalysis, and high-temperature superconductivity; and the geochemical processes involved in water-rock interactions occurring in active hydrothermal systems. In addition, the Analytical Chemistry Laboratory in CMT provides a broad range of analytical chemistry support services to the technical programs at Argonne National Laboratory (ANL)

  4. Chemical Technology Division annual technical report, 1992

    International Nuclear Information System (INIS)

    Battles, J.E.; Myles, K.M.; Laidler, J.J.; Green, D.W.

    1993-06-01

    In this period, CMT conducted research and development in the following areas: (1) electrochemical technology, including advanced batteries and fuel cells; (2) technology for fluidized-bed combustion and coal-fired magnetohydrodynamics; (3) methods for treatment of hazardous waste, mixed hazardous/radioactive waste, and municipal solid waste; (4) the reaction of nuclear waste glass and spent fuel under conditions expected for an unsaturated repository; (5) processes for separating and recovering transuranic elements from nuclear waste streams, treating water contaminated with volatile organics, and concentrating radioactive waste streams; (6) recovery processes for discharged fuel and the uranium blanket in the Integral Fast Reactor (EFR); (7) processes for removal of actinides in spent fuel from commercial water-cooled nuclear reactors and burnup in IFRs; and (8) physical chemistry of selected materials (corium; Fe-U-Zr, tritium in LiAlO 2 in environments simulating those of fission and fusion energy systems. The Division also conducts basic research in catalytic chemistry associated with molecular energy resources and novel' ceramic precursors; materials chemistry of superconducting oxides, electrified metal/solution interfaces, and molecular sieve structures; and the geochemical processes involved in water-rock interactions occurring in active hydrothermal systems. In addition, the Analytical Chemistry Laboratory in CMT provides a broad range of analytical chemistry support services to the technical programs at Argonne National Laboratory (ANL)

  5. Radiopharmacy and radiopharmaceutical products

    International Nuclear Information System (INIS)

    Galy, Gerard; Fraysse, Marc; Hammadi, Akli; Tafani, Mathieu

    2012-01-01

    Written by two radio-pharmacist doctors, this book presents all the theoretical and practical knowledge necessary to radio-pharmacists in charge of the management, the preparation, the control and the delivery of radiopharmaceutical medicines. It presents the scientific, regulatory and technical foundations for the implementation and operation of radiopharmacy in hospitals, addressing themes such as the fundamentals and theories about nuclear physics and radioactivity (production of artificial radionuclides, detectors and measuring instruments, radio-chemistry), radio-biology and radiation protection (biological effects of ionizing radiations, radioprotection, regulations concerning the use of radiopharmaceutical products by medical personnel), the application domains of radiopharmaceutical medicines and products (diagnosis, therapy, biological assessment), and the management of radiopharmacy in a hospital (design, implementation, organizing, operation)

  6. Chemical technology division: Annual technical report 1987

    Energy Technology Data Exchange (ETDEWEB)

    1988-05-01

    Highlights of the Chemical Technology (CMT) Division's activities during 1987 are presented. In this period, CMT conducted research and development in the following areas: (1) high-performance batteries--mainly lithium-alloy/metal sulfide and sodium/sulfur; (2) aqueous batteries (lead-acid, nickel/iron, etc.); (3) advanced fuel cells with molten carbonate or solid oxide electrolytes; (4) coal utilization, including the heat and seed recovery technology for coal-fired magnetohydrodynamics plants and the technology for fluidized-bed combustion; (5) methods for the electromagnetic continuous casting of steel sheet and for the purification of ferrous scrap; (6) methods for recovery of energy from municipal waste and techniques for treatment of hazardous organic waste; (7) nuclear technology related to a process for separating and recovering transuranic elements from nuclear waste, the recovery processes for discharged fuel and the uranium blanket in a sodium-cooled fast reactor, and waste management; and (8) physical chemistry of selected materials in environments simulating those of fission and fusion energy systems. The Division also has a program in basic chemistry research in the areas of fluid catalysis for converting small molecules to desired products; materials chemistry for liquids and vapors at high temperatures; interfacial processes of importance to corrosion science, high-temperature superconductivity, and catalysis; the thermochemistry of various minerals; and the geochemical processes responsible for trace-element migration within the earth's crust. The Division continued to be the major user of the technical support provided by the Analytical Chemistry Laboratory at ANL. 54 figs., 9 tabs.

  7. Chemical Technology Division annual technical report, 1986

    Energy Technology Data Exchange (ETDEWEB)

    1987-06-01

    Highlights of the Chemical Technology (CMT) Division's activities during 1986 are presented. In this period, CMT conducted research and development in areas that include the following: (1) high-performance batteries - mainly lithium-alloy/metal sulfide and sodium/sulfur; (2) aqueous batteries (lead-acid, nickel/iron, etc.); (3) advanced fuel cells with molten carbonate or solid oxide electrolytes; (4) coal utilization, including the heat and seed recovery technology for coal-fired magnetohydrodynamics plants, the technology for fluidized-bed combustion, and a novel concept for CO/sub 2/ recovery from fossil fuel combustion; (5) methods for recovery of energy from municipal waste; (6) methods for the electromagnetic continuous casting of steel sheet; (7) techniques for treatment of hazardous waste such as reactive metals and trichloroethylenes; (8) nuclear technology related to waste management, a process for separating and recovering transuranic elements from nuclear waste, and the recovery processes for discharged fuel and the uranium blanket in a sodium-cooled fast reactor; and (9) physical chemistry of selected materials in environments simulating those of fission and fusion energy systems. The Division also has a program in basic chemistry research in the areas of catalytic hydrogenation and catalytic oxidation; materials chemistry for associated and ordered solutions at high temperatures; interfacial processes of importance to corrosion science, surface science, and catalysis; the thermochemistry of zeolites and related silicates; and the geochemical processes responsible for trace-element migration within the earth's crust. The Division continued to be the major user of the technical support provided by the Analytical Chemistry Laboratory at ANL. 127 refs., 71 figs., 8 tabs.

  8. Chemical technology division: Annual technical report 1987

    International Nuclear Information System (INIS)

    1988-05-01

    Highlights of the Chemical Technology (CMT) Division's activities during 1987 are presented. In this period, CMT conducted research and development in the following areas: (1) high-performance batteries--mainly lithium-alloy/metal sulfide and sodium/sulfur; (2) aqueous batteries (lead-acid, nickel/iron, etc.); (3) advanced fuel cells with molten carbonate or solid oxide electrolytes; (4) coal utilization, including the heat and seed recovery technology for coal-fired magnetohydrodynamics plants and the technology for fluidized-bed combustion; (5) methods for the electromagnetic continuous casting of steel sheet and for the purification of ferrous scrap; (6) methods for recovery of energy from municipal waste and techniques for treatment of hazardous organic waste; (7) nuclear technology related to a process for separating and recovering transuranic elements from nuclear waste, the recovery processes for discharged fuel and the uranium blanket in a sodium-cooled fast reactor, and waste management; and (8) physical chemistry of selected materials in environments simulating those of fission and fusion energy systems. The Division also has a program in basic chemistry research in the areas of fluid catalysis for converting small molecules to desired products; materials chemistry for liquids and vapors at high temperatures; interfacial processes of importance to corrosion science, high-temperature superconductivity, and catalysis; the thermochemistry of various minerals; and the geochemical processes responsible for trace-element migration within the earth's crust. The Division continued to be the major user of the technical support provided by the Analytical Chemistry Laboratory at ANL. 54 figs., 9 tabs

  9. Chemical Technology Division annual technical report, 1988

    International Nuclear Information System (INIS)

    1989-05-01

    Highlights of the Chemical Technology (CMT) Divisions's activities during 1988 are presented. In this period, CMT conducted research and development in the following areas: (1) high-performance batteries (mainly lithium-alloy/metal sulfide, sodium/metal chloride, and sodium/sulfur); (2) aqueous batteries (lead-acid, nickel/iron, etc.); (3) advanced fuel cells with molten carbonate or solid oxide electrolytes; (4) coal utilization, including the heat and seed recovery technology for coal-fired magnetohydrodynamics plants and the technology for fluidized-bed combustion; (5) methods for recovery of energy from municipal waste and techniques for treatment of hazardous chemical water; (6) nuclear technology related to a process for separating and recovering transuranic elements from nuclear waste and for producing /sup 99/Mo from low-enriched uranium targets, the recovery processes for discharged fuel and the uranium blanket in a sodium-cooled fast reactor, and waste management; and (7) physical chemistry of selected materials in environments simulating those of fission and fusion energy systems. The Division also has a program in basic chemistry research in the areas of fluid catalysis for converting small molecules to desired products; materials chemistry for superconducting oxides and associated and ordered solutions at high temperatures; interfacial processes of importance to corrosion science, high-temperature superconductivity, and catalysis; and the geochemical processes responsible for trace-element migration within the earth's crust. The Division continued to be the major user of the technical support provided by the Analytical Chemistry Laboratory at ANL. 53 figs., 16 tabs

  10. Chemical Technology Division annual technical report, 1986

    International Nuclear Information System (INIS)

    1987-06-01

    Highlights of the Chemical Technology (CMT) Division's activities during 1986 are presented. In this period, CMT conducted research and development in areas that include the following: (1) high-performance batteries - mainly lithium-alloy/metal sulfide and sodium/sulfur; (2) aqueous batteries (lead-acid, nickel/iron, etc.); (3) advanced fuel cells with molten carbonate or solid oxide electrolytes; (4) coal utilization, including the heat and seed recovery technology for coal-fired magnetohydrodynamics plants, the technology for fluidized-bed combustion, and a novel concept for CO 2 recovery from fossil fuel combustion; (5) methods for recovery of energy from municipal waste; (6) methods for the electromagnetic continuous casting of steel sheet; (7) techniques for treatment of hazardous waste such as reactive metals and trichloroethylenes; (8) nuclear technology related to waste management, a process for separating and recovering transuranic elements from nuclear waste, and the recovery processes for discharged fuel and the uranium blanket in a sodium-cooled fast reactor; and (9) physical chemistry of selected materials in environments simulating those of fission and fusion energy systems. The Division also has a program in basic chemistry research in the areas of catalytic hydrogenation and catalytic oxidation; materials chemistry for associated and ordered solutions at high temperatures; interfacial processes of importance to corrosion science, surface science, and catalysis; the thermochemistry of zeolites and related silicates; and the geochemical processes responsible for trace-element migration within the earth's crust. The Division continued to be the major user of the technical support provided by the Analytical Chemistry Laboratory at ANL. 127 refs., 71 figs., 8 tabs

  11. A new approach to the analysis of radiopharmaceuticals. Final technical report, January 15, 1987--June 30, 1991

    International Nuclear Information System (INIS)

    Jones, A.G.; Davison, A.; Costello, C.E.

    1998-03-01

    The objective of this research was to investigate analytical techniques that could be used in the study of both the basic chemistry and the radiopharmaceutical chemistry of 99m Tc. First funded in 1981, the work focused initially upon the use of high performance liquid chromatography (HPLC) and various forms of mass spectrometry for the identification of technetium species. This funding allowed the authors to combine HPLC and mass spectrometry to identify radiopharmaceuticals which, although in clinical use, had not previously been characterized. Other techniques that have been examined include resonance Raman spectroscopy and, more significantly, 99 Tc nuclear magnetic resonance spectroscopy (NMR), with the latter not only being used in purely chemical experiments but also in biologic studies. In 1985 a grant to the Department of Chemistry at MIT from DOE allowed the purchase of an X-ray diffractometer and access to this instrument has enabled them to broaden the analytical base with routine structural determinations

  12. Toxic Hazards Research Unit Annual Technical Report: 1984

    Science.gov (United States)

    1984-09-01

    exposed to TOCP exhibited the classic lesions of delayed neuropathy (Smith and Lillie, 1931; Barnes and Denz, 1953; (avanagh, 1954; and Fenton , 1955...Safety of *.i Chemicals in Food, Drugs, and Cosmetics , The staff of the Divi- sion of Pharmacology of the Federal Food and Drug Administration, Austin...Annual Technical Report: 1967, AMRL-TR-67-137 (AD 834723), Aerospace Medical Research Laboratory, Wright-Patterson Air Force Base, Ohio. Fenton , J. C

  13. 6. Radiopharmaceuticals

    International Nuclear Information System (INIS)

    Schiller, P.; Havranek, E.; Majer, J.

    1981-01-01

    Radionuclides commonly used in medicine are surveyed and their nuclear characteristics are presented. The methods are given of their preparation, most frequent use and detection. The list is given of radiopharmaceuticals included in the Czechoslovak Pharmacopoeia CsL 3 , ie., sodium chromate( 51 Cr), sodium iodide( 131 I), hippuran( 131 I), sodium phosphate( 32 P), colloidal gold( 198 Au), rose bengal sodium salt( 131 I), and sodium pertechnetate(sup(99m)Tc) injections. Characteristics, chemical preparation, identification tests, packaging, storage, application and dosage are shown for each preparation. Also listed are important unofficial radiopharmaceuticals, their main characteristics and data on their preparation and application. (B.S.)

  14. Fabrication of sterile experimental radiopharmaceuticals: technical and regulatory requirements; Fabrication des medicaments experimentaux radiopharmaceutiques steriles: exigences reglementaires et techniques

    Energy Technology Data Exchange (ETDEWEB)

    Briand, S

    2008-03-15

    The radiopharmaceuticals devoted to the biomedical research were the object of the directive 2001/20/C.E. transposition that defined again the conditions of implementation of biomedical research using drugs at human use, whom authorization is delivered by A.f.s.s.a.p.s.. In an other hand the law 2006-686 of the 13. june 2006 ( called law T.S.N.) has modified the regulatory dispositions relative to the radiation protection norms. These new dispositions allow to the health facilities to realize their research projects without difficulties for experimental drugs supply. (N.C.)

  15. Technical Support Section annual work plan for FY 1998

    Energy Technology Data Exchange (ETDEWEB)

    Adkisson, B.P.; Allison, K.L.; Effler, R.P.; Hess, R.A.; Keeble, T.A.; Odom, S.M.; Smelcer, D.R.

    1997-12-01

    The Technical Support Section (TSS) of the Instrumentation and Controls (I and C) Division of Oak Ridge National Laboratory (ORNL) provides technical services such as fabrication, modification, installation, calibration, operation, repair, and preventive maintenance of instruments and other related equipment. Because the activities and priorities of TSS must be adapted to the technical support needs of ORNL, the TSS Annual Work Plan is derived from, and is driven directly by, current trends in the budgets and activities of each ORNL division for which TSS provides support. Trends that will affect TSS planning during this period are reductions in the staffing levels of some R and D programs because of attrition or budget cuts. TSS does not have an annual budget to cover operating expenses incurred in providing instrument maintenance support to ORNL. Each year, TSS collects information concerning the projected funding levels of programs and facilities it supports. TSS workforce and resource projections are based on the information obtained and are weighted depending on the percentage of support provided to that division or program. Each year, TSS sets the standard hourly charge rate for the following fiscal year. The Long-Range Work Plan is based on estimates of the affects of the long-range priorities and directions of the Laboratory. Proposed new facilities and programs provide additional bases for long-range planning. After identifying long-range initiatives, TSS planning includes future training requirements, reevaluation of qualifications for new hires, and identification of essential test equipment that will be needed for new work.

  16. Teaching and research in radiopharmaceuticals

    International Nuclear Information System (INIS)

    Wiebe, L.I.

    1998-01-01

    Radiopharmaceuticals comprise a critical element of diagnostic and therapeutic clinical nuclear medicine. As well they contribute to more basic pre-clinical and clinical diagnostic studies such as the evaluation of new drugs and new drug formulations. Their development and utilization is based on the complex interaction of a number of disciplines including medicine, pharmacy, biochemistry, pharmacology, chemistry, physics and engineering. This technically-complex multidisciplinary base has impeded the development of a uniform curriculum of training for basic scientists and professionals who work with radiopharmaceuticals. the range of technical knowledge required is very broad; it ranges from chemical synthesis and radiolabelling, through a maze of biochemistry, pharmacology and now molecular biology, to GMP manufacture, dispensing and clinical consultation concerning use and interpretation of data. Clearly, no single discipline can (nor should) be expected to undertake in-depth training of radiopharmaceutical scientists, but equally clearly, there is need for the development of curricula that will develop specific components of the essential knowledge base. The 'radiopharmaceutical' or 'product' orientation of both teaching and research can be used to provide a focus for academic and professional organizations to develop 'radiopharmacy' curricula that effectively train radiopharmaceutical practitioners for specific roles within the clinical, academic, government and industrial interests of radiopharmaceutical scientists. Currently, there is a plethora of segmented training programs, many of which are inadequately positioned to be of great value to the field or its practitioners. Efforts to re-focus radiopharmacy programs and to build professional recognition for them are bringing about harmonization of performance objectives, and leading to didactic and experiential curricula. The impact and evolution of regulatory processes will demand new and better

  17. Teaching and research in radiopharmaceuticals

    Energy Technology Data Exchange (ETDEWEB)

    Wiebe, L I [Noujaim Institute for Pharmaceutical Oncology Research, University of Alberta, Edmonton (Canada)

    1998-08-01

    Radiopharmaceuticals comprise a critical element of diagnostic and therapeutic clinical nuclear medicine. As well they contribute to more basic pre-clinical and clinical diagnostic studies such as the evaluation of new drugs and new drug formulations. Their development and utilization is based on the complex interaction of a number of disciplines including medicine, pharmacy, biochemistry, pharmacology, chemistry, physics and engineering. This technically-complex multidisciplinary base has impeded the development of a uniform curriculum of training for basic scientists and professionals who work with radiopharmaceuticals. the range of technical knowledge required is very broad; it ranges from chemical synthesis and radiolabelling, through a maze of biochemistry, pharmacology and now molecular biology, to GMP manufacture, dispensing and clinical consultation concerning use and interpretation of data. Clearly, no single discipline can (nor should) be expected to undertake in-depth training of radiopharmaceutical scientists, but equally clearly, there is need for the development of curricula that will develop specific components of the essential knowledge base. The `radiopharmaceutical` or `product` orientation of both teaching and research can be used to provide a focus for academic and professional organizations to develop `radiopharmacy` curricula that effectively train radiopharmaceutical practitioners for specific roles within the clinical, academic, government and industrial interests of radiopharmaceutical scientists. Currently, there is a plethora of segmented training programs, many of which are inadequately positioned to be of great value to the field or its practitioners. Efforts to re-focus radiopharmacy programs and to build professional recognition for them are bringing about harmonization of performance objectives, and leading to didactic and experiential curricula. The impact and evolution of regulatory processes will demand new and better

  18. Technical Direction and Laboratories Fiscal Year 1999 Annual Report

    International Nuclear Information System (INIS)

    CRAWFORD, B.A.

    2000-01-01

    This annual report summarize achievements and list reports issued by members of TDandL, NHC group during Fiscal Year (FY) 1999, (October 1, 1998 through September 30, 1999). This report, issued by this organization, describes work in support of the Hanford Site and other U S . Department of Energy, Richland Operations Office (DOE-RL) programs. It includes information on the organization make-up, interfaces, and mission of the group. The TDandL is a group of highly qualified personnel with diverse disciplines (primarily chemistry specialties) that provide process, analytical, and in-situ chemistry services to engineering customers. This year of operation and interfaces with other contract organizations consumed considerable administrative efforts. Attention was directed to the technical challenges presented by the changing roles, responsibilities, and priorities of Hanford programs

  19. Lung radiopharmaceuticals; Radioformacos pulmonares

    Energy Technology Data Exchange (ETDEWEB)

    Gonzalez, B M [Instituto Nacional de Pediatroa (Mexico)

    1994-12-31

    Indication or main clinical use of Lung radiopharmaceuticals is presented and clasification of radiopharmaceuticals as ventilation and perfusion studies. Perfusion radiopharmaceuticals, main controls for administration quality acceptance. Clearence after blood administration and main clinical applications. Ventilation radiopharmaceuticals, gases and aerosols, characteristics of a ideal radioaerosol, techniques of good inhalation procedure, clinical applications. Comparison of several radiopharmaceuticals reflering to retention time as 50% administered dose, percent administered dose at 6 hours post inhalation, blood activity at 30 and 60 minutes post inhalation, initial lung absorbed dose, cumulated activity.Kinetic description of two radiopharmaceuticals, 99mTcDTPA and 99mTc-PYP.

  20. Engineering Technical Support Center Annual Report Fiscal Year 2015

    Science.gov (United States)

    The United States Environmental Protection Agency (EPA or Agency) Office of Research and Development (ORD) created the Engineering Technical Support Center (ETSC) in 1987, one of several technical support centers created as part of the Technical Support Project (TSP). ETSC provid...

  1. 1980 Annual status report: provision of scientific and technical services

    International Nuclear Information System (INIS)

    1981-01-01

    Two kinds of objectives are pursued at the JRC in direct support of the various General Directorates of the Commission: Technical Evaluations where system analysis techniques are mainly employed and Technical Assistance where laboratory measurement, technical expertises and management of projects are provided

  2. Regulatory and technical reports (abstract index journal): Annual compilation for 1996, Volume 21, No. 4

    Energy Technology Data Exchange (ETDEWEB)

    Sheehan, M.A.

    1997-04-01

    This compilation is the annual cumulation of bibliographic data and abstracts for the formal regulatory and technical reports issued by the U.S. Nuclear Regulatory Commission (NRC) Staff and its contractors.

  3. Regulatory and technical reports (abstract index journal): Annual compilation for 1996, Volume 21, No. 4

    International Nuclear Information System (INIS)

    Sheehan, M.A.

    1997-04-01

    This compilation is the annual cumulation of bibliographic data and abstracts for the formal regulatory and technical reports issued by the U.S. Nuclear Regulatory Commission (NRC) Staff and its contractors

  4. Annual report 1994 of the Verein fuer Kernverfahrenstechnik und Analytik, Rossendorf

    International Nuclear Information System (INIS)

    Haefele, W.

    1995-05-01

    The annual report 1994 of the VKTA presents reports on the scientific and technical activities and the management activities, and an organigram. The scientific-technical activities focus on the subjects of nuclear facilities, nuclear waste management, radioactivity monitoring and analysis, site decontamination and rehabilititation, radiopharmaceuticals, and safety and radiological protection. (DG) [de

  5. KWL Lingen nuclear plant. Technical annual report 2016; KWL Kernkraftwerk Lingen. Technischer Jahresbericht 2016

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    2017-07-01

    The technical annual report 2016 for KWL (Lingen nuclear plant) covers the following sections: dismantling project management and operation, monitoring and clearance; waste management, technical qualification, security and safety, central tasks; licensing and supervision procedures, operational data, radiation monitoring, radioactive materials, in-service inspections.

  6. Core Capabilities and Technical Enhancement -- FY-98 Annual Report

    Energy Technology Data Exchange (ETDEWEB)

    Miller, David Lynn

    1999-04-01

    The Core Capability and Technical Enhancement (CC&TE) Program, a part of the Verification, Validation, and Engineering Assessment Program, was implemented to enhance and augment the technical capabilities of the Idaho National Engineering and Environmental Laboratory (INEEL). The purpose for strengthening the technical capabilities of the INEEL is to provide the technical base to serve effectively as the Environmental Management Laboratory for the Office of Environmental Management (EM). An analysis of EM's science and technology needs as well as the technology investments currently being made by EM across the complex was used to formulate a portfolio of research activities designed to address EM's needs without overlapping work being done elsewhere. An additional purpose is to enhance and maintain the technical capabilities and research infrastructure at the INEEL. This is a progress report for fiscal year 1998 for the five CC&TE research investment areas: (a) transport aspects of selective mass transport agents, (b) chemistry of environmental surfaces, (c) materials dynamics, (d) characterization science, and (e) computational simulation of mechanical and chemical systems. In addition to the five purely technical research areas, this report deals with the science and technology foundations element of the CC&TE from the standpoint of program management and complex-wide issues. This report also provides details of ongoing and future work in all six areas.

  7. Core capabilities and technical enhancement, FY-98 annual report

    Energy Technology Data Exchange (ETDEWEB)

    Miller, D.L.

    1999-04-01

    The Core Capability and Technical Enhancement (CCTE) Program, a part of the Verification, Validation, and Engineering Assessment Program, was implemented to enhance and augment the technical capabilities of the Idaho National Engineering and Environmental Laboratory (INEEL). The purpose for strengthening the technical capabilities of the INEEL is to provide the technical base to serve effectively as the Environmental Management Laboratory for the Department of Energy's Office of Environmental Management (EM). An analysis of EM's science and technology needs as well as the technology investments currently being made by EM across the complex was used to formulate a portfolio of research activities designed to address EM's needs without overlapping work being done elsewhere. An additional purpose is to enhance and maintain the technical capabilities and research infrastructure at the INEEL. This is a progress report for fiscal year 1998 for the five CCTE research investment areas: (a) transport aspects of selective mass transport agents, (b) chemistry of environmental surfaces, (c) materials dynamics, (d) characterization science, and (e) computational simulation of mechanical and chemical systems. In addition to the five purely technical research areas, this report deals with the science and technology foundations element of the CCTE from the standpoint of program management and complex-wide issues. This report also provides details of ongoing and future work in all six areas.

  8. TMI-2 Technical Information and Examination Program. 1982 annual report

    International Nuclear Information System (INIS)

    1983-04-01

    The Department of Energy's Technical Information and Examination Program at Three Mile Island Unit 2 continued the research and development work begun on the island in 1980. The work concentrated in seven major areas: instrumentation and electrical components, radiation and environment, core activities, information and industry coordination, configuration and document control, waste immobilization, and reactor evaluation. The program assists in resolving specific problems at TMI-2 while developing techniques and broadening understanding of accident consequences to improve the overall safety and reliability of nuclear power. The Technical Information and Examination Program aims to communicate applicable information to the nuclear power industry to ensure that the industry can avail itself of the maximum amount of information possible

  9. TMI-2 Technical Information and Examination Program 1983 annual report

    International Nuclear Information System (INIS)

    Scardena, D.E.

    1984-04-01

    The Department of Energy's Technical Information and Examination Program at Three Mile Island Unit 2 continued the research and development work begun on the Island in 1980. The work concentrated in six major areas: waste immobilization, reactor evaluation, data acquisition, information and industry coordination, core activities, and EPICOR II and waste research and disposition. The program assists in resolving specific problems at TMI-2 while developing techniques and broadening understanding of accident consequences to improve the overall safety and reliability of nuclear power. The Technical Information and Examination Program aims to communicate applicable information to the nuclear power industry to ensure that the industry can avail itself to the maximum amount of information possible

  10. TMI-2 Technical Information and Examination Program. 1984 annual report

    International Nuclear Information System (INIS)

    Hess, C.J.

    1985-04-01

    In 1984, the US Department of Energy's Technical Information and Examination Program entered its fifth year of research and development work at Three Mile Island Unit 2 (TMI-2) and at the Idaho National Engineering Laboratory and other supporting laboratories. The work concentrated on six major areas: waste immobilization, reactor evaluation, data acquisition, information and industry coordination, core activities, and EPICOR II and waste research and disposition

  11. Radiopharmaceuticals for bone scintillators

    International Nuclear Information System (INIS)

    Rey, A.M.

    1994-01-01

    One of the diagnostic techniques used in nuclear medicine is the bone scintiscanning with labelled compounds for obtain skeletal images. The main sections in this work are: (1) bone composition and anatomy;(2)skeletal radiopharmaceutical development;(3)physical properties of radionuclides;(4)biological behaviour and chemical structures;(5)radiopharmaceuticals production for skeletal scintillation;(6)kits;(7)dosimetry and toxicity.tabs

  12. Radiopharmaceuticals for nuclear cardiology

    International Nuclear Information System (INIS)

    Leon Cabana, Alba

    1994-01-01

    One of the diagnostic technique periodically used in Nuclear Medicine is the angiographic studi e, employee for detect cardiovascular diseases. The radiopharmaceutical more used in the angiographic ones is 99mTc. Between thetopics described in the present work it find: myocardial infarction, radiopharmaceuticals classification for cardiac studies, labelled proceedings, cardiovascular diseases

  13. Radiopharmaceuticals for therapy

    International Nuclear Information System (INIS)

    Lazarus, C.R.; Maisey, M.N.

    1985-01-01

    Several factors influencing the choice of radiopharmaceutical used in the treatment of benign and malignant disease are discussed. A brief review is given of the routine clinical uses of radiopharmaceuticals including treatments for hyperthyroidism, thyroid cancer, polycythaemia rubra vera and intracavitary therapy. Finally clinical situations using radionuclides under evaluation including the treatment of bone disease, adrenal tumours and monoclonal antibodies are discussed. (UK)

  14. Energy Materials Coordinating Committee, fiscal year 1997. Annual technical report

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    1998-07-31

    The DOE Energy Materials Coordinating Committee (EMaCC) serves primarily to enhance coordination among the Department`s materials programs and to further effective use of materials expertise within the Department. These functions are accomplished through the exchange of budgetary and planning information among program managers and through technical meetings/workshops on selected topics involving both DOE and major contractors. In addition, EMaCC assists in obtaining materials-related inputs for both intra- and interagency compilations. This report summarizes EMaCC activities for FY 1997 and describes the materials research programs of various offices and divisions within the Department.

  15. KBS Annual Report 1982. Summaries of technical reports issued during 1982

    International Nuclear Information System (INIS)

    1983-07-01

    The purpose of the KBS Annual Report is to inform interested organizations and individuals of the research and development work perfomed by the division KBS within the Swedish Nuclear Fuel Supply Co. (SKBF) on the handling, treatment and final storage of nuclear wastes in Sweden. In the Annual Report for 1982 the summaries of 27 technical reports and other publications issued during the year are listed. (K.A.E.)

  16. Center for Space Transportation and Applied Research Fifth Annual Technical Symposium Proceedings

    Science.gov (United States)

    1993-01-01

    This Fifth Annual Technical Symposium, sponsored by the UT-Calspan Center for Space Transportation and Applied Research (CSTAR), is organized to provide an overview of the technical accomplishments of the Center's five Research and Technology focus areas during the past year. These areas include chemical propulsion, electric propulsion, commerical space transportation, computational methods, and laser materials processing. Papers in the area of artificial intelligence/expert systems are also presented.

  17. Radiopharmaceuticals for neurotransmitter imaging

    Energy Technology Data Exchange (ETDEWEB)

    Oh, Seung Jun [Asan Medical Center, University of Ulsan College of Medicine, Seoul (Korea, Republic of)

    2007-04-15

    Neurotransmitter imaging with radiopharmaceuticals plays major role for understanding of neurological and psychiatric disorders such as Parkinson's disease and depression. Radiopharmaceuticals for neurotransmitter imaging can be divided to dopamine transporter imaging radiopharmaceuticals and serotonin transporter imaging radiopharmaceuticals. Many kinds of new dopamine transporter imaging radiopharmaceuticals has a tropane ring and they showed different biological properties according to the substituted functional group on tropane ring. After the first clinical trials with [{sup 123}I] {beta} -CIT, alkyl chain substituent introduced to tropane ring amine to decrease time for imaging acquisition and to increase selectivity. From these results, [{sup 123}I]PE2I, [18F]FE-CNT, [{sup 123}I]FP-CIT and [{sup 18}F]FP-CIT were developed and they showed high uptake on the dopamine transporter rich regions and fast peak uptake equilibrium time within 4 hours after injection. [{sup 11}C]McN 5652 was developed for serotonin transporter imaging but this compound showed slow kinetics and high background radioactivity. To overcome these problems, new diarylsulfide backbone derivatives such as ADAM, ODAM, AFM, and DASB were developed. In these candidates, [{sup 11}C]AFM and [{sup 11}C]DASB showed high binding affinity to serotonin transporter and fast in vivo kinetics. This paper gives an overview of current status on dopamine and serotonin transporter imaging radiopharmaceuticals and the development of new lead compounds as potential radiopharmaceuticals by medicinal chemistry.

  18. The development of cyclotron radiopharmaceuticals

    International Nuclear Information System (INIS)

    Yang, Seung Dae; Chun, K. W.; Suh, Y. S.; Lee, J. D.; Ahn, S. H. and others

    1999-03-01

    The purpose of this project is to develop the radiopharmaceuticals and automatic synthetic unit for labelled compounds, and to establish mass production system of radiopharmaceuticals. These will contribute to the early diagnosis of the disease hard to cure. The contents of this project are as follows, the development of the radiopharmaceutical for imaging of cancer, the development of automatic synthesizer for the synthesis of radio-pharmaceuticals, the development of hormone derivatives labelled with 12 '3I, the development of the radiopharmaceuticals for therapy of cancer labelled with cyclotron produced radionuclides, the development of radiopharmaceuticals for therapy of cancer labelled with cyclotron produced radionuclides, the development of radiopharmaceuticals for imaging of myocardial metabolism

  19. Idaho chemical programs annual technical report, fiscal year 1974

    International Nuclear Information System (INIS)

    Bower, J.R.

    1975-01-01

    The operating experience in fuel processing, waste calcining, and other waste management activities for FY 1974 is summarized. A new zirconium fuel dissolver has performed well, and the first-cycle extraction system shows near-zero losses. Technical support activities include: a flowsheet to reduce acid consumption and volume of liquid wastes in the electrolytic process; a new dissolution process for ternary oxide PWR fuel using zirconium-fluoride-nitric acid dissolvent; a study and recommendation for treatment of fuel storage basin water; progress in design and development of processes for Rover and HTGR fuels, corrosion evaluation of bins containing calcined wastes showing corrosion rates indicative of a safe 500-year or greater storage life; demonstration on a pilot-plant scale of conditions for calcination of stainless steel and Rover fuel wastes as well as commercial wastes; evaluation of equipment alternatives for a new waste calcining facility; studies related to improvements in rare gas recovery and process off-gas treatment; demonstration of stability when various high-level waste solutions are mixed; progress on postcalcination treatment of calcined waste solids (ceramic formation, incorporation in metals, and calcine-concretes); studies on removal of actinides from ICPP wastes; a conceptual design for a proposed radioactive solid-waste repackaging facility for the INEL. Significant progress is reported on the program for determination of burnup for fast breeder reactor fuels. (U.S.)

  20. Aerial Measuring System Technical Integration Annual Report 2002

    Energy Technology Data Exchange (ETDEWEB)

    Bechtel Nevada Remote Sensing Laboratory

    2003-06-01

    Fiscal Year 2002 is the second year of a five-year commitment by the U.S. Department of Energy, National Nuclear Security Administration (NNSA) to invest in development of new and state-of-the-art technologies for the Aerial Measuring Systems (AMS) project. In 2000, NNSA committed to two million dollars for AMS Technical Integration (TI) for each of five years. The tragedy of September 11, 2001, profoundly influenced the program. NNSA redirected people and funding resources at the Remote Sensing Laboratory (RSL) to more immediate needs. Funds intended for AMS TI were redirected to NNSA's new posture of leaning further forward throughout. AMS TI was brought to a complete halt on December 10, 2001. Then on April 30, 2002, NNSA Headquarters allowed the restart of AMS TI at the reduced level of $840,000. The year's events resulted in a slow beginning of several projects, some of which were resumed only a few weeks before the AMS TI Symposium held at RSL on July 30.

  1. Technical and economic feasibility of thermal energy storage. Annual report

    Energy Technology Data Exchange (ETDEWEB)

    Glenn, D.R.

    1976-02-01

    This study provides a first-look at the system elements involved in: (1) creating a market; (2) understanding and deriving the requirements; (3) performing analytical effort; (4) specifying equipment; and (5) synthesizing applications for a thermal energy storage (TES) function. The work reviews implicated markets, energy consumption patterns, TES technologies, and applications. Further, several concepts are developed and evaluated in some detail. Key findings are: (1) there are numerous technical opportunities for TES in the residential and industrial market sectors; (2) apart from sensible heat storage and transfer, significant R and D is required to fully exploit the superior heat densities of latent heat-based TES systems, particularly at temperatures above 600/sup 0/F; (3) industrial energy conservation can be favorably impacted by TES where periodic or batch-operated unit functions characterize product manufacturing processes, i.e. bricks, steel, and ceramics; and (4) a severe data shortage exists for describing energy consumption rates in real time as related to plant process operations--a needed element in designing TES systems.

  2. Proceedings of the Efficient Separations and Processing Cross-Cutting Program Annual Technical Exchange Meeting

    International Nuclear Information System (INIS)

    1995-01-01

    This document contains summaries of technology development presented at the 1995 Efficient Separations and Processing Cross-Cutting Program (ESP) Annual Technical Exchange Meeting. The ESP is sponsored by the US Department of Energy's Office of Environmental Management (EM), Office of Technology Development. The meeting is held annually to promote a free exchange of ideas among technology developers, potential users (for example, EM focus areas), and other interested parties within EM. During this meeting, developers of ESP-funded technologies describe the problems and needs addressed by their technologies; the technical approach, accomplishments, and resolution of issues; the strategy and schedule for commercialization; and evolving potential applications. Presenters are asked to address the following areas: Target waste management problem, waste stream, or data need; scientific background and technical approach; technical accomplishments and resolution of technical issues; schedule and strategy for commercializing and implementing the technology or acquiring needed data; potential alternate applications of the technology or data, including outside of DOE/EM. The meeting is not a program review of the individual tasks or subtasks; but instead focuses on the technical aspects and implementation of ESP-sponsored technology or data. The meeting is also attended by members of the ESP Technical Review Team, who have the opportunity at that time to review the ESP as a whole

  3. Regulatory and technical reports (abstract index journal). Annual compilation for 1984. Volume 9, No. 4

    International Nuclear Information System (INIS)

    1985-01-01

    This compilation consists of bibliographic data and abstracts for the formal regulatory and technical reports issued by the US Nuclear Regulatory Commission (NRC) Staff and its contractors. It is NRC's intention to publish this compilation quarterly and to cumulate it annually

  4. Regulatory and technical reports (abstract index journal): Annual compilation for 1987

    International Nuclear Information System (INIS)

    1988-03-01

    This compilation consists of bibliographic data and abstracts for the formal regulatory and technical reports issued by the US Nuclear Regulatory Commission (NRC) Staff and its contractors. It is NRC's intention to publish this compilation quarterly and to cumulate it annually

  5. Annual technical meeting of the NRC cooperative severe accident research program

    International Nuclear Information System (INIS)

    Silver, E.G.

    1993-01-01

    This brief report summarizes the 1992 annual technical meeting of the NRC Cooperative Severe Accident Research Program (CSARP-92) held at the Hyatt Regency Hotel in Bethesda, Maryland, May 4-8, 1992. The report is taken mainly from coverage of the meeting published in the June 5, 1992, issue of Atomic Energy Clearinghouse. Results of this meeting are formalized at the Water Reactor Safety Information Meetings (WRSIM) that are held annually in October. Nuclear Safety summarizes the annual WRSIM meetings and provides a list of the presentations that were given. Interested readers are encouraged to review listed topics to identify specific topic areas in severe accident research. Sessions were held on in-vessel core melt progression; fuel-coolant interactions; fission-product behavior; direct containment heating; and severe accident code development, assessment, and validation. Summaries of the individual technical sessions and the current state of the art in these areas were given by the chairmen

  6. Radiopharmaceutical scanning agents

    International Nuclear Information System (INIS)

    1976-01-01

    This invention is directed to dispersions useful in preparing radiopharmaceutical scanning agents, to technetium labelled dispersions, to methods for preparing such dispersions and to their use as scanning agents

  7. Radiopharmaceuticals 1994. Nil desperandum

    International Nuclear Information System (INIS)

    Cox, P.H.; Meyer, G.J.

    1995-01-01

    On the basis of the discussions at a symposium held in Duesseldorf and attended by representatives of various interested bodies, European legislation as it affects radiopharmaceuticals is reviewed. Due consideration is given to the new, centralised and decentralised, registration procedures, effective since 1 January 1995. The dossier required to support an application for marketing authorisation is discussed, separate consideration being given to single-photon emitters, therapeutic radio-nuclides and positron-emitting radiopharmaceuticals. The role of the European Pharmacopoiea is also considered. It is concluded that the new, modified procedures for the registration of medicinal products in the European Union may actually inhibit free availability of radiopharmaceuticals within the Community, and that there is a strong case for modification of the European Directives so that radiopharmaceuticals are placed in a separate category to therapeutic drugs, with less stringent registration requirements. (orig.)

  8. Radiopharmaceutical drug review process

    International Nuclear Information System (INIS)

    Frankel, R.

    1985-01-01

    To ensure proper radioactive drug use (such as quality, diagnostic improvement, and minimal radioactive exposure), the Food and Drug Administration evaluates new drugs with respect to safety, effectiveness, and accuracy and adequacy of the labeling. The IND or NDA process is used for this purpose. A brief description of the process, including the Chemical Classification System and the therapeutic potential classification, is presented as it applies to radiopharmaceuticals. Also, the status of the IND or NDA review of radiopharmaceuticals is given

  9. Preparation of radiopharmaceutical formulations

    International Nuclear Information System (INIS)

    Simon, J.; Garlich, J.R.; Frank, R.K.; McMillan, K.

    1998-01-01

    Radiopharmaceutical formulations for complexes comprising at least one radionuclide complexed with a ligand, or its physiologically-acceptable salts thereof, especially 153 samarium-ethylenediaminetetramethylenephosphonic acid, which optionally contains a divalent metal ion, e.g. calcium, and is frozen, thawed, and then administered by injection. Alternatively, the radiopharmaceutical formulations must contain the divalent metal and are frozen only if the time before administration is sufficiently long to cause concern for radiolysis of the ligand. 2 figs., 9 tabs

  10. Radiopharmaceuticals for cerebral studies

    International Nuclear Information System (INIS)

    Leon Cabana, Alba

    1994-01-01

    For obtain good brain scintillation images in nuclear medicine must be used several radiopharmaceuticals. Cerebral studies give a tumors visual image as well as brain anomalities detection and are helpful in the diagnostic diseases . Are described in this work: a cerebrum radiopharmaceuticals classification,labelled compounds proceeding and Tc 99m good properties in for your fast caption, post administration and blood purification for renal way

  11. Regulatory aspects of radiopharmaceuticals

    International Nuclear Information System (INIS)

    Kristensen, K.

    1985-01-01

    Regulatory systems in the field of radiopharmaceuticals have two main purposes: efficacy and safety. Efficacy expresses the quality of the diagnostic and therapeutic process for the patient. Safety involves the patient, the staff, and the environment. The world situation regarding regulations for radiopharmaceuticals is reviewed on the basis of a survey in WHO Member States. The main content of such regulations is discussed. The special properties of radiopharmaceuticals compared with ordinary drugs may call for modified regulations. Several countries are preparing such regulations. Close co-operation and good understanding among scientists working in hospital research, industry and regulatory bodies will be of great importance for the fast and safe introduction of new radiopharmaceuticals for the benefit of the patient. Before introducing new legislation in this field, a radiopharmaceutical expert should analyse the situation in the country and the relationship to the existing regulations. It is expected that the most important factor in promoting the fast introduction of new, safe and effective radiopharmaceuticals will be the training of people working within the regulatory bodies. It is foreseen that the IAEA and WHO will have an important role to play by providing expert advice and training in this area. (author)

  12. Energy Materials Coordinating Committee (EMaCC): Annual technical report, Fiscal year 1987

    International Nuclear Information System (INIS)

    1988-09-01

    The DOE Energy Materials Coordinating Committee (EMaCC) serves primarily to enhance coordination among the Department's materials programs and to further the effective use of materials expertise within the Department. These functions are accomplished through the exchange of budgetary and planning information among program managers and through technical meetings/workshops on selected topics involving both DOE and major contractors. This annual technical report is mandated by the EMaCC terms of reference. This report summarizes EMaCC activities for FY 1987 and describes the materials research programs of various offices and divisions within the Department

  13. 11. annual report of the technical advisory committee on the nuclear fuel waste management program

    International Nuclear Information System (INIS)

    1990-10-01

    The Eleventh Annual Report of the Technical Advisory Committee (TAC) assesses the scientific and technical progress made within the Canadian Nuclear Fuel Waste Management Program (NFWMP) during the period July 1989 to June 1990. The Committee notes that the general concept of a multibarrier system involving geologic media and engineered systems is based on known technologies and current scientific knowledge, and has gained strong international scientific and engineering support as currently the most feasible and practical. TAC continues to endorse the full investigation of the concept of nuclear waste disposal deep in plutonic formations, such as those in the Canadian Shield

  14. Eleventh international symposium on radiopharmaceutical chemistry

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    1995-12-31

    This document contains abstracts of papers which were presented at the Eleventh International Symposium on Radiopharmaceutical Chemistry. Sessions included: radiopharmaceuticals for the dopaminergic system, strategies for the production and use of labelled reactive small molecules, radiopharmaceuticals for measuring metabolism, radiopharmaceuticals for the serotonin and sigma receptor systems, labelled probes for molecular biology applications, radiopharmaceuticals for receptor systems, radiopharmaceuticals utilizing coordination chemistry, radiolabelled antibodies, radiolabelling methods for small molecules, analytical techniques in radiopharmaceutical chemistry, and analytical techniques in radiopharmaceutical chemistry.

  15. Eleventh international symposium on radiopharmaceutical chemistry

    International Nuclear Information System (INIS)

    1995-01-01

    This document contains abstracts of papers which were presented at the Eleventh International Symposium on Radiopharmaceutical Chemistry. Sessions included: radiopharmaceuticals for the dopaminergic system, strategies for the production and use of labelled reactive small molecules, radiopharmaceuticals for measuring metabolism, radiopharmaceuticals for the serotonin and sigma receptor systems, labelled probes for molecular biology applications, radiopharmaceuticals for receptor systems, radiopharmaceuticals utilizing coordination chemistry, radiolabelled antibodies, radiolabelling methods for small molecules, analytical techniques in radiopharmaceutical chemistry, and analytical techniques in radiopharmaceutical chemistry

  16. Annual meeting on nuclear technology '92. Technical session 'Nuclear energy discussion'

    International Nuclear Information System (INIS)

    1992-05-01

    The report contains the six special papers red at the 1992 annual conference on nuclear engineering at Karlsruhe, all of which are individually retrievable from the database. They deal with the following subjects: historical development of the basic trends of technology criticism; communication problems in connection with the conveying of technical facts; psycho-sociological patterns of technology anxiety-mental infection or risk consciousness; field of tension between technology and journalism; handling of insecurities; ethical justifiability of nuclear energy use. (HSCH) [de

  17. Recent advances in radiopharmaceuticals

    International Nuclear Information System (INIS)

    Smith, S.

    2000-01-01

    Full text: Radiopharmaceuticals in Nuclear Medicine may be divided into diagnostic and therapeutic agents. The diagnostic area is perceived to be mature, while the therapeutic side of nuclear medicine is still evolving. There are over 100 diagnostic radiopharmaceutical products available, the greatest number applied in cardiology followed by oncology and neurology. The greatest success in therapeutic nuclear medicine has been achieved in thyroid cancer, hyperthyroidism and bone pain palliation. Those in the field believe the future of nuclear medicine resides in the growth potential of the emerging therapeutic market, hence much of the recent research has been focussed in the development of therapeutic agents for targeting cancers. Radiopharmaceuticals under development or in clinical trials involve the use of radionuclides such as Y-90, Pd-103, Ir-192, Re-188, I-131, Sm-153, Sn-114, Sr-90, Cu-64 and In-111. Advances in cyclotron and camera technology as well as automation has enhanced and widened the potential use of positron emitting radiopharmaceuticals such as F-18 Fluorodeoxyglucose (FDG). However the relationship between FDG uptake and glucose consumption in normal and diseased tissue is still to be defined. Many challenges remain for the nuclear medicine community to apply new knowledge of human biochemistry in the development of new radiopharmaceuticals. A better understanding of effects of radiation and its role in the design of therapeutic agents is undoubtedly pivotal for advancing therapeutic Nuclear Medicine into the future

  18. Therapeutic applications of radiopharmaceuticals

    International Nuclear Information System (INIS)

    Baker, W.J.; Datz, F.L.; Beightol, R.W.

    1987-01-01

    Whether a radiopharmaceutical has diagnostic or therapeutic application depends on both the isotope and pharmaceutical used. For diagnostic applications, the isotope should undergo only γ-decay, since usually only γ-radiation is detected by nuclear medicine cameras. The half-life should be just long enough to allow the procedure to be performed. In contrast, the isotope needed for therapeutic purposes should have particulate radiation, such as a β-particle (electron), since these are locally absorbed an increase the local radiation dose. γ-Radiation, which penetrates the tissues, produces less radiation dose than do Β-particles. Several references dealing with radioactive decay, particulate interactions, and diagnostic and therapeutic applications of radiopharmaceuticals are available. Radiopharmaceuticals can legally be used only by physicians who are qualified by specific training in the safe handling of radionuclides. The experience and training of these physicians must be approved by the Nuclear Regulatory Commission or Agreement State Agency authorized to license the use of radiopharmaceuticals. A list of all byproduct material and procedures is available in the Code of Federal Regulations. Of the many radiopharmaceuticals available for diagnostic and therapeutic use, only those commonly used are discussed in this chapter

  19. Cyclotron produced radiopharmaceuticals

    International Nuclear Information System (INIS)

    Kopicka, K.; Fiser, M.; Hradilek, P.; Hanc, P.; Lebeda, O.

    2003-01-01

    Some of the cyclotron-produced radionuclides may serve as important materials for the production of radiopharmaceuticals. This lecture deals with basic information relating to various aspects of these compounds. In comparison with radionuclides /compounds used for non-medical purposes, radiopharmaceuticals are subject to a broader scale of regulations, both from the safety and efficacy point of view; besides that, there are both radioactive and medical aspects that must be taken into account for any radiopharmaceutical. According to the regulations and in compliance with general rules of work with radioactivity, radiopharmaceuticals should only be prepared/manufactured under special conditions, using special areas and special equipment and applying special procedures (e.g. sterilisation, disinfection, aseptic work). Also, there are special procedures for cleaning and maintenance. Sometimes the requirements for the product safety clash with those for the safety of the personnel; several examples of solutions pertaining to these cases are given in the lecture. Also, the specific role of cyclotron radiopharmaceuticals is discussed. (author)

  20. Quality control of radiopharmaceuticals

    International Nuclear Information System (INIS)

    Kristensen, K.

    1981-01-01

    Quality assurance was introduced in the pharmaceutical field long before it was used in many other areas, and the term quality control has been used in a much broader sense than merely analytical quality control. The term Good Manufacturing Practice (GMP) has been used to describe the system used for producing safe and effective drugs of a uniform quality. GMP has also been used for the industrial production of radiopharmaceuticals. For the preparation and control of radiopharmaceuticals in hospitals a similar system has been named Good Radiopharmacy Practice (GRP). It contains the same elements as GMP but takes into account the special nature of this group of drugs. Data on the assessment of the quality of radiopharmaceuticals in relation to present standards are reviewed. The general conclusion is that the quality of radiopharmaceuticals appears comparable to that of other drugs. It seems possible to establish the production of radiopharmaceuticals, generators and preparation kits in such a way that analytical control of the final product at the hospital may be limited provided the final preparation work is carried out in accordance with GRP principles. The elements of GRP are reviewed. (author)

  1. Click synthesis of PET radiopharmaceuticals

    International Nuclear Information System (INIS)

    Xu Mei; Kuang Chunxiang

    2009-01-01

    Increasing attention has been focused on synthesis radiopharmaceuticals for positron emission tomography (PET). The recent years witnessed applications of click chemistry to PET radiopharmaceutical synthesis,because of its distinctive advantages including high speed,yield and stereospecificity under mild conditions. Synthesis of 18 F-labeled and 11 C-labeled radiopharmaceuticals and intermediates via click chemistry are reviewed. The future trend of click chemistry for the synthesis of PET radiopharmaceutical is prospected. (authors)

  2. Energy Materials Coordinating Committee (EMaCC): Fiscal year 1996. Annual technical report

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    1997-08-01

    The DOE Energy Materials Coordinating Committee (EMaCC) serves primarily to enhance coordination among the Department`s materials programs and to further effective use of materials expertise within the Department. These functions are accomplished through the exchange of budgetary and planning information among program managers and through technical meetings/workshops on selected topics involving both DOE and major contractors. In addition, EMaCC assists in obtaining materials-related inputs for both intra- and interagency compilations. The EMaCC reports to the Director of the Office of Energy Research in his or her capacity as overseer of the technical programs of the Department. This annual technical report is mandated by the EMaCC terms of reference. This report summarizes EMaCC activities for FY 1996 and describes the materials research programs of various offices and divisions within the Department.

  3. Energy Materials Coordinating Committee (EMaCC): Fiscal year 1996. Annual technical report

    International Nuclear Information System (INIS)

    1997-08-01

    The DOE Energy Materials Coordinating Committee (EMaCC) serves primarily to enhance coordination among the Department's materials programs and to further effective use of materials expertise within the Department. These functions are accomplished through the exchange of budgetary and planning information among program managers and through technical meetings/workshops on selected topics involving both DOE and major contractors. In addition, EMaCC assists in obtaining materials-related inputs for both intra- and interagency compilations. The EMaCC reports to the Director of the Office of Energy Research in his or her capacity as overseer of the technical programs of the Department. This annual technical report is mandated by the EMaCC terms of reference. This report summarizes EMaCC activities for FY 1996 and describes the materials research programs of various offices and divisions within the Department

  4. Quality assurance of radiopharmaceuticals

    International Nuclear Information System (INIS)

    Frier, M.; Hesslewood, S.R.

    1980-01-01

    A practical guide has been composed for all persons involved in the preparation and use of radiopharmaceuticals on methods used in quality assurance and their applications. These methods include the calibration of ionization chamber assay calibrators, the determination of radionuclide purity, radiochemical purity and chemical purity, particle size analysis and the measurement of pH. Quality assurance procedures are described for products not described in Compendial Monographs, or where the monograph exists, additional useful information is provided; such radiopharmaceuticals include technetium, indium-labelled and iodine-labelled products. (U.K.)

  5. Drug-radiopharmaceutical interactions

    International Nuclear Information System (INIS)

    Hladik, W.B.; Ponto, J.A.; Stathis, V.J.

    1985-01-01

    Patients seen in the nuclear medicine department have a wide variety of disorders and, consequently, may be receiving any number of therapeutic drugs. For this reason, nuclear medicine professionals should be aware of the potential effects that these pharmacologic agents may have on the bio-distribution of subsequently administered radiopharmaceuticals, commonly referred to as ''drug-radiopharmaceutical interactions.'' Compared with the quantity of literature written about interactions between various therapeutic drugs, the information available on drug-radiopharmaceutical interactions is scarce. However, there has been increasing interest in this subject, particularly during the past five years. Some of the reported interactions are used intentionally to add a new dimension to the nuclear medicine study and increase its diagnostic capabilities, i.e., pharmacologic intervention. These beneficial ''interactions'' are discussed in detail in several other chapters of this book. Other interactions, however, cause changes in the normal distribution of radiopharmaceuticals, which may interfere with the diagnostic utility of various nuclear medicine procedures. The latter group of interactions is the focus of this chapter

  6. Audits of radiopharmaceutical formulations

    International Nuclear Information System (INIS)

    Castronovo, F.P. Jr.

    1992-01-01

    A procedure for auditing radiopharmaceutical formulations is described. To meet FDA guidelines regarding the quality of radiopharmaceuticals, institutional radioactive drug research committees perform audits when such drugs are formulated away from an institutional pharmacy. All principal investigators who formulate drugs outside institutional pharmacies must pass these audits before they can obtain a radiopharmaceutical investigation permit. The audit team meets with the individual who performs the formulation at the site of drug preparation to verify that drug formulations meet identity, strength, quality, and purity standards; are uniform and reproducible; and are sterile and pyrogen free. This team must contain an expert knowledgeable in the preparation of radioactive drugs; a radiopharmacist is the most qualified person for this role. Problems that have been identified by audits include lack of sterility and apyrogenicity testing, formulations that are open to the laboratory environment, failure to use pharmaceutical-grade chemicals, inadequate quality control methods or records, inadequate training of the person preparing the drug, and improper unit dose preparation. Investigational radiopharmaceutical formulations, including nonradiolabeled drugs, must be audited before they are administered to humans. A properly trained pharmacist should be a member of the audit team

  7. Drug interactions with radiopharmaceuticals

    International Nuclear Information System (INIS)

    Hesslewood, S.; Leung, E.

    1994-01-01

    Considerable information on documented drug and radiopharmaceutical interactions has been assembled in a tabular form, classified by the type of nuclear medicine study. The aim is to provide a rapid reference for nuclear medicine staff to look for such interactions. The initiation of drug chart monitoring or drug history taking of nuclear medicine patients and the reporting of such events are encouraged. (orig.)

  8. F-18 Radiopharmaceuticals

    International Nuclear Information System (INIS)

    2001-12-01

    This document includes 8 presentations delivered at the symposium. The topics discussed include: optimization of accelerator production of 18 F- and 18 F 2 -fluorodeoxyglucose; radiopharmaceuticals synthesis, synthesis modules, pharmacopoeia and GLP; quality control; radiation safety of production and application; PET imaging in human medicine. Each presentation has been indexed separately

  9. Radiopharmaceuticals for renal studies

    International Nuclear Information System (INIS)

    Verdera, Silvia

    1994-01-01

    Between the diagnostic techniques using radiopharmaceuticals in nuclear medicine it find renal studies.A brief description about renal glomerular filtration(GFR) and reliability renal plasma flux (ERPF),renal blood flux measurement agents (RBF),renal scintillation agents and radiation dose estimates by organ physiology was given in this study.tabs

  10. Quality control of radiopharmaceuticals

    International Nuclear Information System (INIS)

    Verdera, E.S.

    1994-01-01

    The quality control of radiopharmaceuticals is based in physics, physics-chemical and biological controls. Between the different controls can be enumerated the following: visual aspect,side, number of particle beams,activity,purity,ph,isotonicity,sterility,radioinmunoessay,toxicity,stability and clinical essay

  11. Melanin-binding radiopharmaceuticals

    International Nuclear Information System (INIS)

    Packer, S.; Fairchild, R.G.; Watts, K.P.; Greenberg, D.; Hannon, S.J.

    1980-01-01

    The scope of this paper is limited to an analysis of the factors that are important to the relationship of radiopharmaceuticals to melanin. While the authors do not attempt to deal with differences between melanin-binding vs. melanoma-binding, a notable variance is assumed

  12. Radiopharmaceuticals for thrombus detection

    International Nuclear Information System (INIS)

    Knight, L.C.

    1990-01-01

    Most of the components of the thrombotic and fibrinolytic systems have at some time been evaluated as a means of carrying a radiolabel specifically to thrombi, although very few have been promising enough to emerge from investigational status to routine clinical use. New approaches are being explored, including improved methods of labeling platelets, chemically modified forms of previously tested plasma proteins, and new biomolecules, including monoclonal antibodies specific for fibrin and platelets. The current goal is to find one or more radiotracers that bind specifically and rapidly to thrombi, and that also have a rapid blood disappearance rate, permitting a clear diagnosis within a few hours after injection. Because this test may be needed to assess the course of therapy in an anticoagulated patient, the ideal radiopharmaceutical should be able to locate thrombi without interference by anticoagulants. Until a suitable thrombus-specific radiopharmaceutical becomes generally available, many hospitals will continue to attempt to make a diagnosis with nonspecific radiopharmaceuticals that can at best provide blood pool images to indicate filling defects. Several of the new approaches seem likely to provide the radiopharmaceutical sought, although clinical trials are at an early stage.137 references

  13. Process for preparing radiopharmaceuticals

    International Nuclear Information System (INIS)

    Barak, M.; Winchell, H.S.

    1977-01-01

    A process for the preparation of technetium-99m labeled pharmaceuticals is disclosed. The process comprises initially isolating technetium-99m pertechnetate by adsorption upon an adsorbent packing in a chromatographic column. The technetium-99m is then eluted from the packing with a biological compound to form a radiopharmaceutical

  14. Pain palliative Radiopharmaceuticals

    International Nuclear Information System (INIS)

    Gonzalez, B. M.

    1994-01-01

    A pain relieving agents based on β emitters mainly and in some cases a complex preparation are being given for bone metastasis in relation with breast,prostate and lung carcinoma with good performance in clinical practice.Several radionuclides and radiopharmaceuticals are mentioned giving strength to those newly proposed, 153Sm and 186Re.Bibliography

  15. The development of cyclotron radiopharmaceuticals

    Energy Technology Data Exchange (ETDEWEB)

    Yang, Seung Dae; Chun, K. W.; Suh, Y. S.; Lee, J. D.; Ahn, S. H. and others

    1999-03-01

    The purpose of this project is to developthe radiopharmaceuticals and automatic synthetic unit for labelled compounds, and to establish mass production system of radiopharmaceuticals. These will contribute to the early diagnosis of the disease hard to cure. The contents of this project are as follows, the development of the radiopharmaceutical for imaging of cancer, the development of automatic synthesizer for the synthesis of radio-pharmaceuticals, the development of hormone derivatives labelled with {sup 12}'3I, the development of the radiopharmaceuticals for therapy of cancer labelled with cyclotron produced radionuclides, the development of radiopharmaceuticals for therapy of cancer labelled with cyclotron produced radionuclides, the development of radiopharmaceuticals for imaging of myocardial metabolism.

  16. KBS Annual Report 1983. Including summaries of technical reports issued during 1983

    International Nuclear Information System (INIS)

    1984-06-01

    The purpose of the KBS Annual Report is to inform interested organizations and individuals of the research and development work performed by the division KBS within the Swedish Nuclear Fuel Supply Co (SKBF) on the handling, treatment and final storage of nuclear wastes in Sweden. The Annual Report normally contains a presentation of the legal and organizational situation followed by an account of the progress within different areas of the R and D-work. This account also includes indications of the activities planned for the future. At the end of the report the summaries of 76 technical reports and other publications issued during the year are listed in special appendices. (K.A.E.)

  17. Environmental Science and Research Foundation. Annual technical report, April 11, 1994--December 31, 1994

    International Nuclear Information System (INIS)

    Reynolds, T.D.; Morris, R.C.; Markham, O.D.

    1995-06-01

    This Annual Technical Report describes work conducted for the Department of Energy, Idaho Operations Office, by the Environmental Science and Research Foundation (Foundation) for work under contract DE-AC07-94ID13268. The Foundation began, on April 11, 1994, to conduct environmental surveillance near to and distant from the Idaho National Engineering Laboratory, provide environmental public relations and education related to INEL natural resource issues, and conduct ecological and radioecological research benefiting major DOE-ID programs including Waste Management, Environmental Restoration, Spent Nuclear Fuels, and Infrastructure

  18. Western Research Institute: Annual technical progress report, October 1987--September 1988

    Energy Technology Data Exchange (ETDEWEB)

    1988-12-01

    This report describes the technical progress made by the Western Research Institute of the University of Wyoming Research Institute of the University of Wyoming Research Corporation on work performed for the period October 1, 1987 through September 30, 1988. This research involves five resource areas: oil shale, tar sand, underground coal gasification, advanced process technology, and advanced fuels research. Under the terms of the cooperative agreement, an annual project plan has been approved by DOE. The work reported herein reflects the implementation of the research in the plan and follows the structure used therein. 49 refs., 32 figs., 87 tabs.

  19. SKB Annual Report 1995. Including summaries of Technical Reports issued during 1995

    International Nuclear Information System (INIS)

    1996-05-01

    The annual report covers planning, construction and operation of facilities and systems as well as research, development, demonstration work and information activities. The aim of the program is to start the permanent disposal of spent nuclear fuel around year 2008. Work is undertaken for the development of encapsulation technology on an industrial scale and for design of an encapsulation plant. The siting process for the final repository for spent fuel has started with feasibility studies in a few Swedish municipalities in order to evaluate the potential technical conditions and requirements and the influence on the region. 36 refs, figs

  20. Environmental Science and Research Foundation. Annual technical report, April 11, 1994--December 31, 1994

    Energy Technology Data Exchange (ETDEWEB)

    Reynolds, T.D.; Morris, R.C.; Markham, O.D. [eds.

    1995-06-01

    This Annual Technical Report describes work conducted for the Department of Energy, Idaho Operations Office, by the Environmental Science and Research Foundation (Foundation) for work under contract DE-AC07-94ID13268. The Foundation began, on April 11, 1994, to conduct environmental surveillance near to and distant from the Idaho National Engineering Laboratory, provide environmental public relations and education related to INEL natural resource issues, and conduct ecological and radioecological research benefiting major DOE-ID programs including Waste Management, Environmental Restoration, Spent Nuclear Fuels, and Infrastructure.

  1. Regulatory and technical reports (abstract index journal): Annual compilation for 1994. Volume 19, Number 4

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    1995-03-01

    This compilation consists of bibliographic data and abstracts for the formal regulatory and technical reports issued by the US Nuclear Regulatory Commission (NRC) Staff and its contractors. It is NRC`s intention to publish this compilation quarterly and to cumulate it annually. The main citations and abstracts in this compilation are listed in NUREG number order. These precede the following indexes: secondary report number index, personal author index, subject index, NRC originating organization index (staff reports), NRC originating organization index (international agreements), NRC contract sponsor index (contractor reports), contractor index, international organization index, and licensed facility index. A detailed explanation of the entries precedes each index.

  2. SKB Annual Report 1995. Including summaries of Technical Reports issued during 1995

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    1996-05-01

    The annual report covers planning, construction and operation of facilities and systems as well as research, development, demonstration work and information activities. The aim of the program is to start the permanent disposal of spent nuclear fuel around year 2008. Work is undertaken for the development of encapsulation technology on an industrial scale and for design of an encapsulation plant. The siting process for the final repository for spent fuel has started with feasibility studies in a few Swedish municipalities in order to evaluate the potential technical conditions and requirements and the influence on the region. 36 refs, figs.

  3. [Fortieth Annual] Meeting of the Technical Working Group on Fast Reactors (TWG-FR). Working Material

    International Nuclear Information System (INIS)

    2008-01-01

    The objectives of the meeting were to: - Exchange information on the national programmes on Fast Reactors (FR) and Accelerator Driven Systems (ADS); - Review the progress since the 39th TWG-FR Annual Meeting, including the status of the actions; - Consider meeting arrangements for 2007, 2008 and 2009; - Review the Agency’s ongoing information exchange and co-ordinated research activities in the technical fields relevant to the TWG-FR (FRs and ADS), as well as coordination of the TWG-FR’s activities with other organizations; - Discuss future joint activities in view of the Agency’s Programme and Budget Cycle 2008–2009 (and beyond)

  4. Radiopharmaceuticals in Czechoslovakia

    International Nuclear Information System (INIS)

    Hron, M.; Kronrad, L.; Svoboda, K.; Melichar, F.

    1986-01-01

    The history is briefly described of the production of radiopharmaceuticals in Czechoslovakia for nuclear medicine purposes. 131 I-labelled orthoiodohippurate and rose Bengal were first produced. Currently, 99m Tc is the most frequently requested radionuclide for radiopharmaceutical labelling. The preparation of 99m Tc is described in detail, a flow chart is shown and the network of 99m Tc distribution to hospitals outlined. In addition of 99m Tc and 131 I, UJV Rez produces other radionuclides for nuclear medicine, such as 113m In, 67 Ga, 35 S, 32 P, 203 Hg, 85 Sr. The methods are being developed of the production of 201 Tl, 125 I and 131 I-labelled bromosulfophthalein. (E.S.)

  5. Radioisotopes and radiopharmaceuticals catalogue

    International Nuclear Information System (INIS)

    2002-01-01

    The Chilean Nuclear Energy Commission (CCHEN) presents its radioisotopes and radiopharmaceuticals 2002 catalogue. In it we found physical characteristics of 9 different reactor produced radioisotopes ( Tc-99m, I-131, Sm-153, Ir-192, P-32, Na-24, K-42, Cu-64, Rb-86 ), 7 radiopharmaceuticals ( MDP, DTPA, DMSA, Disida, Phitate, S-Coloid, Red Blood Cells In-Vivo, Red Blood Cells In-Vitro) and 4 labelled compounds ( DMSA-Tc99m, DTPA-Tc99m, MIBG-I131, EDTMP-Sm153 ). In the near future the number of items will be increased with new reactor and cyclotron products. Our production system will be certified by ISO 9000 on March 2003. CCHEN is interested in being a national and an international supplier of these products (RS)

  6. Good radiopharmaceuticals practices

    International Nuclear Information System (INIS)

    Verdera E, Silvia

    1994-01-01

    A careful security must be used in the nuclear medicine laboratory concerning to the proceedings, preparation and dispensation of radiopharmaceuticals. Each control laboratory must look after the radiation protection patients,workers and people in general. Between another routinary activities in the present work it find : equipment prearrangement,installations,handling and support of electronic instruments,proceedings,methodology, results and interpretation of analysis , as well as registry maintenance

  7. Radiopharmaceuticals for diagnosis

    International Nuclear Information System (INIS)

    Kuhl, D.E.

    1990-06-01

    During this grant period 1 January 1988--31 December 1990, we have successfully developed a number of new approaches to fluorine-18 labeled compounds, prepared several new radiotracers for both animal studies and eventual clinical trials, and explored the utility of a high-quality industrial robot in radiopharmaceutical applications. The progress during the last grant period is summarized briefly in the following sections. Publications arising from this research are listed below and can be found in Appendix I. 1 fig

  8. Supply of radiopharmaceuticals in Japan

    International Nuclear Information System (INIS)

    Genka, Tsuguo

    2006-01-01

    Detailed statistics of the application of radiopharmaceuticals in nuclear medicine in Japan are summarized. They are the amount of supply in terms of monetary value and radioactivity, categorized usages of in vivo and in vitro, number of facilities using the radiopharmaceuticals for the time span of 5 years (1998-2002). Obvious tendency of decrease for in vitro use can be seen while the total amount of radiopharmaceuticals is almost unchanged. (author)

  9. Energy materials coordinating committee (EMACC) Fiscal Year 1982. Annual technical report

    Energy Technology Data Exchange (ETDEWEB)

    None, None

    1983-03-01

    The DOE Energy Materials Coordinating Committee (EMaCC) serves primarily to enhance coordination among the Department's materials programs and to further the effective use of materials expertise within the Department. These functions are accomplished through the exchange of budgetary and planning information among program managers and through technical meetings/ workshops on selected topics involving both DOE and major contractors. In addition, the EMaCC aids in obtaining materials - related inputs for both intra- and interagency compilations. Membership in the EMaCC is open to any Department organizational unit; participants are appointed by Division or Office Directors. The current membership is listed in Table 1. The EMACC reports to the Director of the Office of Energy Research in his capacity as overseer of the technical programs of the Department. This annual technical report is mandated by the EMACC terms of reference. In this report are described 1) EMACC activities for FY 1982; 2) a summary of materials funding in the Department from FY 1978 to the present; and 3) on-going materials programs in the Department.

  10. Environmental Science and Research Foundation annual technical report: Calendar year 1996

    International Nuclear Information System (INIS)

    Morris, R.C.; Blew, R.D.

    1997-01-01

    This Annual Technical Report describes work conducted for the Department of Energy, Idaho Operations Office (DOE-ID), by the Environmental Science and Research Foundation (Foundation). The Foundation's mission to DOE-ID provides support in several key areas. The authors conduct an environmental monitoring and surveillance program over an area covering much of the upper Snake River Plain, and provide environmental education and support services related to Idaho National Engineering and Environmental Laboratory (INEEL) natural resource issues. Also, the Foundation, with its University Affiliates, conducts ecological and radioecological research in the Idaho National Environmental Research Park. This research benefits major DOE-ID programs including Waste Management, Environmental Restoration, Spent Nuclear Fuels, and Land Management Issues. The major accomplishments of the Foundation and its University Affiliates during the calendar year 1996 are discussed

  11. Environmental Science and Research Foundation, Inc. annual technical report: Calendar year 1997

    International Nuclear Information System (INIS)

    Reynolds, R.D.; Warren, R.W.

    1998-05-01

    This Annual Technical Report describes work conducted for the Department of Energy, Idaho Operations Office (DOE-ID), by the Environmental Science and Research Foundation (Foundation). The Foundation's mission to DOE-ID provides support in several key areas. The Foundation conducts an environmental monitoring and surveillance program over an area covering much of the upper Snake River Plain, and provides environmental education and support services related to Idaho National Engineering and Environmental Laboratory (INEEL) natural resource issues. Also, the Foundation, with its University Affiliates, conducts ecological and radioecological research on the Idaho National Environmental Research Park. This research benefits major DOE-ID programs including Waste Management, Environmental Restoration, Spent Nuclear Fuels, and Land Management Issues. Summaries are included of the individual research projects

  12. Environmental Science and Research Foundation annual technical report: Calendar year 1996

    Energy Technology Data Exchange (ETDEWEB)

    Morris, R.C.; Blew, R.D. [eds.

    1997-07-01

    This Annual Technical Report describes work conducted for the Department of Energy, Idaho Operations Office (DOE-ID), by the Environmental Science and Research Foundation (Foundation). The Foundation`s mission to DOE-ID provides support in several key areas. The authors conduct an environmental monitoring and surveillance program over an area covering much of the upper Snake River Plain, and provide environmental education and support services related to Idaho National Engineering and Environmental Laboratory (INEEL) natural resource issues. Also, the Foundation, with its University Affiliates, conducts ecological and radioecological research in the Idaho National Environmental Research Park. This research benefits major DOE-ID programs including Waste Management, Environmental Restoration, Spent Nuclear Fuels, and Land Management Issues. The major accomplishments of the Foundation and its University Affiliates during the calendar year 1996 are discussed.

  13. Environmental Science and Research Foundation, Inc. annual technical report: Calendar year 1997

    Energy Technology Data Exchange (ETDEWEB)

    Reynolds, R.D.; Warren, R.W. [eds.

    1998-05-01

    This Annual Technical Report describes work conducted for the Department of Energy, Idaho Operations Office (DOE-ID), by the Environmental Science and Research Foundation (Foundation). The Foundation`s mission to DOE-ID provides support in several key areas. The Foundation conducts an environmental monitoring and surveillance program over an area covering much of the upper Snake River Plain, and provides environmental education and support services related to Idaho National Engineering and Environmental Laboratory (INEEL) natural resource issues. Also, the Foundation, with its University Affiliates, conducts ecological and radioecological research on the Idaho National Environmental Research Park. This research benefits major DOE-ID programs including Waste Management, Environmental Restoration, Spent Nuclear Fuels, and Land Management Issues. Summaries are included of the individual research projects.

  14. Radiopharmaceuticals - current state and trends

    International Nuclear Information System (INIS)

    Muenze, R.

    1981-07-01

    The current state as well as the tendencies of modern radiopharmaceutical development and application is reviewed. After an evaluation of the fundamental preconditions of decay characteristics and pharmaceutical properties the problems concerning sup(99m)Tc-radiopharmaceuticals, metabolizable compounds and the use of specific biological interactions are discussed. (author)

  15. The hospital preparation of radiopharmaceuticals

    International Nuclear Information System (INIS)

    The subject is covered in sections: introduction; preparation ((general - sterilization), production areas (laboratories), working methods for injections, working methods for oral preparations and iodination procedures); analytical testing (general, standards common to injections and oral preparations, standards for injections, standards for oral preparations); reliable methods of preparing sup(99m)Tc-radiopharmaceuticals and 51 Cr-red cells; commercial radiopharmaceutical kits. (U.K.)

  16. Cyclotrons and positron emitting radiopharmaceuticals

    Energy Technology Data Exchange (ETDEWEB)

    Wolf, A.P.; Fowler, J.S.

    1984-01-01

    The state of the art of Positron Emission Tomography (PET) technology as related to cyclotron use and radiopharmaceutical production is reviewed. The paper discusses available small cyclotrons, the positron emitters which can be produced and the yields possible, target design, and radiopharmaceutical development and application. 97 refs., 12 tabs. (ACR)

  17. Placental transfer of selected radiopharmaceuticals

    International Nuclear Information System (INIS)

    Wegst, A.V.

    1992-01-01

    This paper reviews animal experiments carried out to determine the transfer of radiopharmaceuticals from mother to fetus. Animal data are compared to any human data available. The radiopharmaceuticals included in the discussion are Tc-99m pertechnetate, Tc-99m DTPA, Ga-67 citrate and Tl-201 chloride. (6 tab., 5 refs.)

  18. Cyclotrons and positron emitting radiopharmaceuticals

    International Nuclear Information System (INIS)

    Wolf, A.P.; Fowler, J.S.

    1984-01-01

    The state of the art of Positron Emission Tomography (PET) technology as related to cyclotron use and radiopharmaceutical production is reviewed. The paper discusses available small cyclotrons, the positron emitters which can be produced and the yields possible, target design, and radiopharmaceutical development and application. 97 refs., 12 tabs

  19. Radioisotope and radiopharmaceutical generators

    International Nuclear Information System (INIS)

    Barak, M.; Winchell, H.W.

    1975-01-01

    A chromatographic column for generating technetium-99m isotopes and technetium-99m labeled pharmaceuticals in a simple two-step process is described. Technetium-99m pertechnetate in a first step is isolated by adsorption upon an adsorbent packing. Then the technetium-99m in a second step is eluted from the packing, either with an immediately labeled biological compound to form a radiopharmaceutical, or by a controlled volume of eluant to produce a 99m-technetium-bearing eluate of a desired specific concentration. (Official Gazette)

  20. Development of new radiopharmaceuticals

    International Nuclear Information System (INIS)

    1989-12-01

    The possibilities to design and prepare better and more organ-specific radiopharmaceuticals for diagnostic nuclear medicine has increased dramatically in the recent past with a deeper understanding of the relationships between chemical structure and biological activity. Whereas most of the research is performed in well-funded laboratories of industrialized countries, there are several developing countries with adequate resources and expertise as to undertake fruitful research in the field of radiopharmacy. With the aim of promoting advanced research in radiopharmacy by developing new radiodiagnostics agents, in particular, hepatobiliary imaging agents labelled with 99m Tc, and to facilitate exchange of information, the IAEA has established in 1983 the present Research Co-ordination Programme (CRP) with a duration of five years. The report includes detailed results obtained by all participants as well as novel preparation procedures for some of the newest and more promising radiopharmaceuticals developed under the auspices of the CRP. The extensive bibliographic reference listing is considered another important information of particular value for scientists in developing countries who do not always have access to updated scientific information sources. Refs, figs and tabs

  1. Molecularly targeted therapeutic radiopharmaceuticals

    International Nuclear Information System (INIS)

    Saw, M.M.

    2007-01-01

    Full text: It is generally agreed that current focus of nuclear medicine development should be on molecular imaging and therapy. Though, the widespread use of the terminology 'molecular imaging' is quite recent, nuclear medicine has used molecular imaging techniques for more than 20 years ago. A variety of radiopharmaceuticals have been introduced for the internal therapy of malignant and inflammatory lesions in nuclear medicine. In the field of bio/medical imaging, nuclear medicine is one of the disciplines which has the privilege of organized and well developed chemistry/ pharmacy section; radio-chemistry/radiopharmacy. Fundamental principles have been developed more than 40 years ago and advanced research is going well into postgenomic era. The genomic revolution and dramatically increased insight in the molecular mechanisms underlying pathology have led to paradigm shift in drug development. Likewise does in the nuclear medicine. Here, the author will present current clinical and pre-clinical therapeutic radiopharmaceuticals based on molecular targets such as membrane-bound receptors, enzymes, nucleic acids, sodium iodide symporter, etc, in correlation with fundamentals of radiopharmacy. (author)

  2. Radiopharmaceuticals in Radiosynoviorthesis

    International Nuclear Information System (INIS)

    Cruz Arencibia, Jorge; Morin Zorrilla, Jose; Garcia Rodriguez, Enrique; Sagarra Veranes, Marta

    2010-01-01

    The Radiosynoviorthesis is a procedure of Metabolic Radiotherapy, consisting in the intraarticular injection of a radiopharmaceutical with a beta emitting radionuclide for the treatment of chronic synovitis, frequently present in rheumatoid arthritis, haemophilia and other systemic diseases. As this is a safe, effective and a relatively low-cost procedure, It is ordinarily used in Europe, USA and in some Latin American countries . The existing commercial products are based on 90 Y, 169 Er, 186 Re and 32 P, although research is carried out on the use of 188 Re, 166 Ho, among others radionuclides. In Cuba a suspension of Chromium Phosphate (III) labeled with 32 P, is on trial. The above-mentioned suspension has enough characteristics to become an efficient and safe product in practice. (Author)

  3. Organic radiopharmaceuticals: recent advances

    International Nuclear Information System (INIS)

    Wolf, A.P.; Fowler, J.S.

    1979-01-01

    Organic radiopharmaceuticals are considered in light of accelerator and nuclide production requirements, special problems relating to the carrier-free state, including terminology, of the special technology required to prepare and manipulate these compounds and new trends in compound design and synthesis. The emphasis is on medical cyclotrons and the positron-emitting radionuclides, carbon-11, nitrogen-13, oxygen-15, and fluorine-18. New routes to synthetic precursors and organic compounds of high specific activity labeled with carbon-11, fluorine-18, and iodine-123 including monosaccharides, aromatic amines, neuroleptics, fatty acids, steroids, and other classes of compounds are discussed. Some compounds are considered in terms of the development and evaluation of structure-activity relationships and including some newer concepts such as metabolic trapping. 67 references

  4. Radiopharmaceuticals good practices handbook: ARCAL XV radiopharmaceuticals control and production

    International Nuclear Information System (INIS)

    Verdera Presto, Silvia

    1998-01-01

    A safety practice of the therapeutics diagnostic proceeding in nuclear medicine require a permanent provide high quality radiopharmaceuticals manufacture. This work treat to give a guide for all radio pharmacies laboratories that produce,control, fraction and or dispense radiopharmaceuticals products, with attention hospitable radiopharmacy laboratory. Three chapters with recommendations in manufacture good practice in Hospital radiopharmacy, industrial centralized, bibliography and three annexe's about clean area classification,standards work in laminar flux bell, and guarantee and cleaning areas

  5. Radiopharmaceuticals in breast milk

    International Nuclear Information System (INIS)

    Mountford, P.J.; Coakley, A.J.

    1986-01-01

    As assessment has been made of the radiological hazards to an infant following the administration of a radiopharmaceutical to a breast feeding mother. Feeding should be discontinued after administration of most I-131 and I-125 compounds, Ga-67 citrate or Se-78 methionine, and for iodinated compounds where it was possible to resume feeding, a thyroid-blocking agent should be administered. For Tc-99m compounds, pertechnetate had the greatest excretion in milk and interruptions of 12hr and 4hr were considered appropriate for pertechnetate and MAA respectively. Other Tc-99m compounds, Cr-51 EDTA and In-111 leucocytes did not justify an interruption just on the grounds of their associated excretion in milk. The ingestion hazard could be minimized by reducing the administered activity, and in some cases, by the substitution of a radiopharmaceutical with lower breast milk excretion. For Tc-99m lung and brain scans, the absorbed dose due to radiation emitted by the mother (i.e. when cuddling) was less than the ingested dose, but for a Tc-99m bone scan the emitted dose was greater. In all three cases, the emitted dose did not exceed 0 x 5 mGy for the infant in close contact to the mother for one-third of the time. For In-111 leucocytes, the emitted dose was about 2mGy, and it was concluded that close contact should be restricted to feeding times during the first 3 days after injection. 36 references, 2 figures, 5 tables

  6. SKB annual report 1993. Including summaries of technical reports issued during 1993

    International Nuclear Information System (INIS)

    1994-05-01

    This is the annual report on the activities of the Swedish Nuclear and Waste Management Co., SKB. It contains in part I an overview of SKB activities in different fields. Part II gives a description of the research and development work on nuclear waste disposal performed during 1993. Lectures and publications during 1993 as well as reports issued in the SKB technical series are listed in part III. Part IV contains the summaries of all technical reports issued during 1993. SKB is the owner of CLAB, the Central Facility for Interim Storage of Spent Nuclear Fuel, located at Oskarshamn. CLAB was taken into operation in July 1985 and to the end of 1993 in total 1 885 tonnes of spent fuel (measured as uranium) have been received. Transportation from the nuclear sites to CLAB is made by a special ship, M/S Sigyn. At Forsmark the final repository for Radioactive Waste - SFR - was taken into operation in April 1988. The repository is situated in crystalline rock under the Baltic Sea. At the end of 1993 a total of 13 000 m 3 of waste have been deposited in SFR. SKB is in charge of a comprehensive research and development programme on geological disposal of nuclear waste. Some of the main areas for SKB research are: Groundwater movements; Bedrock stability; Groundwater chemistry and nuclide migration; Methods and instruments for in situ characterization of crystalline bedrock; Characterization and leaching of spent nuclear fuel; Properties of bentonite for buffer, backfilling and sealing; Radionuclide transport in biosphere and dose evaluations; Development of performance and safety assessment methodology and assessment models; Construction of an underground research laboratory

  7. DOE SBIR Phase I Grant No. DE-FG02-00ER83067, ''A Flexible and Economical Automated Nucleophilic [18F]Fluorination synthesis System for PET Radiopharmaceuticals.'' Final Technical Report

    International Nuclear Information System (INIS)

    Padgett, Henry C.

    2001-01-01

    Phase I Final Report. A prototype manual remote synthesis system based on the unit operations approach was designed, constructed, and functionally tested. This general-purpose system was validated by its configuration and initial use for the preparation of the PET radiopharmaceutical [F-18]FLT using [F-18]fluoride ion

  8. Experimental nuclear medicine radiopharmaceutical development

    International Nuclear Information System (INIS)

    Harper, P.; Lathrop, K.

    1980-01-01

    This report summarizes progress that has been made on the preparation and biological accumulation of various radiopharmaceuticals including C-hexamethonium, C-cholic acid, Mn-51 and labeled amino acids

  9. Savannah River Ecology Laboratory. Annual technical progress report of ecological research

    International Nuclear Information System (INIS)

    Smith, M.H.

    1996-01-01

    The Savannah River Ecology Laboratory (SREL) is a research unit of the University of Georgia (UGA). The overall mission of the Laboratory is to acquire and communicate knowledge of ecological processes and principles. SREL conducts basic and applied ecological research, as well as education and outreach programs, under a contract with the U.S. Department of Energy (DOE) at the Savannah River Site (SRS) near Aiken, South Carolina. Significant accomplishments were made during the past year in the areas of research, education and service. The Laboratory's research mission was fulfilled with the publication of two books and 143 journal articles and book chapters by faculty, technical and students, and visiting scientists. An additional three books and about 80 journal articles currently are in press. Faculty, technician and students presented 193 lectures, scientific presentations, and posters to colleges and universities, including minority institutions. Dr. J Vaun McArthur organized and conducted the Third Annual SREL Symposium on the Environment: New Concepts in Strewn Ecology: An Integrative Approach. Dr. Michael Newman conducted a 5-day course titled Quantitative Methods in Ecotoxicology, and Dr. Brian Teppen of The Advanced Analytical Center for Environmental Sciences (AACES) taught a 3-day short course titled Introduction to Molecular Modeling of Environmental Systems. Dr. I. Lehr Brisbin co-hosted a meeting of the Crocodile Special Interest Group. Dr. Rebecca Sharitz attended four symposia in Japan during May and June 1996 and conducted meetings of the Executive Committee and Board of the International Association for Ecology (ENTECOL)

  10. Annual technical report of the prototype fast breeder reactor Monju. 2012

    International Nuclear Information System (INIS)

    2013-09-01

    The prototype fast breeder reactor Monju has accumulated technical achievements in order to establish the fast breeder reactor cycle technology in Japan using the operation and maintenance experience, etc. This annual report summarizes the primary achievements and the data related to the plant management in Monju during fiscal 2012. From the aspect of the design evaluation, the following items are summarized: 1) Comprehensive safety assessments of Monju taking into account the accident at Fukushima Daiichi Nuclear Power Station of Tokyo Electric Power Company, 2) Evaluation of nuclear characteristics based on the data of core confirmation test, 3) Evaluation of hydrogen flux from steam generator tubes, 4) Construction of the advanced safeguards system, 5) Development of a plant dynamics analytical model for the Monju ex-vessel fuel storage system. Then, from the aspect of the maintenance technology, the following items are summarized: 1) Response to the administrative order to the defect of maintenance management, 2) Recovery of in vessel transfer machine dropping accident, 3) Work management by introduction of packaged isolation, 4) Evaluation of result of vibration control of RID sampling blower for secondary sodium loop. Furthermore, from the aspect of the plant management, this report summarizes the data related to the main topics, the history of plant condition, the sodium and water purity management, the radioactive waste management, the equipment inspection and so on. (author)

  11. Savannah River Ecology Laboratory. Annual technical progress report of ecological research

    Energy Technology Data Exchange (ETDEWEB)

    Smith, M.H.

    1996-07-31

    The Savannah River Ecology Laboratory (SREL) is a research unit of the University of Georgia (UGA). The overall mission of the Laboratory is to acquire and communicate knowledge of ecological processes and principles. SREL conducts basic and applied ecological research, as well as education and outreach programs, under a contract with the U.S. Department of Energy (DOE) at the Savannah River Site (SRS) near Aiken, South Carolina. Significant accomplishments were made during the past year in the areas of research, education and service. The Laboratory`s research mission was fulfilled with the publication of two books and 143 journal articles and book chapters by faculty, technical and students, and visiting scientists. An additional three books and about 80 journal articles currently are in press. Faculty, technician and students presented 193 lectures, scientific presentations, and posters to colleges and universities, including minority institutions. Dr. J Vaun McArthur organized and conducted the Third Annual SREL Symposium on the Environment: New Concepts in Strewn Ecology: An Integrative Approach. Dr. Michael Newman conducted a 5-day course titled Quantitative Methods in Ecotoxicology, and Dr. Brian Teppen of The Advanced Analytical Center for Environmental Sciences (AACES) taught a 3-day short course titled Introduction to Molecular Modeling of Environmental Systems. Dr. I. Lehr Brisbin co-hosted a meeting of the Crocodile Special Interest Group. Dr. Rebecca Sharitz attended four symposia in Japan during May and June 1996 and conducted meetings of the Executive Committee and Board of the International Association for Ecology (ENTECOL).

  12. Annual technical report of the prototype fast breeder reactor Monju. 2013

    International Nuclear Information System (INIS)

    2014-08-01

    The prototype fast breeder reactor Monju has accumulated technical achievements in order to establish the fast breeder reactor cycle technology in Japan using the operation and maintenance experience, etc. This annual report summarizes the principal achievements and the data related to the plant management in Monju in fiscal 2013. From the aspect of the management and design evaluation, the following items are summarized: 1) Current status of coping with the order from NRA to alter the safety regulations. 2) Implementation status of reformation of Monju. 3) Current status of the additional geological surveys of crush zones at the Monju site. 4) Development of core seismic assessment method for FBR. Then, from the aspect of the operation and maintenance technology, the following items are summarized: 1) Response to the administrative order to the defect of maintenance management (Part 2). 2) Performance confirmation of the failed fuel detection and location system. 3) Deviation from the limiting conditions for operation in the emergency diesel generator periodic test and so on. Furthermore, from the aspect of the plant management, this report summarizes the data related to the main topics, the history of plant condition, the sodium and water purity management, the radioactive waste management, the equipment inspection and so on. (author)

  13. Annual Report for Los Alamos National Laboratory Technical Area 54, Area G Disposal Facility – Fiscal Year 2015

    Energy Technology Data Exchange (ETDEWEB)

    French, Sean B. [Los Alamos National Lab. (LANL), Los Alamos, NM (United States); Stauffer, Philip H. [Los Alamos National Lab. (LANL), Los Alamos, NM (United States); Birdsell, Kay H. [Los Alamos National Lab. (LANL), Los Alamos, NM (United States)

    2016-02-29

    As a condition to the disposal authorization statement issued to Los Alamos National Laboratory (LANL or the Laboratory) on March 17, 2010, a comprehensive performance assessment and composite analysis maintenance program must be implemented for the Technical Area 54, Area G disposal facility. Annual determinations of the adequacy of the performance assessment and composite analysis (PA/CA) are to be conducted under the maintenance program to ensure that the conclusions reached by those analyses continue to be valid. This report summarizes the results of the fiscal year (FY) 2015 annual review for Area G.

  14. Annual Report for Los Alamos National Laboratory Technical Area 54, Area G Disposal Facility - Fiscal Year 2016

    Energy Technology Data Exchange (ETDEWEB)

    Birdsell, Kay Hanson [Los Alamos National Lab. (LANL), Los Alamos, NM (United States); Stauffer, Philip H. [Los Alamos National Lab. (LANL), Los Alamos, NM (United States); Atchley, Adam Lee [Los Alamos National Lab. (LANL), Los Alamos, NM (United States); Miller, Elizabeth D. [Los Alamos National Lab. (LANL), Los Alamos, NM (United States); Chu, Shaoping [Los Alamos National Lab. (LANL), Los Alamos, NM (United States); French, Sean B. [Los Alamos National Lab. (LANL), Los Alamos, NM (United States)

    2017-03-24

    As a condition to the disposal authorization statement issued to Los Alamos National Laboratory (LANL or the Laboratory) on March 17, 2010, a comprehensive performance assessment and composite analysis (PA/CA) maintenance program must be implemented for the Technical Area 54, Area G disposal facility. Annual determinations of the adequacy of the PA/CA are to be conducted under the maintenance program to ensure that the conclusions reached by those analyses continue to be valid. This report summarizes the results of the fiscal year (FY) 2016 annual review for Area G.

  15. Development of radiopharmaceuticals

    Energy Technology Data Exchange (ETDEWEB)

    Park, Kyung Bae; Kim, J R; Shin, B C; Kim, Y M; Cho, U K; Han, K H; Chung, Y J; Shin, H Y; Hong, S B

    1997-09-01

    To overcome many problems caused by external radiation therapy, we have developed a new agent for internal radiation therapy, which is administered directly to the lesions and irradiate {beta}-rays resulting in maximized therapeutic effect and minimized radiation damage to normal tissues or organs to nearby. In the same reasons, we have also developed a new radioactive patch for the treatment of skin cancer using {beta}-emitting radionuclide. We prepared for {sup 166}Ho-chitosan complex ({sup 166}Ho-CHICO) which is potential radiopharmaceuticals for the treatment of liver cancer, peritoneal cancer metastasized from stomach cancer, ovarian cancer, and rheumatoid arthritis in knee joints. We carried out various experiments such as evaluation of absorbed dosimetry, studies on absorption, distribution, metabolism, and excretion (ADME) and clinical trials with {sup 166}Ho-CHICO. For commercialization of {sup 166}Ho-CHICO, we evaluated its toxicity, efficacy and safety, and then prepared documents for submission to the Mininstry of Health and Welfare to get license as an investigational new drug. {sup 166}Ho-Patch for skin cancer treatment was prepared by neutron irradiation of pre-made non-radioactive {sup 165}Ho-Patch. We evaluated the efficacy and safety of {sup 166}Ho-Patch in the treatment of skin cancer using an animal model and in clinical cases. (author). 49 refs., 15 tabs., 36 figs.

  16. Development of radiopharmaceuticals

    International Nuclear Information System (INIS)

    Park, Kyung Bae; Kim, J. R.; Shin, B. C.; Kim, Y. M.; Cho, U. K.; Han, K. H.; Chung, Y. J.; Shin, H. Y.; Hong, S. B.

    1997-09-01

    To overcome many problems caused by external radiation therapy, we have developed a new agent for internal radiation therapy, which is administered directly to the lesions and irradiate β-rays resulting in maximized therapeutic effect and minimized radiation damage to normal tissues or organs to nearby. In the same reasons, we have also developed a new radioactive patch for the treatment of skin cancer using β-emitting radionuclide. We prepared for 166 Ho-chitosan complex ( 166 Ho-CHICO) which is potential radiopharmaceuticals for the treatment of liver cancer, peritoneal cancer metastasized from stomach cancer, ovarian cancer, and rheumatoid arthritis in knee joints. We carried out various experiments such as evaluation of absorbed dosimetry, studies on absorption, distribution, metabolism, and excretion (ADME) and clinical trials with 166 Ho-CHICO. For commercialization of 166 Ho-CHICO, we evaluated its toxicity, efficacy and safety, and then prepared documents for submission to the Mininstry of Health and Welfare to get license as an investigational new drug. 166 Ho-Patch for skin cancer treatment was prepared by neutron irradiation of pre-made non-radioactive 165 Ho-Patch. We evaluated the efficacy and safety of 166 Ho-Patch in the treatment of skin cancer using an animal model and in clinical cases. (author). 49 refs., 15 tabs., 36 figs

  17. New blood flow radiopharmaceutical

    International Nuclear Information System (INIS)

    Sargent, T. III; Shulgin, A.T.; Mathis, C.A.; Budinger, T.F.

    1983-01-01

    Our program for research into the causes of mental disorders such as schizophrenia, manic depressive illness and senile dementia has led us to the development of a new radiopharmaceutical agent, IDNNA (4-iodo-2,5-dimethoxy-N,N-dimethylamphetamine). A series of some 15 different 131 I labeled molecules with various substitutions on the amine were synthesized and tested, and the uptake of the 131 I labeled conpounds in rats was measured. The dimethyl amine (IDNNA) had the best brain uptake and brain/blood ratio. When injected into a dog and scanned with a whole-body scanner, the uptake in the brain could be clearly seen and quantified. Plasma sampling at the same time showed that the maximum brain/blood ratio of 8.7 occurred at 8 min after injection, and the concentration in brain remained high for at least 15 min. Labeling is achieved by reacting 131 ICl and the precursor, 2,5-dimethoxy-N,N-dimethyl amphetamine, in glacial acetic acid; the reaction is complete in less than one minute

  18. Annual technical report of the prototype fast breeder reactor Monju. 2011

    International Nuclear Information System (INIS)

    2012-08-01

    The prototype fast breeder reactor Monju has accumulated technical achievements in order to establish the fast breeder reactor cycle technology in Japan using the operation and maintenance experience, etc. This annual report summarizes the primary achievements and the data related to the plant management in Monju during fiscal 2011. From the aspect of the design evaluation, the following items are summarized: 1) the evaluation of the decay heat removal of Monju core by natural convection, and the safety measures against earthquake and tsunami, which were carried out from the lessons learned at the Fukushima-daiichi accident due to the Great East Japan Earthquake on March 11, 2011, 2) the control rod worth confirmation and the evaluation of nuclear data library based on the data of Core Confirmation Test, which is the first step of Monju system startup test restarted in 2010, 3) the evaluation of the hydrogen concentration behavior, which detects the leak of water from the heat transfer tube of steam generator. Then, from the aspect of the maintenance technology, the following items are summarized: 1) the results of the function confirmation test on the water/steam system, after the long-term suspension, 2) confirmation of the integrity of cracked cylinder liners of emergency diesel generator, 3) replacement of the annulus ventilation duct, 4) evaluation of reduction of the periodic inspection schedule after full power operation. Furthermore, from the aspect of the plant management, this report summarizes the data related to the main topics, the history of plant condition, the sodium and water purity management, the radioactive waste management, the equipment inspection and so on. (author)

  19. Radiopharmaceuticals targeting melanoma

    Energy Technology Data Exchange (ETDEWEB)

    Pham, T.Q.; Berghofer, P.; Liu, X.; Greguric, I.; Dikic, B.; Ballantyne, P.; Mattner, F.; Nguyen, V.; Loc' h, C.; Katsifis, A. [Radiopharmaceuticals Research Institute, Australian Nuclear Science and Technology Organisation, Menai, N.S.W., Sydney (Australia)

    2008-02-15

    Melanoma is one of the most aggressive cancers known with a high rate of mortality and increasing global incidence. So, the development of radiopharmaceuticals for either diagnostic or therapeutic purposes could make enormous contributions to melanoma patient health care. We have been studying melanoma tumours through several targeting mechanisms including melanin or specific receptor based radiopharmaceuticals Structure activity studies indicate that the substitution patterns on radioiodinated benzamides significantly influence the uptake mechanism from melanin to sigma-receptor binding. Furthermore, the position of the iodine as well as the presence of key functional groups and substituents has resulted in compounds with varying degrees of activity uptake and retention in tumours. From these results, a novel molecule 2-(2-(4-(4-iodo benzyl)piperazin-1-yl)-2-oxo-ethyl)isoindoline- 1,3-dione (M.E.L.037) was synthesized, labelled with iodine-123 and evaluated for application in melanoma tumour scintigraphy and radiotherapy. The tumour imaging potential of {sup 123}IM.E.L.037 was studied in vivo in C.57 B.L./ 6 J female mice bearing the B.16 F.0. murine melanoma tumour and in BALB/c nude mice bearing the A.375 human amelanotic melanoma tumour by biodistribution, competition studies and by SPECT imaging. {sup 123}I-M.E.L.037 exhibited high and rapid uptake in the B.16 F.0 melanoma tumour at 1 h (13 % I.D./g) increasing with time to reach 25 % I.D./g at 6 h. A significant uptake was also observed in the eyes (2% I.D., at 3-6 h p.i.) of black mice. No uptake was observed in the tumour or in the eyes of nude mice bearing the A.375 tumour. Due to high uptake and long retention in the tumour and rapid body clearance, standardized uptake values(S.U.V.) of {sup 123}I-M.E.L.037 were 30 and 60, at 24 and 48 h p.i.,respectively. SPECT imaging of mice bearing the B.16 melanoma indicated the radioactivity was predominately located in the tumour followed by the eyes, while no

  20. Regulatory considerations concerning IND radiopharmaceutical drug products

    International Nuclear Information System (INIS)

    Nissel, M.

    1985-01-01

    The Food and Drug Administration is charged by the Food, Drug, and Cosmetic Act, as presently amended, to assure that any drug introduced into interstate commerce is safe and effective for the purposes for which it is labeled. A radiopharmaceutical is, by definition, a new drug unless there is in effect an approved New Drug Application (NDA) for it. Before the data for the NDA are compiled, investigative studies have to be done. Before such studies can be performed in humans, an exemption from the Act is necessary. This exemption, technically the Claimed Exemption for an Investigational New Drug, is termed the IND. Both the scientific and the administrative requirements for an IND are discussed. For radiopharmaceutical drug products (RDP's), the radiation hazards, as well as the pharmacological ones, must be documented. Should the early studies demonstrate a potential for efficacy in a certain condition or disease state, an investigative protocol for an extended clinical trial is presented. The necessary requirements for Institutional Review Board (IRB) approval and consent forms are discussed. For certain research purposes, uniquely for radioactive drugs, an IND is not required for certain specific studies; the requirements for such a research study, conducted under the auspices of an approved radioactive drug research committee, are outlined

  1. Radiopharmaceuticals for hepatobiliary imaging

    International Nuclear Information System (INIS)

    Chervu, L.R.; Nunn, A.D.; Loberg, M.D.

    1982-01-01

    Tests for liver function have by and large centered around clinical laboratory diagnostic procedures for a number of years. Besides these, radiographic imaging procedures, including oral cholecystography and intravenous cholangiography, serve a very useful purpose, but several of them are invasive and involve a certain degree of risk from the administered contrast media as well as discomfort to the patient. The cholescintigraphic procedures, though noninvasive, have not played a significant role in the evaluation of hepatobiliary disorders prior to the introduction of the currently available /sup 99m/Tc-labeled IDAs. These new hepatobiliary agents offer many advantages over the previously utilized radiopharmaceuticals ( 131 I-rose bengal in particular) in terms of the high degree of specificity for localization in the gallbladder with rapid extraction rates by the polygonal cells of the liver and very low excretion via the GU tract. A detailed understanding of the structure distribution relationship of the various groups in the complex enable the design of agents with an improvement in hepatobiliary specificity and other desirable characteristics. In many clinical situations, even in patients with high bilirubin levels, the /sup 99m/Tc-labeled IDAs offer far superior clinical information over the alternative diagnostic imaging modalities. Further, the absorbed radiation dose imparted to the critical organs is far lower than with the older agents. Thus, the introduction of the cholescintigraphic procedures with the /sup 99m/Tc-labeled IDAs have ushered in a new phase in the diagnostic workup of patients with impaired hepatocellular function and other biliary disorders

  2. Energy Materials Coordinating Committee (EMaCC). Annual Technical Report, Fiscal Year 2000

    Energy Technology Data Exchange (ETDEWEB)

    none,

    2001-07-31

    The Energy Materials Coordinating Committee Annual Report (attached, DOE/SC-0040) provides an annual summary of non-classified materials-related research programs supported by various elements within the Department of Energy. The EMaCC Annual Report is a useful working tool for project managers who want to know what is happening in other divisions, and it provides a guide for persons in industry and academia to the materials program within the Department. The major task of EMaCC this year was to make the Annual Report a more user-friendly document by removing redundant program information and shortening the project summaries.

  3. Radiochemical stability of radiopharmaceutical preparations

    International Nuclear Information System (INIS)

    Martins, Patricia de A.; Silva, Jose L. da; Ramos, Marcelo P.S.; Oliveira, Ideli M. de; Felgueiras, Carlos F.; Herrerias, Rosana; Zapparoli Junior, Carlos L.; Mengatti, Jair; Fukumori, Neuza T.O.; Matsuda, Margareth M.N.

    2011-01-01

    The 'in vitro' stability studies of the radiopharmaceutical preparations are an essential requirement for routine practice in nuclear medicine and are an important parameter for evaluating the quality, safety and efficacy required for the sanitary registration of pharmaceutical products. Several countries have published guidelines for the evaluation of pharmaceutical stability. In Brazil, the stability studies should be conducted according to the Guide for Conducting Stability Studies published in the Resolution-RE n. 1, of 29th July 2005. There are also for radiopharmaceutical products, two specific resolutions: RDC-63 regulates the Good Manufacturing Practices for Radiopharmaceuticals and RDC-64 provides the Registration of Radiopharmaceuticals, both published on the 18th December 2009. The radiopharmaceutical stability is defined as the time during which the radioisotope can be safely used for the intended purpose. The radiochemical stability can be affected by a variety of factors, including storage temperature, amount of radioactivity, radioactive concentration, presence or absence of antioxidants or other stabilizing agents. The radiochemical stability studies must be established under controlled conditions determined by the effective use of the product. The aim of this work was to evaluate the radiochemical stability of labeled molecules with 131 I, 123 I, 153 Sm, 18 F, 51 Cr, 177 Lu and 111 In as well as 67 Ga and 201 Tl radiopharmaceuticals. Radiochemical purity was evaluated after production and in the validity period, with the maximum activity and in the recommended storage conditions. The analyses were carried out by thin-layer silica gel plate, paper chromatography and gel chromatography. The experimental results showed to be in accordance with the specified limits for all the analysed products. (author)

  4. Gallium and copper radiopharmaceutical chemistry

    International Nuclear Information System (INIS)

    Green, M.A.

    1991-01-01

    Gallium and copper radionuclides have a long history of use in nuclear medicine. Table 1 presents the nuclear properties of several gallium and copper isotopes that either are used in the routine practice of clinical nuclear medicine or exhibit particular characteristics that might make them useful in diagnostic or therapeutic medicine. This paper will provide some historic perspective along with an overview of some current research directions in gallium and copper radiopharmaceutical chemistry. A more extensive review of gallium radiopharmaceutical chemistry has recently appeared and can be consulted for a more in-depth treatment of this topic

  5. Prenatal radiation doses from radiopharmaceuticals

    International Nuclear Information System (INIS)

    Rojo, A.M.; Gomez Parada, I.M.; Di Trano, J.L.

    1998-01-01

    The radiopharmaceutical administration with diagnostic or therapeutic purpose during pregnancy implies a prenatal radiation dose. The dose assessment and the evaluation of the radiological risks become relevant due to the great radiosensitivity of the fetal tissues in development. This paper is a revision of the available data for estimating fetal doses in the cases of the more frequently used radiopharmaceuticals in nuclear medicine, taking into account recent investigation in placental crossover. The more frequent diagnostic and therapeutic procedures were analyzed according to the radiation doses implied. (author) [es

  6. Radiopharmaceuticals for palliative therapy pain

    International Nuclear Information System (INIS)

    Gaudiano, Javier

    1994-01-01

    Dissemination to bone of various neoplasms is cause of pain with poor response by major analgesics.Indications. Radiopharmaceuticals,description of main characteristics of various β emitter radionuclides.Choose of patients for worm indication of pain palliative therapy with β emitter radiopharmaceuticals is adequate must be careful . Contraindications are recognized.Pre and post treatment controls as clinical examination and complete serology are described.It is essential to subscribe protocols,keep patient well informed,included the physician in charge of the patient as part of the team.Bibliography

  7. Missouri local technical assistance program at Missouri University of Science and Technology (formerly University of Missouri--Rolla) : annual progress report January-December 2007.

    Science.gov (United States)

    2009-02-01

    This annual report is a summary of the activities during 2007 for the Missouri Local Technical Assistance Program (Missouri LTAP), which is located at Missouri University of Science and Technology. The report highlights Missouri LTAPs performance ...

  8. Specific GMP guidelines for radiopharmaceutical products

    International Nuclear Information System (INIS)

    2000-01-01

    These guidelines are intended to complement those provided in ''Good manufacturing practices for pharmaceutical products'', as well as the GMP for sterile pharmaceutical products. The regulatory procedures necessary to control radiopharmaceutical products are in large part determined by the sources of products and methods of manufacture. Manufacturing procedures within the scope of these guidelines include: preparation of radiopharmaceuticals in hospital radiopharmacies, preparation of radiopharmaceuticals in centralized radiopharmacies, production of radiopharmaceuticals in nuclear centres, institutes or industrial manufacturers, preparation and production of radiopharmaceuticals in Positron Emission Tomography (PET) centres

  9. The radiopharmaceutical industry and European Union regulations

    International Nuclear Information System (INIS)

    Fallais, C.J.; Sivewright, S.; Ogle, J.R.

    1997-01-01

    After a brief historical introduction to Council Directives relating to the manufacture of radiopharmaceuticals the work of the Association of Radiopharmaceuticals Producers - Europe (ARPE) is discussed. ARPE has played a significant role as an officially recognized interlocutor with the EEC, influencing decisions on the registration of radiopharmaceuticals and labelling; this role is reviewed and difficulties identified. The future of radiopharmaceuticals is then considered; it is emphasized that harmonization of national laws by the European Council would represent a first step to enabling radiopharmaceutical manufacturers to access the largest possible market for their products. (orig.)

  10. Peptide radiopharmaceuticals in nuclear medicine

    International Nuclear Information System (INIS)

    Blok, D.; Vermeij, P.; Feitsma, R.I.J.; Pauwels, E.J.K.

    1999-01-01

    This article reviews the labelling of peptides that are recognised to be of interest for nuclear medicine or are the subject of ongoing nuclear medicine research. Applications and approaches to the labelling of peptide radiopharmaceuticals are discussed, and drawbacks in their development considered. (orig.)

  11. Radiochemistry in nuclear medicine. Radiopharmaceuticals

    International Nuclear Information System (INIS)

    Samochocka, K.

    1999-01-01

    Radionuclides and radiopharmaceuticals play a kay role in nuclear medicine, both in diagnostics and therapy. Incorporation of radionuclides into biomolecules, and syntheses of radiolabelled compounds of high biological selectivity are a task for radiochemists working in the multidisciplinary field of radiopharmaceutical chemistry. The most commonly used radionuclide, 99m Tc, owes this popularity to its both nearly ideal nuclear properties in respect to medical imaging, and availability from inexpensive radionuclide generators. Also numerous other radionuclides are widely used for medical imaging and therapy. Labelling of biomolecules with radioiodine and various positron emitters is getting increasingly important. This review describes some chemical and radiochemical problems we meet while synthesizing and using 99m Tc-radiopharmaceuticals and radioiodine-labelled biomolecules. Also represented are the recent developments in the design and use of the second generation radiopharmaceuticals based on bifunctional radiochelates. Several principal routes of fast chemical synthesis concerning incorporation of short-lived positron emitters into biomolecules are outlined as well. The search for chemical structures of high biological selectivity, which would be activated by slow neutrons, is related to the method of Neutron Capture Therapy, an interesting option in nuclear medicine. (author)

  12. Database setup insuring radiopharmaceuticals traceability

    International Nuclear Information System (INIS)

    Robert, N.; Salmon, F.; Clermont-Gallerande, H. de; Celerier, C.

    2002-01-01

    Having to organize radiopharmacy and to insure proper traceability of radiopharmaceutical medicines brings numerous problems, especially for the departments which are not assisted with global management network systems. Our work has been to find a solution enabling to use high street software to cover those needs. We have set up a PC database run by the Microsoft software ACCESS 97. Its use consists in: saving data related to generators, isotopes and kits reception and deletion, as well as the results of quality control; transferring data collected from the software that is connected to the activimeter (elutions and preparations registers, prescription book). By relating all the saved data, ACCESS enables to mix all information in order to proceed requests. At this stage, it is possible to edit all regular registers (prescription book, generator and radionuclides follow-up, blood derived medicines traceability) and to quickly retrieve patients who have received a particular radiopharmaceutical, or the radiopharmaceutical that has been given to a particular patient. This user-friendly database provides a considerable support to nuclear medicine department that don't possess any network management for their radiopharmaceutical activity. (author)

  13. Current directions in radiopharmaceutical research

    Energy Technology Data Exchange (ETDEWEB)

    Mather, S J [Department of Nuclear Medicine, St. Bartholomew` s Hospital, London (United Kingdom)

    1998-08-01

    Much of current radiopharmaceutical research is directed towards the development of receptor-binding tracers which are targeted towards biochemical processes. These may be extra or intracellular in nature and hold promise for an imaging approach to tissue characterisation in-vivo. Many of these products are based on proteins which range in size from large monoclonal antibodies to small neuropeptides and share a radiolabelling chemistry based on the use of bifunctional chelating agents. Although developed initially for use with indium-111, considerations of cost and isotope availability have continued to direct the efforts of many researchers towards the use of technetium-99m. While polypeptide-based radiopharmaceuticals may be useful for imaging peripheral cell-surface receptors, access to sites of interest within the cell, or in the brain, requires the development of small lipophilic molecules with retained ability to interact with intracellular targets. The design and synthesis of these compounds presents a particular challenge to the radiopharmaceutical chemist which is being met through either a pendant or integrated approach to the use of technetium coordination with particular emphasis on technetium (v) cores. Progress continues to be made in the application of targeted radionuclide therapy particularly in the development of radiopharmaceuticals for the treatment of malignant bone disease. methods for labelling antibodies with a great variety of cytotoxic radionuclides have now been refined and their use for radioimmunotherapy in the treatment of haematological malignancies shows great promise. The major medical areas for application of these new radiopharmaceuticals will be in oncology, neurology and inflammation but the increasingly difficult regulatory climate in which drug development and health-care now operate will make it essential for researchers to direct their products toward specific clinical problems as well as biological targets. (author) 36 refs

  14. Radiopharmaceuticals for diagnosis. Final report

    Energy Technology Data Exchange (ETDEWEB)

    1994-03-01

    In the period 1969-1986, this project was directed to the evolution of target-specific labeled chemicals useful for nuclear medical imaging, especially radioactive indicators suited to tracing adrenal functions and localizing tumors in the neuroendocrine system. Since 1986, this project research has focused on the chemistry of positron emission tomography (PET) ligands. This project has involved the evaluation of methods for radiochemical syntheses with fluorine-18, as well as the development and preliminary evaluation of new radiopharmaceuticals for positron emission tomography. In the radiochemistry area, the ability to predict fluorine-18 labeling yields for aromatic substitution reactions through the use of carbon-13 NMR analysis was studied. Radiochemical yields can be predicted for some structurally analogous aromatic compounds, but this correlation could not be generally applied to aromatic substrates for this reaction, particularly with changes in ring substituents or leaving groups. Importantly, certain aryl ring substituents, particularly methyl groups, appeared to have a negative effect on fluorination reactions. These observations are important in the future design of syntheses of complicated organic radiopharmaceuticals. In the radiopharmaceutical area, this project has supported the development of a new class of radiopharmaceuticals based on the monoamine vesicular uptake systems. The new radioligands, based on the tetrabenazine structure, offer a new approach to the quantification of monoaminergic neurons in the brain. Preliminary primate imaging studies support further development of these radioligands for PET studies in humans. If successful, such radiopharmaceuticals will find application in studies of the causes and treatment of neurodegenerative disorders such as Parkinson`s disease.

  15. Current directions in radiopharmaceutical research

    International Nuclear Information System (INIS)

    Mather, S.J.

    1998-01-01

    Much of current radiopharmaceutical research is directed towards the development of receptor-binding tracers which are targeted towards biochemical processes. These may be extra or intracellular in nature and hold promise for an imaging approach to tissue characterisation in-vivo. Many of these products are based on proteins which range in size from large monoclonal antibodies to small neuropeptides and share a radiolabelling chemistry based on the use of bifunctional chelating agents. Although developed initially for use with indium-111, considerations of cost and isotope availability have continued to direct the efforts of many researchers towards the use of technetium-99m. While polypeptide-based radiopharmaceuticals may be useful for imaging peripheral cell-surface receptors, access to sites of interest within the cell, or in the brain, requires the development of small lipophilic molecules with retained ability to interact with intracellular targets. The design and synthesis of these compounds presents a particular challenge to the radiopharmaceutical chemist which is being met through either a pendant or integrated approach to the use of technetium coordination with particular emphasis on technetium (v) cores. Progress continues to be made in the application of targeted radionuclide therapy particularly in the development of radiopharmaceuticals for the treatment of malignant bone disease. methods for labelling antibodies with a great variety of cytotoxic radionuclides have now been refined and their use for radioimmunotherapy in the treatment of haematological malignancies shows great promise. The major medical areas for application of these new radiopharmaceuticals will be in oncology, neurology and inflammation but the increasingly difficult regulatory climate in which drug development and health-care now operate will make it essential for researchers to direct their products toward specific clinical problems as well as biological targets. (author)

  16. Proceedings of the Annual Meeting of the Council for Programs in Technical and Scientific Communication (14th, Orlando, Florida, October 7-9, 1987).

    Science.gov (United States)

    Geonetta, Sam C., Ed.

    Based on the notion of "reaching out," this proceedings presents papers from the annual meeting of the Council for Programs in Technical and Scientific Communication. Papers in the proceedings are: "Southern Tech's Technical Writing Certificate" (William S. Pfeiffer); "Reach Out and Quack Someone" (Daniel R. Jones);…

  17. Forty-Fifth Annual Meeting of the Technical Working Group on Fast Reactors (TWG-FR). Presentations

    International Nuclear Information System (INIS)

    2012-01-01

    The objectives of the meeting were to: • Exchange information on the national programmes on Fast Reactors (FR) and Accelerator Driven Systems (ADS); • Review the progress since the 44 th TWG-FR Annual Meeting, including the status of the actions; • Consider topical technical meeting arrangements for 2012-2013, as well as review FR-related activities included in the IAEA Programme & Budget (P&B) biennium 2012-2013; • Review the IAEA’s concluded, on-going and planned coordinated research projects in the technical fields relevant to the TWG-FR (FRs and ADS), as well as coordination of the TWG-FR’s activities with other organizations and international initiatives (GIF, INPRO, NEA, ESNII, etc.)

  18. Meeting of the Technical Working Group on Fast Reactors (TWG-FR) (41st Annual Meeting). Working Material

    International Nuclear Information System (INIS)

    2008-01-01

    The objectives of the meeting were to: - Exchange information on the national programmes on Fast Reactors (FR) and Accelerator Driven Systems (ADS); - Review the progress since the 40th TWG-FR Annual Meeting, including the status of the actions; - Consider meeting arrangements for 2008, 2009, 2010 and beyond; - Review the IAEA’s ongoing information exchange and coordinated research activities in the technical fields relevant to the TWG-FR (FRs and ADS), as well as coordination of the TWG-FR’s activities with other organizations and international initiatives; - Discuss future joint activities in view of IAEA’s Programme and Budget Cycles beyond 2008-2009

  19. Annual activities report of Brazilian Aerospace Technical Center -CTA/IEAv - 1989

    International Nuclear Information System (INIS)

    1989-01-01

    This document reports the research activities on nuclear physics and reactors physics and engineering in the Brazilian Aerospace Technical Center/Advanced Studies Institute, Sao Paulo State, in the year of 1989

  20. TUEV (Technical Control Board) of Rhineland-Westphalia. Annual report 1986

    International Nuclear Information System (INIS)

    1987-01-01

    This annual report of the RW TUEV for 1986 mainly deals with the subject fields of safety engineering, power technology, and environmental protection. Information on tasks and organisation is followed by a more detailed survey of the activities in the subject fields: Steam and pressure technology; material testing; strength and manufacturing control; nuclear energy and radiation protection; pipelines and hazardous substances; environmental protection; mining engineering; electrical and power engineering; equipment safety; construction and conveying engineering; motor vehicle egineering; psychological and medical fields of work; occupational safety; data processing and process automation. The report concludes with the annual financial statements and a list of addresses of the main office and other departments. (HSCH) [de

  1. Meeting of the Technical Working Group on Fast Reactors (TWG-FR) (39th annual meeting). Working material

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    2007-07-01

    The 39th Annual Meeting of the Technical Working Group on Fast Reactors (TWG FR) was held from 15-19 May 2006 in Beijing, China, at the invitation of the China Institute of Atomic Energy (CIAEA). The meeting was attended by TWG-FR Members and Advisers from the following Member States (MS): Belgium (observer), Brazil, China, France, Germany, India, Italy, Japan, the Republic of Kazakhstan, the Republic of Korea, the Russian Federation, Sweden (observer), the United Kingdom, and the United States. Belarus, Switzerland, the European Commission, and OECD/NEA were unable to participate. Moreover, Prof. Carlo Rubbia, CERN director general emeritus, participated, upon IAEA invitation, in the meeting as distinguished scientist and IAEA expert. Mr. S.C. Chetal, from India (Indira Gandhi Centre for Atomic Research, IGCAR), was appointed chairman. The objectives of the meeting were to: - Exchange information on the national programmes on Fast Reactors (FR) and Accelerator Driven Systems (ADS); - Review the progress since the 38th TWG-FR Annual Meeting, including the status of the actions; - Consider meeting arrangements for 2006 and 2007; - Reviewed the Agency's ongoing information exchange and co-ordinated research activities in the technical fields relevant to the TWG-FR (FRs and ADS), as well as co-ordination of the TWG-FR's activities with other organizations; - Discuss future joint activities in view of the Agency's Programme and Budget Cycle 2008-2009 (and beyond)

  2. Residual radioactive contamination from decommissioning: Technical basis for translating contamination levels to annual dose

    International Nuclear Information System (INIS)

    Kennedy, W.E. Jr.; Peloquin, R.A.

    1990-01-01

    This document describes the generic modeling of the total effective dose equivalent (TEDE) to an individual in a population from a unit concentration of residual radioactive contamination. Radioactive contamination inside buildings and soil contamination are considered. Unit concentration TEDE factors by radionuclide, exposure pathway, and exposure scenario are calculated. Reference radiation exposure scenarios are used to derive unit concentration TEDE factors for about 200 individual radionuclides and parent-daughter mixtures. For buildings, these unit concentration factors list the annual TEDE for volume and surface contamination situations. For soil, annual TEDE factors are presented for unit concentrations of radionuclides in soil during residential use of contaminated land and the TEDE per unit total inventory for potential use of drinking water from a ground-water source. Because of the generic treatment of potentially complex ground-water systems, the annual TEDE factors for drinking water for a given inventory may only indicate when additional site data or modeling sophistication are warranted. Descriptions are provided of the models, exposure pathways, exposure scenarios, parameter values, and assumptions used. An analysis of the potential annual TEDE resulting from reference mixtures of residual radionuclides is provided to demonstrate application of the TEDE factors. 62 refs., 5 figs., 66 tabs

  3. Research laboratories annual report 1993

    International Nuclear Information System (INIS)

    1994-08-01

    The 1993 annual report of the Israel Atomic Energy Commission presents, in brief and concise form, recent results and achievements of the well established program of the basic and applied research carried out by the scientists and engineers of the Israel Atomic Energy Commission in collaboration with colleagues at the other institutions in Israel and abroad. In terms of contents, the report presents the usual combination of topical basic applied research. Much of the work has been published or submitted for publication in the international scientific or technical literature. The main headings in the report are: theoretical physics and theoretical chemistry; optics and lasers; solid states and nuclear physics; materials sciences; chemistry; environmental studies and radiopharmaceuticals; radiation effects, dosimetry and radioprotection; and instrumentation and techniques

  4. Verein fuer Kernverfahrenstechnik und Analytik Rossendorf (VKTA). Annual report 1995

    International Nuclear Information System (INIS)

    Haefele, W.

    1996-04-01

    The annual report 1995 presents information from the managing and financial departments and on the activities and achievements of the scientific-technical departments relating to nuclear facilities, radioactive waste management, radioactivity analytics, measurement and management of radioactivity in the environment, radiopharmaceuticals, and safety and radiological protection. The main activities continued to be the management of radwaste resulting from decommissioning of the research reactors and facilities on site; other activities include cooperative activities together with the Siemens company assisting in erection and establishment of isotope production labs in developing countries. There also is an organizational chart of the institution. (DG) [de

  5. Atmospheric Effects of Nuclear Energy Centers (AENEC) Program. Annual technical progress report, July 1975--September 1976

    International Nuclear Information System (INIS)

    Patrinos, A.A.; Hoffman, H.W.

    1977-04-01

    The Technical Memorandum contains information of a preliminary nature from the six participants of the Program describing their activities and presenting the results obtained during the reporting period. The birth of the Program, its definition and evolution are described, and a complete breakdown of responsibilities and tasks assigned to the six AENEC participants is presented

  6. Annual Technical Report, Materials Research Laboratory, 1 July 1982 - 30 June 1983.

    Science.gov (United States)

    1983-06-30

    Technical Report 41 SECTION 6 PROPERTIES OF MATERIALS AT LOW TEMPERATURES Introduction The general motivation for this work is that certain interesting...Professor, Chemis- "Photoelectronic Properties of Cu 3 PS4 and try. Cu 3 PS Se Single Crystals," J. V. Marzik, A. K. Hsieh, K. Dwight and A. Wold. J

  7. Radiopharmaceutical research: trends and novel concepts

    International Nuclear Information System (INIS)

    Wuest, F.

    2005-01-01

    The efficiency of nuclear medicine in diagnosis, therapy and medicinal research strongly depends on the progress to develop novel suitable radiopharmaceuticals. The selection, preparation, and preclinical evaluation of new radiopharmaceuticals is addressed by the field of radiopharmaceutical chemistry. The rapid developments in the field of biotechnology in the post-genome era combined with the recent advances in the instrumentation of SPECT and PET have directed radiopharmaceutical research into a complex chemical science. Current radiopharmaceutical research comprises novel developments of coordination chemistry with [ 99m Tc]technetium pharmaceuticals, the development of non-standard PET radionuclides and the synthesis of 11 C- and 18 F-labelled radiopharmaceuticals at high specific radioactivity. Further developments deal with an increasing alignment to radiotherapeutics and the implementation of PET into the process of drug development and evaluation. (orig.)

  8. Radiation dose estimates for radiopharmaceuticals

    International Nuclear Information System (INIS)

    Stabin, M.G.; Stubbs, J.B.; Toohey, R.E.

    1996-04-01

    Tables of radiation dose estimates based on the Cristy-Eckerman adult male phantom are provided for a number of radiopharmaceuticals commonly used in nuclear medicine. Radiation dose estimates are listed for all major source organs, and several other organs of interest. The dose estimates were calculated using the MIRD Technique as implemented in the MIRDOSE3 computer code, developed by the Oak Ridge Institute for Science and Education, Radiation Internal Dose Information Center. In this code, residence times for source organs are used with decay data from the MIRD Radionuclide Data and Decay Schemes to produce estimates of radiation dose to organs of standardized phantoms representing individuals of different ages. The adult male phantom of the Cristy-Eckerman phantom series is different from the MIRD 5, or Reference Man phantom in several aspects, the most important of which is the difference in the masses and absorbed fractions for the active (red) marrow. The absorbed fractions for flow energy photons striking the marrow are also different. Other minor differences exist, but are not likely to significantly affect dose estimates calculated with the two phantoms. Assumptions which support each of the dose estimates appears at the bottom of the table of estimates for a given radiopharmaceutical. In most cases, the model kinetics or organ residence times are explicitly given. The results presented here can easily be extended to include other radiopharmaceuticals or phantoms

  9. Annual report 1992 on research and development work by the ITP, Institute for Technical Physics

    International Nuclear Information System (INIS)

    1993-03-01

    The present annual report describes the activities undertaken by the ITP in the following areas: 1. Remote sensing by means of microwaves; 2. Nuclear fusion (studies for NET/ITER; superconducting magnets, poloidal field coil development; cryogenic systems; stellarator magnets, plasma heating technology; transmission components; component-related safety investigations); 3. Superconductivity (superconductivity physics, superconducting layers; massive superconductors; magnet developments; cryogenics for superconductivity). The appendix lists all publications or primary reports by the ITP in 1992. (orig./MM) [de

  10. Development of European regulations on radiopharmaceuticals

    International Nuclear Information System (INIS)

    Kristensen, K.

    1990-01-01

    Separate regulatory systems are being developed on the use of radiopharmaceuticals including radiation protection of patients and personnel and on the quality including safety and efficacy of radiopharmaceuticals. Radiation protection legislation has been introduced in most western European Economic Community (EEC). Within the drug field radiopharmaceuticals have been excepted up till now. However, new EEC directive on radiopharmaceuticals will soon come into force. The work done on the preparation of regulations and guidelines will be discussed. This discussion will focus on the problems faced when radiation protection aspects shall be balanced to traditional requirements of pharmaceutical aspects

  11. Association Euratom - Risø National Laboratory, Technical University of Denmark - Annual Progress Report 2007

    DEFF Research Database (Denmark)

    Michelsen, Poul; Korsholm, Søren Bang; Juul Rasmussen, Jens

    The programme of the Research Unit of the Fusion Association Euratom - Risø National Laboratory, Technical University of Denmark, covers work in fusion plasma physics and in fusion technology. The fusion plasma physics research focuses on turbulence and transport, and its interaction with the pla......The programme of the Research Unit of the Fusion Association Euratom - Risø National Laboratory, Technical University of Denmark, covers work in fusion plasma physics and in fusion technology. The fusion plasma physics research focuses on turbulence and transport, and its interaction...... phased out during 2007. Minor activities are system analysis, initiative to involve Danish industry in ITER contracts and public information. A summary is presented of the results obtained in the Research Unit during 2007....

  12. 1998 Chemical Technology Division Annual Technical Report. Applying chemical innovation to environmental problems

    International Nuclear Information System (INIS)

    Ackerman, J.P.; Einziger, R.E.; Gay, E.C.; Green, D.W.; Miller, J.F.

    1999-01-01

    The Chemical Technology (CMT) Division is a diverse technical organization with principal emphases in environmental management and development of advanced energy sources. The Division conducts research and development in three general areas: (1) development of advanced power sources for stationary and transportation applications and for consumer electronics, (2) management of high-level and low-level nuclear wastes and hazardous wastes, and (3) electrometallurgical treatment of spent nuclear fuel. The Division also performs basic research in catalytic chemistry involving molecular energy resources, mechanisms of ion transport in lithium battery electrolytes, and the chemistry of technology-relevant materials. In addition, the Division operates the Analytical Chemistry Laboratory, which conducts research in analytical chemistry and provides analytical services for programs at Argonne National Laboratory (ANL) and other organizations. Technical highlights of the Division's activities during 1998 are presented

  13. Development of radiopharmaceutical for radiosinovectomy

    International Nuclear Information System (INIS)

    Couto, Renata Martinussi

    2009-01-01

    Radiopharmaceuticals prepared with different radionuclides have been used in diagnostic and therapeutic procedures in Nuclear Medicine. The interest in radionuclidic therapy has been increased in last years, with the introduction of new radiopharmaceuticals applied in the destruction of specific cells or to prevent its undesired proliferation. Radiosinovectomy (RSV) is a therapeutic modality that uses radiopharmaceuticals administered in the intra-articular cavity and represents an alternative to the treatment of different arthropaties and, in particular, the arthropaties derived from rheumatoid arthritis and haemophilic. The objective of the present work was to study the labeling of compounds with 90 Y and 177 Lu in order to improve the production conditions and quality control procedures, study the stability of the labeled compounds and preliminary biodistribution studies of the radiopharmaceuticals with potential for RSV applications. The study of the production of 90 Y citrate colloid ( 90 Y-Cit) was based in a labeling procedure using 90 Y Cl 3 solution (37 - 54 MBq) that was previously dried, followed by the addition of yttrium nitrate and sodium citrate in p H 7 at 37 deg C for 30 minutes. The production of hydroxyapatite (HA) labeled with 90 Y was based in a labeling procedure using mono hydrated citric acid, yttrium nitrate and 90 Y Cl 3 solution (37 - 370 MBq). The reaction mixture was incubated for 30 minutes at room temperature and the HA was introduced in aqueous medium and the reaction proceed for 30 minutes under strong stirring. 177 Lu-HA was produced using 177 Lu Cl 3 solution (296 MBq), in presence of lutetium oxide in NaCl medium, p H 7, under continuous stirring for 30 minutes at room temperature. Several reaction parameters were studied for the three radiopharmaceuticals. Labeling yield was determined after particles were centrifuged and washed with NaCl 0,9%. Radiochemical purity was determined by ascending chromatography using different

  14. Energy Materials Coordinating Committee (EMaCC). Annual technical report, Fiscal Year 2001

    Energy Technology Data Exchange (ETDEWEB)

    None, None

    2002-08-01

    The DOE Energy Materials Coordinating Committee (EMaCC) serves primarily to enhance coordination among the Department's materials programs and to further effective use of materials expertise within the Department. These functions are accomplished through the exchange of budgetary and planning information among program managers and through technical meetings/workshops on selected topics involving both DOE and major contractors. In addition, EMaCC assists in obtaining materials-related inputs for both intra- and interagency compilations.

  15. Association Euratom - DTU, Technical University of Denmark, Department of Physics - Annual Progress Report 2011

    DEFF Research Database (Denmark)

    The programme of the Research Unit of the Fusion Association Euratom – DTU, Technical University of Denmark (until 31-12- 2011: Association Euratom – Risø DTU) covers work in fusion plasma physics and in fusion technology. The fusion plasma physics research focuses on turbulence and transport...... temperature superconductors. Other activities are system analysis, initiative to involve Danish industry in ITER contracts and public information. A summary is presented of the results obtained in the Research Unit during 2011....

  16. Transuranic waste program at EG and G Idaho, Inc. Annual technical report

    International Nuclear Information System (INIS)

    Smith, T.H.; Tolman, C.R.

    1980-12-01

    This document summarizes the objectives and technical achievements of the transuranic (TRU) waste research and development program conducted at EG and G Idaho, Inc., during fiscal year 1980. The TRU waste activities covered in this report include: INEL TRU Waste EIS (Environmental Impact Statement), including preparation of the EIS, Support Studies, and the Public Participation Program; INEL TRU Waste Projects, including System Analysis, Stored Waste projects, and Buried Waste projects; and Waste Management Materials Studies, including Process Control and Durability studies

  17. Report of the consultants meeting on good manufacturing practices and clean room requirements for radiopharmaceuticals

    International Nuclear Information System (INIS)

    2000-07-01

    be carried out in special facilities often with shielding and remote handling to protect the operators from radiation exposure. There are international norms for radiation exposure allowed for radiation workers and strong national organizations for monitoring and implementing radiation protection measures. Being part of the national nuclear programmes, radiopharmaceutical production has been from the very beginning subjected to regulations of radioactive material handling, transportation and use. However, the systems of surveillance and control for pharmaceutical products have not been implemented in many places to the same extent as for radiation protection. There are also technical difficulties in harmonizing the requirements of radiation safety and pharmaceutical safety. Simultaneously, there have been several technical developments in the field of Quality Assurance of pharmaceuticals. The concepts of Good Manufacturing Practices (GMP) and the requirements for clean rooms define quality of air for pharmaceutical production areas. Efforts have been made in recent years to apply these concepts also to radiopharmaceutical production. Significant progress appears to have been made in the developed countries and in the technology needed to fulfil these standards. The technical problems in upgrading the facilities of radioisotope laboratories to conform with the clean air requirements and the cost involved are still to be clearly understood in many developing countries. In many countries the regulatory authorities apply the same set of regulations for radiopharmaceuticals as for other pharmaceuticals. Some guidelines for radiopharmaceuticals have been published, e.g. Scandinavian, US FDA, Australian, Canadian and EU guidelines. No such guidelines are yet available from international agencies such as the International Atomic Energy Agency (IAEA) or World Health Organization (WHO). A guideline from an international body of this nature would be very useful for institutions

  18. Energy Materials Coordinating Committee (EMaCC) Fiscal Year 1999 annual technical report

    Energy Technology Data Exchange (ETDEWEB)

    None

    2000-10-31

    The DOE Energy Materials Coordinating Committee (EMaCC) serves primarily to enhance coordination among the Department`s materials programs and to further effective use of materials expertise within the Department. These functions are accomplished through the exchange of budgetary and planning information among program managers and through technical meetings/workshops on selected topics involving both DOE and major contractors. In addition, EMaCC assists in obtaining materials-related inputs for both intra- and interagency compilations. This report summarizes EMaCC activities for FY 1999 and describes the materials research programs of various offices and divisions within the Department.

  19. Association Euratom - DTU, Technical University of Denmark, Department of Physics - Annual Progress Report 2012

    DEFF Research Database (Denmark)

    The programme of the Research Unit of the Fusion Association Euratom – DTU, Technical University of Denmark covers work in fusion plasma physics and in fusion technology. The fusion plasma physics research focuses on turbulence and transport, and its interaction with the plasma equilibrium...... and particles. The effort includes both first principles based modelling, and experimental observations of turbulence and of fast ion dynamics by collective Thomson scattering. Within fusion technology there are activities on fusion materials research (Tungsten and ODSFS). Other activities are system analysis...

  20. Association Euratom - DTU, Technical University of Denmark, Department of Physics - Annual Progress Report 2013

    DEFF Research Database (Denmark)

    The programme of the Research Unit of the Fusion Association Euratom – DTU, Technical University of Denmark covers work in fusion plasma physics and in fusion technology. The fusion plasma physics research focuses on turbulence and transport, and its interaction with the plasma equilibrium...... and particles. The effort includes both first principles based modelling, and experimental observations of turbulence and of fast ion dynamics by collective Thomson scattering. Within fusion technology there are activities on fusion materials research (Tungsten and ODSFS). Other activities are system analysis...

  1. Thirteenth annual report of the Technical Advisory Committee on the Nuclear Fuel Waste Management Program

    Energy Technology Data Exchange (ETDEWEB)

    1993-05-15

    This report details activities since the last reporting period by the Technical Advisory Committee (TAC). The emphasis of the work in the Canadian Nuclear Fuel Waste Management Program (CNFWMP) has been on the writing of the Environmental Impact Statement (EIS) and the associated set of the primary reference document as well as supporting documents. These are in preparation for submission to the Environmental Assessment Review Panel who will lead the national evaluation of the disposal concept under the auspices of the Federal Environmental Assessment Review Office (FEARO).

  2. Nuclear structure theory. Annual technical progress report, October 1, 1976--September 30, 1977

    International Nuclear Information System (INIS)

    French, J.B.; Koltun, D.S.

    1977-01-01

    This report summarizes progress during the past year in the following areas of nuclear structure and reaction theory: (1) statistical spectroscopy, including giant resonances for beta and electromagnetic excitation and sum rules (including inverse-energy-weighted sum rules), statistical methods of truncating shell model spaces and renormalization of operators, study of state labelling and ''chains'' of groups, evaluation of fluctuation measures, technical aspects of operator averaging; (2) meson interactions with nuclei, including scattering and absorption of mesons by nuclei (general methods), models for absorption, single- and double-charge exchange of pions, role of rho mesons

  3. Difficulties and aspects to take into account in the production, use and distribution of new radiopharmaceuticals PET

    International Nuclear Information System (INIS)

    Sanchez, R.; Rayo, J.I.; Serrano, J.; Infante, J.; Luz Dominguez, M.; Garcia, L.; Duran, C.

    2008-01-01

    This article seeks to describe the requirements, legal and technical, for the production, distribution and use of new radiopharmaceuticals PET (other than the 18 F.D.G.), describing the legislative framework in which we find ourselves, the characteristics of a production and types of synthesis and existing modules. A list of susceptible radiopharmaceuticals is presented that are being currently used in nuclear medicine by specifying the real possibilities of their production and use and which are the difficulties we face

  4. Regulatory and Technical Reports (Abstract Index Journal). Annual compilation for 1995, Volume 20, No. 4

    International Nuclear Information System (INIS)

    Sheehan, M.

    1995-04-01

    The Nuclear Regulatory Commission's annual summary of licensed nuclear power reactor data is based primarily on the report of operating data submitted by licensees for each unit for the month of December because that report contains data for the month of December, the year to date (in this case calendar year 1994) and cumulative data, usually from the date of commercial operation. The data is not independently verified, but various computer checks are made. The report is divided into two sections. The first contains summary highlights and the second contains data on each individual unit in commercial operation Section 1 capacity and availability factors are simple arithmetic averages. Section 2 items in the cumulative column are generally as reported by the licensee and notes as to the use of weighted averages and starting dates other than commercial operation are provided

  5. Regulatory and Technical Reports (Abstract Index Journal). Annual compilation for 1995, Volume 20, No. 4

    Energy Technology Data Exchange (ETDEWEB)

    Sheehan, M.

    1995-04-01

    The Nuclear Regulatory Commission`s annual summary of licensed nuclear power reactor data is based primarily on the report of operating data submitted by licensees for each unit for the month of December because that report contains data for the month of December, the year to date (in this case calendar year 1994) and cumulative data, usually from the date of commercial operation. The data is not independently verified, but various computer checks are made. The report is divided into two sections. The first contains summary highlights and the second contains data on each individual unit in commercial operation Section 1 capacity and availability factors are simple arithmetic averages. Section 2 items in the cumulative column are generally as reported by the licensee and notes as to the use of weighted averages and starting dates other than commercial operation are provided.

  6. Quality control in 99m technetium radiopharmaceuticals

    International Nuclear Information System (INIS)

    Leon Cabana, Alba

    1994-01-01

    This work means about the quality control in Tc radiopharmaceuticals preparation at hospitalary levels. Several steps must be used in a Nuclear Medicine Laboratory, such as proceeding,radiopharmaceuticals kits preparation, and dispensation materials,glasses,stopper,physical aspects,identification,ph control,storage,and reactif kits

  7. Physical and Chemical Aspects of PET Radiopharmaceuticals

    International Nuclear Information System (INIS)

    2004-09-01

    On the Workshop 23 contributions were presented. This proceedings includes 21 presentations delivered at the workshop. The topics discussed included: Cyclotron and Target Constructions; Target Chemistry; Radiopharmaceuticals Synthesis; Quality Control of Radiopharmaceuticals; GLP-GMP Design; PET Imaging. Each presentation has been indexed separately

  8. Studies of quality control procedures for radiopharmaceuticals

    International Nuclear Information System (INIS)

    Zivanovic, M.; Trott, N.G.

    1983-01-01

    In this paper, a short description is given of a radiopharmaceutical preparation suite set up at the Royal Marsden Hospital and an account is presented of methods used for quality control of radiopharmaceuticals and of the results obtained over a period of about two and a half years

  9. Radiopharmaceuticals for diagnosis of ischemic heart disease

    Energy Technology Data Exchange (ETDEWEB)

    Komarek, P; Chalabala, M [Institut pro Dalsi Vzdelavani Lekaru a Farmaceutu, Prague (Czechoslovakia)

    1982-01-01

    Radiopharmaceuticals used for diagnosing ischemic heart disease in the experimental and clinical practice are reviewed. The mechanism of their retention by the heart muscle is briefly described. The respective radiopharmaceuticals are divided into preparations imaging disorders in the blood supply of the cardiac muscle, diagnosing the myocardial infarction, and evaluating the contractility of the heart.

  10. Chirality plays important roles in radiopharmaceuticals

    International Nuclear Information System (INIS)

    Shen Yumei

    2006-01-01

    The paper introduces the basic concept of chirality, target specific selectivity and their relationship in radiopharmaceuticals. If the ligands labeled by radionuclides have chiral center, the enantiomers must be separated, or the target specific selectivity will not be good. Chirality is one of the most important factors which must be considered in the study of the structure-activity relationship of radiopharmaceuticals. (authors)

  11. Preparation and control of radiopharmaceuticals in hospitals

    International Nuclear Information System (INIS)

    Kristensen, K.

    1979-01-01

    This guidebook covers the work commonly organized as part of the work in the hospital. It does not cover the manufacture of radiopharmaceuticals on an industrial scale. The work is characterized by the small scale on which manufacture and preparation of radiopharmaceuticals take place

  12. Radiopharmaceuticals. 40 years is nothing

    International Nuclear Information System (INIS)

    Hager, Alfredo A.

    2006-01-01

    The nuclear medicine is today a medical speciality recognized and practised in the whole world. The birth was in the middle of the 20th century in the use of molecules or drugs marked with a radionuclide (radiopharmaceutical), for the diagnostic studies in vivo or in vitro, to obtain a therapeutic effect. Early in the decade of 70, its development and evolution was accentuated thanks to electronics, the contribution of new instruments for detection of diagnosis by images (gamma camera) and to the emergence of new radionuclide (in particular, 99m Tc). (author) [es

  13. Office for Analysis and Evaluation of Operational Data 1996 annual report. Volume 10, Number 3: Technical training

    International Nuclear Information System (INIS)

    1997-12-01

    This annual report of the US Nuclear Regulatory Commission's Office for Analysis and Evaluation of Operational Data (AEOD) describes activities conducted during 1996. The report is published in three parts. NUREG-1272, Vol. 10, No. 1, covers power reactors and presents an overview of the operating experience of the nuclear power industry from the NRC perspective, including comments about trends of some key performance measures. The report also includes the principal findings and issues identified in AEOD studies over the past year and summarizes information from such sources as licensee event reports and reports to the NRC's Operations Center. NUREG-1272, Vol. 10, No. 2, covers nuclear materials and presents a review of the events and concerns during 1996 associated with the use of licensed material in nonreactor applications, such as personnel overexposures and medical misadministrations. Both reports also contain a discussion of the Incident Investigation Team program and summarize both the Incident Investigation Team and Augmented Inspection Team reports. Each volume contains a list of the AEOD reports issued from CY 1980 through 1996. NUREG-1272, Vol. 10, No. 3, covers technical training and presents the activities of the Technical Training Center in support of the NRC's mission in 1996

  14. Energy Materials Coordinating Committee (EMaCC) annual technical report, fiscal year 1984 with fiscal year 1985 data

    Energy Technology Data Exchange (ETDEWEB)

    None

    1985-07-01

    The Department of Energy funded about 374 million dollars of materials science and technology activities in both fiscal years 1984 and 1985. These funds and the commensurate program management responsibilities resided in 21 DOE program offices, each of which has its own mission and responsibilities. The Energy Materials Coordinating Committee (EMaCC) provides a formal mechanism to insure coordinated planning and maximum programmatic effectiveness for the Department's 374 million dollar per year materials effort. The EMaCC reports to the Director of the Office of Energy Research who in turn has oversight responsibilities for proper coordination of the technical programs of the Department. In carrying out this responsibility, EMaCC hosts meetings, organizes working groups, and publishes an annual technical report. This report is mandated by the EMaCC Terms of Reference. Its purpose is to disseminate information on the DOE materials programs for more effective coordination. It describes the materials research programs of various offices and divisions within the Department for FY 1984, contains funding information for FYs 1984 and 1985, and summarizes EMaCC activities for FY 1985.

  15. Energy Materials Coordinating Committee (EMaCC) annual technical report, fiscal year 1984 with fiscal year 1985 data

    International Nuclear Information System (INIS)

    1985-07-01

    The Department of Energy funded about 374 million dollars of materials science and technology activities in both fiscal years 1984 and 1985. These funds and the commensurate program management responsibilities resided in 21 DOE program offices, each of which has its own mission and responsibilities. The Energy Materials Coordinating Committee (EMaCC) provides a formal mechanism to insure coordinated planning and maximum programmatic effectiveness for the Department's 374 million dollar per year materials effort. The EMaCC reports to the Director of the Office of Energy Research who in turn has oversight responsibilities for proper coordination of the technical programs of the Department. In carrying out this responsibility, EMaCC hosts meetings, organizes working groups, and publishes an annual technical report. This report is mandated by the EMaCC Terms of Reference. Its purpose is to disseminate information on the DOE materials programs for more effective coordination. It describes the materials research programs of various offices and divisions within the Department for FY 1984, contains funding information for FYs 1984 and 1985, and summarizes EMaCC activities for FY 1985

  16. Association Euratom - Risoe National Laboratory for Sustainable Energy, Technical University of Denmark. Annual progress report 2010

    Energy Technology Data Exchange (ETDEWEB)

    Korsholm, S.B.; Michelsen, P.K.; Rasmussen, J.J.; Westergaard, C.M. (eds.)

    2011-04-15

    The programme of the Research Unit of the Fusion Association Euratom - Risoe National Laboratory for Sustainable Energy, Technical University of Denmark, covers work in fusion plasma physics and in fusion technology. The fusion plasma physics research focuses on turbulence and transport, and its interaction with the plasma equilibrium and particles. The effort includes both first principles based modelling, and experimental observations of turbulence and of fast ion dynamics by collective Thomson scattering. Within fusion technology there are activities related to development of high temperature superconductors. Other activities are system analysis, initiative to involve Danish industry in ITER contracts and public information. A summary is presented of the results obtained in the Research Unit during 2010. (Author)

  17. Energy Materials Coordinating Committee (EMaCC): Annual technical report, fiscal year 1993

    Energy Technology Data Exchange (ETDEWEB)

    1994-07-01

    The DOE Energy Materials Coordinating Committee (EMaCC) serves primarily to enhance coordination among the Department`s materials programs and to further effective use of materials expertise within the Department. These functions are accomplished through the exchange of budgetary and planning information among program managers and through technical meetings/workshops on selected topics involving both DOE and major contractors. In addition, EMaCC assists in obtaining materials-related inputs for both intra- and interagency compilations. This report summarizes EMaCC activities for FY 1993 and describes the materials research programs of various offices and divisions within the Department. The program descriptions consist of a funding summary for each Assistant Secretary office and the Office of Energy Research, and detailed project summaries with project goals and accomplishments. The FY 1993 budget summary table for DOE Materials Activities in each of the programs is presented.

  18. Energy materials coordinating committee (EMaCC). Annual technical report, fiscal year 2003

    Energy Technology Data Exchange (ETDEWEB)

    none,

    2004-10-18

    The DOE Energy Materials Coordinating Committee (EMaCC) serves primarily to enhance coordination among the Department's materials programs and to further effective use of materials expertise within the Department. These functions are accomplished through the exchange of budgetary and planning information among program managers and through technical meetings/workshops on selected topics involving both DOE and major contractors. In addition, EMaCC assists in obtaining materials-related inputs for both intra- and interagency compilations. Topical subcommittees of the EMaCC are responsible for conducting seminars and otherwise facilitating information flow between DOE organizational units in materials areas of particular importance to the Department. The EMaCC Terms of Reference were recently modified and developed into a Charter that was approved on June 5, 2003. As a result of this reorganization, the existing subcommittees were disbanded and new subcommittees are being formed.

  19. Association Euratom - Risoe National Laboratory for Sustainable Energy, Technical University of Denmark. Annual progress report 2009

    International Nuclear Information System (INIS)

    Korsholm, S.B.; Michelsen, P.K.; Rasmussen, J.J.; Westergaard, C.M.

    2010-04-01

    The programme of the Research Unit of the Fusion Association Euratom - Risoe National Laboratory for Sustainable Energy, Technical University of Denmark, covers work in fusion plasma physics and in fusion technology. The fusion plasma physics research focuses on turbulence and transport, and its interaction with the plasma equilibrium and particles. The effort includes both first principles based modelling, and experimental observations of turbulence and of fast ion dynamics by collective Thomson scattering. Within fusion technology there are activities related to development of high temperature superconductors. Minor activities are system analysis, initiative to involve Danish industry in ITER contracts and public information. A summary is presented of the results obtained in the Research Unit during 2009. (Author)

  20. Association Euratom - Risoe National Laboratory for Sustainable Energy, Technical University of Denmark. Annual progress report 2009

    Energy Technology Data Exchange (ETDEWEB)

    Korsholm, S B; Michelsen, P K; Rasmussen, J J; Westergaard, C M [eds.

    2010-04-15

    The programme of the Research Unit of the Fusion Association Euratom - Risoe National Laboratory for Sustainable Energy, Technical University of Denmark, covers work in fusion plasma physics and in fusion technology. The fusion plasma physics research focuses on turbulence and transport, and its interaction with the plasma equilibrium and particles. The effort includes both first principles based modelling, and experimental observations of turbulence and of fast ion dynamics by collective Thomson scattering. Within fusion technology there are activities related to development of high temperature superconductors. Minor activities are system analysis, initiative to involve Danish industry in ITER contracts and public information. A summary is presented of the results obtained in the Research Unit during 2009. (Author)

  1. Association Euratom - Risoe National Laboratory for Sustainable Energy, Technical University of Denmark. Annual progress report 2008

    Energy Technology Data Exchange (ETDEWEB)

    Korsholm, S.B.; Michelsen, P.K.; Rasmussen, J.J.; Westergaard, C.M. (eds.)

    2009-04-15

    The programme of the Research Unit of the Fusion Association Euratom - Risoe National Laboratory for Sustainable Energy, Technical University of Denmark, covers work in fusion plasma physics and in fusion technology. The fusion plasma physics research focuses on turbulence and transport, and its interaction with the plasma equilibrium and particles. The effort includes both first principles based modelling, and experimental observations of turbulence and of fast ion dynamics by collective Thomson scattering. New activities in technology related to development of high temperature superconductors have been initiated in 2008. Minor activities are system analysis, initiative to involve Danish industry in ITER contracts and public information. A summary is presented of the results obtained in the Research Unit during 2008. (Author)

  2. Annual report on operation, utilization and technical development of research reactors and hot laboratory

    International Nuclear Information System (INIS)

    1990-09-01

    This report describes the activities of the Department of Research Reactor Operation in fiscal year of 1989. It also presents some technical topics on the reactor operation and utilization in details. The Department is responsible for operation of the research reactors, JRR-2 and JRR-4, and the Hot Laboratory. The research reactor JRR-3 was reconstructed to enhance the performance for utilization. The first criticality was achieved on March 22, 1989, and it subsequently went into operation. In connection with the reactor operation, the various research and development activities in the area of fuel management, water chemistry, radiation monitoring and material irradiation have been made. In the Hot Laboratory, post-irradiation examinations of fuels and materials have been carried out along with the development of related techniques. (author)

  3. Transuranic-waste program at EG and G Idaho, Inc. Annual technical report

    International Nuclear Information System (INIS)

    McKinley, K.B.

    1982-11-01

    This report summarizes the objectives and accomplishments of Transuranic (TRU) Waste Program conducted at EG and G Idaho, Inc., during FY 1982. The TRU Waste Program included: (1) Preparation of a revised draft of the Recommendation of a Long-Term Strategy (RLTS) document; (2) Preparation of environmental documentation, including a technical report, Environmental and Other Evaluations of Alternatives for Management of Defense Transuranic Waste at the Idaho National Engineering Laboratory, IDO-10103, as well as two environmental evaluations; (3) Preparation of a certification plan and procedures; (4) A nondestructive examination (NDE) project, which includes development of real-time radiography for waste certification, and container integrity equipment for waste container certification; (5) Development of an assay system; (6) Completion of a conceptual design for the Stored Waste Examination Pilot Plant (SWEPP) and SWEPP Support; and (7) Gas-generation analyses and tests. These TRU waste projects were funded at $1640K

  4. Nuclear structure theory. Annual technical progress report, July 1, 1975--September 30, 1976

    International Nuclear Information System (INIS)

    French, J.B.; Koltun, D.S.

    1976-01-01

    This report summarizes progress during the past year in the following areas of nuclear structure and reaction theory: Meson interactions with nucleons and nuclei, including elastic and inelastic scattering of pions, three-body theories of scattering and absorption of pions by deuterons, π-p bremsstrahlung, and multiple-excitation models for meson absorption by heavier nuclei. Studies of the inverse scattering problem including 1 S 0 nucleon-nucleon scattering; the relativistic two-body problem, particularly for relativistic effects at low energies: the unitary-pole expansion in nucleon-nucleon scattering with hard-core interactions. Statistical spectroscopy including: strength distributions and sum rules(both energy weighted and inverse energy weighted) for nuclear excitations; fluctuations and correlations in spectra, strengths and expectation values; studies of Garvey-Kelson and similar mass relationships; spectroscopy in huge spaces including spectral methods for renormalization of the interaction and for using (two + three)-body Skyrme interactions; technical aspects of operator averaging

  5. Association Euratom - Risoe National Laboratory for Sustainable Energy, Technical University of Denmark. Annual progress report 2008

    International Nuclear Information System (INIS)

    Korsholm, S.B.; Michelsen, P.K.; Rasmussen, J.J.; Westergaard, C.M.

    2009-04-01

    The programme of the Research Unit of the Fusion Association Euratom - Risoe National Laboratory for Sustainable Energy, Technical University of Denmark, covers work in fusion plasma physics and in fusion technology. The fusion plasma physics research focuses on turbulence and transport, and its interaction with the plasma equilibrium and particles. The effort includes both first principles based modelling, and experimental observations of turbulence and of fast ion dynamics by collective Thomson scattering. New activities in technology related to development of high temperature superconductors have been initiated in 2008. Minor activities are system analysis, initiative to involve Danish industry in ITER contracts and public information. A summary is presented of the results obtained in the Research Unit during 2008. (Author)

  6. Association Euratom - Risoe National Laboratory, Technical Univ. of Denmark. Annual progress report 2007

    International Nuclear Information System (INIS)

    Michelsen, P.K.; Korsholm, S.B.; Rasmussen, J.J.

    2008-04-01

    The programme of the Research Unit of the Fusion Association Euratom - Risoe National Laboratory, Technical University of Denmark, covers work in fusion plasma physics and in fusion technology. The fusion plasma physics research focuses on turbulence and transport, and its interaction with the plasma equilibrium and particles. The effort includes both first principles based modelling, and experimental observations of turbulence and of fast ion dynamics by collective Thomson scattering. The activities in technology on investigations of radiation damage of fusion reactor materials have been phased out during 2007. Minor activities are system analysis, initiative to involve Danish industry in ITER contracts and public information. A summary is presented of the results obtained in the Research Unit during 2007. (Author)

  7. Association Euratom - Risoe National Laboratory, Technical Univ. of Denmark. Annual progress report 2007

    Energy Technology Data Exchange (ETDEWEB)

    Michelsen, P.K.; Korsholm, S.B.; Rasmussen, J.J. (eds.)

    2008-04-15

    The programme of the Research Unit of the Fusion Association Euratom - Risoe National Laboratory, Technical University of Denmark, covers work in fusion plasma physics and in fusion technology. The fusion plasma physics research focuses on turbulence and transport, and its interaction with the plasma equilibrium and particles. The effort includes both first principles based modelling, and experimental observations of turbulence and of fast ion dynamics by collective Thomson scattering. The activities in technology on investigations of radiation damage of fusion reactor materials have been phased out during 2007. Minor activities are system analysis, initiative to involve Danish industry in ITER contracts and public information. A summary is presented of the results obtained in the Research Unit during 2007. (Author)

  8. Association Euratom - Risoe National Laboratory for Sustainable Energy, Technical University of Denmark. Annual progress report 2010

    International Nuclear Information System (INIS)

    Korsholm, S.B.; Michelsen, P.K.; Rasmussen, J.J.; Westergaard, C.M.

    2011-04-01

    The programme of the Research Unit of the Fusion Association Euratom - Risoe National Laboratory for Sustainable Energy, Technical University of Denmark, covers work in fusion plasma physics and in fusion technology. The fusion plasma physics research focuses on turbulence and transport, and its interaction with the plasma equilibrium and particles. The effort includes both first principles based modelling, and experimental observations of turbulence and of fast ion dynamics by collective Thomson scattering. Within fusion technology there are activities related to development of high temperature superconductors. Other activities are system analysis, initiative to involve Danish industry in ITER contracts and public information. A summary is presented of the results obtained in the Research Unit during 2010. (Author)

  9. Facilitation of the Estuary/Ocean Subgroup and the Expert Regional Technical Group, Annual Report for 2015

    Energy Technology Data Exchange (ETDEWEB)

    Johnson, Gary E. [Pacific Northwest National Lab. (PNNL), Richland, WA (United States)

    2015-08-01

    This document is the annual report for the period September 1, 2014 through August 31, 2015 for the project—Facilitation of the Estuary/Ocean Subgroup (EOS) and the Expert Regional Technical Group (ERTG). Pacific Northwest National Laboratory (PNNL) conducted the project for the Bonneville Power Administration (BPA). The EOS and ERTG are part of the research, monitoring, and evaluation (RME) and habitat restoration efforts, respectively, developed by the Action Agencies (BPA, U.S. Army Corps of Engineers [Corps or USACE], and U.S. Bureau of Reclamation) in response to obligations arising from the Endangered Species Act as a result of operation of the Federal Columbia River Power System (FCRPS) and implemented under the Columbia Estuary Ecosystem Restoration Program (CEERP). BPA/Corps (2015) explain the CEERP and the role of RME and the ERTG. For the purposes of this report, the lower Columbia River and estuary (LCRE) includes the floodplain from Bonneville Dam down through the lower river and estuary into the river’s plume in the ocean. The main purpose of this project is to facilitate EOS and ERTG meetings and work products. Other purposes are to provide technical support for CEERP adaptive management, CEERP restoration design challenges, and tributary RME. From 2002 through 2008, the EOS worked to design the federal RME program for the estuary/ocean (Johnson et al. 2008). From 2009 to the present day, EOS activities have involved RME implementation; however, EOS activities were minimal during the current reporting period. PNNL provided technical support to CEERP’s adaptive management process by convening 1.2 meetings of the Action Agencies (AAs) and drafting material for the “CEERP 2015 Restoration and Monitoring Plan” (BPA/Corps 2015).

  10. Clean room installations in a radiopharmaceutical facility

    International Nuclear Information System (INIS)

    2000-01-01

    The standards of radiopharmaceuticals on the facility, working environment and preparation control strategy are yet to be generated. In general, radiopharmaceuticals have short half-lives and emit gamma radiation. Due to its unique characteristics, its preparation has to be made in the fume hood and hot cell to avoid radiation exposure to workers. Considering radiation protection, the working environment has to be maintained under negative pressure so that dispersion of radiopharmaceuticals should be avoided. On the contrary, a positively pressurized working environment gives clean atmosphere and prevents contamination with harmful microorganisms during preparation. Hence, it is required to harmonize for mentioned contradictory conditions in preparation of radiopharmaceuticals for the safety of workers and its quality assurance as well. Therefore, it is reasonable that good manufacturing practice for radiopharmaceutical production facility should be constituted according to the standards for production of biological agents accompanied with a radiation shielding

  11. Universitaet Mainz, Institut fuer Kernchemie. Annual report 2005

    International Nuclear Information System (INIS)

    Kratz, J.V.

    2006-11-01

    Compiled by the employees of the institute, the present 2005 annual report gives an overview of the scientific activities of the working groups of the Institute for Nuclear Chemistry. It is also intended as a account to all those who have promoted us financially and idealistically on the use of what has been not an insubstantial amount of public funds. The report again covers three main fields of research: nuclear chemistry in terms of fundamental problems; radiopharmaceutical chemistry and the use radiochemical methods for medical purposes; and highly sensitive and selective analyses for environmental, technical and biological problems. The report also describes the status of the institute's technical facilities and new technical developments. Finally it gives an account of the institute's output in terms of publications, conference contributions, dissertations, diploma theses, state examination theses and on the contributions of its teaching staff to study and advanced training programs

  12. SKB annual report 1991. Including summaries of technical reports issued during 1991

    International Nuclear Information System (INIS)

    1992-05-01

    This is the annual report on the activities of the Swedish Nuclear Fuel and Waste Management Co., SKB. SKB is the owner of CLAB, the central facility for interim storage of spent nuclear fuel, located at Oskarshamn. CLAB was taken into operation in July 1985 and to the end of 1991 in total 1514 tonnes of spent fuel (measured as uranium) have been received. Transportation from the nuclear sites to CLAB is made by a special ship, M/S Sigyn. At Forsmark the final repository for Radioactive Waste (SFR) was taken into operation in April 1988. The repository is situated in crystalline rock under the Baltic Sea. The first construction phase includes rock caverns for 60000 m 3 of waste. A second phase for additional 30000 m 3 is planned to be built and commissioned around the year 2000. At the end of 1991 a total of 7900 m 3 of waste have been deposited in SFR. SKB is in charge of a comprehensive research and development programme on geological disposal of nuclear waste. The total cost for R and D during 1991 was 182.7 MSEK of which 15.9 MSEK came from participants outside Sweden. Geological site-investigations are a substantial part of the programme. SKB is also the managing participant of the international Stripa-project under OECD/NEA. Cost calculations for the total nuclear waste management system, including decommissioning of all reactors, are updated annually. The total cost is estimated to 55 billion SEK. SKB also handles matters pertaining to prospecting and enrichment as well as stockpiling of uranium as strategic reserves for the Swedish nuclear power industry. Consulting service from SKB and associated expert groups are available on a commercial basis. Information activities are an integrated and important part of the Swedish radioactive waste management system. During 1991 successful public information activities have been carried out using mobile exhibitions in a tailor-made trailer and on the SKB ship M/S Sigyn. (au)

  13. Radiopharmaceuticals production activities in Egypt

    International Nuclear Information System (INIS)

    Raieh, M.

    1998-01-01

    Applications of radiopharmaceuticals and labelled compounds in the field of nuclear medicine in Egypt have increased so rapidly in the last few years. At present, a large number of hospitals are utilizing these radioisotopic techniques for both diagnosis and treatment. The following production activities are taking place in the Egyptian Radioisotope Production laboratories. By utilizing the research reactor a large number of radioisotopes which find wide applications in nuclear medicine were produced, such as iodine-131, phosphorus-32, sodium-24, potassium-42 and molybdenum-99 / technetium-99m generators. Gallium-67, indium-111 and iodine-123 will be produced locally after installation of the cyclotron at the end of 1998. A large number of Tc-99m based kits for diagnostic medical applications have been produced. Also, many radiopharmaceuticals labelled with iodine-131 were produced. The radioisotope production laboratory is able to supply many hospitals with the radioimmunoassay kits of the thyroid related hormones (T4, T3 and TSH). Research and development activities are taking place in the field of monoclonal antibodies and tumor markers with special consideration of AFP, CEA, PSA and βhCG. (author)

  14. Fourth international radiopharmaceutical dosimetry symposium

    International Nuclear Information System (INIS)

    Schlafke-Stelson, A.T.; Watson, E.E.

    1986-04-01

    The focus of the Fourth International Radiopharmaceutical Dosimetry Symposium was to explore the impact of current developments in nuclear medicine on absorbed dose calculations. This book contains the proceedings of the meeting including the edited discussion that followed the presentations. Topics that were addressed included the dosimetry associated with radiolabeled monoclonal antibodies and blood elements, ultrashort-lived radionuclides, and positron emitters. Some specific areas of discussion were variations in absorbed dose as a result of alterations in the kinetics, the influence of radioactive contaminants on dose, dose in children and in the fetus, available instrumentation and techniques for collecting the kinetic data needed for dose calculation, dosimetry requirements for the review and approval of new radiopharmaceuticals, and a comparison of the effect on the thyroid of internal versus external irradiation. New models for the urinary blader, skeleton including the active marrow, and the blood were presented. Several papers dealt with the validity of traditional ''average-organ'' dose estimates to express the dose from particulate radiation that has a short range in tissue. These problems are particularly important in the use of monoclonal antibodies and agents used to measure intracellular functions. These proceedings have been published to provide a resource volume for anyone interested in the calculation of absorbed radiation dose

  15. Radiopharmaceuticals used in nuclear cardiology

    International Nuclear Information System (INIS)

    Costa, H.

    1985-01-01

    During the last years, since short physical mean life radionuclides have started to be used, radionuclide scanning has been experienced with remarkable culmination. There are detector devices, which jointly with computation equipments, allow to obtain multiple images per second as properly rapid gammagraphic series, in order to obtain whole hemodynamic data or to generate functional images no representing an anatomical structure but reporting about cardiac dynamics at regional level. In these techniques, employed in Nuclear Cardiology, the following radionuclides and radiopharmaceuticals are used: radiolabeled albumin 99m Tc red blood cells, 113m In-transferrin, very short physical mean life radionuclides, such as 195m Au, 178 Ta, 191 Ir. In addition, 113 Xe for coronary flow measurements; radiolabeled microspheres and macroparticles for angiogammagraphy; 129 Cs, 43 K, 81 Rb, 82 Rb and 201 Ti, the most largerly used, for myocardial gammagraphy. It is pointed out that fatty acids are the newest, basically if are radioiodate, and some 99m Tc labeled long chain hydrocarbons. It is expressed that 99m Tc-Sn-pyrophosphate has been used for myocardial infarction. Working on the development of new radiopharmaceuticals, basically fatty acids and 99m Tc chelating agents, for the improvement of these techniques is carried out. (author)

  16. The development of new radiopharmaceuticals

    International Nuclear Information System (INIS)

    Britton, K.E.

    1990-01-01

    The development of new radiopharmaceuticals is the basis of the continuing growth of nuclear medicine. Chemical interactions of electron clouds in their three-dimensional conformations bring together, in the process of molecular recognition, the reaction of antibody and antigen, receptor and ligand, enzyme and substrate, hormone and response site. This convergence enables the computer design of molecules such as ligands to fit computer-displayed conformational models showing active centres, positive and negative charges and other interactions. Indeed, given a particular molecule, a complementary binding structure can be devised. The hybridoma approach to monoclonal antibody production is being superceded by the bacterial bioengineer. The gene for the hypervariable region from the spleen cells of immunized mouse can be coupled with the myeloma gene. The polymerase chain reaction can duplicate the DNA a million times over in 20 min and the result transfected into a bacterial plasmid to produce the antibody. These scientific problems are soluble in principle and are being solved. However, so much damage to this developing biological field is being done by regulatory authorities that one must ask who should or can regulate the regulators. The problems have to be overcome in order to provide the new radiopharmaceuticals that are the food and wine of nuclear medicine. (orig.)

  17. Production of radiopharmaceuticals by cyclotrons

    International Nuclear Information System (INIS)

    Schmitz, F.; Van Naemen, J.; Monclus, M.; Van Gansbeke, B.; Kadiata, M.; Ekelmans, D.; Moray, M.; Penninckx, R.; Goldman, S.

    2004-01-01

    Companies specialized in the development and installation of accelerator-based systems dedicated to the medical applications brought on the market cyclotrons well fitted to the requests of the industrial community or universities and so covering every segment of the market. These machines are fully automatic, and need reduced maintenance; they are highly specialized for defined tasks. They can produce high beam intensity and realize dual beam irradiation. Also the prices are reducing considerably. The targets and the automatic system follow the same trend. Unfortunately, the flexibility of these devices for new area of research and development has been dramatically reduced. The growing number of PET cameras has increased the popularity of PET tracers used for nuclear imaging. Consequently, there is a growing demand for these radiopharmaceuticals compounds labeled with short-lived radioisotopes for clinical applications. From a research and development tool in the eighties, PET has now grown up to a clinical tool. Moreover, depending of the social welfare, reimbursement of some PET examinations is granted, which accelerates the trend for an extended use of PET tracers. Regulatory affairs try to establish and standardize the control on these radiopharmaceutical compounds produced in a growing number of local radio pharmacies owning a baby cyclotron. On the other hand, the attention of equipment suppliers was brought in the setting up of a total quality control follow up. These efforts were successively achieved by getting for instance the ISO 9001 certificate

  18. Technical Advisory Committee on the nuclear fuel waste management program : thirteenth annual report

    International Nuclear Information System (INIS)

    Shemilt, L.W.

    1993-03-01

    Since the last reporting period by the Technical Advisory Committee (TAC) the emphasis of the work in the Canadian Nuclear Fuel Waste Management Program (CNFWMP) has been on the writing of the Environmental Impact Statement (EIS) and the associated set of nine primary reference documents as well as supporting documents. These are in preparation for submission to the Environmental Assessment Review Panel who will lead the national evaluation of the disposal concept under the auspices of the Federal Environmental Assessment Review Office (FEARO). The disposal concept developed over the last fourteen years by Atomic Energy of Canada Limited (AECL) and anticipated to be presented by means of the EIS in 1994, is based on a multiple system of natural and man-made barriers wherein nuclear waste is first enclosed in corrosion-resistant containers, designed to last at least 500 years, and then placed in a vault excavated 500 - 1000 m deep in granitic rocks of the Canadian Shield. After container emplacement either in or on the floor of the vault, and with a surrounding buffer material of a bentonite clay/sand mixture, the vault will be backfilled and sealed with crushed rock, buffer and sand, as will be the shafts and exploratory boreholes. The case study being presented by AECL to demonstrate the safety of this concept and the technology to implement it, relies on computer simulations of a hypothetical disposal site with geological characteristics similar to those at the Underground Research Laboratory (URL) in the Whiteshell Research Area (WRA) located in Manitoba. The preliminary simulation results suggest that safe containment can be achieved provided that the waste is surrounded by a sparsely-fractured zone of rock wherein movement of contaminants carried by groundwater is modelled as a diffusive as opposed to a advective process. The principal focus of work during the past year within the environmental and safety assessment has been to complete the Post

  19. Semi-annual technical report, September 30, 1999 - March 31, 2000

    Energy Technology Data Exchange (ETDEWEB)

    Schumacher, Dorin

    2000-04-01

    The Consortium for Plant Biotechnology Research, Inc. (CPBR) continues to operate according to objectives outlined in the proposal funded through the cooperative agreement. The italicized objectives below are addressed in this report, which covers the period September 30,1999 through March 31, 2000. (1) Update the research agenda using information obtained from member companies. (2) Identify and implement research projects that are deemed by industrial, scientific, and sponsoring agency evaluation to address significantly the problems and future of U.S. energy resources and that are relevant to the Department of Energy's mission. Specifically: (1) Announce research grants competition through a Request for Preproposals. (2) Conduct a dual-stage review process: Stage one--industrial and DOE review of preproposals; and Stage two--peer review, scientific consultants' review, DOE review of full proposals and Project Recommendation Committee evaluation and recommendation for funding. (3) Board of Directors approval of recommended awards. (4) Conduct ongoing project management. (5) Obtain semiannual, annual and final reports for evaluation of research goals and technology transfer. (6) Present reports to DOE.

  20. Quality assurance considerations related to in-house radiopharmaceutical preparations

    International Nuclear Information System (INIS)

    Finn, R.D.; Boothe, T.E.

    1990-01-01

    The Food and Drug Administration through its interpretation of the Food, Drug and Cosmetic Act with various amendments not only oversees the clinical investigation of new drugs, including short-lived radiopharmaceuticals but also monitors specific basic research protocols through the activities of the approved Radioactive Drug Research Committees. Concurrent with the technical improvements being made with positron emission tomographs is the increased availability of a variety of radiolabeled substrates possessing the unique potential to serve as indicators of in vivo alteration of biochemical processes. The syntheses of certain positron emitting radioligands with specific emphasis on the quality control procedures and current good manufacturing practices are discussed

  1. Energy Materials Coordinating Committee (EMaCC), fiscal year 1985. Annual technical report

    International Nuclear Information System (INIS)

    1986-05-01

    The DOE Energy Materials Coordinating Committee (EMaCC) serves primarily to enhance coordination among the Department's materials programs and to further the effective use of materials expertise within the Department. These functions are accomplished through the exchange of budgetary and planning information among program managers and through technical meeting/workshops on selected topics involving both DOE and major contractors. Four topical subcommittees on Structural Ceramics, Batteries and Fuel Cells, Radioactive Waste Containment, and Steel are established and are continuing their own program. The FY 1985 and FY 1986 meeting program is given. The EMaCC aids in obtaining materials-related inputs for both intra- and inter-agency compilations. Brief summaries of the materials research programs associated with each office and division are presented, including tables listing individual projects and the FY 1985 budgets for each. More details on the individual projects within the divisions and the specific tasks or subcontracts within the various projects are given in the paragraph descriptions

  2. Annual report of Technical Development Division of the Tono Geoscience Center, PNC in 1996 fiscal year

    International Nuclear Information System (INIS)

    1997-04-01

    This is a report collected working results of research and development conducted at Technical Development Division of the Tono Geoscience Center, PNC (Power Reactor and Nuclear Fuel Development Corporation) in 1996 fiscal year. In this fiscal year, Ore Bed Analysis and Evaluation Group entered into this division by changing name of Resource Analysis and Evaluation Group, which was shared to conduct some actions such as survey of resource information, analysis of potential, evaluation of ore bed, and so forth. The other conducted works were same as those in last fiscal year. Beside them, as taking the Monju reactor accident on December 8, 1995 an opportunity, safety management of facility was reconsidered as the most important item, preparation of the mining facilities such as renewal of lifting winder in vertical road for survey, new construction of general management building, preparation around the precipitation pond, and so on were executed, as a response to normal work for the yearly elapsed change in the Tono Mine. (G.K.)

  3. Energy Materials Coordinating Committee (EMaCC), fiscal year 1985. Annual technical report

    Energy Technology Data Exchange (ETDEWEB)

    None

    1986-05-01

    The DOE Energy Materials Coordinating Committee (EMaCC) serves primarily to enhance coordination among the Department's materials programs and to further the effective use of materials expertise within the Department. These functions are accomplished through the exchange of budgetary and planning information among program managers and through technical meeting/workshops on selected topics involving both DOE and major contractors. Four topical subcommittees on Structural Ceramics, Batteries and Fuel Cells, Radioactive Waste Containment, and Steel are established and are continuing their own program. The FY 1985 and FY 1986 meeting program is given. The EMaCC aids in obtaining materials-related inputs for both intra- and inter-agency compilations. Brief summaries of the materials research programs associated with each office and division are presented, including tables listing individual projects and the FY 1985 budgets for each. More details on the individual projects within the divisions and the specific tasks or subcontracts within the various projects are given in the paragraph descriptions.

  4. Second Annual AEC Scientific Computer Information Exhange Meeting. Proceedings of the technical program theme: computer graphics

    Energy Technology Data Exchange (ETDEWEB)

    Peskin,A.M.; Shimamoto, Y.

    1974-01-01

    The topic of computer graphics serves well to illustrate that AEC affiliated scientific computing installations are well represented in the forefront of computing science activities. The participant response to the technical program was overwhelming--both in number of contributions and quality of the work described. Session I, entitled Advanced Systems, contains presentations describing systems that contain features not generally found in graphics facilities. These features can be roughly classified as extensions of standard two-dimensional monochromatic imaging to higher dimensions including color and time as well as multidimensional metrics. Session II presents seven diverse applications ranging from high energy physics to medicine. Session III describes a number of important developments in establishing facilities, techniques and enhancements in the computer graphics area. Although an attempt was made to schedule as many of these worthwhile presentations as possible, it appeared impossible to do so given the scheduling constraints of the meeting. A number of prospective presenters 'came to the rescue' by graciously withdrawing from the sessions. Some of their abstracts have been included in the Proceedings.

  5. Pulverized coal firing of aluminum melting furnaces. First annual technical progress report, May 1978-June 1979

    Energy Technology Data Exchange (ETDEWEB)

    West, C.E.; Hines, J.E.; Stewart, D.L. Jr.; Yu, H.

    1979-10-01

    The ultimate objective of this program is the commercial demonstration of an efficient, environmentally acceptable coal firing process suitable for implementation on melting furnaces throughout the aluminum industry. To achieve this goal, the program has been divided into two phases. Phase I has begun with the design and construction of a 350 lb/h (coal) staged slagging cyclone combustor (SSCC) attached to a 7-ft dia aluminum melting ladle furnace. Process development will culminate with a 1000 pph prototype SSCC firing a 40,000 lb capacity open hearth melting furnace at the Alcoa Laboratories. Phase II implementation is currently planned for Alcoa's Lafayette, IN, Works, where two of the ingot plant's five open hearth melting furnaces will be converted to utilize coal. In addition to confirmation of data gathered in Phase I, the effect of extended production schedule operation on equipment and efficiencies will be determined. This work would begin in 1982 pursuant to technical and economic evaluation of the process development at that time. A major design subcontract for assistance in the design of the SSCC is 80% completed.

  6. Energy materials coordinating committee (EMaCC). Annual technical report, fiscal year 2004

    Energy Technology Data Exchange (ETDEWEB)

    none,

    2005-08-31

    The DOE Energy Materials Coordinating Committee (EMaCC) serves primarily to enhance coordination among the Department's materials programs and to further effective use of materials expertise within the Department. These functions are accomplished through the exchange of budgetary and planning information among program managers and through technical meetings/workshops on selected topics involving both DOE and major contractors. In addition, EMaCC assists in obtaining materials-related inputs for both intra- and interagency compilations. Topical subcommittees of the EMaCC are responsible for conducting seminars and otherwise facilitating information flow between DOE organizational units in materials areas of particular importance to the Department. The EMaCC Terms of Reference were recently modified and developed into a Charter that was approved on June 5, 2003. As a result of this reorganization, the existing subcommittees were disbanded and new subcommittees are being formed. The FY 2004 budget summary for DOE Materials Activities is presented on page 8. The distribution of these funds between DOE laboratories, private industry, academia and other organizations is presented in tabular form on page 10. Following the budget summary is a set of detailed program descriptions for the FY 2004 DOE Materials activities. These descriptions are presented according to the organizational structure of the Department. A mission statement, a budget summary listing the project titles and FY 2004 funding, and detailed project summaries are presented for each Assistant Secretary office, the Office of Science, and the National Nuclear Security Administration. The project summaries also provide DOE, laboratory, academic and industrial contacts for each project, as appropriate.

  7. Energy materials coordinating committee (EMaCC). Annual technical report, fiscal year 2002

    Energy Technology Data Exchange (ETDEWEB)

    none,

    2003-08-08

    The DOE Energy Materials Coordinating Committee (EMaCC) serves primarily to enhance coordination among the Department's materials programs and to further effective use of materials expertise within the Department. These functions are accomplished through the exchange of budgetary and planning information among program managers and through technical meetings/workshops on selected topics involving both DOE and major contractors. In addition, EMaCC assists in obtaining materials-related inputs for both intra- and interagency compilations. Topical subcommittees of the EMaCC are responsible for conducting seminars and otherwise facilitating information flow between DOE organizational units in materials areas of particular importance to the Department. The EMaCC Terms of Reference were recently modified and developed into a Charter that was approved on June 5, 2003. As a result of this reorganization, the existing subcommittees were disbanded and new subcommittees are being formed. The EMaCC Charter and the memorandum approving it are presented in the Appendix of this report. The FY 2002 budget summary for DOE Materials Activities is presented on page 8. The distribution of these funds between DOE laboratories, private industry, academia and other organizations is presented in tabular form on page 10. Following the budget summary is a set of detailed program descriptions for the FY 2002 DOE Materials activities. These descriptions are presented according to the organizational structure of the Department. A mission statement, a budget summary listing the project titles and FY 2002 funding, and detailed project summaries are presented for each Assistant Secretary office, the Office of Science, and the National Nuclear Security Administration. The project summaries also provide DOE, laboratory, academic and industrial contacts for each project, as appropriate.

  8. Energy materials coordinating committee (EMaCC). Annual technical report, fiscal year 2005

    Energy Technology Data Exchange (ETDEWEB)

    None, None

    2006-09-29

    The DOE Energy Materials Coordinating Committee (EMaCC) serves primarily to enhance coordination among the Department's materials programs and to further effective use of materials expertise within the Department. These functions are accomplished through the exchange of budgetary and planning information among program managers and through technical meetings/workshops on selected topics involving both DOE and major contractors. In addition, EMaCC assists in obtaining materials-related inputs for both intra- and interagency compilations. Topical subcommittees of the EMaCC are responsible for conducting seminars and otherwise facilitating information flow between DOE organizational units in materials areas of particular importance to the Department. The EMaCC Terms of Reference were recently modified and developed into a Charter that was approved on June 5, 2003. As a result of this reorganization, the existing subcommittees were disbanded and new subcommittees are being formed. The FY 2004 budget summary for DOE Materials Activities is presented on page 8. The distribution of these funds between DOE laboratories, private industry, academia and other organizations is presented in tabular form on page 10. Following the budget summary is a set of detailed program descriptions for the FY 2004 DOE Materials activities. These descriptions are presented according to the organizational structure of the Department. A mission statement, a budget summary listing the project titles and FY 2004 funding, and detailed project summaries are presented for each Assistant Secretary office, the Office of Science, and the National Nuclear Security Administration. The project summaries also provide DOE, laboratory, academic and industrial contacts for each project, as appropriate.

  9. Radiopharmaceuticals

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    1971-07-01

    Radioisotopes are being used to an ever-increasing extent in medicine for diagnosis and therapy. In this contributed article, Walter Wolf, of the School of Pharmacy, University of Southern California, Los Angeles, USA, and Alexandru T. Balaban, formerly a senior research officer in the IAEA Division of Research and Laboratories and now working in the chemistry section of the Institute of Atomic Physics, Bucharest, Romania, discuss some applications, and consider possible developments. (author)

  10. Radiopharmaceuticals drug interactions: a critical review

    International Nuclear Information System (INIS)

    Santos-Oliveira, Ralph; Smith, Sheila W.; Carneiro-Leao, Ana Maria A.

    2008-01-01

    Radiopharmaceuticals play a critical role in modern medicine primarily for diagnostic purposes, but also for monitoring disease progression and response to treatment. As the use of image has been increased, so has the use of prescription medications. These trends increase the risk of interactions between medications and radiopharmaceuticals. These interactions which have an impact on image by competing with the radiopharmaceutical for binding sites for example can lead to false negative results. Drugs that accelerate the metabolism of the radiopharmaceutical can have a positive impact (i.e. speeding its clearance) or, if repeating image is needed, a negative impact. In some cases, for example in cardiac image among patients taking doxirubacin, these interactions may have a therapeutic benefit. The incidence of drug-radiopharmaceuticals adverse reactions is unknown, since they may not be reported or even recognized. Here, we compiled the medical literature, using the criteria of a systematic review established by the Cochrane Collaboration, on pharmaceutical-drug interactions to provide a summary of documented interactions by organ system and radiopharmaceuticals. The purpose is to provide a reference on drug interactions that could inform the nuclear medicine staff in their daily routine. Efforts to increase adverse event reporting, and ideally consolidate reports worldwide, can provide a critically needed resource for prevention of drug-radiopharmaceuticals interactions. (author)

  11. Occupational exposure in the production of radiopharmaceuticals in Cuba

    International Nuclear Information System (INIS)

    Amador, Z. H.; Soria, M. A.

    2016-01-01

    The aim of this paper is to show the experiences in controlling occupational exposure production of radiopharmaceuticals in the Isotope Center (CENTIS) of the Republic of Cuba. data corresponding period 1996-2014 to 896 records are processed. The percentage distributions of the annual effective dose (E), the equivalent dose in the hands (Hp (0.07)) and the equivalent dose in crystalline (Hp (3)), are presented. The annual performance of the average values ​​of these dose quantities is plotted. The results of the internal dosimetry are processed. Annual activities manipulated radioisotopes greater contribution and its relation to the distribution of the collective dose directly linked S of staff, they are evaluated. The ALARA principle is implemented and maintained, based on qualitative and quantitative analysis, as appropriate. The (63-98)% of workers are monitored to E and the (80-100)% for Hp (0.07) and Hp (3), receives less than 10% of annual exposure limits. Groups of workers Radiopharmacy and Inspection and Testing are the greatest contribution to the collective dose, whose S to E equal to or greater than 2 mSv is the (9-62)% of total annual S. The maximum value of S is 98.3 mSv recorded man-1 and this occurs in 2011, however the highest value of 99Mo activity is handled in 2012 and a later year for 131I. They are identified as the most effective means for optimizing radiation safety the use of electronic dosimeters, internal shields process in hot cells and glove boxes and shields for collection of radioactive waste. a reduction in personnel exposure between (10-27)% is obtained. It is shown that exposure of workers in the production of radiopharmaceuticals in Cuba is acceptably low. (author)

  12. Uncertainty sources in radiopharmaceuticals clinical studies

    International Nuclear Information System (INIS)

    Degenhardt, Aemilie Louize; Oliveira, Silvia Maria Velasques de

    2014-01-01

    The radiopharmaceuticals should be approved for consumption by evaluating their quality, safety and efficacy. Clinical studies are designed to verify the pharmacodynamics, pharmacological and clinical effects in humans and are required for assuring safety and efficacy. The Bayesian analysis has been used for clinical studies effectiveness evaluation. This work aims to identify uncertainties associated with the process of production of the radionuclide and radiopharmaceutical labelling as well as the radiopharmaceutical administration and scintigraphy images acquisition and processing. For the development of clinical studies in the country, the metrological chain shall assure the traceability of the surveys performed in all phases. (author)

  13. Savannah River Ecology Laboratory, Annual Technical Progress Report of Ecological Research, June 30, 2002

    Energy Technology Data Exchange (ETDEWEB)

    Paul M. Bertsch, (Director)

    2002-06-30

    The Savannah River Ecology Laboratory (SREL) is a research unit of The University of Georgia (UGA) and has been conducting ecological research on the Savannah River Site (SRS) near Aiken, South Carolina for 50 years. The overall mission of the Laboratory is to acquire and communicate knowledge of ecological processes and principles. SREL conducts fundamental and applied ecological research, as well as education and outreach programs, under a Cooperative Agreement with the U.S. Department of Energy (DOE). The Laboratory's research mission during the 2002 fiscal year was fulfilled with the publication of 76 journal articles and book chapters by faculty, technical staff, students, and visiting scientists. An additional 50 journal articles have been submitted or are in press. Other noteworthy events took place as faculty members, staff, and graduate students received awards. These are described in the section titled Special Accomplishments of Faculty, Staff, Students, and Administration on page 51. Notable scientific accomplishments include work conducted on contaminant transport, stable isotopes, sandhills ecology, and phytoremediation: (1) A collaborative study between Dr. Tom Hinton at SREL and scientists at SRTC demonstrated the feasibility of using illite clay to sequester 137Cs in sediments along the P and R reactor cooling canal system, where approximately 3,000 acres of land are contaminated. Overall, the study showed significant decreases in cesium concentrations and bioavailability following the addition of illite with no sign of harm to the ecosystem. While the cesium remains sequestered from the biosphere, its radioactivity decays and the process progresses from contaminant immobilization to remediation. (2) SREL's stable isotope laboratory is now fully functional. Stable isotope distributions in nature can provide important insights into many historical and current environmental processes. Dr. Christopher Romanek is leading SREL's research

  14. Savannah River Ecology Laboratory Annual Technical Progress Report of Ecological Research, June 30, 2001

    Energy Technology Data Exchange (ETDEWEB)

    Bertsch, Paul M.; Janecek, Laura; Rosier, Brenda

    2001-06-30

    The Savannah River Ecology Laboratory (SREL) is a research unit of the University of Georgia (UGA) and has been conducting ecological research on the Savannah River Site (SRS) in South Carolina for 50 years. The overall mission of the Laboratory is to acquire and communicate knowledge of ecological processes and principles. SREL conducts fundamental and applied ecological research, as well as education and outreach programs, under a Cooperative Agreement with the U.S. Department of Energy (DOE) SRS near Aiken, South Carolina. The Laboratory's research mission during the 2001 fiscal year was fulfilled with the publication of one book and 83 journal articles and book chapters by faculty, technical staff, students, and visiting scientists. An additional 77 journal articles have been submitted or are in press. Other noteworthy events took place as faculty members and graduate students received awards. These are described in the section Special Accomplishments of Faculty, Staff, Students, and Administration on page 54. Notable scientific accomplishments include work conducted on contaminant transport, global reptile decline, phytoremediation, and radioecology. Dr. Domy Adriano authored the second edition of his book ''Trace Elements in Terrestrial Environments: Biogeochemistry, Bioavailability, and Risks of Metals'', which was recently published by Springer-Verlag. The book provides a comprehensive treatment of many important aspects of trace elements in the environment. The first edition of the book, published in 1986, has become a widely acclaimed and cited reference. International attention was focused on the problem of reptile species decline with the publication of an article on this topic in the journal ''Bioscience'' in August, 2000. The article's authors included Dr. Whit Gibbons and a number of other SREL herpetologists who researched the growing worldwide problem of decline of reptile species. Factors related

  15. Savannah River Ecology Laboratory, Annual Technical Progress Report of Ecological Research, June 30, 2002

    International Nuclear Information System (INIS)

    Paul M. Bertsch,

    2002-01-01

    The Savannah River Ecology Laboratory (SREL) is a research unit of The University of Georgia (UGA) and has been conducting ecological research on the Savannah River Site (SRS) near Aiken, South Carolina for 50 years. The overall mission of the Laboratory is to acquire and communicate knowledge of ecological processes and principles. SREL conducts fundamental and applied ecological research, as well as education and outreach programs, under a Cooperative Agreement with the U.S. Department of Energy (DOE). The Laboratory's research mission during the 2002 fiscal year was fulfilled with the publication of 76 journal articles and book chapters by faculty, technical staff, students, and visiting scientists. An additional 50 journal articles have been submitted or are in press. Other noteworthy events took place as faculty members, staff, and graduate students received awards. These are described in the section titled Special Accomplishments of Faculty, Staff, Students, and Administration on page 51. Notable scientific accomplishments include work conducted on contaminant transport, stable isotopes, sandhills ecology, and phytoremediation: (1) A collaborative study between Dr. Tom Hinton at SREL and scientists at SRTC demonstrated the feasibility of using illite clay to sequester 137Cs in sediments along the P and R reactor cooling canal system, where approximately 3, 000 acres of land are contaminated. Overall, the study showed significant decreases in cesium concentrations and bioavailability following the addition of illite with no sign of harm to the ecosystem. While the cesium remains sequestered from the biosphere, its radioactivity decays and the process progresses from contaminant immobilization to remediation. (2) SREL's stable isotope laboratory is now fully functional. Stable isotope distributions in nature can provide important insights into many historical and current environmental processes. Dr. Christopher Romanek is leading SREL's research in this area

  16. Positron emitting radiopharmaceuticals for cancer

    International Nuclear Information System (INIS)

    Krohn, K.A.; Graham, M.M.

    1989-01-01

    Cancer is principally a biochemical disease involving abnormal enzymology, gene expression and/or membrane composition. Cytotoxic chemical treatments, including radiation products, are important in controlling cancer. It therefore follows that imaging of the biochemical differences between tumor and normal tissues should lead to more effective therapy. Metabolic imaging should identify the best new treatment protocol for an individual patient and may identify specific causes of resistance to therapy. Methods have been developed for imaging the metabolism of energy substrates (glucose and O 2 ), and DNA precursors (thymidine) and for specifically identifying hormone-dependent tumors (estrogen or testosterone) and hypoxic tissues (bioreductive alkylators). Together these new radiopharmaceuticals are leading to better cancer therapy, not just improving diagnosis, but more by following the different responses of tumor and surrounding normal tissues to cytotoxic therapy

  17. Radiopharmaceutical agents for skeletal scanning

    International Nuclear Information System (INIS)

    Jansen, S.E.; Van Aswegen, A.; Loetter, M.G.; Minnaar, P.C.; Otto, A.C.; Goedhals, L.; Dedekind, P.S.

    1987-01-01

    The quality of bone scan images obtained with a locally produced and with an imported radiopharmaceutical bone agent, methylene diphosphonate (MDP), was compared visually. Standard skeletal imaging was carried out on 10 patients using both agents, with a period of 2 to 7 days between studies with alternate agents. Equal amounts of activity were administered for both agents. All images were acquired on Polaroid film for subsequent evaluation. The acquisition time for standard amount of counts per study was recorded. Three physicians with applicable experience evaluated image quality (on a 4 point scale) and detectability of metastasis (on a 3 point scale). There was no statistically significant difference (p 0,05) between the two agents by paired t-test of Hotelling's T 2 analysis. It is concluded that the imaging properties of the locally produced and the imported MDP are similar

  18. Characterization of aerosols containing radiopharmaceuticals

    International Nuclear Information System (INIS)

    Cunha, Kenya Dias da; Santos, Maristela Souza

    2008-01-01

    The objective of this study is to present the main lines of action of the Laboratorio de Caracterizacao de Aerossois (LCA /IRD) in the study of aerosols, the techniques available and the capability of these techniques as a tool in the biokinetics behavior study of radiopharmaceuticals and evaluating the particle exposed individuals containing these molecules. The LCA provides the following analytical techniques: spectrometry alpha, gamma and alpha counting and gross beta; PIXE (Particle Induced X rays Emission) and mass spectrometry-based flight time measurement of molecular ions ( 252 Cf-PDMS - 252 Cf-Plasma Desorption Mass Spectrometry). This technique is used to identify compounds mass to 10 000 a.m.u. The combination of these techniques has been applied to the study in vitro of the toxicology of the metals and radionuclides both in the respiratory tract as in the gastrointestinal

  19. Computational system for activity calculation of radiopharmaceuticals

    African Journals Online (AJOL)

    STORAGESEVER

    2008-12-29

    Dec 29, 2008 ... 2National Nuclear Energy Commission, Brazil. Accepted 24 October ... radiopharmaceuticals in use around the world with ... ment with a very important aspects: no profits ends. The tool ... The software interface is showed in ...

  20. Radiopharmaceutical chemistry for positron emission tomography

    NARCIS (Netherlands)

    Elsinga, PH

    Radiopharmaceutical chemistry includes the selection, preparation, and preclinical evaluation of radiolabeled compounds. This paper describes selection criteria for candidates for positron emission tomography (PET) investigations. Practical aspects of nucleophilic and electrophilic

  1. The IAEA Activities on Supporting Development of Therapeutic Radiopharmaceuticals and Capacity Building in Member States

    International Nuclear Information System (INIS)

    Pillai, M.R.A.; Haji-Saeid, M.; Zaknun, J.; Ramamoorthy, N.

    2009-01-01

    The IAEA activities on supporting development of therapeutic radiopharmaceuticals are focused on identified radionuclides that can be produced in large quantities and making use of carrier molecules which can be synthesized locally or procured from commercial sources or already available in MS from other related programs. The main emphasis is on 90 Y and 177 Lu based products, which cover the hard beta energy and soft beta energy range respectively, and also since both these radionuclides can be produced in large quantities with very high specific activity and high radionuclidic purity. The services to MS are provided through implementing Coordinated Research Projects (CRP), Technical Cooperation (TC) projects, technical meetings and regional training courses in addition to documenting practically useful technical information related to these products though IAEA publications. The CRP is a group activity in which nearly 15 participants from as many countries come together to work towards an identified objective. Two of the completed CRPs in this area are: (i) Comparative evaluation of therapeutic radiopharmaceuticals (2002-2005) that focussed on the development of 'in vitro' and 'in vivo' techniques for evaluating new generation therapeutic radiopharmaceuticals; and (ii) Development of generator technologies for therapeutic radionuclides (2004-2007) that addressed technologies for 90 Sr/ 90 Y and 188 W/ 188 Re generators and which can be easily adapted by MS. The participants in the CRP on 'Comparative evaluation of therapeutic radiopharmaceuticals' used the somatostatin analogue, DOTATATE as the lead molecule for developing radiopharmaceuticals and testing the efficacy by in vitro biological assays and animal biodistribution studies. A significant outcome of the CRP was that 177 Lu-DOTATATE therapy is now practised in several of the CRP participating countries including Brazil, India, Italy, and Poland. The major outcome of the CRP on 'Development of generator

  2. Metabolic radiopharmaceutical therapy in nuclear medicine

    International Nuclear Information System (INIS)

    Reguera, L.; Lozano, M. L.; Alonso, J. C.

    2016-01-01

    In 1986 the National Board of Medical Specialties defined the specialty of nuclear medicine as a medical specialty that uses radioisotopes for prevention, diagnosis, therapy and medical research. Nowadays, treatment with radiopharmaceuticals has reached a major importance within of nuclear medicine. The ability to treat tumors with radiopharmaceutical, Radiation selective therapy has become a first line alternative. In this paper, the current situation of the different therapies that are sued in nuclear medicine, is reviewed. (Author)

  3. Radiation decomposition of technetium-99m radiopharmaceuticals

    International Nuclear Information System (INIS)

    Billinghurst, M.W.; Rempel, S.; Westendorf, B.A.

    1979-01-01

    Technetium-99m radiopharmaceuticals are shown to be subject to autoradiation-induced decomposition, which results in increasing abundance of pertechnetate in the preparation. This autodecomposition is catalyzed by the presence of oxygen, although the removal of oxygen does not prevent its occurrence. The initial appearance of pertechnetate in the radiopharmaceutical is shown to be a function of the amount of radioactivity, the quantity of stannous ion used, and the ratio of /sup 99m/Tc to total technetium in the preparation

  4. Report of the Task Force on radiopharmaceuticals

    International Nuclear Information System (INIS)

    Lacker, D.K.; Porter, B.J.; Watkins, G.

    1975-01-01

    The procedures for evaluation of IND and NDA applications were reviewed by FDA and the state members of the Task Force believe that there is significant progress being made toward expeditious handling of these items. Progress toward publication of the final rule on radiopharmaceuticals has reduced the need for state regulatory activity in investigational aspects of radiopharmaceutical research to the point that the original concept for the training is no longer valid

  5. Rational development of radiopharmaceuticals for HIV-1

    International Nuclear Information System (INIS)

    Lau, Chuen-Yen; Maldarelli, Frank; Eckelman, William C.; Neumann, Ronald D.

    2014-01-01

    The global battle against HIV-1 would benefit from a sensitive and specific radiopharmaceutical to localize HIV-infected cells. Ideally, this probe would be able to identify latently infected host cells containing replication competent HIV sequences. Clinical and research applications would include assessment of reservoirs, informing clinical management by facilitating assessment of burden of infection in different compartments, monitoring disease progression and monitoring response to therapy. A “rational” development approach could facilitate efficient identification of an appropriate targeted radiopharmaceutical. Rational development starts with understanding characteristics of the disease that can be effectively targeted and then engineering radiopharmaceuticals to hone in on an appropriate target, which in the case of HIV-1 (HIV) might be an HIV-specific product on or in the host cell, a differentially expressed gene product, an integrated DNA sequence specific enzymatic activity, part of the inflammatory response, or a combination of these. This is different from the current approach that starts with a radiopharmaceutical for a target associated with a disease, mostly from autopsy studies, without a strong rationale for the potential to impact patient care. At present, no targeted therapies are available for HIV latency, although a number of approaches are under study. Here we discuss requirements for a radiopharmaceutical useful in strategies targeting persistently infected cells. The radiopharmaceutical for HIV should be developed based on HIV biology, studied in an animal model and then in humans, and ultimately used in clinical and research settings

  6. Radiopharmaceutical development and clinical needs

    International Nuclear Information System (INIS)

    Vieira, M.R.

    1998-01-01

    The use of radionuclides for medical applications has continued to grow at a very rapid pace. The use of radiotracers for nuclear medicine imaging and for radiotherapy of cancer as well as certain benign disorders is firmly established as an important clinical modality. Over the past ten years, nuclear medicine has experienced an evolution towards functional studies and novel therapeutic approaches. New radionuclides are required for these applications. In the developmental stages, each new isotope has to go through a phase of careful scrutiny and evaluation, and practical concerns related to the cost of production and availability must be addressed. The development of 18 F-labeled radiopharmaceuticals has opened a completely new area of investigation. Research on bioconjugates (this term includes radiolabeled antibodies, peptides, receptor-specific and other bioactive molecules) has experienced rapid growth because of the promise of a number of these ''bioactive molecules'' to serve as selective carriers of radionuclides for tumor-associated and other specific antigens/receptors ''in vivo''. The new concept of nuclear medicine, particularly when applied to the field of oncology is directed towards the physiological mechanisms and the study of molecular disfunctions. The search for new radiopharmaceuticals thus aims at studying tumors at a tissue and molecular level. Examples of this new approach are scans utilizing the following substances: -guanethidine and noradrenaline analogues such as meta-iodo-benzyl-guanidine labeled with iodine-131 or iodine-123 aimed at targeting neuroendocrine cells and their secretory granules; -various monoclonal antibodies directed at different tumor types, both for diagnostic and therapeutic purposes. Radioimmunotherapy is considered particularly suited for treatment of tumors not easily amenable to surgery and for the treatment of small disseminated lesions; -somatostatin analogs tagged with indium-111 or more recently with Yttrium

  7. Annual technical report

    International Nuclear Information System (INIS)

    Yang, T.F.; Gierszewski, P.

    1982-01-01

    This paper describes a Monte Carlo study of the thermal conductivity and impurity transport in a tokamak with an optimized bundle divertor configuration. This configuration has been designed to obtain the best plasma performance. When collisions and electric fields are included, the thermal conductivity was found to be 40% larger than that of an axisymmetric neoclassical value. Without a divertor the oxygen impurity was found to diffuse towards the center of the plasma as predicted theoretically. However, this impurity diffused outwardly when the divertor was turned on. Few impurity particles diffused into the plasma when launched in the scrape-off layer. This optimized bundle divertor meets the engineering constraints of a power producing reactor

  8. Annual technical progress report

    International Nuclear Information System (INIS)

    1980-01-01

    During the present contract period Phaedrus has begun operation as a true tandem mirror. This was accomplished by achieving the rf sustained mode in which the plug densities were built up by a combination of central cell gas puffing and plug ICRH following stream gun turn off. It was demonstrated that the tandem mirror plasma could be sustained by plug ICRH for up to 1 msec following decay of the external plasma. In this mode plasma characteristics were no longer dominated by problems associated with a high conductivity stream gun plasma in the external region (as was the case in many previous experiments in Phaedrus). Among these problems were (1) line tying which significantly reduced instabilities in a way that would not apply to reactors and (2) low electron temperatures which had been held to approx. 20 eV

  9. Forty-Fifth Annual Meeting of the Technical Working Group on Fast Reactors (TWG-FR). Working Material

    International Nuclear Information System (INIS)

    2012-01-01

    The objectives of the meeting were to: • Exchange information on the national programmes on Fast Reactors (FR) and Accelerator Driven Systems (ADS); • Review the progress since the 44 th TWG-FR Annual Meeting, including the status of the actions; • Consider topical technical meeting arrangements for 2012-2013, as well as review FR-related activities included in the IAEA Programme & Budget (P&B) biennium 2012-2013; • Review the IAEA’s concluded, on-going and planned coordinated research projects in the technical fields relevant to the TWG-FR (FRs and ADS), as well as coordination of the TWG-FR’s activities with other organizations and international initiatives (GIF, INPRO, NEA, ESNII, etc.). The 45th Meeting of the TWG-FR reached the following conclusions/recommendations: • The participants expressed satisfaction and appreciation for the large amount of new information on on-going activities carried out by the Member States in the field of FR and ADS exchanged during the meeting; • Also the organizations which have participated to the TWG-FR meeting for the first time expressed their appreciation for the lively discussion and the results and thanked the IAEA for inviting them at the meeting; • The meeting was very useful in particular for collecting inputs and advice in view of the preparation of the IAEA Programme & Budget 2014-2015 (and then 2016-2017) in the area of FR and ADS technology development; • The TWG-FR remains an unique international forum for information exchange in the field of fast neutron systems and for promoting RT&D activities in this area; • Due to the increasing interest in FR and in view of the forthcoming realizations, it would be advisable to increase the involvement of industries, regulators and other R&D organizations; • The annual TWG-FR meeting should focused on exchange of information on national and international programmes, avoiding duplications or overlapping’s with other IAEA initiatives in the field;

  10. Annual meeting on nuclear technology '92. Technical session 'Nuclear energy discussion'. Proceedings. Jahrestagung Kerntechnik '92. Fachsitzung 'Kernenergie-Diskussion'. Berichtsheft

    Energy Technology Data Exchange (ETDEWEB)

    1992-05-01

    The report contains the six special papers red at the 1992 annual conference on nuclear engineering at Karlsruhe, all of which are individually retrievable from the database. They deal with the following subjects: historical development of the basic trends of technology criticism; communication problems in connection with the conveying of technical facts; psycho-sociological patterns of technology anxiety-mental infection or risk consciousness; field of tension between technology and journalism; handling of insecurities; ethical justifiability of nuclear energy use. (HSCH).

  11. Monoclonal antibody hapten radiopharmaceutical delivery

    International Nuclear Information System (INIS)

    Goodwin, D.A.; McTigue, M.

    1986-01-01

    One hundred μg of monoclonal antibody (MoAb) CHA255 with a binding constant Kb of 4 x 10 9 was complexed with indium-111 labelled BLEDTA II, BLEDTA IV, benzyl EDTA, and an EDTA conjugate of Fab. The 24-h tumour and organ distribution of BALB/c mice bearing KHJJ tumours was studied for each compound alone, the antibody complex, and 3 h following a chelate chase of the antibody complex. Whole body biological half-life was measured for 7 days with and without a chelate chase for each antibody complex. The 24-h whole body counts dropped 20 to 60% and blood concentration fell over 89% within 3 h of administering the chelate chase. Theoretical equivalent human organ doses were calculated from the 24-h organ concentrations, effective half-life, and MIRD 11 S values (absorbed dose per cumulated activity). Liver and spleen were the target organs, with the dose ranging from 0.50 to 3.91 rads mCi -1 . The reduction in organ radiation dose varied up to 95% following the chelate chase. Rapid selective renal clearance of chelate labelled radiopharmaceuticals by competitive inhibition (chelate chase) of their reversible binding to monoclonal antibodies enhances tumour imaging and improves the radiation dosimetry. (author)

  12. Gallium and copper radiopharmaceutical chemistry

    International Nuclear Information System (INIS)

    Green, M.A.; John, E.K.; Barnhart, A.J.

    1990-01-01

    Several isotopes of gallium and copper exhibit nuclear properties that make them attractive for applications in nuclear medicine, most notably Ga-67, Ga-68, Cu-67 and Cu-62. Of these, gamma-emitting Ga-67 has historically found the greatest clinical use, based on the observation that tracer gallium(III) citrate rapidly produces Ga-67 transferrin upon intravenous injection and then slowly affords selective Ga-67 localization in sites of abscess and certain tumors. Copper-67 has received attention as a potential label for tissue-selective monoclonal antibodies, since its associated γ-photons can be used for external imaging and its β - -emissions could be used for radiation therapy. Positron-emitting gallium-68 and copper-62, being available from parent/daughter generator systems, have attracted interest as potential labels for radiopharmaceuticals used in positron emission tomography (PET) because they could reduce the dependence of this imaging technology on hospital-based cyclotrons. The 10 min. half-life of Cu-62 is particularly well-suited to the time frame of PET studies of tissue perfusion, an application for which Cu(II)-bis(thiosemicarbazone) derivatives appear promising. The 68 min. half-life of Ga-68 makes it appropriate for PET studies over longer imaging time spans

  13. [Nuclear cardiology with new radiopharmaceuticals].

    Science.gov (United States)

    Bunko, H

    1994-08-01

    In the field of nuclear cardiology, 99mTc labeled myocardial perfusion agents such as MIBI, Tetrofosmin and Teboroxime, 111In-antimyosin for imaging of myocardial necrosis, 123I-betamethyl-iodophenylpentadecanoic acid (BMIPP) for imaging of myocardial fatty acid metabolism and 123I-metaiodobenzylguanidine (MIBG) for imaging of myocardial adrenergic function are introduced recently in Japan. Improved image quality and simultaneous evaluation of myocardial perfusion, function and wall motion can be obtained with use of 99mTc labeled myocardial perfusion agents. 111In-antimyosin enables specific imaging of myocardial necrosis which leads to the use for wide variety of heart diseases. Discrepancy of the myocardial perfusion and metabolism in case of stunned myocardium or cardiomyopathy can be evaluated by 123I-BMIPP in conjunction with perfusion agent. Recently wide variety of diseases which may have cardiac adrenergic abnormality are targeted for 123I-MIBG imaging. These new radiopharmaceuticals are expected to be powerful tool for evaluation of the pathophysiology including severity and prognosis and evaluation of the etiology of the various heart diseases.

  14. Technical meeting (TM) to 'Review of national programmes on fast reactors and accelerator driven systems (ADS)'. Technical Working Group on Fast Reactors (TWG-FR) (37th annual meeting). Working material

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    2004-07-01

    The objectives of the 37th Annual Meeting of the Technical Working Group on Fast Reactors, were to: 1) exchange information on the national programmes on Fast Reactors (FR) and Accelerator Driven Systems (ADS); 2) review the progress since the 36th TWG-FR Annual Meeting, including the status of the actions; 3) consider meeting arrangements for 2004 and 2005; 4) review the Agency's co-ordinated research activities in the field of FRs and ADS, as well as co-ordination of the TWG-FR's activities with other organizations. The participants made presentations on the status of the respective national programmes on FR and ADS development. A summary of the highlights for the period since the 36th TWG-FR Annual Meeting is included in this proceedings. Annex IV contains the Review of National Programs on Fast Reactors and Accelerator Driven Systems (ADS), and the TWG-FR Activity Report for the Period May 2003-April 2004.

  15. Annual report of Department of Research Reactor and Tandem Accelerator, JFY2007. Operation, utilization and technical development of JRR-3, JRR-4, NSRR and tandem accelerator

    International Nuclear Information System (INIS)

    Miyazaki, Osamu; Awa, Yasuaki; Isaka, Koji; Kutsukake, Kenichi; Komeda, Masao; Shibata, Ko; Hiyama, Kazuhisa; Suzuki, Mayu; Sone, Takuya; Ohuchi, Tomoaki; Terakado, Yuichi; Sataka, Masao

    2009-06-01

    The Department of Research Reactors and Tandem Accelerator is in charge of the operation, utilization and technical development of JRR-3(Japan Research Reactor-3), JRR-4(Japan Research Reactor-4), NSRR(Nuclear Safety Research Reactor) and Tandem Accelerator. This annual report describes a summary of activities of services and technical developments carried out in the period between April 1, 2007 and March 31, 2008. The activities were categorized into five service/development fields: (1) Operation and maintenance of research reactors and tandem accelerator. (2) Utilization of research reactors and tandem accelerator. (3) Upgrading of utilization techniques of research reactors and tandem accelerator. (4) Safety administration for research reactors and tandem accelerator. (5) International cooperation. Also contained are lists of publications, meetings, granted permissions on lows and regulations concerning atomic energy, commendation, plans and outcomes in service and technical developments and so on. (author)

  16. Annual report of Department of Research Reactor and Tandem Accelerator, JFY2010. Operation, utilization and technical development of JRR-3, JRR-4, NSRR and Tandem Accelerator

    International Nuclear Information System (INIS)

    Ishii, Tetsuro; Nakamura, Kiyoshi; Kawamata, Satoshi; Yamada, Yusuke; Kawashima, Kazuhiro; Asozu, Takuhiro; Nakamura, Takemi; Arai, Masaji; Yoshinari, Shuji; Sataka, Masao

    2012-03-01

    The Department of Research Reactors and Tandem Accelerator is in charge of the operation, utilization and technical development of JRR-3(Japan Research Reactor No.3), JRR-4(Japan Research Reactor No.4), NSRR(Nuclear Safety Research Reactor) and Tandem Accelerator. This annual report describes a summary of activities of services and technical developments carried out in the period between April 1, 2010 and March 31, 2011. The activities were categorized into five service/development fields: (1) Operation and maintenance of research reactors and tandem accelerator, (2) Utilization of research reactors and tandem accelerator, (3) Upgrading of utilization techniques of research reactors and tandem accelerator, (4) Safety administration for research reactors and tandem accelerator, (5) International cooperation. Also contained are lists of publications, meetings, granted permissions on lows and regulations concerning atomic energy, commendation, outcomes in service and technical developments and so on. (author)

  17. Radiopharmaceuticals For Detection Of Inflammation And Infection

    International Nuclear Information System (INIS)

    Nurlaila, Z.

    2002-01-01

    Feeling of pain in the body could be caused by reaction of inflantation and infection as well. One of the methods could be used to detect the reaction is nuclear technique using radiopharmaceutical as radiotracer. Some radiopharmaceuticals having specific accunulation mechanism to diagnose the presence of inflamations and infections with satisfactory results. Among those radiophannaceuticals are technetium-99m-hexamethylpropileneamine-white blood cell ( 99m Tc-HMPAO-WBC), indium-111-oxine-white blood cell ( 111 In-oksin-WBC). technetium-99m-immunoglobuline G ( 99m Tc-lgG) and technetium-99m-infecton ( 99m Tc-infecton). In visualization using this method. the information of a serial previous medical treatment of the patient should be known, because cer1ain medicament, could influence the biological characteristic of radiopharmaceuticals and hence. a missed diagnosis could be resulted. This review discusses several radiopharmaceuticals for inflamation and infection, diagnoses their accumulation, mechanism in the body. Besides, the radiopharmaceuticals interaction with several drugs are also reviewed

  18. Quality controls of radiopharmaceuticals used in nuclear medicine

    International Nuclear Information System (INIS)

    Gomez de Castiglia, S.I.; Fraga de Suarez, A.H.; Mitta, A.E.A.

    1981-01-01

    Chromatographic quality controls for Tc-99m; In-113m; I-131; Tl-201 and Ga-67 radiopharmaceuticals are described. Moreover, a chromatographic system which allows to separate different radiopharmaceuticals from In-113m is pointed out. (author) [es

  19. Radiopharmaceutical development of radiolabelled peptides

    Energy Technology Data Exchange (ETDEWEB)

    Fani, Melpomeni; Maecke, Helmut R. [University Hospital Freiburg, Department of Nuclear Medicine, Freiburg (Germany)

    2012-02-15

    Receptor targeting with radiolabelled peptides has become very important in nuclear medicine and oncology in the past few years. The overexpression of many peptide receptors in numerous cancers, compared to their relatively low density in physiological organs, represents the molecular basis for in vivo imaging and targeted radionuclide therapy with radiolabelled peptide-based probes. The prototypes are analogs of somatostatin which are routinely used in the clinic. More recent developments include somatostatin analogs with a broader receptor subtype profile or with antagonistic properties. Many other peptide families such as bombesin, cholecystokinin/gastrin, glucagon-like peptide-1 (GLP-1)/exendin, arginine-glycine-aspartic acid (RGD) etc. have been explored during the last few years and quite a number of potential radiolabelled probes have been derived from them. On the other hand, a variety of strategies and optimized protocols for efficient labelling of peptides with clinically relevant radionuclides such as {sup 99m}Tc, M{sup 3+} radiometals ({sup 111}In, {sup 86/90}Y, {sup 177}Lu, {sup 67/68}Ga), {sup 64/67}Cu, {sup 18}F or radioisotopes of iodine have been developed. The labelling approaches include direct labelling, the use of bifunctional chelators or prosthetic groups. The choice of the labelling approach is driven by the nature and the chemical properties of the radionuclide. Additionally, chemical strategies, including modification of the amino acid sequence and introduction of linkers/spacers with different characteristics, have been explored for the improvement of the overall performance of the radiopeptides, e.g. metabolic stability and pharmacokinetics. Herein, we discuss the development of peptides as radiopharmaceuticals starting from the choice of the labelling method and the conditions to the design and optimization of the peptide probe, as well as some recent developments, focusing on a selected list of peptide families, including somatostatin

  20. Multi-disciplinary collaboration in radiopharmaceutical chemistry

    International Nuclear Information System (INIS)

    Nozaki, Tadashi

    1989-01-01

    Various possibilities often exist in each step of radiopharmaceutical preparation, and multi-disciplinary knowledge and collaboration are necessary for improved choice of the preparation conditions. In the radionuclide production step, proton bombardment of a separated nuclide target usually exceeds other bombardments of natural targets. Isotope separation by laser-chemical method is expected to soon offer several enriched nuclides useful as the target in enough amount and moderate price. The design and preparation of radiopharmaceuticals will be directly influenced by further progress of enzymology and immunology. Nondestructive, continuous observation of chemical changes in vivo is a longing of radiochemists, and may be realized gradually through elaborate examination of chemical effects in Mossbauer absorption, γ-γ angular correlation, EC X-ray properties, and positron annihilation. Present knowledge and techniques in radiopharmaceutical chemistry, on the other hand, can be utilized effectively in other fields of life sciences

  1. Use of radiopharmaceuticals for treating bone metastases

    International Nuclear Information System (INIS)

    Alberti Ramírez, Alejandro; Morín Zorrilla, José; Cruz Arencibia, Jorge

    2016-01-01

    Cancer prevalence is estimated at around 2% of the population and on average between 64-80% of patients with solid tumors develop bone metastases, being breast tumors, lung and prostate those who do more frequency. In this paper an estimate of the prevalence of bone pain from metastases, with reference to the data reported in the literature is presented. the different treatment techniques are summarized for pain management with special emphasis on Radionuclidic therapy, analyzing the different factors to consider for the selection of suitable radiopharmaceutical. cost data and cost-benefit of some radiopharmaceuticals for the purpose to take into account during their selection are provided. It is concluded that although the treatment of metastatic bone disease requires multidisciplinary therapies, Radionuclidic therapy is not sufficiently used, particularly by inadequate perception of risks and costs of radiopharmaceuticals, despite the undeniable support of its efficacy and tolerability. (author)

  2. Radiopharmaceutical potential of I-131 labelled diazepam

    International Nuclear Information System (INIS)

    Yurt, F.; Unek, P.; Asikoglu, M.; Baggi, S.; Erener, G.; Ozkilic, H.; Uluc, F.; Tuglular, I.

    1998-01-01

    In this study, diazepam is a derivative of the 1.4 benzodiazepine family that the most widely used drug as anticonvulsant agent has been labeled with I-131, as a new radiopharmaceutical and its radiopharmaceutical potential has been determined. Labeling of diazepam has been performed by iodogen method and optimum labeling conditions have been determined. Optimum reaction conditions are 1 mg for iodogen amount; 1-5 mg for diazepam amount, 15-20 minutes for reaction time and room temperature for reaction temperature. Specific activity of labeled compound was 0,15 Ci/mmol level. N-octanol/water ratio was found 1.9 for 131 IDZ ( 131 I labeled diazepam). In vivo experiments have been carried out to determine radiopharmaceutical potentials of labeled compound. Biodistribution studies on rats showed that 131 IDZ have accumulated in kidneys, liver, lungs and brain tissues. Scintigraphic results taken with gamma camera on rabbits agree with biodistribution results of rats. (author)

  3. Exposure of croatian population to radiopharmaceuticals

    International Nuclear Information System (INIS)

    Prlic, I.; Suric Mihic, M.; Marovic, G.; Mestrovic, T.; Mrcela, I.; Cerovac, Z.; Golubovic, D.; Hajdinjak, M.

    2010-01-01

    The aim of this paper is to call attention to the exposure of Croatian population to open sources of ionising radiation used in medical diagnostics, radiopharmaceuticals in particular, whose initial activity is very high. Without proper exposure monitoring, it is not possible to establish the effective dose per capita, but we have estimated it to be between 6.8 μSv and 7.0 μSv for this type of internal exposure, based on a very loose assumption that about 35,000 diagnostic procedures with radiopharmaceuticals are performed in Croatia every year. This calls for further research that would eventually lead to limiting the doses received through exposure to radiopharmaceuticals. (authors)

  4. Radiopharmaceuticals for thyroid imaging: a review

    International Nuclear Information System (INIS)

    Nishiyama, H.

    1979-01-01

    A review of radiopharmaceuticals which have been used for thyroid imaging was made with special emphasis on palpable thyroid nodules. An attempt was made to evaluate cold nodules derived from imaging methods using radioiodine or Tc-99m pertechnetate, followed by a successive application of another radiopharmaceutical. An attempt was also made to understand the patho-physiology of various thyroid disorders. The latter was based on the accumulated cases with discordant images between radioiodine and Tc-99m pertechnetate, and also on the iodine content within the gland by means of fluorescent techniques. Better radiopharmaceuticals are anxiously awaited in order to realize the distinction between benign and malignant thyroid disorders at the preoperative decision-making stage

  5. The safe and effective use of radiopharmaceuticals

    International Nuclear Information System (INIS)

    Trott, N.G.

    1982-01-01

    In the medical applications of radionuclides, we have to arrange effective radiation protection of patients, staff and general public, maintain high standards of pharmaceutical safety and ensure that the radiopharmaceuticals are effective in use. The influence of the 1976 Council of the European Communities Euratom Directive in producing legislation in the United Kingdom controlling medical work with radioactivity is discussed. Attention is drawn to current studies in the dosimetry of radiopharmaceuticals, and some of the problems that continue to arise in evaluating the dosimetry and possible hazards of isotopes of iodine are discussed. Developments in facilities for preparing radiopharmaceuticals in hospital laboratories are considered and a short report is given of an extensive study of quality control procedures which showed that it was difficult to justify their use as a routine on established products. (Author)

  6. Applications and development trend of radiopharmaceuticals

    International Nuclear Information System (INIS)

    Kim, J.R.

    1978-01-01

    Present status of radiopharmaceuticals applications and the trend of the development are extensively reviewed and discussed. The followings are manifested: a) Among the various radionuclides, those of short lived, accelerator produced, and having moderate radiation energies are becoming popular. b) Diagnosis using various labelled molecules are considered to be the most active field in nuclear medicine. c) Development of radiopharmaceuticals for tumor localization studies is one of the trends. d) The use of various convenient kits of both in-vitro radioligand assay, and in-vivo instant labelling is now an enormous domain in nuclear medicine. A great stride is also made in the development of automation technique. Upon it, an urgent development of some new radiopharmaceuticals having local characteristics is proposed. (author)

  7. Radiopharmaceutical prescription in nuclear medicine departments

    International Nuclear Information System (INIS)

    Biechlin-Chassel, M.L.; Lao, S.; Bolot, C.; Francois-Joubert, A.

    2010-01-01

    In France, radiopharmaceutical prescription is often discussed depending to which juridical structure the nuclear medicine department is belonging. According to current regulation, this prescription is an obligation in a department linked to hospital with a pharmacy department inside. But situation remains unclear for independent nuclear medicine departments where physicians are not constrained to prescribe radiopharmaceuticals. However, as radiographers and nurses are only authorized to realize theirs acts in front of a medical prescription, one prescription must be realized. Nowadays, computerized prescription tools have been developed but only for radiopharmaceutical drugs and not for medical acts. In the aim to achieve a safer patient care, the prescription regulation may be applied whatever differences between nuclear medicines departments. (authors)

  8. Synthesis of the radiopharmaceuticals for positron emission tomography

    International Nuclear Information System (INIS)

    Biricova, V.; Kuruc, J.

    2007-01-01

    In this paper is shown a short overview of the biogenic positron radiopharmaceuticals production and a brief summary of some PET preparation synthesis. At the end the overview of some forward-looking positron radionuclides, which can be used for a preparation of the PET radiopharmaceuticals is said. A short review of diagnostic use of PET radiopharmaceuticals is presented (authors)

  9. Annual report 1979/1980

    International Nuclear Information System (INIS)

    Muenze, R.

    1981-11-01

    The annual report concentrates result of investigations in the field of the production of radioisotopes, the synthesis of radioactive compounds and their characterization. Main topics are the production of 99 Mo and the application of radioactive compounds in nuclear medicine especially as radiopharmaceuticals. A list of publications and lectures is enclosed. (author)

  10. In vitro test for pyrogenes in radiopharmaceuticals

    Energy Technology Data Exchange (ETDEWEB)

    Jovanovic, V; Zmbova, B; Bzenic, J [Institut za Nuklearne Nauke Boris Kidric, Belgrade (Yugoslavia); Berkes, J [Institut za Biohemije, Belgrade (Yugoslavia)

    1978-05-01

    Procedure and results of determination of pyrogenic substances in radiopharmaceutical preparations by an in vitro method based on the reaction between bacterial endotoxine and Limulus Amebocyte Lysate are presented. The advantage of this method as compared to the test in experimental animals performed so far has also been analyzed and proved by the fact that it enables avoidance of introduction of radioactive materials in experimental animals and of radiation effects on the results obtained in efficiency studies. The in vitro method is a quick one and requires only small quantities of the radiopharmaceutical preparation to be examined.

  11. Present status and prospect of copper radiopharmaceuticals

    International Nuclear Information System (INIS)

    Chen Huawei; Li Hongfeng; Liu Boli

    1996-01-01

    In the past decade most of the efforts of copper radiopharmaceuticals research has been focused on bis(thiosemicarbazonato) copper complexes for use in myocardial and brain imaging agents. In the present work, the analogs of bis(thiosemicarbazone) is studied in labeling antibodies and tumors. The retention mechanism of Cu-PTSM is investigated. Other kinds of ligands, BAT (N 2 S 2 ) for example, can be used to prepare neutral copper complexes in order to obtain brain radiopharmaceuticals in future. (60 refs.)

  12. Fetal absorbed doses by radiopharmaceutical administration

    International Nuclear Information System (INIS)

    Rojo, Ana M; Gomez Parada, Ines M.; Di Trano, Jose L.

    2000-01-01

    The radiopharmaceutical administration with diagnostic or therapeutic purpose during pregnancy implies a prenatal radiation dose. The dose assessment and the evaluation of the radiological risks become relevant due to the great radiosensitivity of the fetal tissues in development. This paper is a revision of the available data for estimating fetal doses in the cases of the more frequently used radiopharmaceuticals in nuclear medicine, taking into account recent investigation in placental crossover. The more frequent diagnostic and therapeutic procedures were analyzed according to the radiation doses implied. (author)

  13. Tc: chemistry and radiopharmaceuticals: a prospectus

    International Nuclear Information System (INIS)

    Tulip, T.H.

    1987-01-01

    The recent explosion in technetium chemistry evident in this symposium promises to continue unabated. As in the past, radiopharmaceutical applications will lead to new Tc chemistry. In this lecture the author will discuss those areas which appear most fertile based on chemical and radiopharmaceutical criteria. Among these will be new organometallic Tc chemistry (e.g., Tc(CNR) 6 cations), Tc complexes as metabolic tracers (e.g., Tc-analogs to FDG), and peptide-based Tc chelators (e.g., Tc-metallothionein)

  14. A study of effluent control technologies employed by radiopharmaceutical users and suppliers

    International Nuclear Information System (INIS)

    Leventhal, L.; Slider, J.; Chakoff, E.; Chen, J.I.; Savage, E.

    1980-01-01

    The quantities of radiopharmaceuticals produced for in-vivo diagnostic and therapy procedures has been estimated to be growing at the rate of 16% per year, based on 1978 sales figures. Nuclear medicine facilities are experiencing an average annual growth rate of 5% per year. The principle radionuclides produced and used for nuclear medicine are 131 I, 131 Xe, and sup(9m)Tc. Of particular concern is that amount of these radionuclides which might become airborne and escape into the environment during the process of manufacture or during aliquotting or administration by hospital personnel. Therefore, a study was made of the effluent control technology employed by radiopharmaceutical suppliers and users. Generally, the means used to control airborne radioactive effluents fall into two classes according to function. The controls either dilute and direct the effluent to a specific point of release or hold up the effluent to reduce by decay the amount of radioactivity released. Radiopharmaceutical suppliers and hospitals were contacted, and a survey made of the control technology used. The classes and types of effluent control equipment and their general characteristics, cost and effectiveness were determined. It was concluded that control equipment was readily available, reliable, and effective in reducing radioactive releases from radiopharmaceutical facilities. (author)

  15. Quality control procedures for iodinated radiopharmaceuticals 131I-Hippuran and 131I-Risa

    International Nuclear Information System (INIS)

    Toledo e Souza, I.T. de; Pereira, N.P.S. de; Silva, C.P.G. da.

    1986-02-01

    A rapid miniaturized chromatography system was developed for fast determination of the proportion of inorganic radioactive iodide from radiopharmaceutical 131 I-Hippuran and 131 I-Risa. The technical parameters associated with miniaturized chromatography system were evaluated. One of the problems found in this system was the movement of the 131 I-Risa from the origin with consequent overestimation of the inorganic iodide. A correct spot placement eliminated this problem. (Author) [pt

  16. Molecular modelling and radiopharmaceutical design

    International Nuclear Information System (INIS)

    Neves, M.; Gano, L.; Costa, M.C.; Raminhos, H.; Rosado, M.; Fausto, R.

    2002-01-01

    Aim: Among several headings for radiopharmaceuticals (RPs) design, molecular modelling (MM) could be used for the prediction of ligands and metal-complexes structures. Using MM it is also possible to simulate molecular interactions between predicted structures and specific biomolecules. Bisphosphonates (BPs) are ligands that are able to coordinate radioactive metals, such as 153 Sm, 166 Ho, 186 Re, etc., but they are all polymeric complexes difficult to characterize. It is reported that the bone uptake does not depend on the nature of metal center, but is primarily driven by the nature of the ligand, as in the case of HEDP-M (M= 99m Tc, 186 Re, 113 Sn). So, it would be interesting to estimate the relevant molecular properties of BPs by MM, simulate their interaction with hydroxyapatite (HAP) the main bone component, and then correlate the predicted molecular parameters with experimental data obtained from HAP binding and biodistribution studies of BPs carrying radioactive metals. Materials and Methods: The molecular structures and preferred conformations of BPs differing in the length of the aliphatic chain attached to their substituted amine groups (pami-dronate, olpadronate and ibandronate) were obtained using the second-generation CVFF 950 (version 1.01) force field of Hwang et al. Simulation of the interactions between the studied BPs and HAP were performed using a Cerius-2 system of programs running on a Silicon Graphics O2 workstation. BPs- 153 Sm complexes were synthesized and characterized by ITLC. Their binding to HAP and in vivo biodistribution studies were carried out as usual described in literature. Results: A direct correlation could be established between in vitro BPs affinity towards HAP and their corresponding energies from the Coulomb interactions involving the N and P atoms of the studied BPs bound to the HAP (0,0,1) surface and the nearest Ca atoms of HAP. The BPs- 153 Sm showing the highest binding to HAP and skeletal uptake are those which

  17. Radiopharmaceutical therapy of brain tumours

    International Nuclear Information System (INIS)

    Riva, P.; Franceschi, G.; Frattarelli, M.; Casi, M.; Santimaria, M.; Cremonini, A.M.; Guiducci, G.; Riva, N.

    1999-01-01

    Full text: The loco-regional radioimmunotherapy (RIT) of high-grade malignant glioma may represent a further favourable therapeutic approach, able to ameliorate the ominous prognosis of these diseases. The anti-tenascin monoclonal antibodies (MAbs) are directly injected in the tumoral bed after the operation. In the first pilot study, 81 glioblastoma patients received the MAbs (BC2 and BC4) labelled with 131 I (mean dose 2035 MBq). The toxicity was absent. The median survival was prolonged up to 25 months and the response rate (PR + CR + NED: no evidence of disease in cases with minimal lesions after customary treatments) was 44%. More recently, 90 Y instead of 131 I was employed. The benzyl-DTPA chelator was utilized for 90 Y conjugation. A phase I study was performed in 20 glioblastoma patients, who previously received all conventional regimens, but with progressive tumour. They were intralesionally given escalating 90 Y doses (185, 370, 555, 740, 925 MBq), 4 cases were included in each incremental level. No change in haematology, liver and renal parameters were encountered. The brain MTD was 925 MBq. The radiopharmaceutical remained in high amount only in the neoplastic area and did not diffuse in normal brain region nor in normal organs. The radiation dose to the tumour was, on average, 0.54 Gy per MBq of 90 Y administered (about 4 times higher in comparison to 131 I). Now a phase II study has been initiated. 30 evaluable patients (23 glioblastoma and 7 anaplastic astrocytoma; 8 newly diagnosed and 22 recurrent tumours) who have been already treated with surgery and radiotherapy, underwent loco-regional RIT, by administering a mean 90 Y dose of 740 MBq; in many cases multiple cycles were given. The median survival of patients who had the antibody infusion when their tumour burden was reduced was 28 months. The objective response consisted of 8 PD, 5 SD, 11 PR, 1 CR and 4 NED. The global response rate (PR + CR + NED) was 53.3% (47.8% in glioblastoma and 75.7% in

  18. Annual Report for Los Alamos National Laboratory Technical Area 54, Area G Disposal Facility - Fiscal Year 2011

    Energy Technology Data Exchange (ETDEWEB)

    French, Sean B. [Los Alamos National Laboratory; Shuman, Rob [WPS: WASTE PROJECTS AND SERVICES

    2012-05-22

    As a condition to the Disposal Authorization Statement issued to Los Alamos National Laboratory (LANL or the Laboratory) on March 17, 2010, a comprehensive performance assessment and composite analysis maintenance program must be implemented for the Technical Area 54, Area G disposal facility. Annual determinations of the adequacy of the performance assessment and composite analysis are to be conducted under the maintenance program to ensure that the conclusions reached by those analyses continue to be valid. This report summarizes the results of the fiscal year 2011 annual review for Area G. Revision 4 of the Area G performance assessment and composite analysis was issued in 2008 and formally approved in 2009. These analyses are expected to provide reasonable estimates of the long-term performance of Area G and, hence, the disposal facility's ability to comply with Department of Energy (DOE) performance objectives. Annual disposal receipt reviews indicate that smaller volumes of waste will require disposal in the pits and shafts at Area G relative to what was projected for the performance assessment and composite analysis. The future inventories are projected to decrease modestly for the pits but increase substantially for the shafts due to an increase in the amount of tritium that is projected to require disposal. Overall, however, changes in the projected future inventories of waste are not expected to compromise the ability of Area G to satisfy DOE performance objectives. The Area G composite analysis addresses potential impacts from all waste disposed of at the facility, as well as other sources of radioactive material that may interact with releases from Area G. The level of knowledge about the other sources included in the composite analysis has not changed sufficiently to call into question the validity of that analysis. Ongoing environmental surveillance activities are conducted at, and in the vicinity of, Area G. However, the information generated by

  19. Medical application of nuclear science: nuclear medicine and production of radiopharmaceuticals

    International Nuclear Information System (INIS)

    Cornet, L.

    1997-01-01

    Nuclear science in attendance on medicine or from Radium to Radiopharmaceuticals. By a brief historical reminder of the evolution of the radioactivity and development of nuclear science, we could see a very early interest and application of the radioactivity in the medical field. Main steps: Detection of natural radioactivity/Discovery of artificial radioactivity/First treatment of leukaemia and thyroid/First nuclear reactor/First radioisotope laboratory in hospital/First scintigraphy/First radiopharmaceutical/First cyclotron and cyclotron products/First immunoscintigraphy/Biotechnology and radioisotope/Evolution of technics [equipment for diagnosis (imaging, scintigraphy) and therapy]/Evolution of production technics and concept of products (generators of Technetium) and machines, reactor, cyclotron/Evolution of importance and interest of nuclear medicine/Creation of international association of nuclear medicine and producers (example ARPR)/Evolution of safety and pharmaceuticals regulation. After the sixties, period extremely rich in invention of products, characterized by a high fertility specially due to a non-restrictive regulation in terms of safety and pharmaceutical consideration, the evolution of technics, the importance of costs (investment, research, healthcare and the evolution of the regulations) have smoothly but continuously transformed the contexts and different actors. Consequences and facts: Rationalization and standardization of the catalogues, total integration of radiopharmaceuticals into the pharmaceutical laws, stop of nuclear research reactors, increase of number of cyclotrons, transformation of size and role of the producers and nuclear centers, risk in supply of some raw materials like Molybdenum, medical nuclear application as a worldwide business

  20. The current situation and future prospects of radiopharmaceuticals

    International Nuclear Information System (INIS)

    Ando, Atsushi

    2001-01-01

    Radiopharmaceuticals play an important role in nuclear medicine. In this paper, nuclear medicine relating to radiopharmaceuticals was briefly described. And I would like to focus on the current situation and future prospects of radiopharmaceuticals. Nuclear medicine in this century should take the following directions. Firstly, cancer treatment by radionuclides will be one of the promising fields in oncology. Secondly, in order to achieve evidence-based medicine, sensitive, quantitative imaging using the nuclides will be necessary in nuclear medicine. Under these circumstances, it is important to develop radiopharmaceuticals for sensitive, quantitative imaging and therapeutic radiopharmaceuticals. (author)

  1. Technical progress report. Private sector initiatives between the United States and Japan. January 1989 - December 1989; ANNUAL

    International Nuclear Information System (INIS)

    1990-01-01

    This annual report for calendar year 1989 describes the efforts performed under the Private Sector Initiatives contract. The report also describes those efforts that have continued with private funding after being initiated under this contract

  2. Technical progress report. Private sector initiatives between the United States and Japan. January 1991 - December 1991; ANNUAL

    International Nuclear Information System (INIS)

    1993-01-01

    This annual report for calendar year 1991 describes the efforts performed under the Private Sector Initiatives contract. The report also describes those efforts that have continued with private funding after being initiated under this contract

  3. Radiopharmaceuticals in China. Current status and prospects

    Energy Technology Data Exchange (ETDEWEB)

    Jia, Hong-Mei; Liu, Bo-Li [Beijing Normal Univ. (China). Key Laboratory of Radiopharmaceuticals

    2014-04-01

    The review provides an overview of the current status of radiopharmaceuticals in China for in vivo clinical use and also describes some important advances in the past three decades. Development of the diagnostic and therapeutic radiopharmaceuticals as well as basic research on radiopharmaceutical chemistry are being introduced. The radiotracers developed in China include: (1) Brain perfusion imaging agents and CNS radiotracers for β-amyloid plaques, σ{sub 1} receptors, and dopamine D{sub 2} or D{sub 4} receptors; (2) {sup 99m}Tc- and {sup 18}F-labeled myocardial perfusion imaging agents; (3) tumor imaging agents including integrin-targeting radiotracer, novel sentinel lymph node imaging agents, hypoxia imaging agents, {sup 99m}Tc-labeled glucose derivatives, σ{sub 2} receptor imaging agents, folate receptor imaging agents, and potential radiotracers for imaging of human telomerase reverse transcriptase expression; (4) Potential infection imaging agents; (5) Potential asialoglycoprotein receptor imaging agents; (6) Other imaging agents. Moreover, some prospects of research and development of radiopharmaceuticals in the near future are discussed. (orig.)

  4. Radiopharmaceutical chelates and method of external imaging

    International Nuclear Information System (INIS)

    Loberg, M.D.; Callery, P.S.; Cooper, M.

    1977-01-01

    A chelate of technetium-99m, cobalt-57, gallium-67, gallium-68, indium-111 or indium-113m and a substituted iminodiacetic acid or an 8-hydroxyquinoline useful as a radiopharmaceutical external imaging agent. The invention also includes preparative methods therefor

  5. Pain palliative Radiopharmaceuticals; Radiofarmacos paliativos del dolor

    Energy Technology Data Exchange (ETDEWEB)

    Gonzalez, B M [Instituto Nacional de Pediatria (Mexico)

    1994-12-31

    A pain relieving agents based on {beta} emitters mainly and in some cases a complex preparation are being given for bone metastasis in relation with breast,prostate and lung carcinoma with good performance in clinical practice.Several radionuclides and radiopharmaceuticals are mentioned giving strength to those newly proposed, 153Sm and 186Re.Bibliography.

  6. Radiopharmaceuticals for diagnosis and treatment of arthritis

    International Nuclear Information System (INIS)

    Hosain, F.; Haddon, M.J.; Hosain, H.; Drost, J.K.; Spencer, R.P.

    1990-01-01

    A brief review is given of radiopharmaceuticals for the diagnosis and treatment of arthritis. Topics covered include the pathophysiology of arthritis and the basis for the use of radiotracers, diagnostic procedures and radiotracer applications and therapeutic approaches and radionuclide applications. (UK)

  7. Safety and efficacy of radiopharmaceuticals 1987

    International Nuclear Information System (INIS)

    Kristensen, K.; Norbygaard, E.

    1987-01-01

    In this text aspects of the development of new radiopharmaceuticals are reviewed with particular reference to products of biological origin such as monoclonal antibodies and human cells. Also included in this survey are the legal aspects of the introduction of new pharmaceuticals and good radiopharmacy practice

  8. Radiopharmaceutical quality control-Pragmatic approach

    International Nuclear Information System (INIS)

    Barbier, Y.

    1994-01-01

    The quality control must be considered in a practical manner. The radiopharmaceuticals are drugs. They must satisfy the quality assurance control. These products are then conform to Pharmacopeia. But sometimes the user must control some data especially radiochemical purity and pH value. On all the administered solutions four controls are compulsory: radionuclide identity, administered radioactivity, organoleptic character and pH

  9. Design and Development of New Radiopharmaceuticals

    Energy Technology Data Exchange (ETDEWEB)

    Wagner, Jr., H. N.; Stern, H. S.; Rhodes, B. A.; Reba, R. C.; Hosain, F.; Zolle, I. [Johns Hopkins Medical Institutions, Baltimore, MD (United States)

    1969-05-15

    The major factors in the design of a new radiopharmaceutical for radioisotope scintigraphy are the photon energy of the radionuclide, the ability to incorporate the radionuclide insuitable chemical and biological form, the radiation dose to the patient, and the cost of production of the radiopharmaceutical. In this laboratory, the radionuclides, indium-113m and ytterbium-169, and technetium-99m, have been incorporated into a variety of radiopharmaceuticals. These include particles suitable for lung and liver studies, chelates for brain and kidney studies, and ionic forms for blood pool imaging. Studies in experimental animals and man indicate that these agents offer certain advantages over previously available radiopharmaceuticals. By providing larger numbers of photons, they permit more precise temporal and spatial resolution. The longer half-life of the tin-113 parent radionuclide from which indium-113m can be eluted makes indium-113m readily available, even at sites distant from the source of production. The tin-indium generator system need be purchased only every five months rather than weekly as in the case of the widely used molybdenum-technetium system. The ytterbium-radionuclide in the chemical form of a chelate is particularly useful as an inexpensive agent that provides high photon yields for renal and brain imaging. The rapid and complete biological excretion results in low radiation dose while the longer physical half-life greatly extends the shelf-life. (author)

  10. 18F based radiopharmaceuticals and automation of synthesis. New 18F radiopharmaceuticals

    International Nuclear Information System (INIS)

    Garg, P.K.; Garg, S.

    2007-01-01

    Fluorine-18 is one of the most commonly used positron emitting isotopes for clinical and research needs with a physical half-life of 110 min. PET isotopes deposit higher radiation absorbed dose than nuclear medicine isotopes. Because of their relatively short half-life, larger quantities of these isotopes are used at the start of synthesis. Therefore, increased shielding and remote automated synthesis are essential for their safe handling. Unlike other radiopharmaceuticals, it is not practical to produce PET radiopharmaceuticals at a central location for subsequent distribution to clinical and research facilities around the country. This limitation compels various academic and research facilities to manufacture their own PET radiopharmaceuticals for in-house use. For multiple reasons, 18 F fluorodeoxyglucose ([ 18 F]FDG) is one of the most commonly used radiopharmaceuticals. The synthesis of [ 18 F]FDG has been optimized and automated, thus allowing independent laboratories to produce this radiopharmaceutical safely. Nonetheless, these laboratories should acquire resources and expertise to fulfil ever increasing regulatory requirements for the safe production and usage of PET radiopharmaceuticals. In addition to [ 18 F]FDG, a wide array of new and novel radiotracers is being developed to explore various biological processes. This paper emphasizes the fact that it is possible to accomplish research and fulfil clinical needs within an academic setting with modest resources. A careful assessment of the need for due diligence in radiation safety issues is very important for the longevity of any PET research endeavour. (author)

  11. Annual meeting on nuclear technology '88. Technical session on focal points of the atomic energy law and the radiation protection law in 1988

    International Nuclear Information System (INIS)

    1988-06-01

    This issue of Annual Meeting on Nuclear Technology reports presents the papers of the technical session on 'Focal points of the atomic energy law and the radiation protection law in 1988'. The titles are: Is there a binding link between decisions of the atomic energy authority and criminal law? Conclusions to be drawn from the Alkem case court decision. - Recent developments in atomic energy law. - Current radiation protection law. - Codetermination at plant level in a nuclear installation. - The legal position of foreigners from neigbour countries in the field of atomic energy law. The licensing of nuclear installations near the border. (RST) [de

  12. Annual activities report of Brazilian Aerospace Technical Center -CTA/IEAv - 1989; Relatorio anual de atividades - CTA/IEAv - 1989

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    1990-12-31

    This document reports the research activities on nuclear physics and reactors physics and engineering in the Brazilian Aerospace Technical Center/Advanced Studies Institute, Sao Paulo State, in the year of 1989.

  13. Annual activities report of Brazilian Aerospace Technical Center -CTA/IEAv - 1989; Relatorio anual de atividades - CTA/IEAv - 1989

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    1989-12-31

    This document reports the research activities on nuclear physics and reactors physics and engineering in the Brazilian Aerospace Technical Center/Advanced Studies Institute, Sao Paulo State, in the year of 1989.

  14. Institute of Bioinorganic and Radiopharmaceutical Chemistry. Annual report 1993

    International Nuclear Information System (INIS)

    Johannsen, B.

    1994-02-01

    The subjects of the present report are described in this volume in 41 reports dealing with various aspects of radiotracers for nuclear medicine. This first part describes synthetic work on 11 C-tracers and precursors. The papers on technetium/rhenium chemistry describes the efforts to gain a deeper insight into the reactions taking place in intricate Tc/Re-ligand systems, to design more suitable and variable chelate units, and to start functionalizing these complexes in order to make them mimics of biochemical substrates or drugs. Progress has been achieved in the complexation of SH-containing peptides, mainly by the introduction of N-alkylation, which remarkably influences the properties of the complexes, by systematic alteration of the peptide chain length and derivatization. (orig./EF)

  15. Annual report of Department of Research Reactor and Tandem Accelerator, JFY2011. Operation, utilization and technical development of JRR-3, JRR-4, NSRR and tandem accelerator

    International Nuclear Information System (INIS)

    Ishii, Tetsuro; Nakamura, Kiyoshi; Kawamata, Satoshi; Ishikuro, Yasuhiro; Kawashima, Kazuhito; Kabumoto, Hiroshi; Nakamura, Takemi; Tamura, Itaru; Kawasaki, Sayuri; Sataka, Masao

    2013-03-01

    The Department of Research Reactors and Tandem Accelerator is in charge of the operation, utilization and technical development of JRR-3(Japan Research Reactor No.3), JRR-4(Japan Research Reactor No.4), NSRR(Nuclear Safety Research Reactor) and Tandem Accelerator. This annual report describes a summary of activities of services and technical developments carried out in the period between April 1, 2011 and March 31, 2012. The activities were categorized into six service/development fields: (1) Recovery from the Great East Japan Earthquake, (2) Operation and maintenance of research reactors and tandem accelerator, (3) Utilization of research reactors and tandem accelerator, (4) Upgrading of utilization techniques of research reactors and tandem accelerator, (5) Safety administration for research reactors and tandem accelerator, (6) International cooperation. Also contained are lists of publications, meetings, granted permissions on lows and regulations concerning atomic energy, number of staff members dispatched to Fukushima for the technical assistance, commendation, outcomes in service and technical developments and so on. (author)

  16. Radiopharmaceuticals and applications; Preparacoes radiofarmaceuticas e suas aplicacoes

    Energy Technology Data Exchange (ETDEWEB)

    Oliveira, Rita [Universidade Fernando Pessoa, Porto (Portugal). Fac. de Ciencias da Saude; Santos, Delfim; Ferreira, Domingos; Coelho, Pedro [Universidade do Porto (Portugal). Fac. da Farmacia; Veiga, Francisco, E-mail: fveiga@ci.uc.pt [Universidade de Coimbra (Portugal). Fac. de Farmacia

    2006-04-15

    Radiopharmaceuticals are substances without pharmacological activity that are used in Nuclear Medicine for diagnosis and therapy for several diseases. Diagnosis radiopharmaceuticals generally emit {gamma} radiation or positrons ({beta}+), because their decay originates penetrating electromagnetic radiation that can cross the tissues and be externally detected. Therapeutic radiopharmaceuticals must include in their composition ionized particles emission nucleus ({alpha}, {beta}{sup -} or Auger electrons), since their action is based in selective tissue destruction. There are two main methods for image acquisition: SPECT (Single Photon Emission Computerized Tomography) that uses {gamma} emission radionuclides ({sup 99m}Tc, {sup 123}I, {sup 67}Ga, {sup 201}Tl) and PET (Positron Emission Tomography) that uses positron emission radionuclides like {sup 11}C, {sup 13}N, {sup 15}O, {sup 18}F. Radiopharmaceuticals can be classified into perfusion radiopharmaceuticals (first generation) or specific radiopharmaceuticals (second generation). Perfusion radiopharmaceuticals are transported in the blood e reach the target organ in the direct proportion of the blood stream. Specific radiopharmaceuticals contain a biologically active molecule that binds to cellular receptors that must remain biospecific after binding to the radiopharmaceutical. For this type of radiopharmaceuticals, tissue or organ uptake is determined by the biomolecule capacity of recognizing receptors in those biological structures. Radiopharmaceuticals are produced ready to use, in cold kits or in autologal preparations. According to the preparation type there is a different quality control procedure. Most of the radiopharmaceuticals used nowadays are of the perfusion type. Research focus in the development of specific radiopharmaceuticals that can provide information, at the molecular level, of biochemical alterations associated to different pathologies. (author)

  17. The technical results of the Swedish nuclear weapons programme - a compilation of FOAs annual reports 1945-1972

    International Nuclear Information System (INIS)

    Oliver, L.; Stenholm, L.

    2002-02-01

    The aim with this report is to summarise FOAs nuclear weapons related research that was performed 1945-1972. The report is a compilation of FOAs annual reports that originally were in a classified form but have now - mostly - been declassified. References to separate reports in the different research areas are included in the report

  18. 76 FR 18649 - Technical Revisions to Actuarial Information on Form 5500 Annual Return/Report for Pension Plans...

    Science.gov (United States)

    2011-04-05

    ... to Actuarial Information on Form 5500 Annual Return/Report for Pension Plans Electing Funding Alternatives Under Pension Relief Act of 2010 AGENCY: Employee Benefits Security Administration, Labor. ACTION... retroactively available to defined benefit pension plans under the Preservation of Access to Care for Medicare...

  19. Proceedings of the ninth annual DOE low-level waste management forum: executive summary, technical and special session summaries, attendees

    International Nuclear Information System (INIS)

    Anon.

    1988-01-01

    This first volume of proceedings contains summaries of each of six technical sessions as well as three special sessions held during the conference. The six technical sessions were: Disposal technology and facility development (15 papers); Institutional and regulatory issues (10); Performance assessment (14); Waste characterization and verification (7); Site closure and stabilization (6); and Waste treatment (8). The three special sessions were: 1) Review of criteria for guidance on alternative disposal technology; 2) Hazardous waste regulatory update; and 3) Challenges to meeting the 1993 deadline. All papers have been indexed for inclusion on the Energy Data Base

  20. Magnetic Fusion Energy Program. Volume I. Introduction, technical summaries, list of publications, etc., Appendices A-K. Annual report

    International Nuclear Information System (INIS)

    Aamodt, R.E.; Byrne, R.N.; Catto, P.J.

    1979-12-01

    An abstract was prepared for the progress summary on transport theory for open and closed magnetic configurations. Seven abstracts were prepared for included appendices of more detailed work on individual devices. Also included is a list of publications, technical presentations, and DOE program contributions

  1. Development of an injectable formulation for the preparation of radiopharmaceutical 68Ga-DOTA-Sar gastrin

    International Nuclear Information System (INIS)

    Castillo P, M.

    2015-01-01

    The CCK2 receptor (cholecystokinin) is located in areas of the central and peripheral nervous system and is over expressed in several types of human cancer, as medullar thyroid, lung and ovarian carcinomas. One of the endogenous ligands for the CCK2 receptor is the gastrin, so that radiolabeled peptides analogues to gastrin as Sar gastrin (Gln-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Nle-Asp-Phe-NH 2 ) have been proposed as potential diagnostic radiopharmaceuticals for obtaining tumors images with CCK2 receptors over expressed. The 68 Ga is an ideal candidate for the peptides radiolabelled and has favorable characteristics to be used for diagnostic purposes by imaging with Positron emission tomography (PET). This work aimed to verify the technical documentation of the production process of radiopharmaceutical 68 Ga-DOTA-Sar gastrin for its sanitary registration before the Comision Federal contra Riesgos Sanitarios (COFEPRIS) in Mexico. For optimization of the production process was assessed a factorial design of two variables with mixed levels (27 combinations), where the dependent variable was the radiochemical purity. The analytical method used for evaluating the content of Sar gastrin peptide in the injectable formulation was also validated by High-performance liquid chromatography. Subsequently the validation of the production process was carried out by manufacturing of lots in single-dose of the optimized injectable formulation of the radiopharmaceutical 68 Ga-DOTA-Sar gastrin and the stability study was conducted at different times to determine the useful life time. The following was established as the optimal pharmaceutical formulation: 185 MBq of 68 Ga, 50 μg de DOTA-Sar gastrin, 14 mg of sodium acetate and 0.5 m L of buffer acetates, 1.0 M, ph 4.22 in 2.5 m L of the vehicle. The analytical method used to determine the radiochemical purity of the formulation satisfied the requirements for the intended analytical application. The lots in

  2. Adverse reactions to radiopharmaceuticals and their reporting

    International Nuclear Information System (INIS)

    Keeling, D.

    1988-01-01

    Adverse reactions to radiopharmaceuticals are uncommon and the great majority that do occur are relatively trivial and require little or no treatment. Reporting schemes for such reactions are in operation in a number of countries but they vary in their effectiveness and the best collect only a minority of cases; only 10-15% of total reactions in the United Kingdom, for instance. Radiopharmaceutical reaction reports in the UK for the period 1982-1987 are summarised in a table and then discussed. Reliable incidence figures for such reactions are difficult to obtain. The UK figure is estimated here to be near 1 per 2000. The great majority of reactions reported are of an idiopathic hypersensitivity nature and are related to the chemical form of the material; radiation has very rarely caused recognisable problems since the discontinuance of colloid gold for lymphatic clearance studies. The value of such reaction reports is their role as a forewarning to doctors

  3. Detection of sentinel nodes with radiopharmaceuticals

    International Nuclear Information System (INIS)

    Yokoyama, Kunihiko; Michigishi, Takatoshi; Kinuya, Seigo; Konishi, Shota; Nakajima, Kenichi; Tonami, Norihisa

    2000-01-01

    Sentinel lymph nodes have been found to be an indicator of lymph node metastasis in breast cancer. In Japan, the theory and concept of sentinel lymph nodes in breast cancer have begun to be applied to carcinomas of the digestive system. Based on clinical experience in the detection of sentinel lymph nodes with radiopharmaceuticals, differences and similarities between the radiopharmaceuticals, methods, and techniques used to detect sentinel lymph nodes have been assessed in relation to breast cancer and carcinomas of the digestive system (including carcinomas of the esophagus and large intestine). The greatest difference between the methods used for breast and digestive cancers is the site of administration of the radiopharmaceutical. In breast cancer, the radiopharmaceutical is administered into a superficial organ (i.e., the mammary gland), whereas in carcinomas of the digestive system, it is administered into a deep organ (i.e., digestive tract). Another obvious difference is in lymph flow, i.e., the flow of the mammary glands is subcutaneous whereas lymph flow in the digestive tract is submucosal. Two radionuclide diagnostic methods are available to detect sentinel lymph nodes: sentinel lymphoscintigraphy with a gamma camera and a method that involves the use of a gamma probe intraoperatively. Radiopharmaceuticals used to detect sentinel lymph nodes must be smoothly transferred from the site of administration into the lymph, and uptake by the sentinel lymph node must continue for a long time without excessive flowing to lower reaches. The optimal particle size remains a matter of controversy, and no radiopharmaceuticals appropriate for lymphoscintigraphy have ever been approved in Japan. The authors compared the pharmacokinetics of three different radiopharmaceuticals used for sentinel lymphoscintigraphy in breast cancer ( 99m Tc-labeled albumin, 99m Tc-labeled tin colloid, and 99m Tc-labeled phytic acid) and founded that the detection rate was lowest with

  4. Innovative radiopharmaceuticals in oncology and neurology

    CERN Document Server

    Barbet, Jacques; Chérel, Michel; Guilloteau, Denis

    2017-01-01

    The aim of this Research Topic was to assemble a series of articles describing basic, preclinical and clinical research studies on radiopharmaceuticals and nuclear medicine. The articles were written by attendees of the third Nuclear Technologies for Health Symposium (NTHS, 10th-11th March 2015, Nantes, Frances) under the auspices of the IRON LabEx (Innovative Radiopharmaceuticals for Oncology and Neurology Laboratory of Excellence). This French network, gathering approximately 160 scientists from 12 academic research teams (Funded by “investissements d’Avenir”), fosters transdisciplinary projects between teams with expertise in chemistry, radiochemistry, radiopharmacy, formulation, biology, nuclear medicine and medical physics. The 12 articles within this resulting eBook present a series of comprehensive reviews and original research papers on multimodality imaging and targeted radionuclide therapy; illustrating the different facets of studies currently conducted in these domains.

  5. Computational chemistry and metal-based radiopharmaceuticals

    International Nuclear Information System (INIS)

    Neves, M.; Fausto, R.

    1998-01-01

    Computer-assisted techniques have found extensive use in the design of organic pharmaceuticals but have not been widely applied on metal complexes, particularly on radiopharmaceuticals. Some examples of computer generated structures of complexes of In, Ga and Tc with N, S, O and P donor ligands are referred. Besides parameters directly related with molecular geometries, molecular properties of the predicted structures, as ionic charges or dipole moments, are considered to be related with biodistribution studies. The structure of a series of oxo neutral Tc-biguanide complexes are predicted by molecular mechanics calculations, and their interactions with water molecules or peptide chains correlated with experimental data of partition coefficients and percentage of human protein binding. The results stress the interest of using molecular modelling to predict molecular properties of metal-based radiopharmaceuticals, which can be successfully correlated with results of in vitro studies. (author)

  6. Radiochemical syntheses further radiopharmaceuticals for positron emission tomography and new strategies for their production

    CERN Document Server

    Kilbourn, Michael R; Kilbourn, Michael R

    2015-01-01

    This book describes methods and procedures for preparing PET radiopharmaceuticals, and highlights new methods for conducting radiochemical reactions with carbon-11 (C11) and fluorine-18 (F18), which are two of the most commonly used radionuclides in positron emission tomography (PET) imaging.     Provides reliable methods for radiochemical syntheses and reactions, including all essential information to duplicate the procedure     Eliminates the time-consuming process of searching journal articles and extracting pertinent details from lengthy experimental sections or supporting information     Focuses on an emerging and important area for pharmaceutical and medical applications     Encompasses technical, regulatory, and application aspects     Includes solid-phase radiochemistry, transition-metal catalyzed radiochemistry, microfluidics, click chemistry, green radiochemistry and new strategies for radiopharmaceutical quality control.

  7. Radiopharmaceutical chelates and method of external imaging

    International Nuclear Information System (INIS)

    1976-01-01

    The preparation of the following chemicals is described: chelates of technetium-99m, cobalt-57, gallium-67, gallium-68, indium-111 or indium-113m and a substituted iminodiacetic acid or an 8-hydroxyquinoline useful as a radiopharmaceutical external imaging agent. The compounds described are suitable for intravenous injection, have an excellent in vivo stability and are good organ seekers. Tin(II) choride or other tin(II) compounds are used as chelating agents

  8. Radiation absorbed dose from medically administered radiopharmaceuticals

    International Nuclear Information System (INIS)

    Roedler, H.D.; Kaul, A.

    1975-01-01

    The use of radiopharmaceuticals for medical examinations is increasing. Surveys carried out in West Berlin show a 20% average yearly increase in such examinations. This implies an increased genetic and somatic radiation exposure of the population in general. Determination of radiation exposure of the population as well as of individual patients examined requires a knowledge of the radiation dose absorbed by each organ affected by each examination. An extensive survey of the literature revealed that different authors reported widely different dose values for the same defined examination methods and radiopharmaceuticals. The reason for this can be found in the uncertainty of the available biokinetic data for dose calculations and in the application of various mathematical models to describe the kinetics and calculation of organ doses. Therefore, the authors recalculated some of the dose values published for radiopharmaceuticals used in patients by applying biokinetic data obtained from exponential models of usable metabolism data reported in the literature. The calculation of organ dose values was done according to the concept of absorbed fractions in its extended form. For all radiopharmaceuticals used in nuclear medicine the energy dose values for the most important organs (ovaries, testicles, liver, lungs, spleen, kidneys, skeleton, total body or residual body) were recalculated and tabulated for the gonads, skeleton and critical or examined organs respectively. These dose values are compared with those reported in the literature and the reasons for the observed deviations are discussed. On the basis of recalculated dose values for the gonads and bone-marrow as well as on the basis of results of statistical surveys in West Berlin, the genetically significant dose and the somatically (leukemia) significant dose were calculated for 1970 and estimated for 1975. For 1970 the GSD was 0.2 mrad and the LSD was 0.7 mrad. For 1975 the GSD is estimated at < 0.5 mrad and the

  9. Radiopharmaceuticals to 99mTc

    International Nuclear Information System (INIS)

    Leon Cabana, Alba

    1994-01-01

    Studies about 99m Tc had demonstrated that have favorable properties for support diagnostic proceedings in nuclear medicine. This physical and chemical properties used for obtain another radiopharmaceuticals have been employed through re actives kits labelled with Tc 99m . A brief description was given about 99m utilities in diagnostic techniques such as endothelium reticular system,renal and hepatic studies,bone scintillators,cardiac diagnostic and cerebral perfusion

  10. Considerations and controversies in the selection of radiopharmaceuticals

    International Nuclear Information System (INIS)

    Chilton, H.M.; Cowan, R.J.

    1987-01-01

    When a radiopharmaceutical is selected for a specific study, multiple factors must be considered to ensure that optimum clinical information will be provided with minimum radiation exposure to the patient and laboratory personnel. In this endeavor, certain questions must be considered. What are the nuclear properties of the available radiopharmaceuticals? For the organ to be studied, are there multiple radiopharmaceutical localization pathways? If so, which is best suited to provide the desired diagnostic information? Does the presence of certain clinical factors preclude the use of some radiopharmaceuticals and require the use of others? Do certain radiopharmaceuticals have overriding radiopharmacologic properties which limit their usefulness for the evaluation of certain clinical situations? Finally, how significant are non-clinical properties such as cost, availability, and product formulation? In this chapter, some of these areas and several situations which illustrate the radiopharmaceutical selection process are discussed

  11. The ARPANSA quality assurance program for radiopharmaceuticals

    International Nuclear Information System (INIS)

    Baldas, J.; Ivanov, Z.

    2003-01-01

    Full text: The Australian Radiation Protection and Nuclear Safety Agency (ARPANSA) conducts a radiopharmaceutical quality assurance test program in which radiopharmaceuticals used in nuclear medicine in Australia are tested for compliance with specifications. Where the radiopharmaceutical is the subject of a monograph in the British Pharmacopoeia or the European Pharmacopoeia, then the specifications given in these Pharmacopoeias are adopted. Where a monograph is only available in the US Pharmacopoeia, then this specification is generally adopted. In other cases the specifications quoted have been adopted by this Agency. Animal biodistribution testing was discontinued in 1997 due to resource limitation. Samples for testing were obtained through commercial channels. All technetium-99m cold kits were reconstituted according to the directions in the package insert using Sodium Pertechnetate [ 99m Tc] injection. The results of testing conducted by the ARPANSA during 1984-1999 are summarised. A significant cause of failure to meet full specifications has been due to non-compliance of the vial/package labels. Copyright (2003) The Australian and New Zealand Society of Nuclear Medicine Inc

  12. Association Euratom - Risø National Laboratory for Sustainable Energy, Technical University of Denmark - Annual Progress Report 2009

    DEFF Research Database (Denmark)

    Korsholm, Søren Bang; Michelsen, Poul; Juul Rasmussen, Jens

    The programme of the Research Unit of the Fusion Association Euratom - Risø National Laboratory for Sustainable Energy, Technical University of Denmark, covers work in fusion plasma physics and in fusion technology. The fusion plasma physics research focuses on turbulence and transport, and its...... superconductors. Minor activities are system analysis, initiative to involve Danish industry in ITER contracts and public information. A summary is presented of the results obtained in the Research Unit during 2009....

  13. Association Euratom - Risø National Laboratory for Sustainable Energy, Technical University of Denmark - Annual Progress Report 2008

    DEFF Research Database (Denmark)

    Korsholm, Søren Bang; Michelsen, Poul; Juul Rasmussen, Jens

    The programme of the Research Unit of the Fusion Association Euratom - Risø National Laboratory for Sustainable Energy, Technical University of Denmark, covers work in fusion plasma physics and in fusion technology. The fusion plasma physics research focuses on turbulence and transport, and its...... been initiated in 2008. Minor activities are system analysis, initiative to involve Danish industry in ITER contracts and public information. A summary is presented of the results obtained in the Research Unit during 2008....

  14. Annual meeting on nuclear technology '85. Technical session on nuclear power plant simulators. Jahrestagung Kerntechnik '85. Fachsitzung Simulatoren bei Kernkraftwerken

    Energy Technology Data Exchange (ETDEWEB)

    1987-01-01

    The ten lectures read at this Technical Session deal with nuclear power plant simulators and their functions for the training of control room personnel, with test facilities for analysis and simulation of incidents and the relevant plant behaviour, and with the computer codes for fast simulation of reactor processes. The papers explain in particular the HAMMLAB project, the COSIMA fast core simulator, and the OPAL simulator for the KWU convoy process information system named PRINS.

  15. A study on bacterial endotoxins test of radiopharmaceuticals with limulus agent

    Energy Technology Data Exchange (ETDEWEB)

    Suozhen, Bai; Kai, Luyu; Cheng, Luo [Academia Sinica, Beijing, BJ (China). Inst. of Atomic Energy; Ruiting, Zhang; Zhenmin, Xia [National Inst. for the Control of Pharmaceutical and Biological Products (China)

    1989-08-01

    The feasibility of endotoxins test of radiopharmaceuticals with limulus agent and the approach to take off the inhibition/enhancement effect of radiopharmaceuticals on limulus agent have been studied. Results of the test for 8 radiopharmaceuticals have been given.

  16. The progress on researching method and metabolism of positron radiopharmaceutical

    International Nuclear Information System (INIS)

    Gan Hongmei; Qiao Jinping; Kong Aiying; Zhu Lin

    2010-01-01

    Positron radiopharmaceuticals are mainly used for PET studies, which are used in the field of nuclear medicine as tracers in the diagnosis and treatment of many diseases. They have important position and function in the clinical diagnosis and treatment. Metabolism or biotransformation will happen when PET radio-pharmaceuticals enter into the body. Understanding the metabolic fate of radiopharmaceutical probes is essential for an accurate analysis and interpretation of positron emission tomography imaging. The recent research progress on PET radiopharmaceuticals metabolism was reviewed in this paper, including the metabolism characteristics, research methods, analytical techniques and so on. (authors)

  17. Radiopharmaceuticals drug interactions: a critical review

    Directory of Open Access Journals (Sweden)

    Ralph Santos-Oliveira

    2008-12-01

    Full Text Available Radiopharmaceuticals play a critical role in modern medicine primarily for diagnostic purposes, but also for monitoring disease progression and response to treatment. As the use of image has been increased, so has the use of prescription medications. These trends increase the risk of interactions between medications and radiopharmaceuticals. These interactions which have an impact on image by competing with the radiopharmaceutical for binding sites for example can lead to false negative results. Drugs that accelerate the metabolism of the radiopharmaceutical can have a positive impact (i.e. speeding its clearance or, if repeating image is needed, a negative impact. In some cases, for example in cardiac image among patients taking doxirubacin, these interactions may have a therapeutic benefit. The incidence of drug-radiopharmaceuticals adverse reactions is unknown, since they may not be reported or even recognized. Here,we compiled the medical literature, using the criteria of a systematic review established by the Cochrane Collaboration, on pharmaceutical-drug interactions to provide a summary of documented interactions by organ system and radiopharmaceuticals. The purpose is to provide a reference on drug interactions that could inform the nuclear medicine staff in their daily routine. Efforts to increase adverse event reporting, and ideally consolidate reports worldwide, can provide a critically needed resource for prevention of drug-radiopharmaceuticals interactions.Os radiofármacos desempenham função crítica na medicina moderna, primariamente para fins diagnósticos, mas também no monitoramento da progressão de doenças assim como na avaliação de respostas ao tratamento. O uso da tecnologia por imagem tem crescido e conseqüentemente as prescrições de medicamentos (radiofármacos em especial com esse propósito. Este fato, aumenta o risco de interações entre medicamentos e radiofármacos. Interações que podem ter um impacto na

  18. GPHS-RTGs in support of the Cassini Mission. Semi annual technical report, 30 September 1996--30 March 1997

    International Nuclear Information System (INIS)

    1997-01-01

    The technical progress achieved during the period 27 January through 30 September 1996 through 30 March 1997 on Contract DE-AC03-91SF18852 Radioisotope Thermoelectric Generators and Ancillary Activities is described. This report is organized by program task structure: spacecraft integration and liaison; engineering support; safety; qualified unicouple production; ETG fabrication, assembly, and test; ground support equipment (GSE); RTG shipping and launch support; designs, reviews, and mission applications; project management, quality assurance, reliability, contract changes, CAGO acquisition (operating funds), and CAGO maintenance and repair; and CAGO acquisition (capital funds)

  19. Proceedings of the Canadian Society for Bioengineering CSBE/SCGAB 2009 annual general meeting and technical conference

    International Nuclear Information System (INIS)

    2009-01-01

    This conference was attended by experts on current issues in engineering of an urban ecosystem, composting, biofuels and green energy. The meeting provided a forum to discuss advances in the application of engineering principles and practices dealing with biological systems for the production of food, bioproducts and energy. The discussions focused on engineering practices in agriculture, forestry, bioresources, biochemistry and biosystems. The 7 technical sessions of the conference were entitled: aquaculture; safety and training; bioprocessing; energy production and biofuels; environment and ecology; soil and water; and development of technologies. The conference feature 58 presentations, of which 9 have been catalogued separately for inclusion in this database. refs., tabs., figs

  20. Application of a small molecule radiopharmaceutical concept to improve kinetics

    International Nuclear Information System (INIS)

    Jeong, Jae Min

    2016-01-01

    Recently, large molecules or nanoparticles are actively studied as radiopharmaceuticals. However, their kinetics is problematic because of a slow penetration through the capillaries and slow distribution to the target. To improve the kinetics, a two-step targeting method can be applied by using small molecules and very rapid copper-free click reaction. Although this method might have limitations such as internalization of the first targeted conjugate, it will provide high target-to-non-target ratio imaging of radiopharmaceuticals. The majority of radiopharmaceuticals belong to small molecules of which the molecular weight is less than 2000 Da, and the molecular size is smaller than 2 nm generally. The outstanding feature of the small molecule radiopharmaceuticals compared to large molecules is with their kinetics. Their distribution to target and clearance from non-target tissues are very rapid, which is the essential requirement of radiopharmaceuticals. In conclusion, the small molecule radiopharmaceuticals generally show excellent biodistribution properties; however, they show poor efficiency of radioisotope delivery. Large molecule or nanoparticle radiopharmaceuticals have advantages of multimodal and efficient delivery, but lower target-to-non-target ratio. Two-step targeting using a bio-orthogonal copper-free click reaction can be a solution of the problem of large molecule or nanoparticle radiopharmaceuticals. The majority of radiopharmaceuticals belong to small molecules of which the molecular weight is less than 2000 Da, and the molecular size is smaller than 2 nm generally. The outstanding feature of the small molecule radiopharmaceuticals compared to large molecules is with their kinetics. Their distribution to target and clearance from non-target tissues are very rapid, which is the essential requirement of radiopharmaceuticals

  1. Application of a small molecule radiopharmaceutical concept to improve kinetics

    Energy Technology Data Exchange (ETDEWEB)

    Jeong, Jae Min [Dept. of Nuclear Medicine, Seoul National University College of Medicine, Seoul (Korea, Republic of)

    2016-06-15

    Recently, large molecules or nanoparticles are actively studied as radiopharmaceuticals. However, their kinetics is problematic because of a slow penetration through the capillaries and slow distribution to the target. To improve the kinetics, a two-step targeting method can be applied by using small molecules and very rapid copper-free click reaction. Although this method might have limitations such as internalization of the first targeted conjugate, it will provide high target-to-non-target ratio imaging of radiopharmaceuticals. The majority of radiopharmaceuticals belong to small molecules of which the molecular weight is less than 2000 Da, and the molecular size is smaller than 2 nm generally. The outstanding feature of the small molecule radiopharmaceuticals compared to large molecules is with their kinetics. Their distribution to target and clearance from non-target tissues are very rapid, which is the essential requirement of radiopharmaceuticals. In conclusion, the small molecule radiopharmaceuticals generally show excellent biodistribution properties; however, they show poor efficiency of radioisotope delivery. Large molecule or nanoparticle radiopharmaceuticals have advantages of multimodal and efficient delivery, but lower target-to-non-target ratio. Two-step targeting using a bio-orthogonal copper-free click reaction can be a solution of the problem of large molecule or nanoparticle radiopharmaceuticals. The majority of radiopharmaceuticals belong to small molecules of which the molecular weight is less than 2000 Da, and the molecular size is smaller than 2 nm generally. The outstanding feature of the small molecule radiopharmaceuticals compared to large molecules is with their kinetics. Their distribution to target and clearance from non-target tissues are very rapid, which is the essential requirement of radiopharmaceuticals.

  2. Difficulties and aspects to take into account in the production, use and distribution of new radiopharmaceuticals PET; Difficultes et aspects a prendre en compte dans la production, l'utilisation et la distribution des nouveaux radiopharmaceutiques TEP

    Energy Technology Data Exchange (ETDEWEB)

    Sanchez, R.; Rayo, J.I.; Serrano, J.; Infante, J.; Luz Dominguez, M.; Garcia, L.; Duran, C. [Hospital Infanta Cristina, Servicio de Medicina Nuclear, Badajoz (Spain)

    2008-10-15

    This article seeks to describe the requirements, legal and technical, for the production, distribution and use of new radiopharmaceuticals PET (other than the {sup 18}F.D.G.), describing the legislative framework in which we find ourselves, the characteristics of a production and types of synthesis and existing modules. A list of susceptible radiopharmaceuticals is presented that are being currently used in nuclear medicine by specifying the real possibilities of their production and use and which are the difficulties we face.

  3. Preparation of Radiopharmaceuticals Labeled with Metal Radionuclides

    Energy Technology Data Exchange (ETDEWEB)

    Welch, M.J.

    2012-02-16

    The overall goal of this project was to develop methods for the production of metal-based radionuclides, to develop metal-based radiopharmaceuticals and in a limited number of cases, to translate these agents to the clinical situation. Initial work concentrated on the application of the radionuclides of Cu, Cu-60, Cu-61 and Cu-64, as well as application of Ga-68 radiopharmaceuticals. Initially Cu-64 was produced at the Missouri University Research Reactor and experiments carried out at Washington University. A limited number of studies were carried out utilizing Cu-62, a generator produced radionuclide produced by Mallinckrodt Inc. (now Covidien). In these studies, copper-62-labeled pyruvaldehyde Bis(N{sup 4}-methylthiosemicarbazonato)-copper(II) was studied as an agent for cerebral myocardial perfusion. A remote system for the production of this radiopharmaceutical was developed and a limited number of patient studies carried out with this agent. Various other copper radiopharmaceuticals were investigated, these included copper labeled blood imaging agents as well as Cu-64 labeled antibodies. Cu-64 labeled antibodies targeting colon cancer were translated to the human situation. Cu-64 was also used to label peptides (Cu-64 octriatide) and this is one of the first applications of a peptide radiolabeled with a positron emitting metal radionuclide. Investigations were then pursued on the preparation of the copper radionuclides on a small biomedical cyclotron. A system for the production of high specific activity Cu-64 was developed and initially the Cu-64 was utilized to study the hypoxic imaging agent Cu-64 ATSM. Utilizing the same target system, other positron emitting metal radionuclides were produced, these were Y-86 and Ga-66. Radiopharmaceuticals were labeled utilizing both of these radionuclides. Many studies were carried out in animal models on the uptake of Cu-ATSM in hypoxic tissue. The hypothesis is that Cu-ATSM retention in vivo is dependent upon the

  4. ANL Technical Support Program for DOE Environmental Restoration and Waste Management. Annual report, October 1992--September 1993

    International Nuclear Information System (INIS)

    Bates, J.K.; Bourcier, W.L.; Bradley, C.R.

    1994-06-01

    This report is an overview of the progress during FY 1993 for the Technical Support Program that is part of the ANL Technology Support Activity for DOE Environmental Restoration and Waste Management (EM). The purpose is to evaluate, before hot start-up of the Defense Waste Processing Facility (DWPF) and the West Valley Demonstration Project (WVDP), factors that are anticipated to affect glass reaction in an unsaturated environment typical of what may be expected for the candidate Yucca Mountain repository site. Specific goals for the testing program include the following: reviewing and evaluating available data on parameters that will be important in establishing the long-term performance of glass in a repository environment; performing tests to further quantify the effects of important variables where there are deficiencies in the available data; and initiating long-term tests to determine glass performance under a range of conditions applicable to repository disposal

  5. Gas-Cooled Thermal Reactor Program. Annual technical progress report for the period ending September 30, 1981

    International Nuclear Information System (INIS)

    1982-03-01

    This report provides descriptions and results of the technical effort during FY81 on the Gas-Cooled Thermal Reactor Program. The FY81 work was organized according to the Work Breakdown Structure (WBS) for the National HTGR Program, and fell within five of the WBS tasks. The work on Market Definition and Development (WBS 03) was associated with estimating product costs for HTGR systems and their alternatives, projecting markets and market penetrations for these systems, and providing costs and market input to application analyses and component design. The Plant Technology (WBS 13) effort was mainly in the development of the systems dynamic computer code, STAR, for the transient analysis of HTGR's in reformer applications. The analysis of pebble bed reactors (PBR) was performed under Technology Transfer (WBS 15). The effort on components and systems within the nuclear heat source for reforming plants was performed under High Temperature Nuclear Heat Source (WBS 42)

  6. DOE-DARPA High-Performance Corrosion-Resistant Materials (HPCRM), Annual HPCRM Team Meeting & Technical Review

    Energy Technology Data Exchange (ETDEWEB)

    Farmer, J; Brown, B; Bayles, B; Lemieux, T; Choi, J; Ajdelsztajn, L; Dannenberg, J; Lavernia, E; Schoenung, J; Branagan, D; Blue, C; Peter, B; Beardsley, B; Graeve, O; Aprigliano, L; Yang, N; Perepezko, J; Hildal, K; Kaufman, L; Lewandowski, J; Perepezko, J; Hildal, K; Kaufman, L; Lewandowski, J; Boudreau, J

    2007-09-21

    The overall goal is to develop high-performance corrosion-resistant iron-based amorphous-metal coatings for prolonged trouble-free use in very aggressive environments: seawater & hot geothermal brines. The specific technical objectives are: (1) Synthesize Fe-based amorphous-metal coating with corrosion resistance comparable/superior to Ni-based Alloy C-22; (2) Establish processing parameter windows for applying and controlling coating attributes (porosity, density, bonding); (3) Assess possible cost savings through substitution of Fe-based material for more expensive Ni-based Alloy C-22; (4) Demonstrate practical fabrication processes; (5) Produce quality materials and data with complete traceability for nuclear applications; and (6) Develop, validate and calibrate computational models to enable life prediction and process design.

  7. Facilitation of the Estuary/Ocean Subgroup and the Expert Regional Technical Group, Fiscal Year 2013 Annual Report

    Energy Technology Data Exchange (ETDEWEB)

    Johnson, Gary E.; Sather, Nichole K.

    2013-10-30

    This project covers facilitation of the Estuary/Ocean Subgroup (EOS) for federal research, monitoring, and evaluation (RME) and the Expert Regional Technical Group (ERTG) for estuary habitat restoration. The EOS is part of the research, monitoring, and evaluation effort that the Action Agencies (Bonneville Power Administration [BPA], U.S. Army Corps of Engineers [Corps], U.S. Bureau of Reclamation) developed in response to obligations arising from the Endangered Species Act as applied to operation of the Federal Columbia River Power System (FCRPS). The EOS is tasked by National Marine Fisheries Service (NMFS) and the Action Agencies (AAs) to design and coordinate implementation of the federal RME plan for the lower Columbia River and estuary, including the river’s plume in the ocean. Initiated in 2002, the EOS is composed of members from BPA, the Corps, NMFS, and Pacific Northwest National Laboratory’s (PNNL’s) Marine Sciences Laboratory, and other agencies as necessary.

  8. Characterization of atmospheric emissions of a radiopharmaceutical' s production unit

    Energy Technology Data Exchange (ETDEWEB)

    Siqueira, Gessilane M.; Barreto, Alberto A.; Maletta, Paulo G.M.; Alves, Thaís A.N., E-mail: gessilane.siqueira@cdtn.br, E-mail: aab@cdtn.br, E-mail: pgmm@cdtn.br, E-mail: aryadnenasc@gmail.com [Centro de Desenvolvimento da Tecnologia Nuclear (CDTN/CNEN-MG), Belo Horizonte - MG (Brazil)

    2017-07-01

    Cyclotrons are radiative facilities capable of synthesizing radioisotopes that will be used for the production of radiopharmaceuticals. The increasing use of these substances in diagnostic therapies and procedures in nuclear medicine implies the need to increase the production of radiopharmaceuticals. In this context, it is fundamental, from the point of view of environmental radioprotection, to characterize atmospheric emissions from this type of production, in order to make feasible studies of radiological impacts, especially with a view to human health and environmental preservation. It is premise that facilities must ensure the radiological safety of exposed individuals through the control of discharges into the environment. This work aims to characterize the atmospheric emissions behavior of a Radiopharmaceutical Research and Production Unit (RRPU). The emission data for the radionuclides C-11, F-18, and N-13, associated to the production of radiopharmaceuticals ({sup 18}F-FES, {sup 18}F-FDG, {sup 18}FCOL, {sup 18}F-FLT, Na{sup 18}F) during the year 2016 were analyzed. Emissions data are collected every 10 seconds from a sensor installed in the unit's exhaust system. The pre-processing of these data was done by spreadsheets (Excel®) and exported to a statistical package (Minitab16®) to characterize the behavior of these emissions. The results of this study aim to contribute: to the study of atmospheric dispersion of radionuclides in the region of interest; to evaluate the operational control measures of the investigated facility; and to evaluate the radiological impacts in the region neighboring the facility. This methodology has been used in atmospheric dispersion modeling studies in the RRPU and the results showed that the annual doses from the emissions are within the limits established by the radioprotection norms of the Brazilian National Nuclear Energy Commission. Additionally, it is believed that the information generated in this study

  9. Radiopharmaceuticals for nuclear cardiology; Radiofarmacos para cardiologica nuclear

    Energy Technology Data Exchange (ETDEWEB)

    Leon Cabana, Alba [Universidad de la Republica, Facultad de Quimica (Uruguay)

    1994-12-31

    One of the diagnostic technique periodically used in Nuclear Medicine is the angiographic studi e, employee for detect cardiovascular diseases. The radiopharmaceutical more used in the angiographic ones is 99mTc. Between thetopics described in the present work it find: myocardial infarction, radiopharmaceuticals classification for cardiac studies, labelled proceedings, cardiovascular diseases.

  10. Factors and pharmaceuticals that affect the radiopharmaceuticals bio distributions

    International Nuclear Information System (INIS)

    Gonzalez, B.M.

    1994-01-01

    The pattern of biodistribution of radiopharmaceuticals may be affected by various agents and therapeutical procedures, chemotherapy agents, thyroid hormones, metals, radiotherapy, surgery, anesthetic agents, dialysis other radiopharmaceutical interactions. Recommendations for the detection of altered biodistribution in patients by causes not directly related with the pathology itself was given. pathology itself was given

  11. Radiopharmaceuticals for oncology: status and newer trends- an overview

    International Nuclear Information System (INIS)

    Ramamoorthy, N.; Prabhakar, G.

    1997-01-01

    Radiopharmaceuticals have provided a powerful means in the diagnosis and follow up of cancer patients. Radiopharmaceuticals for the treatment of metastatic thyroid cancer and palliation of metastatic bone pain are in extensive use. Newer agents are on the anvil for more efficacious diagnosis and therapy. This article gives an overview of the status and trends in this context. (author)

  12. Sixth international radiopharmaceutical dosimetry symposium: Proceedings. Volume 2

    Energy Technology Data Exchange (ETDEWEB)

    S.-Stelson, A.T. [ed.] [comp.; Stabin, M.G.; Sparks, R.B. [eds.; Smith, F.B. [comp.

    1999-01-01

    This conference was held May 7--10 in Gatlinburg, Tennessee. The purpose of this conference was to provide a multidisciplinary forum for exchange of state-of-the-art information on radiopharmaceutical dosimetry. Attention is focused on the following: quantitative analysis and treatment planning; cellular and small-scale dosimetry; dosimetric models; radiopharmaceutical kinetics and dosimetry; and animal models, extrapolation, and uncertainty.

  13. Molecular design of 99Tcm labelled radiopharmaceuticals. Pt.2

    International Nuclear Information System (INIS)

    Wang Xuebin; Chu Jinfeng

    2003-01-01

    The structure-activity relationship of 99 Tc m labelled radiopharmaceuticals and the correlative contents of computer aided drug design are introduced. Of them, quantitative structure-activity relationship and its application to design 99 Tc m labelled radiopharmaceuticals are narrated on emphases

  14. Ionisation constants of radiopharmaceuticals by HPLC

    Energy Technology Data Exchange (ETDEWEB)

    Stylli, C.G.; Theobald, A.E.

    It has long been recognised that the pKsub(a) of drugs and radiopharmaceuticals is an important determinant of their biological distribution. In this study an HPLC method for pKa measurement has been developed for radiotracers. It has been validated with several amines and used to estimate the pKsub(a) values of some Tc-99m PnAO complexes by observing the change in chromatographic retention with change in mobile phase pH. The pKsub(a) values were estimated from the data by three methods: derivative analysis, quadratic regression, and the Henderson - Hasselbalch equation.

  15. Ionisation constants of radiopharmaceuticals by HPLC

    International Nuclear Information System (INIS)

    Stylli, C.G.; Theobald, A.E.

    1986-01-01

    It has long been recognised that the pKsub(a) of drugs and radiopharmaceuticals is an important determinant of their biological distribution. In this study an HPLC method for pKa measurement has been developed for radiotracers. It has been validated with several amines and used to estimate the pKsub(a) values of some Tc-99m PnAO complexes by observing the change in chromatographic retention with change in mobile phase pH. The pKsub(a) values were estimated from the data by three methods: derivative analysis, quadratic regression, and the Henderson - Hasselbalch equation. (author)

  16. Results of quality control studies of technetium 99m labelled radiopharmaceuticals prepared from kits

    International Nuclear Information System (INIS)

    McLean, J.R.; Rockwell, L.J.; Welsh, W.J.

    1978-01-01

    This report summarizes the results of quality control studies of Tc 99m labelled normal serum albumin and macro-aggregated albumin radiopharmaceuticals prepared from commercially available kits. It includes all analyses performed since the inception of the program in 1976 until the end of 1977. The results presented herein were obtained through the application of various in vitro tests and animal (mouse) bio-distribution studies. It is hoped that a similar report will be published annually for the benefit of hospital nuclear medicine departments and kit manufacturers. (auth)

  17. Trends in radiopharmaceutical dispensing in a regional nuclear pharmacy

    International Nuclear Information System (INIS)

    Basmadjian, G.P.; Johnston, J.; Barker, K.; Ice, R.D.

    1982-01-01

    Dispensing trends for radiopharmaceuticals at a regional nuclear pharmacy over a 51-month period were studied. dispensing records of a regional nuclear pharmacy were analyzed with a forecasting procedure that uses univariate time data to produce time trends and autoregressive models. The overall number of prescriptions increased from 3500 to 5500 per quarter. Radiopharmaceuticals used in nuclear cardiology studies increased from less than 0.1% to 17.5% of total prescriptions dispensed, while radiopharmaceuticals used for brain imaging showed a steady decline from 29% to 11% of total prescriptions dispensed. The demand for other radiopharmaceuticals increased in areas such as renal studies, bone studies, lung studies, liver-function studies, and 67 Ga tumor-uptake studies, and declined slightly for static liver studies. Changes in dispensing trends for radiopharmaceuticals will continue as the practice of nuclear medicine concentrates more on functional studies and as newer imaging techniques become used for other purposes

  18. Evaluation of quality control of radiopharmaceuticals in Nuclear Medicine service

    International Nuclear Information System (INIS)

    Tavares, Jamille A. Lopes; Lira, Renata F. de; Santos, Marcus Aurelio P. dos

    2014-01-01

    Radiopharmaceuticals are a type of pharmaceutical preparation associated with radionuclides with purpose of diagnosis and therapy. Nuclear Medicine Services (NMS) should perform quality control of radiopharmaceuticals according to the recommendations of the manufacturer and scientific evidences accepted by the National Agency Sanitary Surveillance ( Brazilian ANVISA). This study evaluated the quality of the main radiopharmaceuticals in a NMS of the state of Pernambuco in relation to pH and radiochemical purity. The results showed that 96.8% of the radiopharmaceuticals showed radiochemical purity and all pH values were within the range recommended by the American pharmacopoeia. The study found that the quality control when inserted into the NMS, provides important data that allows exclusion of radiopharmaceuticals with low radiochemistry purity, favoring a reliable diagnosis and ensuring good radiation protection practices and biosecurity for patient and occupationally exposed individuals

  19. The IAEA Activities on Supporting Development of Therapeutic Radiopharmaceuticals and Capacity Building in Member States

    Energy Technology Data Exchange (ETDEWEB)

    Pillai, M R.A.; Haji-Saeid, M; Zaknun, J; Ramamoorthy, N [Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna (Austria)

    2009-07-01

    The IAEA activities on supporting development of therapeutic radiopharmaceuticals are focused on identified radionuclides that can be produced in large quantities and making use of carrier molecules which can be synthesized locally or procured from commercial sources or already available in MS from other related programs. The main emphasis is on {sup 90}Y and {sup 177}Lu based products, which cover the hard beta energy and soft beta energy range respectively, and also since both these radionuclides can be produced in large quantities with very high specific activity and high radionuclidic purity. The services to MS are provided through implementing Coordinated Research Projects (CRP), Technical Cooperation (TC) projects, technical meetings and regional training courses in addition to documenting practically useful technical information related to these products though IAEA publications. The CRP is a group activity in which nearly 15 participants from as many countries come together to work towards an identified objective. Two of the completed CRPs in this area are: (i) Comparative evaluation of therapeutic radiopharmaceuticals (2002-2005) that focussed on the development of 'in vitro' and 'in vivo' techniques for evaluating new generation therapeutic radiopharmaceuticals; and (ii) Development of generator technologies for therapeutic radionuclides (2004-2007) that addressed technologies for {sup 90}Sr/{sup 90}Y and {sup 188}W/{sup 188}Re generators and which can be easily adapted by MS. The participants in the CRP on 'Comparative evaluation of therapeutic radiopharmaceuticals' used the somatostatin analogue, DOTATATE as the lead molecule for developing radiopharmaceuticals and testing the efficacy by in vitro biological assays and animal biodistribution studies. A significant outcome of the CRP was that {sup 177}Lu-DOTATATE therapy is now practised in several of the CRP participating countries including Brazil, India, Italy, and Poland. The major outcome of the CRP

  20. Radiopharmaceuticals labelled with positron-emitting radioisotopes

    International Nuclear Information System (INIS)

    Comar, D.; Berridge, M.; Maziere, B.; Crouzel, C.

    1982-01-01

    This chapter reviews the preparation of radioisotopes for biochemical and physiological studies and the principal methods for their incorporation into radiopharmaceuticals, while pointing out the problems encountered with their use and considering their medical interest in the following areas: distribution and flow of fluids, metabolic and pharmacokinetic studies. Inorganic and organic radiopharmaceuticals presently in use and most probable to be used in the future are reviewed. It is anticipated that three types of products labelled with 15 O, 13 N, 11 C and 18 F will be developed in the future. The first type includes products which trace general phenomena such as fluid movement or metabolism of sugars, fats and proteins. The compromise between physiological accuracy and imaging technology is discussed in relation to the use of 11 C and 18 F. The second type of product is one to measure more specific parameters such as those of molecular transport kinetics, membrane permeability, cellular pH and receptor-ligand interactions, again with particular reference to 11 C and 18 F. The third type of product discussed is that intended for pharmacology studies, particular reference being made to 68 Ga, 82 Rb. Extensive bibliography. (U.K.)

  1. Preparation of kits for 99Tcm radiopharmaceuticals

    International Nuclear Information System (INIS)

    1992-05-01

    This publication details preparation under Good Manufacturing Practices (GMP) of thirteen widely used 99 Tc m radiopharmaceuticals and their quality assurance practices. The objective of this document is to present to those who intend to launch a kit preparation programme a set of preparation procedures and other relevant information gathered during kit production over a period of more than a decade, to serve as a good starting point. The manuals and monographs included in the document are based on the experience gained in two major centres. The publication of this material is intended to give a typical example, and not the only possible procedure for preparing the kits. Following the essentials of these kit preparation procedures, it is always possible to make alterations to the composition of the kits. The kits described here concern widely used 99 Tc m radiopharmaceuticals which do not require a Single Photon Emission Computed Tomography (SPECT) camera. These examples of the ''first generation'' of kits are not very intricate to prepare. Although it is advisable to have only one agent for a given intended use, a few agents for each purpose, e.g. EHDP and MDP for bone imagining, have been included in the document so that the reader can have some flexibility in selecting a particular kit. 24 refs, 2 figs

  2. In search of scar seeking radiopharmaceuticals

    Energy Technology Data Exchange (ETDEWEB)

    Salehi, N.; Lawlor, J.M.; Lichtenstein, M.; Allaway, M.; Barencevic, A. [Royal Melbourne Hospital, Melbourne, VIC (Australia). Department of Nuclear Medicine]|[University of Melbourne, VIC (Australia)

    1998-03-01

    Full text: Sensitive detection of acute peri-osseous scar tissue should be valuable for detection of partial ligamentous, tears and other common rheumatological conditions including back pain and ligamentous scars. Our aim was to investigate acute scar uptake of {sup 99m}Tc(V)-DMSA (dimercapto-succinic-acid), {sup 99m}Tc-DMAD (di- methyl-aminodiphosphonate) compared to {sup 99m}Tc-MDP (methylen-diphosphonate), the standard bone-scanning radiopharmaceutical. New Zealand white rabbits were anaesthetised and had 5-7cm of their mid-line abdominal wall surgically incised. At 24, 48, 72, 96 and 240 hours post surgery, 74 MBq (2 mCi) of the above radiopharmaceuticals were injected intravenously and scintigraphy performed 2.5 hours later. Relative count rate in scar is tabulated. In conclusion, the increased activity in the acute surgical site and lesser bone uptake confirmed that Tc (V)-DMSA and Tc-DMAD are superior to Tc- MDP for detection of new scar tissue in the region of bone. 1 tab.

  3. Annual report on operation, utilization and technical development of hot laboratories. From April 1, 2001 to March 31, 2002

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    2003-01-01

    This is an annual report in a fiscal year of 2001 that describes activities of the Reactor Fuel Examination Facility (RFEF), the Waste Safety Testing Facility (WASTEF), and the Research Hot Laboratory (RHL) in the Department of Hot laboratories. In RFEF, PIEs including destructive and nondestructive tests were performed on a BWR fuel assembly and/or its fuel rod irradiated in the Fukushima-2 Nuclear Power Station Unit-1 and a fuel assembly with UO{sub 2}-Gd{sub 2}O{sub 3} and mixed oxide (MOX) fuel pellets for Japan Nuclear Cycle Development Institute. In addition, 34 fuel assemblies irradiated in the nuclear ship ''Mutsu'' were conveyed from Mutsu Establishment, and re-assembly and PIEs for the assemblies were carried out. In WASTEF, tests for evaluating barrier performance in terms of disposal of waste, high temperature tests for evaluating stable on TRansUraniums (TRU) nitrides, leaching tests on Rock-like OXide (ROX) fuels were performed. The slow Strain Rate Tests (SSRT) apparatuses were installed for investigation of Irradiation-Assisted Stress Corrosion Cracking (IASCC) on light water structural materials, and characterization tests for the apparatus were performed. In RHL, PIEs for light water reactor materials, fusion materials, and target materials of Proton Accelerator Facilities were carried out for laboratories in Japan Atomic Energy Research Institute. PIEs for zirconium alloys for ultra-high burn-up irradiated in the Kashiwazaki Nuclear Power Station Unit-5 were also performed. In order to investigate roots cause of pipe rupture in Hamaoka Nuclear Power Station Unit-1 of Chubu Electric Power Company, several examinations including SEM observation, EPMA, and Vickers hardness test were performed in those three facilities. The data from the examinations greatly contribute to clarify roots cause of the pipe rupture. (author)

  4. Annual report on operation, utilization and technical development of hot laboratories. From April 1, 2001 to March 31, 2002

    International Nuclear Information System (INIS)

    2003-01-01

    This is an annual report in a fiscal year of 2001 that describes activities of the Reactor Fuel Examination Facility (RFEF), the Waste Safety Testing Facility (WASTEF), and the Research Hot Laboratory (RHL) in the Department of Hot laboratories. In RFEF, PIEs including destructive and nondestructive tests were performed on a BWR fuel assembly and/or its fuel rod irradiated in the Fukushima-2 Nuclear Power Station Unit-1 and a fuel assembly with UO 2 -Gd 2 O 3 and mixed oxide (MOX) fuel pellets for Japan Nuclear Cycle Development Institute. In addition, 34 fuel assemblies irradiated in the nuclear ship ''Mutsu'' were conveyed from Mutsu Establishment, and re-assembly and PIEs for the assemblies were carried out. In WASTEF, tests for evaluating barrier performance in terms of disposal of waste, high temperature tests for evaluating stable on TRansUraniums (TRU) nitrides, leaching tests on Rock-like OXide (ROX) fuels were performed. The slow Strain Rate Tests (SSRT) apparatuses were installed for investigation of Irradiation-Assisted Stress Corrosion Cracking (IASCC) on light water structural materials, and characterization tests for the apparatus were performed. In RHL, PIEs for light water reactor materials, fusion materials, and target materials of Proton Accelerator Facilities were carried out for laboratories in Japan Atomic Energy Research Institute. PIEs for zirconium alloys for ultra-high burn-up irradiated in the Kashiwazaki Nuclear Power Station Unit-5 were also performed. In order to investigate roots cause of pipe rupture in Hamaoka Nuclear Power Station Unit-1 of Chubu Electric Power Company, several examinations including SEM observation, EPMA, and Vickers hardness test were performed in those three facilities. The data from the examinations greatly contribute to clarify roots cause of the pipe rupture. (author)

  5. ANL technical support program for DOE Environmental Restoration and Waste Management. Annual report, October 1991--September 1992

    Energy Technology Data Exchange (ETDEWEB)

    Bates, J.K.; Bradley, C.R.; Buck, E.C.; Cunnane, J.C.; Dietz, N.L.; Ebert, W.L.; Emery, J.W.; Feng, X.; Gerding, T.J.; Gong, M.; Hoh, J.C.; Mazer, J.J.; Wronkiewicz, D.J. [Argonne National Lab., IL (United States); Bourcier, W.L.; Morgan, L.E.; Newton, L.; Nielsen, J.K.; Phillips, B.L. [Lawrence Livermore National Lab., CA (United States); Ewing, R.C.; Wang, L. [Univ. of New Mexico, Albuquerque, NM (United States); Li, H.; Tomozawa, M. [Rensselaer Polytechnic Inst., Troy, NY (United States)

    1993-05-01

    A program was established for DOE Environmental Restoration and Waste Management (EM) to evaluate factors that are anticipated to affect waste glass reaction during repository disposal, especially in an unsaturated environment typical of what may be expected for the proposed Yucca Mountain repository site. This report covers progress in FY 1992 on the following tasks: 1. A compendium of the characteristics of high-level nuclear waste borosilicate glass has been written. 2. A critical review of important parameters that affect the reactivity of glass in an unsaturated environment is being prepared. 3. A series of tests has been started to evaluate the reactivity of fully radioactive glasses in a high-level waste repository environment and compare it to the reactivity of synthetic, nonradioactive glasses of similar composition. 4. The effect of radiation upon the durability of waste glasses at a high glass surface area-to-liquid volume (SA/V) ratio and a high gas-to-liquid volume ratio will be assessed. These tests address both vapor and high SA/V liquid conditions. 5. A series of tests is being performed to compare the extent of reaction of nuclear waste glasses at various SAN ratios. Such differences in the SAN ratio may significantly affect glass durability. 6. A series of natural analogue tests is being analyzed to demonstrate a meaningful relationship between experimental and natural alteration conditions. 7. Analytical electron microscopy (AEM), infrared spectroscopys and nuclear resonant profiling are being used to assess the glass/water reaction pathway by identifying intermediate phases that appear on the reacting glass. Additionally, colloids from the leach solutions are being studied using AEM. 8. A technical review of AEM results is being provided. 9. A study of water diffusion involving nuclear waste glasses is being performed. 10. A mechanistically based model is being developed to predict the performance of glass over repository-relevant time periods.

  6. Biomass as Feedstock for a Bioenergy and Bioproducts Industry: The Technical Feasability of a Billion-Ton Annual Supply

    Energy Technology Data Exchange (ETDEWEB)

    Perlack, R.D.

    2005-12-15

    The U.S. Department of Energy (DOE) and the U.S. Department of Agriculture (USDA) are both strongly committed to expanding the role of biomass as an energy source. In particular, they support biomass fuels and products as a way to reduce the need for oil and gas imports; to support the growth of agriculture, forestry, and rural economies; and to foster major new domestic industries--biorefineries--making a variety of fuels, chemicals, and other products. As part of this effort, the Biomass R&D Technical Advisory Committee, a panel established by the Congress to guide the future direction of federally funded biomass R&D, envisioned a 30 percent replacement of the current U.S. petroleum consumption with biofuels by 2030. Biomass--all plant and plant-derived materials including animal manure, not just starch, sugar, oil crops already used for food and energy--has great potential to provide renewable energy for America's future. Biomass recently surpassed hydropower as the largest domestic source of renewable energy and currently provides over 3 percent of the total energy consumption in the United States. In addition to the many benefits common to renewable energy, biomass is particularly attractive because it is the only current renewable source of liquid transportation fuel. This, of course, makes it invaluable in reducing oil imports--one of our most pressing energy needs. A key question, however, is how large a role could biomass play in responding to the nation's energy demands. Assuming that economic and financial policies and advances in conversion technologies make biomass fuels and products more economically viable, could the biorefinery industry be large enough to have a significant impact on energy supply and oil imports? Any and all contributions are certainly needed, but would the biomass potential be sufficiently large to justify the necessary capital replacements in the fuels and automobile sectors? The purpose of this report is to determine

  7. World Radiopharmaceutical Therapy Council: A report on the 5th International Radiopharmaceutical Therapy Colloquium and the Final Planning Meeting of the World Radiopharmaceutical Therapy Council held at Santiago, Chile, 29 September, 2002

    International Nuclear Information System (INIS)

    Turner, J.V.

    2003-01-01

    -stenosis of coronary arteries following balloon angioplasty was presented by Achim Kropp of Dresden, Amalia Peix of Havana, and June-Key Chung from Seoul who also reported encouraging radiation synovectomy results. Hans Biersack described preliminary studies from Bonn with 188Re MAG3 RC-160 and 188Re-DOTATOC radiopeptides and the potential clinical applications of other 188Re radiopharmaceuticals for radiopeptide therapy and radioimmunotherapy were contemplated, given the daily on-site supply of radionuclide from the 188W/188Re generator. The Final Planning Meeting of the World Radiopharmaceutical Therapy Council, chaired by Harvey Turner, was held during the last session of the Colloquium and discussion was facilitated by a panel of members of the International Task Force of the Council comprising Horacio Amaral, Suresh Srivastava and Alan Perkins. A Preliminary Draft Charter of the World Radiopharmaceutical Therapy Council had been prepared by the Task Force with notable contributions from Sandy McEwan and Chaitanya Divgi and had been circulated to all attendees of the Foundation Planning Meeting of the Council held during the Annual Scientific Meeting of the Society of Nuclear Medicine, June 2001 in Toronto. This draft document was presented for detailed discussion at the Final Planning Meeting in Chile and embodied the principles of global cooperation in therapeutic nuclear medicine outlined in the first issue of the Journal. A Consensus Draft Charter subsequently prepared by the International Task Force was then submitted to the Assembly of Delegates of the World Federation of Nuclear Medicine and Biology on 1st October 2002. The proposal that the World Radiopharmaceutical Therapy Council become an affiliated body of the World Federation of Nuclear Medicine and Biology was adopted without dissent, having been proposed by the President, Horacio Amaral and supported by the Incoming President, Myung Chul Lee. The World Radiopharmaceutical Therapy Council will become an

  8. Good Practice for Introducing Radiopharmaceuticals for Clinical Use

    International Nuclear Information System (INIS)

    2016-02-01

    The use of new radiopharmaceuticals can provide extremely valuable information in the evaluation of cancer, as well as heart and brain diseases. Information that often times cannot be obtained by other means. However, there is a perceived need in many Member States for a useful reference to facilitate and expedite the introduction of radiopharmaceuticals already in clinical use in other countries. This publication intends to provide practical support for the introduction of new radiotracers, including recommendations on the necessary steps needed to facilitate and expedite the introduction of radiopharmaceuticals in clinical use, while ensuring that a safe and high quality product is administered to the patient at all times

  9. Radiation hygiene problems of radiopharmaceutical preparation at nuclear medicine units

    International Nuclear Information System (INIS)

    Pekarek, J.; Kukacka, R.

    1977-01-01

    The problems of magistral radiopharmaceuticals preparation are indicated and the layout of a unit for the magistral preparation of radiopharmaceuticals is described. The results are briefly reported of a study of radiation load of laboratory personnel preparing radiopharmaceuticals as against doctors actually applying them. It was found that the exposure of hands to ionizing radiation represents the highest hazard for the laboratory personnel. The most important radiation protection principles are pointed out, such as the use of protective clothing, regular preventive medical examinations, appropriately shielded radionuclides and radionuclide generators to be supplied by manufacturers, and a more frequent rotation of personnel working with active and nonactive preparations. (L.O.)

  10. The radiopharmaceuticals labelled with technetium-99m and the radiopharmacy

    International Nuclear Information System (INIS)

    Bodenant, V.

    1998-01-01

    In less than fifty years, the place of nuclear medicine is become primordial. Among all the radiopharmaceuticals used in nuclear medicine, the technetium-99m is the most used because of its physico-chemical properties and its great availability with the molybdenum-99m - technetium-99m generator. Since 1992, the radiopharmaceuticals, the packages, the generators are included in the pharmaceutic monopole. They are now under the reliability of the radio-pharmacist. This thesis has for object to introduce these different radiopharmaceuticals labelled with technetium-99m and to show the primordial place of the radio-pharmacist in a service of nuclear medicine. (N.C.)

  11. Analytics of radiochmical impurities in radiopharmaceutics. Pt. 4

    International Nuclear Information System (INIS)

    Heide, L.; Stamm, A.; Boegl, W.

    1981-01-01

    The radiopharmaceutics have been compiled in the present volume in the form of a medicament encyclopaedia. The term radiopharmaceutic has been very broadly covered so that one can find pharmaceutics which are applied in clinical routine as well as for veterinary tests or are being or have been tested. Preparates for radio-immuno assays are also recorded. All analysis methods are considered even if these only slightly differ from one another. Methods described in the literature are given which have resulted in a bad or no separation of the radiopharmaceutics from the impurities. (orig./MG) [de

  12. Breast feeding's interruption following radiopharmaceutical administration to nursing mothers

    International Nuclear Information System (INIS)

    Rojo, A.M.; Gomez Parada, I.M.; Dubner, D.; Gisone, P.; Perez de Serrano, M.

    1995-01-01

    The radiopharmaceutical administration to lactating women for therapeutic or diagnostic purpose can achieve a radiological risk to the breast feeding child due to levels of radioactivity in the breast milk. International recommendations regarding safe assumption of nursing mother after radiopharmaceutical administration were analysed. We examined the formula proposed by Rommey et al. to establish objective guidelines in case of the administration of radiopharmaceutical to nursing mothers. The ICRP 54 metabolic model for iodine was modified in order to calculate the suppression breast feeding's period according to the radioactivity measured in the breast milk. (author). 6 refs., 1 fig., 1 tab

  13. Universitaet Mainz, Institut fuer Kernchemie. Annual report 1998

    International Nuclear Information System (INIS)

    Denschlag, H.O.

    1999-03-01

    The annual report concentrates on three research activities of major interest: (1) Nuclear chemistry in the sense of approaches to fundamental problems which also relate to nuclear physics (nuclear fission, chemistry of the heaviest elements, excitation of giant dipole resonance, Halo nuclei, radiochemical astrophysics (structure of neutron-rich nuclei, prediction of half-lives and P n -values, elemental abundances), metal clusters in vacuum). (2) Radiopharmaceutical chemistry and applications in nuclear medicine (synthesis of radiopharmaceuticals using 3 H and 18 F, in vitro and in vivo evaluation of radiopharmaceuticals, diagnostics using PET, solid-state target systems, development and test of radiopharmaceuticals using isotopes of As, Y, Nb, Nd, and Re). (3) Environmental analysis (humic acid complexes of actinides and lanthanides, disintegration products of cellulose, ultratrace analysis using RIMS, determination of Th and U in the environment and in urine, AOX determination in waste waters, anthropogenic γ emitters in ground level air). (orig./CB) [de

  14. Radiopharmaceuticals in metastatic bone pain palliation

    International Nuclear Information System (INIS)

    Garcia, Enrique; Alberti, Alejandro; Cruz Arencibia, Jorge; Morin Zorrilla, Jose

    2012-01-01

    In the present work the current status of the use of Radiopharmaceuticals in the treatment of the pain provoked by bony metastasis is revised. Particular attention is devoted to the used doses, the effectiveness and security of the existent products in the market and in development. The convenience of the routine use in the case of multiple metastasis is established, since the results are adequate and the risks acceptable. The doses are examined, the adverse effects and the importance of the costs is indicated and related with it the supply of Radionuclides. Reference is made so much to the practice of countries developed as to that of countries of smaller resources. It is pointed out the Cuban experience and the perspectives of the use in our country.(author)

  15. Use of radiopharmaceuticals in Finland in 1997

    International Nuclear Information System (INIS)

    Korpela, H.

    1999-04-01

    The use of radiopharmaceuticals in diagnostics and therapy has been surveyed by STUK - Radiation and Nuclear Safety Authority. In 1997 the number of nuclear medicine examinations was 51,700, and the number of treatments 2,240. In 1994 the number of nuclear medicine examinations had been 50,900, and the number of treatments 2,150. In 1997 the collective effective dose received by patients was 207 manSv, and the mean effective dose received by the population was 0.04 mSv per person. In 1994 the collective effective dose had been 220 manSv. Numbers of nuclear medicine examinations and treatments have not changed much from 1994. The collective effective dose has slightly decreased. The main reason for the reduction is decreased use of the radionuclide 131 I. (orig.)

  16. Good practice in the production of radiopharmaceuticals

    International Nuclear Information System (INIS)

    Cruz Arencibia, Jorge

    2012-01-01

    In the paper the evolution of concepts regarding the quality of the pharmaceutical products is analyzed in the framework of the production of radiopharmaceuticals at CENTIS. The world trends range from the quality control of the fi nal product to the comprehensive concept of quality management. It is concluded from the analysis that CENTIS has an appropriate system of Good Manufacturing Practice as a result of 15 years of systematic, growing and qualified attention to the issue, in correspondence with the world tendencies and the continuous support of CECMED, the Cuban regulatory authority. That is certified by the fact that all the production processes of CENTIS have been licensed and all the CENTIS products in the market have been registered. The existing conditions at CENTIS are favorable to establish and certificate a Quality Management System. (author)

  17. Use of radiopharmaceuticals in Finland in 1997

    International Nuclear Information System (INIS)

    Korpela, H.

    1999-02-01

    A survey on the use of radiopharmaceuticals in diagnostics and therapy has been made by STUK Radiation and Nuclear Safety Authority in Finland. In 1997 the number of nuclear medicine examinations was 51 700 and that of the therapeutic treatments was 2 240. In 1994 the number of nuclear medicine examinations was 50 900 and that of therapeutic treatments was 2 150. The collective effective dose to the patients was 207 manSv and the mean effective dose to the population was 0.04 mSv per person. In 1994 the collective effective dose was 220 manSv. The numbers of nuclear medicine examinations and of therapeutic treatments have not changed much when compared to those in 1994. The collective effective dose has decreased. The main reason for that is the decreased use of the radionuclide 131 I. (orig.)

  18. Rationale and radiopharmaceuticals for myocardial imaging

    International Nuclear Information System (INIS)

    Poe, N.D.

    1976-01-01

    Static radionuclide imaging procedures are now available for evaluating regional myocardial perfusion and for detecting acute myocardial infarction. Thallium-201, a radiopharmaceutical which possesses many of the characteristics of potassium analogs, at present is receiving the greatest attention as a regional blood flow indicator. Ischemic lesions appear as areas of decreased tracer uptake. Unfortunately, this agent is expensive, is in limited supply and has a photopeak which is low for optimum imaging. Positive infarct images can be obtained with various technetium-99m chelates. Pyrophosphate appears to be the best of the technetium compounds studied to date although the mechanism of uptake of the chelates has not yet been fully elucidated. Therefore, quantitative measurements of infarct size are not justified. As perfusion imaging and infarct imaging provide useful, complementary data, a dual tracer approach to evaluating patients with suspected coronary artery disease and/or myocardial infarction is probably justifiable

  19. Laboratory methods to evaluate therapeutic radiopharmaceuticals

    International Nuclear Information System (INIS)

    Arteaga de Murphy, C.; Rodriguez-Cortes, J.; Pedraza-Lopez, M.; Ramirez-Iglesias, MT.; Ferro-Flores, G.

    2007-01-01

    The overall aim of this coordinated research project was to develop in vivo and in vitro laboratory methods to evaluate therapeutic radiopharmaceuticals. Towards this end, the laboratory methods used in this study are described in detail. Two peptides - an 8 amino acid minigastrin analogue and octreotate - were labelled with 177 Lu. Bombesin was labelled with 99 mTc, and its diagnostic utility was proven. For comparison, 99 mTc-TOC was used. The cell lines used in this study were AR42J cells, which overexpress somatostatin receptors found in neuroendocrine cancers, and PC3 cells, which overexpress gastric releasing peptide receptors (GRP-r) found in human prostate and breast cancers. The animal model chosen was athymic mice with implanted dorsal tumours of pathologically confirmed cell cancers. The methodology described for labelling, quality control, and in vitro and in vivo assays can be easily used with other radionuclides and other peptides of interest. (author)

  20. Use of radiopharmaceuticals in Finland in 1997

    Energy Technology Data Exchange (ETDEWEB)

    Korpela, H

    1999-04-01

    The use of radiopharmaceuticals in diagnostics and therapy has been surveyed by STUK - Radiation and Nuclear Safety Authority. In 1997 the number of nuclear medicine examinations was 51,700, and the number of treatments 2,240. In 1994 the number of nuclear medicine examinations had been 50,900, and the number of treatments 2,150. In 1997 the collective effective dose received by patients was 207 manSv, and the mean effective dose received by the population was 0.04 mSv per person. In 1994 the collective effective dose had been 220 manSv. Numbers of nuclear medicine examinations and treatments have not changed much from 1994. The collective effective dose has slightly decreased. The main reason for the reduction is decreased use of the radionuclide {sup 131}I. (orig.) 4 refs.

  1. Development of peptide and protein based radiopharmaceuticals.

    Science.gov (United States)

    Wynendaele, Evelien; Bracke, Nathalie; Stalmans, Sofie; De Spiegeleer, Bart

    2014-01-01

    Radiolabelled peptides and proteins have recently gained great interest as theranostics, due to their numerous and considerable advantages over small (organic) molecules. Developmental procedures of these radiolabelled biomolecules start with the radiolabelling process, greatly defined by the amino acid composition of the molecule and the radionuclide used. Depending on the radionuclide selection, radiolabelling starting materials are whether or not essential for efficient radiolabelling, resulting in direct or indirect radioiodination, radiometal-chelate coupling, indirect radiofluorination or (3)H/(14)C-labelling. Before preclinical investigations are performed, quality control analyses of the synthesized radiopharmaceutical are recommended to eliminate false positive or negative functionality results, e.g. changed receptor binding properties due to (radiolabelled) impurities. Therefore, radionuclidic, radiochemical and chemical purity are investigated, next to the general peptide attributes as described in the European and the United States Pharmacopeia. Moreover, in vitro and in vivo stability characteristics of the peptides and proteins also need to be explored, seen their strong sensitivity to proteinases and peptidases, together with radiolysis and trans-chelation phenomena of the radiopharmaceuticals. In vitro biomedical characterization of the radiolabelled peptides and proteins is performed by saturation, kinetic and competition binding assays, analyzing KD, Bmax, kon, koff and internalization properties, taking into account the chemical and metabolic stability and adsorption events inherent to peptides and proteins. In vivo biodistribution can be adapted by linker, chelate or radionuclide modifications, minimizing normal tissue (e.g. kidney and liver) radiation, and resulting in favorable dosimetry analyses. Finally, clinical trials are initiated, eventually leading to the marketing of radiolabelled peptides and proteins for PET/SPECT-imaging and therapy

  2. High temperature turbine technology program. Phase II. Technology test and support studies. Annual technical progress report, January 1, 1979-December 31, 1979

    Energy Technology Data Exchange (ETDEWEB)

    1980-01-01

    Work performed on the High Temperature Turbine Technology Program, Phase II - Technology Test and Support Studies during the period from January 1, 1979 through December 31, 1979 is summarized. Objectives of the program elements as well as technical progress and problems encountered during this Phase II annual reporting period are presented. Progress on design, fabrication and checkout of test facilities and test rigs is described. LP turbine cascade tests were concluded. 350 hours of testing were conducted on the LP rig engine first with clean distillate fuel and then with fly ash particulates injected into the hot gas stream. Design and fabrication of the turbine spool technology rig components are described. TSTR 60/sup 0/ sector combustor rig fabrication and testing are reviewed. Progress in the design and fabrication of TSTR cascade rig components for operation on both distillate fuel and low Btu gas is described. The new coal-derived gaseous fuel synthesizing facility is reviewed. Results and future plans for the supporting metallurgical programs are discussed.

  3. Introduction to the use of FRAM on the effectiveness assessment of a radiopharmaceutical dispatches process

    Energy Technology Data Exchange (ETDEWEB)

    Pereira, Ana G.A.A., E-mail: agaap@ien.gov.br [Instituto de Engenharia Nuclear (IEN/CNEN-RJ), Rio de Janeiro, RJ (Brazil)

    2013-07-01

    This article aims to make an introduction to the use of Functional Resonance Analysis Method (FRAM) on the effectiveness assessment of a specific radiopharmaceutical dispatching process. The main purpose was to provide a didactic view of the method application to further in-depth analysis. The investigation also provided a relevant body of knowledge of radiopharmaceuticals dispatches processes. This work uses the term 'effectiveness assessment' instead of 'risk assessment' due to the broader meaning the former provide. The radiopharmaceutical dispatching process is the final task of a dynamic system designed to attend several medical facilities. It is comprised by functions involving mostly human activities, such as checking and packaging the product and measuring the radiopharmaceutical nuclear activity. Although the dispatch process has well-known steps for its completion, the human factor is the fundamental mechanism of work and control, being susceptible of irregular and instable performance. As a socio-technical system, the risk assessment provided by FRAM may be of importance for safety and quality improvements, even more if considered the nuclear nature of the product, which makes risk assessment critical and mandatory. A system is safe if it is resistant and resilient to perturbations. Identification and assessment of possible risks is, therefore, an essential prerequisite for system safety. Although this seems obvious, most risk assessments are conducted under relative ignorance of the full behavior of the system. Such condition has lead to an approach to assess the risks of intractable systems (i.e., systems that are incompletely described or under specified), namely Resilience Engineering. Into this area, the Functional Resonance Analysis Method has been developed in order to provide concepts, terminology and a set of methods capable of dealing with such systems. The study was conducted following the Functional Resonance Analysis

  4. Introduction to the use of FRAM on the effectiveness assessment of a radiopharmaceutical dispatches process

    International Nuclear Information System (INIS)

    Pereira, Ana G.A.A.

    2013-01-01

    This article aims to make an introduction to the use of Functional Resonance Analysis Method (FRAM) on the effectiveness assessment of a specific radiopharmaceutical dispatching process. The main purpose was to provide a didactic view of the method application to further in-depth analysis. The investigation also provided a relevant body of knowledge of radiopharmaceuticals dispatches processes. This work uses the term 'effectiveness assessment' instead of 'risk assessment' due to the broader meaning the former provide. The radiopharmaceutical dispatching process is the final task of a dynamic system designed to attend several medical facilities. It is comprised by functions involving mostly human activities, such as checking and packaging the product and measuring the radiopharmaceutical nuclear activity. Although the dispatch process has well-known steps for its completion, the human factor is the fundamental mechanism of work and control, being susceptible of irregular and instable performance. As a socio-technical system, the risk assessment provided by FRAM may be of importance for safety and quality improvements, even more if considered the nuclear nature of the product, which makes risk assessment critical and mandatory. A system is safe if it is resistant and resilient to perturbations. Identification and assessment of possible risks is, therefore, an essential prerequisite for system safety. Although this seems obvious, most risk assessments are conducted under relative ignorance of the full behavior of the system. Such condition has lead to an approach to assess the risks of intractable systems (i.e., systems that are incompletely described or under specified), namely Resilience Engineering. Into this area, the Functional Resonance Analysis Method has been developed in order to provide concepts, terminology and a set of methods capable of dealing with such systems. The study was conducted following the Functional Resonance Analysis Method. At first, the

  5. Annual report of Department of Research Reactor and Tandem Accelerator, JFY2012. Operation, utilization and technical development of JRR-3, JRR-4, NSRR, Tandem Accelerator and RI Production Facility

    International Nuclear Information System (INIS)

    Murayama, Yoji; Ishii, Tetsuro; Nakamura, Kiyoshi; Uno, Yuki; Ishikuro, Yasuhiro; Kawashima, Kazuhito; Ishizaki, Nobuhiro; Matsumura, Taichi; Nagahori, Kazuhisa; Odauchi, Shouji; Maruo, Takeshi

    2014-03-01

    The Department of Research Reactor and Tandem Accelerator is in charge of the operation, utilization and technical development of JRR-3(Japan Research Reactor No.3), JRR-4(Japan Research Reactor No.4), NSRR(Nuclear Safety Research Reactor), Tandem Accelerator and RI Production Facility. This annual report describes a summary of activities of services and technical developments carried out in the period between April 1, 2012 and March 31, 2013. The activities were categorized into five service/development fields: (1) Operation and maintenance of research reactors and tandem accelerator, (2) Utilization of research reactors and tandem accelerator, (3) Upgrading of utilization techniques of research reactors and tandem accelerator, (4) Safety administration for department of research reactor and tandem accelerator, (5) International cooperation. Also contained are lists of publications, meetings, granted permissions on laws and regulations concerning atomic energy, number of staff members dispatched to Fukushima for the technical assistance, outcomes in service and technical developments and so on. (author)

  6. Preparation and quality control of technetium-99m radiopharmaceuticals

    International Nuclear Information System (INIS)

    Samuels, D.L.

    1978-11-01

    Appropriate procedures for the production and quality control of technetium-99m based radiopharmaceuticals in hospital radiopharmacy consistent with the recently published Australian Code of Good Manufacturing Practice are discussed

  7. ANSTO - Annual Report 1996-1997

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    1997-09-01

    Highlights of achievements during 1996-1997 at the Australian Nuclear Science and technology (ANSTO) include: release of the new ANSTO Strategic Plan for the period till June 2000 and the establishment of a Technical Advisory Committee (TAC) of the Board. In accordance with the Strategic Plan, ANSTO has continued to focus its activities in six core business areas. The major outcomes and outputs of this work are outlined. The majority of ANSTO strategic research was directed at several topics launched during the year, including: international cooperative research to enhance safety of nuclear facilities and safeguards for nuclear materials, environmental dynamics, global climate change, radioactive waste management, ecological sustainability of the mining and mineral industries, radionuclides and radiopharmaceuticals for the 21st century and the design and process of novel interfaces. During the year major upgrades were made to he National Medical Cyclotron (NMC) and the Australian National Tandem Accelerator for Applied Research (ANTARES). The Annual Report documents the uses of these facilities by universities, industry, medicine and Government. Details are also provided of the organization development and support which support the core scientific areas. The financial statement for the year under review is also included tabs, ills, figs.

  8. ANSTO - Annual Report 1996-1997

    International Nuclear Information System (INIS)

    1997-09-01

    Highlights of achievements during 1996-1997 at the Australian Nuclear Science and technology (ANSTO) include: release of the new ANSTO Strategic Plan for the period till June 2000 and the establishment of a Technical Advisory Committee (TAC) of the Board. In accordance with the Strategic Plan, ANSTO has continued to focus its activities in six core business areas. The major outcomes and outputs of this work are outlined. The majority of ANSTO strategic research was directed at several topics launched during the year, including: international cooperative research to enhance safety of nuclear facilities and safeguards for nuclear materials, environmental dynamics, global climate change, radioactive waste management, ecological sustainability of the mining and mineral industries, radionuclides and radiopharmaceuticals for the 21st century and the design and process of novel interfaces. During the year major upgrades were made to he National Medical Cyclotron (NMC) and the Australian National Tandem Accelerator for Applied Research (ANTARES). The Annual Report documents the uses of these facilities by universities, industry, medicine and Government. Details are also provided of the organization development and support which support the core scientific areas. The financial statement for the year under review is also included

  9. Preparation of radiopharmaceutical formulations; Fremstilling av radioaktive farmasoeytiske blandinger

    Energy Technology Data Exchange (ETDEWEB)

    Simon, J.; Garlich, J.R.; Frank, R.K.; McMillan, K

    1998-03-16

    Radiopharmaceutical formulations for complexes comprising at least one radionuclide complexed with a ligand, or its physiologically-acceptable salts thereof, especially {sup 153}samarium-ethylenediaminetetramethylenephosphonic acid, which optionally contains a divalent metal ion, e.g. calcium, and is frozen, thawed, and then administered by injection. Alternatively, the radiopharmaceutical formulations must contain the divalent metal and are frozen only if the time before administration is sufficiently long to cause concern for radiolysis of the ligand. 2 figs., 9 tabs.

  10. Production, control and utilization of radioisotopes including radiopharmaceuticals

    International Nuclear Information System (INIS)

    Muenze, R.

    1985-05-01

    From April 29th to May 5th, 1984 27 participants from 21 developing countries stayed within an IAEA Study Tour ('Production, Control and Utilization of Radioisotopes including Radiopharmaceuticals') in the GDR. In the CINR, Rossendorf the reactor, the cyclotron, the technological centre as well as the animal test laboratory were visited. The participants were made familiar by 10 papers with the development, production and control of radiopharmaceuticals in the CINR, Rossendorf. (author)

  11. Consequences of radiopharmaceutical extravasation and therapeutic interventions: a systematic review

    Energy Technology Data Exchange (ETDEWEB)

    Pol, Jochem van der; Voeoe, Stefan [Maastricht University Medical Centre (MUMC+), Department of Radiology and Nuclear Medicine, Postbox 5800, Maastricht (Netherlands); Bucerius, Jan; Mottaghy, Felix M. [Maastricht University Medical Centre (MUMC+), Department of Radiology and Nuclear Medicine, Postbox 5800, Maastricht (Netherlands); University Hospital, RWTH Aachen University, Department of Nuclear Medicine, Aachen (Germany)

    2017-07-15

    Radiopharmaceutical extravasation can potentially lead to severe soft tissue damage, but little is known about incidence, medical consequences, possible interventions, and effectiveness of these. The aims of this study are to estimate the incidence of extravasation of diagnostic and therapeutic radiopharmaceuticals, to evaluate medical consequences, and to evaluate medical treatment applied subsequently to those incidents. A sensitive and elaborate literature search was performed in Embase and PubMed using the keywords ''misadministration'', ''extravasation'', ''paravascular infiltration'', combined with ''tracer'', ''radionuclide'', ''radiopharmaceutical'', and a list of keywords referring to clinically used tracers (i.e. ''Technetium-99m'', ''Yttrium-90''). Reported data on radiopharmaceutical extravasation and applied interventions was extracted and summarised. Thirty-seven publications reported 3016 cases of diagnostic radiopharmaceutical extravasation, of which three cases reported symptoms after extravasation. Eight publications reported 10 cases of therapeutic tracer extravasation. The most severe symptom was ulceration. Thirty-four different intervention and prevention strategies were performed or proposed in literature. Extravasation of diagnostic radiopharmaceuticals is common. {sup 99m}Tc, {sup 123}I, {sup 18}F, and {sup 68}Ga labelled tracers do not require specific intervention. Extravasation of therapeutic radiopharmaceuticals can give severe soft tissue lesions. Although not evidence based, surgical intervention should be considered. Furthermore, dispersive intervention, dosimetry and follow up is advised. Pharmaceutical intervention has no place yet in the immediate care of radiopharmaceutical extravasation. (orig.)

  12. Radiopharmaceutical regulation and Food and Drug Administration policy.

    Science.gov (United States)

    Rotman, M; Laven, D; Levine, G

    1996-04-01

    The regulatory policy of the Food and Drug Administration (FDA) on radiopharmaceuticals flows from a rigid, traditional, drug-like interpretation of the FDC Act on the licensing of radiopharmaceuticals. This contributes to significant delays in the drug-approval process for radiopharmaceuticals, which are very costly to the nuclear medicine community and the American public. It seems that radiopharmaceuticals would be better characterized as molecular devices. Good generic rule-making principles include: use of a risk/benefit/cost analysis; intent based on sound science; performance standards prepared by outside experts; a definite need shown by the regulatory agency; to live with the consequences of any erroneous cost estimates; and design individual credential requirements so that additional training results in enhanced professional responsibility. When these common elements are applied to current FDA policy, it seems that the agency is out of sync with the stated goals for revitalizing federal regulatory policies as deemed necessary by the Clinton administration. Recent FDA rulings on positron-emission tomography, Patient Package inserts, and on medical device service accentuate the degree of such asynchronization. Radiopharmaceutical review and licensing flexibility could be dramatically improved by excluding radiopharmaceuticals from the drug category and reviewing them as separate entities. This new category would take into account their excellent record of safety and their lack of pharmacological action. Additionally, their evaluation of efficacy should be based on their ability to provide useful scintiphotos, data, or responses of the physiological system it portends to image, quantitate, or describe. To accomplish the goal of transforming the FDA's rigid, prescriptive policy into a streamlined flexible performance-based policy, the Council on Radionuclides and Radiopharmaceuticals proposal has been presented. In addition, it is suggested that the United

  13. Radiopharmaceuticals for cerebral studies; Radiofarmacos para Estudios Cerebrales

    Energy Technology Data Exchange (ETDEWEB)

    Leon Cabana, Alba [Universidad de la Republica, Facultad de Quimica (Uruguay)

    1994-12-31

    For obtain good brain scintillation images in nuclear medicine must be used several radiopharmaceuticals. Cerebral studies give a tumors visual image as well as brain anomalities detection and are helpful in the diagnostic diseases . Are described in this work: a cerebrum radiopharmaceuticals classification,labelled compounds proceeding and Tc 99m good properties in for your fast caption, post administration and blood purification for renal way.

  14. Radionuclide production and radiopharmaceutical chemistry with BNL cyclotrons

    International Nuclear Information System (INIS)

    Lambrecht, R.M.; Wolf, A.P.

    1985-01-01

    The Brookhaven National Laboratory (BNL) radiopharmaceutical chemistry program focuses on production and utilization of radionuclides having a half-life of > 2 hr. However, a major portion of the BNL program is devoted to short-lived radionuclides, such as 11 C and 18 F. Activities encompassed in the program are classified into seven areas: cyclotron parameters, radiochemistry, design and rapid synthesis of radiopharmaceuticals and labeled compounds, radiotracer evaluation in animals, studies in humans, technology transfer, and several other areas

  15. Regulatory requirements for radiopharmaceutical radiochemistry and radiation dosimetry

    International Nuclear Information System (INIS)

    Bonnyman, J.

    1985-01-01

    The Australian Department of Health is responsible for ensuring that radiopharmaceuticals are safe and effective and that their use does not result in unnecessary radiation exposure. Section B1 requirements of New Drug Form 4 (NDF4) fall into the following sections - manufacture, product specifications, quality assurance testing, stability studies and expiry dating. It covers ready to inject pharmaceuticals, radioactive formulations used to prepare a radiopharmaceutical, generators and cold kits

  16. Trends in radiopharmaceutical dispensing in a regional nuclear pharmacy

    International Nuclear Information System (INIS)

    Basmadjian, G.P.; Barker, K.; Johnston, J.; Stinchcomb, R.; Tarman, B.; Ice, R.D.

    1983-01-01

    In the last five years, the practice of nuclear medicine has undergone changes due to the advent of new imaging technologies and radiopharmaceuticals. These changes have had an impact upon the number and the type of radiopharmaceuticals dispensed in centralized nuclear pharmacies. With the advent of Computerized Axial Tomography Scanners (CAT), sophistication and wider acceptance of the Ultrasound imaging modality, nuclear medicine has had to change directions from utilizing radiopharmaceuticals for static organ imaging to functional type imaging and to resort to the use of new radiopharmaceuticals or to find other uses for the existing radiopharmaceuticals. The following trends in radiopharmaceutical dispensing in a regional nuclear pharmacy are evident: Brain procedures have declined by about 67% while nuclear cardiology studies have increased by over 2000%. Bone scans have increased by 72% while liver, renal and lung studies have shown no significant increase. These changes will continue as the practice of nuclear medicine concentrates more on functional studies and relegates other studies to newer imaging modalities

  17. Annual report of Department of Research Reactor and Tandem Accelerator, JFY2014. Operation, Utilization and Technical Development of JRR-3, JRR-4, NSRR, Tandem Accelerator and RI Production Facility

    International Nuclear Information System (INIS)

    Osa, Akihiko; Imahashi, Masaki; Hirane, Nobuhiko; Motome, Yuiko; Tayama, Hidekazu; Tamura, Itaru; Harada, Yuko; Sakata, Mami; Kadokura, Masakazu; Takita, Chiharu

    2017-02-01

    The Department of Research Reactor and Tandem Accelerator is in charge of the operation, utilization and technical development of JRR-3 (Japan Research Reactor No.3), JRR-4 (Japan Research Reactor No.4), NSRR (Nuclear Safety Research Reactor), Tandem Accelerator and RI Production Facility. This annual report describes the activities of our department in fiscal year of 2014. We carried out the operation and maintenance, utilization, upgrading of utilization techniques, safety administration, and international cooperation. Also contained are lists of publications, meetings, granted permissions on laws and regulations concerning atomic energy, outcomes in service and technical developments and so on. (author)

  18. Annual report of Department of Research Reactor and Tandem Accelerator, JFY2013. Operation, Utilization and Technical Development of JRR-3, JRR-4, NSRR, Tandem Accelerator and RI Production Facility

    International Nuclear Information System (INIS)

    Kashima, Yoichi; Murayama, Yoji; Nakamura, Kiyoshi; Uno, Yuki; Hirane, Nobuhiko; Ohuchi, Hitoshi; Ishizaki, Nobuhiro; Matsumura, Taichi; Nagahori, Kazuhisa; Harada, Yuko; Kadokura, Masakazu; Machi, Sumire; Takita, Chiharu

    2015-02-01

    The Department of Research Reactor and Tandem Accelerator is in charge of the operation, utilization and technical development of JRR-3(Japan Research Reactor No.3), JRR-4(Japan Research Reactor No.4), NSRR(Nuclear Safety Research Reactor), Tandem Accelerator and RI Production Facility. This annual report describes the activities of our department in fiscal year of 2013. We carried out the operation and maintenance, utilization, upgrading of utilization techniques, safety administration and international cooperation. Also contained are lists of publications, meetings, granted permissions on laws and regulations concerning atomic energy, outcomes in service and technical developments and so on. (author)

  19. Annual Research Technical Report 2003

    International Nuclear Information System (INIS)

    Alonso V, G.; Viais J, J.; Mendoza G, G.; Ramirez S, J.R.; Castillo M, J.A.

    2005-09-01

    This report has among its objectives to carry out the Probabilistic Safety Analysis Level 1 for the IRIS inside the project of development of reactors of IV Generation. To generate computational calculation tools for the analysis of the reactors of IV Generation. To generate computational tools to optimize the use of the nuclear fuel. (Author)

  20. Annual Research Technical Report 2004

    International Nuclear Information System (INIS)

    Alonso V, G.; Viais J, J.; Mendoza G, G.; Ramirez S, J. R.; Castillo M, J. A.

    2005-09-01

    In this work it plans to be carried out the Probabilistic Safety Analysis level 1 for the Modified Design of the IRIS Reactor. To generate computational tools of calculation of the analysis of the reactors of IV Generation and to optimize the use of nuclear fuel. To elaborate the economic analysis of the IRIS Reactor. (Author)

  1. Annual Research Technical Report 2002

    International Nuclear Information System (INIS)

    Alonso V, G.

    2005-09-01

    To study the principles of reactors design of Light Water of IV generation, to look for collaborations to participate in the development of some of them and to generate computational tools that allow us the appropriate analysis of these reactors. (Author)

  2. Radiopharmaceutical Stem Cell Tracking for Neurological Diseases

    Directory of Open Access Journals (Sweden)

    Paulo Henrique Rosado-de-Castro

    2014-01-01

    Full Text Available Although neurological ailments continue to be some of the main causes of disease burden in the world, current therapies such as pharmacological agents have limited potential in the restoration of neural functions. Cell therapies, firstly applied to treat different hematological diseases, are now being investigated in preclinical and clinical studies for neurological illnesses. However, the potential applications and mechanisms for such treatments are still poorly comprehended and are the focus of permanent research. In this setting, noninvasive in vivo imaging allows better understanding of several aspects of stem cell therapies. Amongst the various methods available, radioisotope cell labeling has become one of the most promising since it permits tracking of cells after injection by different routes to investigate their biodistribution. A significant increase in the number of studies utilizing this method has occurred in the last years. Here, we review the different radiopharmaceuticals, imaging techniques, and findings of the preclinical and clinical reports published up to now. Moreover, we discuss the limitations and future applications of radioisotope cell labeling in the field of cell transplantation for neurological diseases.

  3. Automation of cells of radiopharmaceuticals production

    International Nuclear Information System (INIS)

    Negrini, Aguinaldo Donizete

    2010-01-01

    The 67 Ga is an important radiopharmaceutical used to identify inflammatory processes in chronic illnesses, diagnosis by image of tumors in soft tissues and the possibility to evaluate the result for therapeutic intervention. In the present work a module of 67 Ga processing was developed with the objective to reduce the interventions in the hot cell, in order to avoid oxidation caused by metallic materials, and consuming in hoses of the peristaltic pumps, that release residues that blocked the valves used in the process. With materials such as: acrylic, PVC, PEEK e teflon and they are used vacuum as method (way) of fluid transferences instead of peristaltic pump in the majority of the procedures, with this improvements the system can make shorter the lengths of transference hoses, increasing the yield in the process with less interventions for maintenance and time exposure of the workers, guaranteeing the quality and reducing the time of the processing. using a mobile system for displacement of the processing module making in the cleanness and maintenance of the cell that works with radioactive material. Reducing the time of exposure dose of the workers in compliance with RDC-17 of ANVISA, which ruling the Good Manufacturing Practice Procedures. (author)

  4. Drug interaction with radiopharmaceuticals: a review

    International Nuclear Information System (INIS)

    Bernardo-Filho, Mario; Santos-Filho, Sebastiao David; Moura, Egberto Gaspar de; Maiworm, Adalgisa Ieda; Bernardo, Luciana Camargo; Brito, Lavinia de Carvalho; Orlando, Margarida Maria de Camoes; Penas, Maria Exposito; Cardoso, Valbert Nascimento

    2005-01-01

    Clinical images are worthwhile in Health Sciences and their analysis and correct interpretation aid the professionals,such as physicians, physiotherapists and occupational therapists, to make decisions and take subsequent therapeutic and/or rehabilitation measures. Other factors, besides the state of the disease, may interfere and affect the bioavailability of the radiopharmaceuticals (radiobiocomplexes) and the quality of the SPECT and PET images. Furthermore, the labeling of some of these radiobiocomplexes, such as plasma proteins, white blood cells and red blood cells, with 99m T, can also be modified. These factors include drugs (synthetic and natural) and dietary conditions, as well as some medical procedures (invasive or non-invasive), such as radiation therapy, surgical procedures, prostheses, cardioversion, intubation, chemo perfusion, external massage, immunotherapy, blood transfusion and hemodialysis. In conclusion, the knowledge about these factors capable of interfering with the bioavailability of the radiobiocomplexes is worthwhile for secure diagnosis. Moreover, the development of biological models to study these phenomena is highly relevant and desirable.(author)

  5. Role of radiopharmaceuticals in detection of osteomyelitis

    International Nuclear Information System (INIS)

    Mack, J.M.; Spencer, R.P.

    1990-01-01

    Osteomyelitis can present as a significant diagnostic problem in medicine. Knowledge of the presence and extent of infection involving bone is important in determining treatment. In this paper the authors review the role played by radiopharmaceutical techniques in establishing the diagnosis of osteomyelitis. Osteomyelitis has been recognized as one of the most serious complications of emergency surgery to repair severe bone trauma. It is also a complication of surgery for prosthesis placement. In still other instances, osteomyelitis can be of hematogenous origin, without a major wound site. Unlike other infections, it rarely presents with acute symptoms. Osteomyelitis is divided into two categories that are time related: acute, in which clinical signs and symptoms of bone infection have been present for less than 1 month, and chronic, in which symptoms have been present for more than 1 month. The acute type is usually caused by Staphylococcus aureus in children (often secondary to skin infection), whereas in adults it can be secondary to intravenous drug abuse. Predisposing factors such as diabetes mellitus, peripheral vascular disease, and sickle cell disease are important to the outcome of osteomyelitis. One way to determine the microbe causing the infection is direct bone biopsy from the site of suspected osteomyelitis. There is one important limitation for needle biopsy in the diagnosis of osteomyelitis. Biopsies are contraindicated in the small bones of the hands and feet, because of risk of pathologic fracture (and may be relatively contraindicated after diphosphonate therapy and loss of bone mineral)

  6. Rhenium radioisotopes for therapeutic radiopharmaceutical development

    International Nuclear Information System (INIS)

    Knapp, F.F. Jr.; Beets, A.L.; Pinkert, J.; Kropp, J.; Lin, W.Y.; Wang, S.Y.

    2001-01-01

    Rhenium-186 and rhenium-188 represent two important radioisotopes which are of interest for a variety of therapeutic applications in oncology, nuclear medicine and interventional cardiology. Rhenium-186 is directly produced in a nuclear reactor and the 90 hour half-life allows distribution to distant sites. The relatively low specific activity of rhenium-186 produced in most reactors, however, permits use of phosphonates, but limits use for labelled peptides and antibodies. Rhenium-188 has a much shorter 16.9 hour half-life which makes distribution from direct reactor production difficult. However, rhenium-188 can be obtained carrier-free from a tungsten-188/rhenium-188 generator, which has a long useful shelf-life of several months which is cost-effective, especially for developing regions. In this paper we discuss the issues associated with the production of rhenium-186- and rhenium-188 and the development and use of various radiopharmaceuticals and devices labelled with these radioisotopes for bone pain palliation, endoradiotherapy of tumours by selective catheterization and tumour therapy using radiolabelled peptides and antibodies, radionuclide synovectomy and the new field of vascular radiation therapy. (author)

  7. Application of lectins to tumor imaging radiopharmaceuticals

    International Nuclear Information System (INIS)

    Kojima, Shuji; Jay, M.

    1986-01-01

    We investigated the in vitro binding of 125 I-lectins to Ehrlich ascites tumor (EAT) cells and in vivo uptake of 125 I-lectins in Ehrlich solid tumor (EST) bearing mice. In in vitro binding assays, phaseolus vulgaris agglutinin (PHA), pisum sativum agglutinin (PSA), and concanavalia agglutinin (Con A) showed a high affinity for EAT cells. The in vivo biodistribution of 125 I-lectins showed 125 I-PSA to be significantly taken up into EST tissues 24 h postinjection. After IV injection of 125 I-PSA, uptake of the radioactivity into the tumor tissues reached a maximum at 6 h, and thereafter decreased. Rapid disappearance of the radioactivity from blood and its excretion into kidney soon after injection of 125 I-PSA were observed. When compared with the biodistribution of 67 Ga-citrate in EST bearing mice 24 h postinjection, tumor to liver (T/B), tumor to muscle (T/M), and tumor to blood (T/B) ratios were superior for 125 I-PSA. At 6 h postinjection, the T/B-ratio of 125 I-PSA was 2.5, and this value may be sufficient to enable discernable diagnostic images. Our results suggest that PSA might be a useful tumor imaging radiopharmaceutical. (orig.)

  8. Absolute counting of 188Re radiopharmaceuticals

    International Nuclear Information System (INIS)

    Ravindra, Anuradha; Kulkarni, D.B.; Joseph, Leena; Kulkarni, M.S.

    2018-01-01

    Rhenium-188 is radiopharmaceutical that belongs to the group of strong beta-weak gamma emitters. It emits high energy beta particles, (E β m ax = 2.12MeV) and weak gamma rays (E γ = 155 keV) hence makes it suitable for wide variety of therapeutic as well as diagnostic applications. Therapeutic applications include therapy of tumors, radionuclide synovectomy, bone pain palliation, intra vascular radiation therapy etc. 188 Re-labeled medicines have been employed increasingly in the therapy of tumors and vascular restenosis. To ensure that patient receives the appropriate radiation dose during the treatment, both the activity standardization and the determination of sensitivity coefficient of the secondary standard for 188 Re have become important tasks. This paper presents the methods and results obtained for the following measurements a) Standardisation of the 188 Re by using the 4π proportional counter (4πPC)-gamma extrapolation method b) Determination of sensitivity coefficient (pA/MBq) of the secondary standard ionization chamber type Centronic IG12, 20A for 188 Re

  9. Manufacturing on the radiopharmaceuticals produced by cyclotron

    International Nuclear Information System (INIS)

    Ueda, Nobuo

    1994-01-01

    Radiopharmaceutical (RP) produced by cyclotrons are widely used for the in vivo diagnosis of various diseases such as cancer, cerebral vascular disorders and cardiac diseases. The nuclides used as RPs and their nuclear reactions, and the quantity of RPs supplied in Japan in the last five years are shown. These RPs are delivered to about 1,100 hospitals in Japan. Thallium-201 and iodine-123 showed very high growth rate. Recently, two new I-123 RPs, BMIPP and MIBG which are heart-imaging agents, have been supplied. It suggests that the quantity of I-123 will increase much more in future. The image diagnostic method using RPs is called in vivo nuclear medicine, and has become the indispensable means for medical institutions together with X-ray CT, nuclear magnetic resonance imaging and ultrasonic diagnosis. The RPs for in vivo diagnosis generally used at present are classified into those labeled with the RIs produced with cyclotrons and those labeled with Tc-99m formed by the decay of Mo-99. The quantity being used is overwhelmingly more in the latter, but the former shows the tendency of growth. The commercial production of cyclotron RIs for medical use, the chemical forms and the diagnostic purposes of the RPs using cyclotron RIs, and the state of use of the cyclotron-produced RPs are reported. (K.I.)

  10. Development of radiopharmaceuticals and industrial constraints

    International Nuclear Information System (INIS)

    Zimmermann, R.

    2005-01-01

    The development process of a diagnostic or therapeutic radiopharmaceutical does not really differ from the development of a classical drug. Some specific properties of these nuclear medicine tools mainly linked to the ease to follow their distribution in the human body allow to save a couple of years out of the dozen of years required to bring a drug on the market. Overall development costs can be significantly reduced for the same reason. An industrial who wants to invest in such a business bases its analysis on other criteria that need to evaluate the medical, safety and regulatory environment at the time of drug launching. Competition is obviously a major decision criteria, but in order to evaluate the market potential, other data must be available such as the analysis of the medical landscape, the reimbursement issues, the technology evolution, the investment needs or the development of other imaging modalities, among others. In fact all these parameters concentrate toward a common criteria, the profitability of the project. Nuclear medicine moved from an art and crafts era towards the industrial era and hence plunged from the twentieth to the twenty first century in the economic reality with all its constraints and consequences. (author)

  11. IKO Annual Report 1976

    International Nuclear Information System (INIS)

    1977-01-01

    The IKO Annual Report of 1976 relates their progress in different projects and project fields. The fields covered include electron scattering, pion and muon physics, theory, radio- and nuclear chemistry, technical department, MEA, nuclear reactions and nuclear spectroscopy

  12. Traceability in the pharmaceutical industry: application to radiopharmaceutical production

    International Nuclear Information System (INIS)

    Zanette, Camila; Melero, Laura T.U.H.; Araujo, Elaine B. de; Mengatti, Jair; Silva, Katia S. de S.

    2011-01-01

    The development of tools to promote the traceability of the drugs in the pharmaceutical industry during all the production chain is a necessary requisite. The traceability system is applied to enable the identification of the origin, destination and exact location of the drug. Traceability optimizes the process chain, reduces errors, is a requirement for quality process, promotes safety for the user and assists in pharmacovigilance. The health regulatory agency in Brazil (ANVISA) will implement a tracking system for medicaments with RDC no. 59 of 2009, to control distribution since the producer until the patients in order to prevent the traffic and adulteration of drugs. Thus, this study discusses the importance and impact of the new traceability system proposed by ANVISA in the production and distribution of radiopharmaceuticals from the Nuclear and Energy Research Institute (IPEN-CNEN). The radiopharmaceuticals have a difference track when compared with another drug classes. In this context, this RDC would increase the price of the medicines by up to 10%, since it provides deployment of a single stamp supplied by the Mint. Considering that radiopharmaceuticals are not sold to the final consumer (patients), but only for accredited medical clinics and nuclear medicine physicians, and the transport of radiopharmaceuticals is performed by specialized companies licensed by CNEN (National Nuclear Energy Commission), the use of the stamp to ensure authenticity and prevent falsification should not be appropriated and represents and additional cost for the radiopharmaceuticals. (author)

  13. Aptamers as radiopharmaceuticals for nuclear imaging and therapy

    International Nuclear Information System (INIS)

    Gijs, Marlies; Aerts, An; Impens, Nathalie; Baatout, Sarah; Luxen, André

    2016-01-01

    Today, radiopharmaceuticals belong to the standard instrumentation of nuclear medicine, both in the context of diagnosis and therapy. The majority of radiopharmaceuticals consist of targeting biomolecules which are designed to interact with a disease-related molecular target. A plethora of targeting biomolecules of radiopharmaceuticals exists, including antibodies, antibody fragments, proteins, peptides and nucleic acids. Nucleic acids have some significant advantages relative to proteinaceous biomolecules in terms of size, production, modifications, possible targets and immunogenicity. In particular, aptamers (non-coding, synthetic, single-stranded DNA or RNA oligonucleotides) are of interest because they can bind a molecular target with high affinity and specificity. At present, few aptamers have been investigated preclinically for imaging and therapeutic applications. In this review, we describe the use of aptamers as targeting biomolecules of radiopharmaceuticals. We also discuss the chemical modifications which are needed to turn aptamers into valuable (radio-)pharmaceuticals, as well as the different radiolabeling strategies that can be used to radiolabel oligonucleotides and, in particular, aptamers.

  14. Use of the microwave oven in the radiopharmaceutical preparations in nuclear medicine

    International Nuclear Information System (INIS)

    Soroa Gfeller, Victoria E.; Cabrejas, Raul C.; Mc Elfresh, H.

    2000-01-01

    Several of the 99mTc radiopharmaceuticals require heating in water bath for 30 minutes before successfully completing the labelling process and thus produce optimal diagnostic images with low background and no free 99mTc. Sulphur colloid 99mTc (99mTc-Sc) enables visualization of liver, spleen, bone marrow reticuloendothelial system, lymphoscintigraphy and sentinel node detection. Sestamibi (99mTc-MIBI) is used for identifying myocardium ischemia and tissue metabolically active. Both compounds were the aim of our work, as the objective was to shorten the preparation time while maintaining experimental animal and clinical biodistribution. 99mTc-Sc assays were the most difficult to perform. The best results were achieved through a combination of water heated boiling bath (5 minutes), microwave oven during 18-20 seconds and cooling the preparation previous to intravenous injection, although still the optimal technical parameters have to be achieved. Sestamibi-Tc99m assays showed repeatable results with high labelling efficiency (90-96%) oven energy 40-50% during 14-17 seconds. We conclude that we successfully have reduced the time of both preparations. Sc-99mTc should still to be perfected, the radiopharmaceutical can be used in lymphoscintigraphy scans but it is not recommended for liver and spleen images results. Sestamibi-Tc99m successfully shorten time consumed in the preparation and it is cost effective, results are repeatable and the compound shows a 6 h stability. (author)

  15. Auger Emitting Radiopharmaceuticals for Cancer Therapy

    Science.gov (United States)

    Falzone, Nadia; Cornelissen, Bart; Vallis, Katherine A.

    Radionuclides that emit Auger electrons have been of particular interest as therapeutic agents. This is primarily due to the short range in tissue, controlled linear paths and high linear energy transfer of these particles. Taking into consideration that ionizations are clustered within several cubic nanometers around the point of decay the possibility of incorporating an Auger emitter in close proximity to the cancer cell DNA has immense therapeutic potential thus making nuclear targeted Auger-electron emitters ideal for precise targeting of cancer cells. Furthermore, many Auger-electron emitters also emit γ-radiation, this property makes Auger emitting radionuclides a very attractive option as therapeutic and diagnostic agents in the molecular imaging and management of tumors. The first requirement for the delivery of Auger emitting nuclides is the definition of suitable tumor-selective delivery vehicles to avoid normal tissue toxicity. One of the main challenges of targeted radionuclide therapy remains in matching the physical and chemical characteristics of the radionuclide and targeting moiety with the clinical character of the tumor. Molecules and molecular targets that have been used in the past can be classified according to the carrier molecule used to deliver the Auger-electron-emitting radionuclide. These include (1) antibodies, (2) peptides, (3) small molecules, (4) oligonucleotides and peptide nucleic acids (PNAs), (5) proteins, and (6) nanoparticles. The efficacy of targeted radionuclide therapy depends greatly on the ability to increase intranuclear incorporation of the radiopharmaceutical without compromising toxicity. Several strategies to achieve this goal have been proposed in literature. The possibility of transferring tumor therapy based on the emission of Auger electrons from experimental models to patients has vast therapeutic potential, and remains a field of intense research.

  16. 48{sup th} Annual meeting on nuclear technology (AMNT 2017). Key topic / Enhanced safety and operation excellence. Technical session: Operation and safety of nuclear installations, fuel

    Energy Technology Data Exchange (ETDEWEB)

    Hollands, Thorsten [Gesellschaft fuer Anlagen- und Reaktorsicherheit (GRS) gGmbH, Garching (Germany). Bereich Reaktorsicherheitsforschung

    2017-12-15

    The sessions Fuel and Materials and Containment and SFP, as part of the Technical Sessions Operation and Safety of Nuclear Installations, Fuel implemented in the Key Topic Enhanced Safety and Operation Excellence were chaired by Dr. Thorsten Hollands (Gesellschaft fuer Anlagen- und Reaktorsicherheit (GRS) gGmbH) and Dr. Erwin Fischer (PreussenElektra GmbH) who was the keynote coordinator for the Technical Sessions. Both sessions consist of a keynote lecture followed by technical presentations.

  17. Molecular target in oncology. Opportunity for radiopharmaceuticals development

    International Nuclear Information System (INIS)

    Navarro Marques, Fabio Luiz

    2016-01-01

    Cancer is a cellular multifactorial disease, regulated by changes in phenotype characteristics, such as adhesion, invasion, migration, and tumorigenesis; genotypic status of commonly altered genes (KRAS and p53); microenvironmental conditions, such pH, oxygen and nutrient supply. All these features provide opportunities for radiopharmaceuticals development, both for diagnostic and therapy. For both applications, radiopharmaceuticals molecules can be divided in small synthetic molecules, small peptides (natural or modified), large molecules such as antibody or nanoparticles. The characteristics of those molecules and use will guide the choice of the radionuclide to be used for labeling it. In the presentation, data from literature and research ongoing in the Faculty of Medicine of the University of São Paulo/Brazil will be used for demonstrate the potential for radiopharmaceuticals development. (author)

  18. Ensuring quality while going local: IAEA helps Cuba produce radiopharmaceuticals

    International Nuclear Information System (INIS)

    Jawerth, Nicole

    2015-01-01

    Cancer and cardiovascular disease are health conditions Cuba will now be able to more readily diagnose and treat thanks to its newly built facility for producing key radiopharmaceuticals. Nuclear medicine requires a constant and reliable supply of these radioactive drugs, prepared according to what the industry calls good manufacturing practices (GMP), and there have so far been limitations in getting them to the island nation. “Through our work with the IAEA, we now have a dedicated GMP compliant facility and the expertise to meet most of our national needs for diagnostic and therapeutic radiopharmaceuticals for helping patients,” said René Leyva Montaña, Director of Production at the Isotope Centre (CENTIS), Cuba’s centre dedicated to radiopharmaceutical production.

  19. Radiation Protection, double-blind studies with radiopharmaceuticals

    International Nuclear Information System (INIS)

    Pujadas, M. C.; Camacho, C.; Guasp, M.; Villaescusa, J. I.

    2009-01-01

    In a double-blind randomized controlled clinical trial (RCT) subjects and researchers do not know the assignment to treatment groups to ovoid the appearance of subjective biases of information. The employment of radiopharmaceuticals in double-blind RCTs raises a dilemma from the point ov view of the radiological protection. On the one hand, the obligation to act in cases of contamination and/or risk of irradiation exists, but on the other hand the duty of keeping the blind study also exists. In this paper some of the possible problems that arise when conducting a double-blind RCT with radiopharmaceuticals from the point of view of the radiological protection are presented. We comment our experience with the radiopharmaceutical Alpharadin and, in addition, we propose useful recommendations based on the randomness of the decontamination process. (Author) 7 refs.

  20. 188Re(V) Nitrido Radiopharmaceuticals for Radionuclide Therapy.

    Science.gov (United States)

    Boschi, Alessandra; Martini, Petra; Uccelli, Licia

    2017-01-19

    The favorable nuclear properties of rhenium-188 for therapeutic application are described, together with new methods for the preparation of high yield and stable 188 Re radiopharmaceuticals characterized by the presence of the nitride rhenium core in their final chemical structure. 188 Re is readily available from an 188 W/ 188 Re generator system and a parallelism between the general synthetic procedures applied for the preparation of nitride technetium-99m and rhenium-188 theranostics radiopharmaceuticals is reported. Although some differences between the chemical characteristics of the two metallic nitrido fragments are highlighted, it is apparent that the same general procedures developed for the labelling of biologically active molecules with technetium-99m can be applied to rhenium-188 with minor modification. The availability of these chemical strategies, that allow the obtainment, in very high yield and in physiological condition, of 188 Re radiopharmaceuticals, gives a new attractive prospective to employ this radionuclide for therapeutic applications.

  1. Design of GMP compliance radiopharmaceutical production facility in MINT

    International Nuclear Information System (INIS)

    Anwar Abd Rahman; Shaharum Ramli; M Rizal Mamat Ibrahim; Rosli Darmawan; Yusof Azuddin Ali; Jusnan Hashim

    2005-01-01

    In 1985, MINT built the only radiopharmaceutical production facility in Malaysia. The facility was designed based on IAEA (International Atomic Energy Agency) standard guidelines which provide radiation safety to the staff and the surrounding environment from radioactive contamination. Since 1999, BPFK (Biro Pengawalan Farmaseutikal Kebangsaan) has used the guidelines from Pharmaceutical Inspection Convention Scheme (PICS) to meet the requirements of the Good Manufacturing Practice (GMP) for Pharmaceutical Products. In the guidelines, the pharmaceutical production facility shall be designed based on clean room environment. In order to design a radiopharmaceutical production facility, it is important to combine the concept of radiation safety and clean room to ensure that both requirements from GMP and IAEA are met. The design requirement is necessary to set up a complete radiopharmaceutical production facility, which is safe, has high production quality and complies with the Malaysian and International standards. (Author)

  2. 188Re(V) Nitrido Radiopharmaceuticals for Radionuclide Therapy

    Science.gov (United States)

    Boschi, Alessandra; Martini, Petra; Uccelli, Licia

    2017-01-01

    The favorable nuclear properties of rhenium-188 for therapeutic application are described, together with new methods for the preparation of high yield and stable 188Re radiopharmaceuticals characterized by the presence of the nitride rhenium core in their final chemical structure. 188Re is readily available from an 188W/188Re generator system and a parallelism between the general synthetic procedures applied for the preparation of nitride technetium-99m and rhenium-188 theranostics radiopharmaceuticals is reported. Although some differences between the chemical characteristics of the two metallic nitrido fragments are highlighted, it is apparent that the same general procedures developed for the labelling of biologically active molecules with technetium-99m can be applied to rhenium-188 with minor modification. The availability of these chemical strategies, that allow the obtainment, in very high yield and in physiological condition, of 188Re radiopharmaceuticals, gives a new attractive prospective to employ this radionuclide for therapeutic applications. PMID:28106830

  3. Knowledge-based automated radiopharmaceutical manufacturing for Positron Emission Tomography

    International Nuclear Information System (INIS)

    Alexoff, D.L.

    1991-01-01

    This article describes the application of basic knowledge engineering principles to the design of automated synthesis equipment for radiopharmaceuticals used in Positron Emission Tomography (PET). Before discussing knowledge programming, an overview of the development of automated radiopharmaceutical synthesis systems for PET will be presented. Since knowledge systems will rely on information obtained from machine transducers, a discussion of the uses of sensory feedback in today's automated systems follows. Next, the operation of these automated systems is contrasted to radiotracer production carried out by chemists, and the rationale for and basic concepts of knowledge-based programming are explained. Finally, a prototype knowledge-based system supporting automated radiopharmaceutical manufacturing of 18FDG at Brookhaven National Laboratory (BNL) is described using 1stClass, a commercially available PC-based expert system shell

  4. Quality assurance of radiopharmaceuticals - specifications and test procedures

    International Nuclear Information System (INIS)

    Baldas, J.; Bonnyman, J.; Colmanet, S.F.; Ivanov, Z.; Lauder, R.A.

    1990-10-01

    The authors report on a Radiopharmaceutical Quality Assurance Test Programme carried out by the Australian Radiation Laboratory in which radiopharmaceuticals used in nuclear medicine in Australia are tested for compliance with specifications. Where the radiopharmaceutical is the subject of a monograph in the British Pharmacopoeia or the European Pharmacopoeia, then the specifications given in the Pharmacopoeia are adopted. In other cases the specifications given have been adopted by this Laboratory and have no legal status. In some cases test procedures described have been taken from various Pharmacopoeias or methods published in the literature. In other cases test methods described have been developed at this Laboratory. It should be noted that, unless stated otherwise, specifications listed apply at all times up until product expire

  5. Analytical techniques for the determination of radiochemical purity of radiopharmaceuticals prepared from kits. Part II

    International Nuclear Information System (INIS)

    MacLean, J.R.; Rockwell, L.J.; Welsh, W.J.

    The evaluation of efficacy of commercially available kits used for the preparation of radiopharmaceuticals is one aspect of the Radiation Protection Bureau's radiopharmaceutical quality control program. This report describes some of the analytical methodology employed in the program. Many of the tests can be performed rapidly and with a minimum of special equipment, thus enabling the confirmation of radiopharmaceutical purity prior to patient administration

  6. Role of the tunisian central pharmacy in the import of radio-pharmaceutical products

    International Nuclear Information System (INIS)

    Souissi Jaziri, Camelia; Moulahi, L.

    2013-01-01

    In Tunisia the centralized organization of the medicine sector has a strategic and economic importance. It presents particular characteristics concerning the importation and the control of drugs. Tcp has a monopoly on the importation of drugs for the country, which enters in the state policy for the control of drug purchasing costs, their availability in different region of the country and their guarantee and quality. The Tcp has a crucial role in the availability of drugs and in the holding safety stock and strategic reserve of the imported pharmaceutical products, either for the public or private sector. The Tcp has to stock up medicaments, chemical and pharmaceutical products, objects of bandages, instruments, accessory tools and other supplies necessary for the human and veterinary medicine. The Tcp packages any specialized or not medicament and all other products or supplies. The Tcp provides medicaments and products entering within the framework of its task to different health groups and hospitals. The Tcp provides distributors, laboratories and pharmacies over the country. In Tunisia the import of radioisotopes used in the medical domain is attributed to the Tcp. The objective is to centralize purchases and to guarantee: the security, the availability as well as the traceability. The Tcp supply radiopharmaceutical products for diagnostic and therapy purposes according to an authorization delivered annually by the National Center of Radiation Protection (NCRP). An authorization of removal used at the customs allows the clearance of products at the level of the air freights by the transit service of the Tcp. Regarding the evolution of purchases of radio-pharmaceutical products, their importation remained stable during the last three years. Indeed, it is approximately around 1MDT annually (954 121 DT in 2010, 939 956 in 2011 and 1047 967 in 2012). Sources of supply are divided between 4 suppliers: International IBA-CISBIO (49.9 pour cent), COVIDIEN EX (TYCO

  7. Recent developments in the field of 123I-radiopharmaceuticals

    International Nuclear Information System (INIS)

    Machulla, H.J.; Knust, E.J.

    1984-01-01

    Due to its advantageous nuclear physical properties iodine-123 is an excellent label for radiopharmaceuticals very well suited for measurements by γ-cameras and single-photon emission tomography. The development of 123 I-radiopharmaceuticals should be based on a clear biochemical concept, reliable labelling procedures and careful pharmacokinetic studies in order to evaluate the physiological behaviour of the radioiodinated compounds being analogues of metabolic substrates. The development of 123 I-labelled fatty acids and biogenic amines clearly proved the successful use of 123 I for labelling compounds applied in medical diagnosis. (orig.) [de

  8. EEC directives and guidelines applicable to radiopharmaceuticals - 1993

    International Nuclear Information System (INIS)

    Cox, P.H.

    1993-01-01

    The manufacture, scale and supply of radiopharmaceuticals in the EEC is regulated by directives that are incorporated into the national laws of the member states. The situation as of 1 January 1993 was not too optimistic, however, as the processing of licensing applications had been completely misjudged. Not one product had been registered as of 1 January. The costs involved are also high and since the European market for radiopharmaceuticals is relatively small, the market cannot afford this. It would appear that the EEC directives are inadquate and too non-specific, so revision is indicated. (orig.)

  9. The transport of radiopharmaceuticals in the United States

    Energy Technology Data Exchange (ETDEWEB)

    Ferate, F.D. [U. S. Dept. of Transportation, Washington, DC (United States)

    2004-07-01

    Among all the various uses of radioactive materials for peaceful purposes, the creation and use of radiopharmaceuticals to diagnose and treat medical ailments has probably brought the greatest benefit to humanity. The use of radionuclides in medicine has mushroomed over the past 20 years, as has the number of nuclides and procedures which are now routinely used in hospitals and clinics around the globe. Parallel to the growth in the use of radiopharmaceuticals has been the growth in shipments of these nuclides and their compounds to the locations where they are used.

  10. The transport of radiopharmaceuticals in the United States

    International Nuclear Information System (INIS)

    Ferate, F.D.

    2004-01-01

    Among all the various uses of radioactive materials for peaceful purposes, the creation and use of radiopharmaceuticals to diagnose and treat medical ailments has probably brought the greatest benefit to humanity. The use of radionuclides in medicine has mushroomed over the past 20 years, as has the number of nuclides and procedures which are now routinely used in hospitals and clinics around the globe. Parallel to the growth in the use of radiopharmaceuticals has been the growth in shipments of these nuclides and their compounds to the locations where they are used

  11. New radiopharmaceuticals currently used in clinical nuclear medicine

    International Nuclear Information System (INIS)

    Hladik, W.B. III

    1997-01-01

    During 1996 and 1997, six new radiopharmaceuticals have been approved by the U.S. Food and Drug Administration for use in the diagnosis and/or management of patients with various disease states. Four of these new agents are antibody-based diagnostic radiotracers, and one is a therapeutic agent. One radio-pharmaceutical that has been available for several years has been approved for a new, unique indication. Our discussion focuses on the physicochemical and pharmacokinetic properties of these recently released agents as well as their specific role in the management of patients

  12. A short history of radiopharmaceutical research in Australia

    International Nuclear Information System (INIS)

    Baker, R.

    1989-01-01

    A brief summary is given of radiopharmaceuticals research carried out in Australia. Historically, a number of the larger hospital radiopharmacies have been, and still are, involved with 99m Tc-cold kit production. Originally, this scenario evolved because the nuclear medicine community was denied access to state-of-the-art products available overseas. Although the situation has improved in recent times, most such departments continue kit production, having made a large capital investment in sterile facilities, equipment and staff. Australian Nuclear Science and Technology Organization has a leading role in radiopharmaceutical research and some of the topics which have occupied its scientists over the last few years are outlined

  13. Depyrogenation, sterilization and deproteination of radiopharmaceuticals with an ultrafilter

    Energy Technology Data Exchange (ETDEWEB)

    Suzuki, K; Tamate, K; Nakayama, T [National Inst. of Radiological Sciences, Chiba (Japan)

    1984-01-01

    A newly developed filter holder is described for an ultrafiltration method used in the removal of pyrogen, enzyme and bacteria in the preparation of intravenously injectable radiopharmaceuticals. Penetration ratios of bovine serum albumin, glutamate dehydrogenase and Escherichia coli endotoxin through the PTGC ultrafilter (NMWL = 10,000) were measured; these results are useful for estimating penetration ratios of other macromolecules. Attempts to obtain i.v. injectable /sup 13/NH, L- /sup 13/N-glutamate and 3- /sup 123/I-iodotyrosine radiopharmaceuticals were successful; after ultrafiltration, pyrogen, bacteria or protein were not detected.

  14. Stannous ion determination in99mTc - radiopharmaceutical kits

    International Nuclear Information System (INIS)

    Almeida, M.A.T.M. de; Silva, C.P.G. da.

    1989-10-01

    Two simple and selective methods for determination of stannous ion in radiopharmaceutical kits are proposed. One of this permits the estimation of stannic ion. The first method used is a potentiometric tiration of Sn +2 in HCl medium using KIO 3 solution under nitrogen gas and a redox platinum electrode. The second method consist of a compleximetric tiration of tin (Sn +2 and Sn +4 ) using EDTA standart solution at pH 5.5-5.6 without use of nitrogen gas. The employed procedures indicates that both the methods can be used for routine quantitative determination of tin in most labeled radiopharmaceuticals. (author) [pt

  15. Which radiopharmaceuticals for to-morrow. Heart and brain investigations

    International Nuclear Information System (INIS)

    Maziere, B.

    1994-01-01

    This paper is a critical review of the various radiopharmaceuticals which have been or are presently designed for functional imaging of brain or heart using positron (PET) or single photon emission tomography. Currently used radiopharmaceuticals have been classified into two broad categories: 'passive' radiotracers intended to visualize the perfusion of the organ and 'active' or 'specific' radiotracers used to investigate metabolism or neurotransmission processes. Moreover, the potential interest of radioactive peptides or oligonucleotides which would be biologically stable in vivo and which could target proteins involved in inter or intra-cellular communications will be reviewed. (authors). 47 refs

  16. Effects of radiation exposure from radiopharmaceuticals used in diagnostic studies

    International Nuclear Information System (INIS)

    Witcofski, R.L.

    1981-01-01

    In the United States about 90 percent of man-made radiation exposure to the general population is from the use of radiation in diagnostic medicine. Although the doses of radiation from these procedures to individuals are generally quite small, large numbers of people are exposed. Estimates of the radiation doses associated with such use in the healing arts are approximately 15 million person-rem to the general population from diagnostic x ray and 3.3 million person-rem from the diagnostic use of radiopharmaceuticals. The purpose of this paper is to present what is known about the possible effects of radiation from diagnostic radiopharmaceuticals

  17. Design of radiopharmaceuticals for monitoring gene transfer therapy

    International Nuclear Information System (INIS)

    Lambrecht, R.M.; Staehler, P.; Kley, J.; Spiegel, M.; Gross, C.; Graepler, F.T.C.; Gregor, M.; Lauer, U.; Oberdorfer, F.

    1998-01-01

    The development of radiopharmaceuticals for monitoring gene transfer therapy with emission tomography is expected to lead to improved management of cancer by the year 2010. There are now only a few examples and approaches to the design of radiopharmaceuticals for gene transfer therapy. This paper introduces a novel concept for the monitoring of gene therapy. We present the optimisation of the labelling of recombinant human β-NGF ligands for in vitro studies prior to using 123 I for SPET and 124 I for PET studies. (author)

  18. Drug interaction with radiopharmaceuticals: a review

    Directory of Open Access Journals (Sweden)

    Mario Bernardo-Filho

    2005-10-01

    Full Text Available Clinical images are worthwhile in Health Sciences and their analysis and correct interpretation aid the professionals,such as physicians, physiotherapists and occupational therapists, to make decisions and take subsequent therapeutic and/or rehabilitation measures. Other factors, besides the state of the disease, may interfere and affect the bioavailability of the radiopharmaceuticals (radiobiocomplexes and the quality of the SPECT and PET images. Furthermore, the labeling of some of these radiobiocomplexes, such as plasma proteins, white blood cells and red blood cells, with 99mT, can also be modified. These factors include drugs (synthetic and natural and dietary conditions, as well as some medical procedures (invasive or non-invasive, such as radiation therapy, surgical procedures, prostheses, cardioversion, intubation, chemoperfusion, external massage, immunotherapy, blood transfusion and hemodialysis. In conclusion, the knowledge about these factors capable of interfering with the bioavailability of the radiobiocomplexes is worthwhile for secure diagnosis. Moreover, the development of biological models to study these phenomena is highly relevant and desirable.Imagens clínicas são valiosas em Ciências da Saúde e a análise e a interpretação correta das mesmas auxiliam os profissionais, como médico, fisioterapeuta, terapeuta ocupacional, na tomada de decisões e subseqüentes ações terapêuticas e/ou de reabilitação. Além das doenças outros fatores podem interferir e afetar a biodisponibilidade dos radiofármacos (radiobiocomplexos e a qualidade das imagens (SPECT e PET. Além disso, a marcação de alguns desses radiobiocomplexos com Tc-99m, como proteínas plasmáticas, leucócitos e hemácias, também pode ser modificada. Entre esses fatores, estão drogas (sintéticas e naturais e condições alimentares, assim como alguns procedimentos médicos (invasivos e não invasivos, como a radioterapia, processos cirúrgicos, pr

  19. Radiopharmaceuticals for diagnosis and therapy of cancer

    International Nuclear Information System (INIS)

    Wiebe, L.I.

    1998-01-01

    This paper addresses the utilization of three very distinct enzyme systems for imaging in oncology. The first of these is an enzyme encoded by a viral gene that is not present in non-infected mammalian cells. This enzyme is a nucleoside kinase that converts selected unnatural nucleosides to nucleotides in virus-infected or gene-transfected cells, but not in normal cells. The most commonly used viral kinase in gene therapy today is Herpes simplex virus type-1 thymidine kinase (HSV tk). The imaging applications of this gene therapy system are demonstrated using data from a murine tumour gene therapy model, with 123 IVFRU as the diagnostic radiopharmaceutical. The second enzyme system is endogenous to mammalian cells, but is found in highest concentrations in tissues of neutral crest derivation. The overall biochemical pathway of interest involves the conversion of tyrosine to either dopamine (neurotransmitter pathway), or to melanin (pigmentation pathway). In this system tyrosinase is the 'branching' enzyme, converting dopa to dopaquinone, thereby averting its conversion to dopamine. With selective agents, the tracer can be trapped in this 'melanin pathway', which is particularly active in melanomas. Data on the development of radioiodinated tyrosinase substrates, based on S-cysteaminyl phenol (SCAP), a highly specific tyrosinase substrate, are presented to illustrate this concept. The final example is that of endogenous enzymes that are virtually ubiquitous in biodistribution. One class of enzymes, the reductases, are particularly active in the liver and their activity is amplified in tissues that are hypoxic. They are important in radiotherapy, where they can be utilized to bioreductively activate compounds that can restore the radiosensitivity of hypoxic cells. The 2-nitroimidazoles are of special interest because they are easily reducible by a number of reductases, a process that is made selective by the reversibility of reduction in the presence of cellular

  20. Kinetic model for the dosimetry of radiopharmaceuticals contaminated by Mo-99

    International Nuclear Information System (INIS)

    Shearer, D.R.; Pezzullo, J.C.

    1986-01-01

    Radiopharmaceuticals tagged with Tc-99m may become contaminated with breakthrough products from the Mo-99/Tc-99m generator. If a fraction of the contaminant becomes bound to the radiopharmaceutical, the dose to the radiopharmaceutical target organ from the contaminant must be considered. The dose to the contaminant target organ may then be calculated as the sum of the doses from a) the initially unbound contaminant, and b) the contaminant later released by degradation of the radiopharmaceutical. This paper presents a model which takes the above processes into account. The model is illustrated with clinical data derived from Mo-99 contaminated radiopharmaceuticals. 5 references, 2 figures, 6 tables

  1. Intergrated approach to quality control procedures of radioisotopes and radiopharmaceuticals

    International Nuclear Information System (INIS)

    Rohani Mohamad

    1986-01-01

    Various aspects of the quality control procedures for radioisotopes and radiopharmaceuticals have been discussed. The paper high lighted those procedures that are important in ensuring the efficacy of the product. It also gives a general idea of the various procedures that are actually carried out by the Quality Control Section. (A.J.)

  2. WIPR 2013 - Radiopharmaceuticals: from research to industry - Book of abstracts

    International Nuclear Information System (INIS)

    2015-01-01

    This workshop aims at presenting the latest progress in the field of radioimmunotherapy: radiopharmaceutical production, radiochemistry, radiolabelling, nuclear imaging and clinical applications. The presentations have been divided into 4 sessions: 1) alpha or beta radioimmunotherapy, 2) peptides or antibodies, 3) the benefits from nuclear imaging, and multimodal imaging

  3. Influence of sweeteners in the biodistribution of radiopharmaceutical ...

    African Journals Online (AJOL)

    Influence of sweeteners in the biodistribution of radiopharmaceutical and laboratory tests in rats. Michelly Pires Queiroz, Vanessa Santos de Arruda Barbosa, Cecília Maria de Carvalho Xavier Holanda, Janette Monroy Osório, Tarciso Bruno Montenegro Sampaio, Christina da Silva Camillo, Aldo Cunha Medeiros, Marília ...

  4. Guidance for nuclear medicine staff on radiopharmaceuticals drug interaction

    International Nuclear Information System (INIS)

    Santos-Oliveira, Ralph

    2009-01-01

    Numerous drug interactions related to radiopharmaceuticals take place every day in hospitals many of which are not reported or detected. Information concerning this kind of reaction is not abundant, and nuclear medicine staff are usually overwhelmed by this information. To better understand this type of reaction, and to help nuclear medicine staff deal with it, a review of the literature was conducted. The results show that almost all of radiopharmaceuticals marketed around the world present drug interactions with a large variety of compounds. This suggests that a logical framework to make decisions based on reviews incorporating adverse reactions must be created. The review also showed that researchers undertaking a review of literature, or even a systematic review that incorporates drug interactions, must understand the rationale for the suggested methods and be able to implement them in their review. Additionally, a global effort should be made to report as many cases of drug interaction with radiopharmaceuticals as possible. With this, a complete picture of drug interactions with radiopharmaceuticals can be drawn. (author)

  5. Harvard-MIT research program in short-lived radiopharmaceuticals

    Energy Technology Data Exchange (ETDEWEB)

    Adelstein, S.J.

    1991-01-01

    This report presents research on radiopharmaceuticals. The following topics are discussed: antibody labeling with positron-emitting radionuclides; antibody modification for radioimmune imaging; labeling antibodies; evaluation of technetium acetlyacetonates as potential cerebral blood flow agents; and studies in technetium chemistry. (CBS)

  6. Cyclotron targets and production technologies used for radiopharmaceuticals in NPI

    Czech Academy of Sciences Publication Activity Database

    Fišer, Miroslav; Kopička, Karel; Hradilek, Pavel; Hanč, Petr; Lebeda, Ondřej; Panek, T.; Vognar, M.

    2003-01-01

    Roč. 53, č. 2 (2003), s. A737-A743 ISSN 0011-4626 R&D Projects: GA AV ČR KSK4055109 Keywords : cyclotron * radiopharmaceuticals Subject RIV: CH - Nuclear ; Quantum Chemistry Impact factor: 0.263, year: 2003

  7. Quality assurance of radiopharmaceuticals-specifications and test procedures

    International Nuclear Information System (INIS)

    Baldas, J.; Bonnyman, J.; Pojer, P.M.

    1981-08-01

    This report is a compilation of test methods used and specifications adopted for the Radiopharmaceutical Quality Assurance Test Programme conducted by the Australian Radiation Laboratory. In some cases test procedures described have been taken from various Pharmacopoeias or methods published in the literature. In other cases test methods have been developed at the ARL

  8. Radioisotope requirements and usage in the radiopharmaceutical industry

    International Nuclear Information System (INIS)

    Langton, M.A.

    1995-01-01

    Radioisotopes are used extensively in many different productive and beneficial human endeavors. Amersham International, a U.K.-based company originating in the British Scientific Civil Service during World War II, has been actively involved in many of these activities for more than 50 yr. Today they are one of the world's largest suppliers of radioactive compounds and scaled radiation sources for use in industrial quality and safety assurance, life science research, and medicine. This paper outlines one of these applications: the use of radioisotopes as radiopharmaceuticals. Radiopharmaceuticals are radioactive nuclides and labeled compounds that have been developed for the diagnosis and treatment of (human) disease. They are manufactured via highly controlled processes and have gone through regulatory scrutiny and approval far in excess of other radioisotopes used in other applications. Radiopharmaceuticals can be conveniently split into two categories. One type is simply an active analog that mimics the physiological behavior of its inactive counterpart in the body. The other involves an actual pharmacological compound that exhibits the desired physiological behavior, which is then labeled with a radionuclide suitable for either imaging or the delivery of a therapeutic radiation dose as appropriate but which plays no part in the mechanism of action of the drug. The latter type, which is the more common of the two, can be supplied either as an active compounded product or as a open-quotes cold kit,close quotes which is then labeled with the appropriate radiopharmaceutical-grade radionuclide to yield the final product

  9. Routine clinical use of radiopharmaceuticals in Latin American developing countries

    International Nuclear Information System (INIS)

    Mitta, A.E.

    1985-01-01

    The paper describes the routine clinical use of radiopharmaceuticals in the developing countries of Latin America made possible by: (1) the International Atomic Energy Agency (IAEA), which sent experts and equipment to many countries and made a substantial bibliographic contribution on the subject; (2) the Latin American Association of Societies of Nuclear Biology and Medicine (ALASBIMN), which fostered the exchange of data on techniques of radiopharmaceutical preparation and quality control by providing materials for tests, etc., and by publishing quality control manuals in some countries, finally in 1982 producing the Manual of Radiopharmaceutical Quality Control, in collaboration with the Inter-American Nuclear Energy Commission (CIEN) and published by the Organization of American States (OAS); (3) the countries themselves under agreements between their atomic energy commissions; (4) radiopharmacy courses organized by universities, either alone or in collaboration with the IAEA, WHO, etc.; (5) professional workers who established radiopharmaceutical services at private centres. Finally, the societies of nuclear medicine and biology in each country, the World Federation of Nuclear Medicine and Biology, the ALASBIMN, the IAEA, etc. organized symposia and meetings which afforded opportunities to professionals of these countries to receive and exchange information, since in Latin America, given its language and human characteristics, the problems are similar. The countries referred to are Argentina, Brazil, Mexico, Uruguay, Bolivia, Paraguay, Chile, Peru, Ecuador, Colombia, Venezuela, Costa Rica, Guatemala, Puerto Rico, El Salvador and Panama; little is known about Honduras, Nicaragua, the Dominican Republic and Cuba. (author)

  10. Towards a harmonized radiopharmaceutical regulatory framework in Europe

    International Nuclear Information System (INIS)

    Decristoforo, A.; Penuelas, I.

    2009-01-01

    Despite European unification regarding a common legal framework for many aspects of pharmaceutical production including industrial manufacture of pharmaceuticals, the practice of pharmacy in general, and of radiopharmacy in particular, differs substantially and are mainly regulated at the national level. Herein the authors discuss major European documents relevant for radiopharmacy practice in Europe and recent developments on the national level especially regarding the small-scale preparation of radiopharmaceuticals (R P). Issues related to marketing authorization (and exemptions from it), standards of preparation, quality requirements, regulations of clinical trials and education will be outlined. Standards for the industrial preparation of pharmaceuticals are defined in Good Manufacturing Practice (GMP), not taking into account specific requirements for the small scale, extemporaneous preparation of R P. The European Association of Nuclear Medicine EANM has published several documents based on GMP and called Good Radiopharmaceutical Practice (cGRPP) to specifically address this in an attempt to harmonize R P preparation across Europe. Clinical trials have been hampered by the introduction of directive 2001/20/E C again aimed at the marketing track of industrial production and currently a number of activities are ongoing to counterbalance this problem in radiopharmaceutical research. Additionally, the role of the European Pharmacopoeia in regulating quality requirements and the need for specific education and training in the small scale radiopharmaceutical preparation are also discussed.

  11. Sixth international symposium on radiopharmaceutical chemistry: Abstracts: Final report

    International Nuclear Information System (INIS)

    1986-01-01

    The 113 abstracts are arranged under the following section headings: alkyl spiperone derivatives labeled with fluorine, synthesis of compounds labeled with positron emitters, technetium compounds, positron emitters (target design and synthesis), indium and gallium, halogens, labeled proteins and antibodies, radiopharmaceuticals for brain and SPECT, general, and receptor radioligands

  12. Dispersion for the preparation of an injectable radiopharmaceutical scanning agent

    International Nuclear Information System (INIS)

    Wolfangel, R.G.

    1976-01-01

    The invention deals with the preparation of a dispersion of a tin (II) sulphur colloid in an aqueous solution with additions of a stabilizing agent. Labelled with sup(99m)Tc, the dispersion can be used as an injectable radiopharmaceutical scanning agent. (VJ) [de

  13. Positron emitting nuclides and their synthetic incorporation in radiopharmaceuticals

    International Nuclear Information System (INIS)

    Fowler, J.S.

    1976-01-01

    11 C, 13 N, and 15 O has potential applicability to the study of metabolism in humans. Problems in the synthesis of radiopharmaceuticals labeled with 11 C, 13 N, and 18 F are described: quality control, radiation exposure, carboxylic acids, glucose, amines, amino acids, nitrosources, fluoroethanol. 54 references

  14. Radiopharmaceutical therapy in Dominican Republic. Present and future

    International Nuclear Information System (INIS)

    Johny Osvaldo de los Santos

    2005-01-01

    Full text: In this paper we present experience in Dominican Republic on Radiopharmaceutical Therapy. In our country, there are 8 Center with Nuclear Medicine Department. Only, 7 centers are working with Radiopharmaceutical Therapy. Radioiodine treatment with I-131 in Thyroid diseases(Thyroid Cancer and Hyperthyroidism). This is only Nuclear Medicine therapy available in Dominican Republic. The objectives of this paper are to analyze and assess the difficulties and facilities for the development of Radiopharmaceutical Therapy in Dominican Republic. We made surveys with the help of Nuclear Medicine Physicians of different Nuclear Medicine departments. 8 Nuclear Physicians accepted the interview. Two of these Nuclear Medicine Centers are Department of a Cancer Center and they have many patients for therapies. In the majority opinion of Physicians, Cost of Radiopharmaceuticals is principal problem to use Therapy in Dominican Republic. In addition the following problems were identified: Lack of awareness about new therapy in Nuclear Medicine among Physicians of other specialties, lack of adequate training in the current trends of radionuclide therapy and finally lack of basic infrastructure, equipment and finances to buy radiopharmaceuticals and introduce radionuclide therapy. For this reason, Nuclear Medicine Centers prefer to work with only I-131 Therapy and they do not have new programs to start other therapies. In the near future, our department of Nuclear Medicine will work with I-131, pain palliation, treatment of metastatic disease and Treatment of benign diseases. We have interest in offering other therapies in the department and we hope that other departments with more resources, have the same interest, to enhance practice of radionuclide therapy in our country. (author)

  15. Radiopharmacy and radiopharmaceuticals in Brazil: sanitarians aspects related to a project of an industry of PET radiopharmaceuticals

    International Nuclear Information System (INIS)

    Santos-Oliveira, Ralph; Benevides, Clayton Augusto; Hwang, Suy Ferreira; Salvi, Roberto Paulo Camara; Freitas, Ione Maria Acioly Teixeira Ricarte de

    2008-01-01

    The increasing use of radiopharmaceuticals for PET (Positron Emission Tomography) has come to the attention of nuclear medicine staff and regulatory bodies. The aim of this study is to provide a national reference in radiopharmacy that could help all nuclear medicine staff and specially the Brazilian's regulatory bodies focused on the industrial project. (author)

  16. American Vocational Education Research Association (AVERA) Annual Research Meeting in Conjunction with the Annual Convention of the Association for Career and Technical Education. Proceedings (Orlando, Florida, December 11-13, 1999).

    Science.gov (United States)

    Camp, William G., Ed.

    This document contains 14 research papers presented at the American Vocational Education Research Association (AVERA) annual meeting. The following papers are included: "Factors that Influence Students to Attend 4-Year Automotive Programs" (Gregory G. Belcher, Robert L. Frisbee); "The Training Needs of Vocational Teachers for…

  17. GPHS-RTGs in support of the Cassini RTG Program. Semi annual technical progress report, September 26, 1994--April 2, 1995

    International Nuclear Information System (INIS)

    1995-01-01

    The technical progress achieved during the period 26 September 1994 through 2 April 1995 on Contract DE-AC03-91SF18852 Radioisotope Thermoelectric Generators and Ancillary Activities is described herein. Monthly technical activity for the period 27 February 1995 through 2 April 1995 is included in this progress report. The report addresses tasks, including: spacecraft integration and liaison; engineering support; safety; qualified unicouple production; ETG Fabrication, assembly, and test; ground support equipment; RTG shipping and launch support; designs, reviews, and mission applications; project management, quality assurance, reliability, contract changes, CAGO acquisition (operating funds), and CAGO maintenance and repair; and CAGO acquisition (capital funds)

  18. Proceedings of the Annual Meeting of the Technical Documentation Division (21st) Held in Monterey, California on 23-25 May 1979.

    Science.gov (United States)

    1979-05-01

    COMMITTEE I FRG REP FR REP US/EUROPEAN JOINT EFFORT SIMULATIONJIN CENTRAL CONF REVIEW JINI MTRO GRU TEST SUB- LOGISTICS I OTHER SCOMMOL GRU COMCOMMITTEE SIUB...was made to the DOD activity summary given at general membership Session II. The GAO interest in technical manuals 4as related to the USAF and USN

  19. New technologies for production of radiopharmaceuticals and other medical preparations

    International Nuclear Information System (INIS)

    Bazaniak, Z.; Iller, E.; Mikolajczak, R.

    2004-01-01

    The Radioisotope Centre POLATOM belongs to the group of R and D institutions whose profile of activities comprises, besides applied research work, also manufacturing of a range of products based on implementation of the Centre's own developments. The Centre possesses considerable experience in its area of expertise: forty-six years of manufacturing of various radiation sources and radiopharmaceuticals, performing metrology and analysis of radioactive materials, which makes OBRI a unique R and D unit. The Centre is a chief manufacturer supplier of radiopharmaceuticals for nuclear medicine in Poland, and also an active exporter with a market of several tens countries. The current trends in the Centre activity assume combination of R and D work with practical application of its results for production purposes. The undertaken research topics are studied in co-operation with domestic and foreign scientific institutions. (author)

  20. Impact of risk considerations on dosimetry of radiopharmaceuticals

    International Nuclear Information System (INIS)

    Eckerman, K.F.

    1981-01-01

    Estimates of the absorbed dose from clinical procedures involving the administration of radiopharmaceuticals are used primarily to determine the presumed risk of various procedures so that, in-so-far as possible, the selection of a given procedure can be based on a comparison of risk. Although this has been the basic objective, risk evaluation has generally been separated from the dosimetry considerations. In the recent revision of its radiation protection guidance, the International Commission on Radiological Protection (ICRP) has embodied risk considerations in its recommendations and risk concepts have become an integral part of the dosimetric framework. The impact of these considerations on the dosimetric assessments of radiopharmaceuticals and the resulting need for additional information is discussed

  1. Developments in radioisotope production and labelling of radiopharmaceuticals

    International Nuclear Information System (INIS)

    Lambrecht, R.M.

    1998-01-01

    Recent developments in both reactor and accelerator production of radioisotopes finding applications in nuclear medicine and in biomedical research are summarised. The priorities for the production of 48 different cyclotron radioisotopes; and for 42 reactor produced radioisotopes finding biomedical applications are identified. Each includes 5 generator systems. The rapid expansion of cyclotron based radioisotope production and automated synthesis of short-lived radiopharmaceuticals with the position-emitting radionuclides continues to gain momentum. Recent feasibility studies of the cyclotron production of 186 Re, 99m Tc and of 99 Mo are cited as examples of motivation to develop accelerator alternatives to use of nuclear reactors for medical radioisotope production. Examples of SPET and PET radiopharmaceuticals labelled with 131 I, 123 I, 124 I, 18 F, and with therapeutic radionuclides are highlighted. (author)

  2. Procedures of quality control of radiopharmaceutical activity counters

    International Nuclear Information System (INIS)

    Oliveira, A.E. de; Iwahara, A.; Gaast, H.A. van der; Buckman, S.M.

    1999-01-01

    The Radionuclides Metrology Supervision-Ionizing Radiation Metrology National Laboratory maintain and distributes the brazilian standards for radioactivity measurements. The Brazilian Institute for Metrology, Regulation and Industrial Quality (INMETRO), which is the brazilian authority for standards verification, is coordinating the enhancement of the standards distribution. Concerning to the nuclear medicine related radioisotopes, this network will provide for calibration of brazilian hospitals and clinics instruments, assuring great accuracy of the radiopharmaceuticals activities. This work gives details of the calibration quality control procedures recommended by the Radionuclides Metrology Supervisory (Brazilian National Nuclear Energy Commission) and the Radioactive Standards Division of the Australian Nuclear Technology and Science Organization (ANSTO). This information can be used as a guide for the brazilian nuclear medicine services guaranty on the accuracy and precision of the radiopharmaceuticals activity measurements measurements

  3. Influence of radioactive contaminants on absorbed dose estimates for radiopharmaceuticals

    International Nuclear Information System (INIS)

    Watson, E.E.; Stabin, M.G.

    1986-01-01

    Several popular radiopharmaceutical products contain low levels of radioactive contaminants. These contaminants increase the radiation absorbed dose to the patient without any increased benefit and, in some cases, with a decrease in image quality. The importance of a contaminant to the radiation dosimetry picture is a function of 1) the contaminant level, 2) the physical half-life of the contaminant, 3) the organ uptake and the biological half-time of the contaminant in the various body systems, and 4) the decay mode, energy, etc. of the contaminant. The general influence of these parameters is discussed in this paper; families of curves are included that reflect the changing importance of contaminant dosimetry with respect to the primary radionuclide as a function of these variables. Several specific examples are also given of currently used radiopharmaceutical products which can contain radioactive contaminants (I-123, In-111, Tl-201, Ir-191m, Rb-82, Au-195m). 7 references, 8 figures, 4 tables

  4. Cerenkov Luminescence Tomography for In Vivo Radiopharmaceutical Imaging

    Directory of Open Access Journals (Sweden)

    Jianghong Zhong

    2011-01-01

    Full Text Available Cerenkov luminescence imaging (CLI is a cost-effective molecular imaging tool for biomedical applications of radiotracers. The introduction of Cerenkov luminescence tomography (CLT relative to planar CLI can be compared to the development of X-ray CT based on radiography. With CLT, quantitative and localized analysis of a radiopharmaceutical distribution becomes feasible. In this contribution, a feasibility study of in vivo radiopharmaceutical imaging in heterogeneous medium is presented. Coupled with a multimodal in vivo imaging system, this CLT reconstruction method allows precise anatomical registration of the positron probe in heterogeneous tissues and facilitates the more widespread application of radiotracers. Source distribution inside the small animal is obtained from CLT reconstruction. The experimental results demonstrated that CLT can be employed as an available in vivo tomographic imaging of charged particle emitters in a heterogeneous medium.

  5. Abbreviated New Drug Applications (ANDAS): Future trend in radiopharmaceuticals

    International Nuclear Information System (INIS)

    Kishore, R.

    1990-01-01

    The Drug Price Competition and Patent Term Restoration Act (commonly called Waxman Hatch Amendment) of 1984, to the Federal Food, Drug, and Cosmetic Act provided for abbreviated new drug applications (ANDAs) if the conditions specified in the Code of Federal Regulations (CFR) Title 21, subsection 312.55 are met. Under this subsection, reports of nonclinical laboratory studies and clinical investigations can be omitted. New drugs approved under these regulations are so called generic drugs as opposed to listed or pioneer (innovator) drugs. As the patents on more and more radiopharmaceuticals reach their expiration, the radiopharmaceutical industry is likely to produce more of these generic versions of innovator drugs. The ANDAs are required to contain information specified under subsections 314.50(a), (b), (d)(1) and (3), (e), and (g)

  6. Infection imaging with radiopharmaceuticals in the 21st century

    Energy Technology Data Exchange (ETDEWEB)

    Das, Satya S.; Wareham, David W. [St. Bartholomew' s Hospital, London (United Kingdom). Dept. of Medical Microbiology; Britton, Keith E. [St. Bartholomew' s Hospital, London (United Kingdom). Dept. of Nuclear Medicine; Hall, Anne V. [Harefield Hospital, Middlesex (United Kingdom). Microbiology Dept.

    2002-09-01

    Infection continues to be a major cause of morbidity and mortality worldwide. Nuclear medicine has an important role in aiding the diagnosis of particularly deep-seated infections such as abscesses, osteomyelitis, septic arthritis, endocarditis, and infections of prosthetic devices. Established techniques such as radiolabelled leucocytes are sensitive and specific for inflammation but do not distinguish between infective and non-infective inflammation. The challenge for Nuclear Medicine in infection imaging in the 21st century is to build on the recent trend towards the development of more infection specific radiopharmaceuticals, such as radiolabelled anti-infectives (e.g. 99 m Tc ciprofloxacin). In addition to aiding early diagnosis of infection, through serial imaging these agents might prove very useful in monitoring the response to and determining the optimum duration of anti-infective therapy. This article reviews the current approach to infection imaging with radiopharmaceuticals nd the future direction it might take. (author)

  7. Infection imaging with radiopharmaceuticals in the 21st century

    International Nuclear Information System (INIS)

    Das, Satya S.; Wareham, David W.; Britton, Keith E.; Hall, Anne V.

    2002-01-01

    Infection continues to be a major cause of morbidity and mortality worldwide. Nuclear medicine has an important role in aiding the diagnosis of particularly deep-seated infections such as abscesses, osteomyelitis, septic arthritis, endocarditis, and infections of prosthetic devices. Established techniques such as radiolabelled leucocytes are sensitive and specific for inflammation but do not distinguish between infective and non-infective inflammation. The challenge for Nuclear Medicine in infection imaging in the 21st century is to build on the recent trend towards the development of more infection specific radiopharmaceuticals, such as radiolabelled anti-infectives (e.g. 99 m Tc ciprofloxacin). In addition to aiding early diagnosis of infection, through serial imaging these agents might prove very useful in monitoring the response to and determining the optimum duration of anti-infective therapy. This article reviews the current approach to infection imaging with radiopharmaceuticals nd the future direction it might take. (author)

  8. Radiopharmaceuticals using radioactive compounds in pharmaceutics and medicine

    International Nuclear Information System (INIS)

    Theobald, A.

    1989-01-01

    This review of the latest techniques and developments indicates the importance of radiopharmaceutical techniques in the development of drug compounds. It presents practical demonstrations, offers practical exercises, as well as the underlying theoretical considerations: it will supplement existing (mostly American) texts in this subject, since most industrial pharmaceutical companies have a keen interest in the area and most pharmaceutical courses include the subject at degree level. The authors emphasize the pharmaceutical applications throughout. They review targeting aspects, including cell and protein labelling: and discuss radiotracers in testing dosage forms and formulation studies. Safety and legislation are considered, with reviews of the handling techniques, radiation monitoring, radiochromatography and the use of computer techniques. The latter part of the work discusses standards for radiopharmaceuticals, sterility and pyrogen testing, as well as both radiochromatographic and electrophoretic methods and their importance to quality control. (author)

  9. Proceedings of the Annual DTIC (Defense Technical Information Center) Users Conference Held at Alexandria, Virginia on 24-26 October 1984

    Science.gov (United States)

    1984-10-26

    34 telecommuting ," meaning people do not necessarily have to go from one place to another but all ■we need is for the information to flow from one... absentee ballot system. There are many users who for one reason or another cannot attend the annual meeting. These sites were essentially...newsletter and read it, the User Council established an absentee ballot system. We did receive a number of ballots that way. As best we could, we

  10. Technical committee meeting on Liquid Metal Fast Reactor (LMFR) developments. 33rd annual meeting of the International Working Group on Fast Reactors (IWG-FR). Working material

    International Nuclear Information System (INIS)

    2000-01-01

    Over the past 33 years, the IAEA has actively encouraged and advocated international cooperation in fast reactor technology. The present publication contains information on the status of fast reactor development and on worldwide activities in this advanced nuclear power technology during 1999/2000, as reported at the 33. annual meeting of the International Working Group on Fast Reactors. It is intended to provide information regarding the current status of LMFR development in IAEA Member States

  11. Deficiencies in product labelling instructions and quality control directions for 99mTc radiopharmaceuticals.

    Science.gov (United States)

    Buroni, Federica E; Lodola, Lorenzo; Persico, Marco G; Aprile, Carlo

    2014-02-01

    The aim of the study was to identify deficiencies in product labelling instructions for reconstitution and in the quality control directions detailed in the technical leaflets (TLs) or summary product characteristic (SPC) sheets of commonly used technetium labelling cold kits. The reconstitution and quality control directions in 25 TLs/SPCs were evaluated to identify deficiencies, incompleteness, restrictions, errors, impracticability, and vagueness. In addition, their congruence with the statements given in the relative European Pharmacopoeia (Ph. Eur. VII ed.) monography and diagnostic reference levels of Directive 97/43/EURATOM was evaluated. Deficiencies in information were scored and classified into five categories: 1, absent or incomplete; 2, restrictive; 3, inconsistent or wrong; 4, impractical; and 5, vague. In the 25 documents analyzed a total of 141 deficiencies were found (corresponding to 40.2% of the total scores assigned), and more frequently they pertained to quality control procedures (70.9%), followed by those related to quantitative composition (14.9%), preparation (8.5%), and particle size (5.7%). Nearly 80% of these deficiencies were classified as type 1 - that is, absent or incomplete information. The indications in TLs and SPCs should provide useful information for maintaining the quality and purity of the radiopharmaceutical preparation and ensure the safety level and effectiveness required by law. However, the instructions are often suboptimal or even erroneous, and consequently there are countless failures or difficulties, which represent an impediment to good laboratory practice. We believe that a 'smart' review of radiopharmaceutical documentation would be beneficial in order to align these indications to the real needs of the operators involved in routine in-house nuclear medicine practice.

  12. Airtight miniaturized chromatography: a safer method for radiopharmaceutical quality control

    International Nuclear Information System (INIS)

    Coupal, J.J.; Shih, W.J.; Ryo, U.Y.

    1988-01-01

    Miniaturized chromatography is widely used for quality control of radiopharmaceuticals. Recently, published chromatography procedures have illustrated or described chromatography chambers open to the air in use, suggesting that volatile toxic mobile phases are harmless to people in the vicinity. The authors describe the results of their search for an inexpensive closed chromatography chamber that can be used to derive safely the benefits from conventional miniaturized chromatography

  13. Adherence of radiopharmaceuticals and labeled cells to intravenous tubing

    International Nuclear Information System (INIS)

    Segall, G.M.; Gurevich, N.; McDougall, I.R.

    1986-01-01

    A survey of 67 nuclear medicine departments revealed no agreement on which radiolabeled agents could be injected through intravenous lines (IVs) and which required direct venipuncture. Labeled cells and several common radiopharmaceuticals were tested for adherence to intravenous tubing. Residual activity remaining in the tubing after an adequate flush was less than 1% of the injected dose in each case. Administration of radiolabeled agents through existing IVs is an acceptable alternative to direct venipuncture in many cases

  14. To the radiotoxicity of {sup 99m}Tc radiopharmaceuticals

    Energy Technology Data Exchange (ETDEWEB)

    Ftacnikova, S [Inst. of Preventive and Clinical Medicine, 83301 Bratislava (Slovakia)

    1996-12-31

    In this paper the radiotoxicity and RBE values of Auger electrons for {sup 99m}Tc radiopharmaceuticals were discussed. Expression for the expected RBE for {sup 99m}Tc compounds is given. For the Auger electrons emitted in the decay of {sup 99m}Tc the RBE(Auger) = 10 and a value of 20 for the radiation weighing factor were recommended. (J.K.) 4 refs.

  15. Molecular Engineering of Technetium and Rhenium Based Radiopharmaceuticals

    International Nuclear Information System (INIS)

    Zubieta, J.

    2003-01-01

    The research was based on the observation that despite the extraordinarily rich coordination chemistry of technetium and rhenium and several notable successes in reagent design, the extensive investigations by numerous research groups on a variety of N 2 S 2 and N 3 S donor type ligands and on HYNIC have revealed that the chemistries of these ligands with Tc and Re are rather complex, giving rise to considerable difficulties in the development of reliable procedures for the development of radiopharmaceutical reagents

  16. Radiopharmaceuticals and other compounds labelled with short-lived radionuclides

    CERN Document Server

    Welch, Michael J

    2013-01-01

    Radiopharmaceuticals and Other Compounds Labelled with Short-Lived Radionuclides covers through both review and contributed articles the potential applications and developments in labeling with short-lived radionuclides whose use is restricted to institutions with accelerators. The book discusses the current and potential use of generator-produced radionuclides as well as other short-lived radionuclides, and the problems of quality control of such labeled compounds. The book is useful to nuclear medicine physicians.

  17. Improving radiopharmaceutical supply chain safety by implementing bar code technology.

    Science.gov (United States)

    Matanza, David; Hallouard, François; Rioufol, Catherine; Fessi, Hatem; Fraysse, Marc

    2014-11-01

    The aim of this study was to describe and evaluate an approach for improving radiopharmaceutical supply chain safety by implementing bar code technology. We first evaluated the current situation of our radiopharmaceutical supply chain and, by means of the ALARM protocol, analysed two dispensing errors that occurred in our department. Thereafter, we implemented a bar code system to secure selected key stages of the radiopharmaceutical supply chain. Finally, we evaluated the cost of this implementation, from overtime, to overheads, to additional radiation exposure to workers. An analysis of the events that occurred revealed a lack of identification of prepared or dispensed drugs. Moreover, the evaluation of the current radiopharmaceutical supply chain showed that the dispensation and injection steps needed to be further secured. The bar code system was used to reinforce product identification at three selected key stages: at usable stock entry; at preparation-dispensation; and during administration, allowing to check conformity between the labelling of the delivered product (identity and activity) and the prescription. The extra time needed for all these steps had no impact on the number and successful conduct of examinations. The investment cost was reduced (2600 euros for new material and 30 euros a year for additional supplies) because of pre-existing computing equipment. With regard to the radiation exposure to workers there was an insignificant overexposure for hands with this new organization because of the labelling and scanning processes of radiolabelled preparation vials. Implementation of bar code technology is now an essential part of a global securing approach towards optimum patient management.

  18. Radiopharmaceuticals - pattern and development and utilisation in India

    International Nuclear Information System (INIS)

    Iya, V.K.; Mani, R.S.

    1990-01-01

    The availability of research reactors at an early stage of India's Atomic Energy Programme led to developemental efforts in the field of radiopharmaceuticals. The use of several 125 I-labelled compounds like Rose-Bengal, hippuran, etc. for imaging has been replaced over the years by 99m Tc compounds; the final formulations are prepared at the hospital using generators and cold kits supplied by the Board of Radioisotope Technology. Parallel with the development of short-lived generators in radiopharmaceuticals came advances in imaging and instrumentation techniques, the scanners being replaced by sophisticated gamma cameras, with capabilities for tomography and computerisation. About 40 centres in India have the modern instrumentation and equipment needed for carrying out nuclear medicine procedures. Further growth of nuclear medicine centres in the country has, however, been limited by the need to import such advanced high cost instumentation not currently available from indigeneous sources. Regarding in-vitro radiopharmaceuticals, some RIA and IRMA kits and procedures have been developed. These include assay of T 3 , T 4 and TSH in the thyroid group of hormones. There are over a hundred and fifty medical laboratories carrying out RIA procedures. (author)

  19. Recent radiopharmaceutical research at the AAEC Research Establishment

    International Nuclear Information System (INIS)

    Wilson, J.G.; Boyd, R.E.

    1985-12-01

    During the past few years a large part of the radiochemical research carried out at Lucas Heights has been devoted to the synthesis of ligands capable of forming chelate complexes with technetium-99m, as part of a search for tumour-localising radiopharmaceuticals. An account is given of the synthesis and biological evaluation of a range of these compounds and of the investigation of certain biochemical and biological properties affecting the clinical application of both ligands and radiopharmaceuticals. In addition to the search for novel Tc-99m radiopharmaceuticals, major research programs on the development of Tc-99m generating systems have been in progress at Lucas Heights for several years. Work on the AAEC's Mark III Tc-99m technetium generator has been brought to a successful conclusion. A new type of Tc-99m generator, which uses an insoluble zirconium molybdate gel and provides high yields of pertechnetate by a simple elution technique, has also been developed. Studies are in progress on the osmium-iridium generator

  20. Synthesis and formulation of 99m Tc-ECD radiopharmaceutical

    International Nuclear Information System (INIS)

    Ocampo G, B.E.

    1998-01-01

    Nuclear medicine is a medical specialty which uses radioactive compounds (radionuclides) for diagnostic and therapeutic purposes. 99m Tc is the more common radionuclide used in many studies in nuclear medicine because its advantages: it has a photopeak of 140 KeV and a half-life of 6 hours; it can be eluted from a Molybdenum 99 generator, so radiopharmaceuticals can be prepared on site. Ethyl cysteine dimer (ECD) labelled with reduced Technetium 99m has been purposed recently as a promising radiopharmaceutical for brain perfusion imaging 99m Tc-ECD is a lipophilic neutral complex which cross the brain blood barrier and show high brain uptake. The objective of this work was synthesize and to design a freeze dried formulation for the instant preparation of 99m Tc-ECD complex useful for brain perfusion imaging. We obtained a freeze dried stable formulation for the preparation of 99m Tc-ECD kit with a radiochemical purity higher than 90 %, which fulfills with the quality control of radiopharmaceuticals. Furthermore, we developed analytic techniques for the determination of the different chemical compounds into the lyophilized kit. (Author)

  1. Radionuclides, radiotracers and radiopharmaceuticals for in vivo diagnosis

    International Nuclear Information System (INIS)

    Wiebe, L.I.

    1984-01-01

    Radioactive tracers for in vivo clinical diagnosis fall within a narrow, strictly-defined set of specifications in respect of their physical properties, chemical and biochemical characteristics, and medical applications. The type of radioactive decay and physical half-life of the radionuclide are immutable properties which, along with the demands of production and supply, limit the choice of radionuclides used in medicine to only a small fraction of those known to exist. In use, the biochemical and physiological properties of a radiotracer are dictated by the chemical form of the radionuclide. This chemical form may range from elemental, molecular or ionic, to complex compounds formed by coordinate or covalent bonding of the radionuclide to either simple organic or inorganic molecules, or complex macromolecules. Few of the radiotracers which are tested in model systems ever become radiopharmaceuticals in the strictest sense. Radionuclides, radiotracers and radiopharmaceuticals in use are reviewed. Drug legislation and regulations concerning drug manufacture, as well as hospital ethical constraints and legislation concerning unsealed sources of radiation must all be satisfied in order to translate a radiopharmaceutical from the laboratory to clinical use. (author)

  2. Radionuclides, radiotracers and radiopharmaceuticals for in vivo diagnosis

    Science.gov (United States)

    Wiebe, Leonard I.

    Radioactive tracers for in vivo clinical diagnosis fall within a narrow, strictly-defined set of specifications in respect of their physical properties, chemical and biochemical characteristics, and (approved) medical applications. The type of radioactive decay and physical half-life of the radionuclide are immutable properties which, along with the demands of production and supply, limit the choice of radionuclides used in medicine to only a small fraction of those known to exist. In use, the biochemical and physiological properties of a radiotracer are dictated by the chemical form of the radionuclide. This chemical form may range from elemental, molecular or ionic, to complex compounds formed by coordinate or covalent bonding of the radionuclide to either simple organic or inorganic molecules, or complex macromolecules. Few of the radiotracers which are tested in model systems ever become radiopharmaceuticals in the strictest sense. Radionuclides, radiotracers and radiopharmaceuticals in use are reviewed. Drug legislation and regulations concerning drug manufacture, as well as hospital ethical constraints and legislation concerning unsealed sources of radiation must all be satisfied in order to translate a radiopharmaceutical from the laboratory to clinical use.

  3. Bone-seeking radiopharmaceuticals in skeletal malignancy: evolution, not revolution

    International Nuclear Information System (INIS)

    MacFarlane, D.

    2003-01-01

    Many advanced malignancies are complicated by skeletal metastases, with attendant pain and disability. External beam radiotherapy is still the most effective treatment for isolated lesions. Bone-seeking radiopharmaceuticals were perceived as a means of delivering radiation to multiple lesions simultaneously. A wide variety of radioisotopes have been used in this endeavor, with myelosuppression being the most significant potential adverse effect. Benefits of treatment are modest, including a transient improvement in pain control and perhaps prolongation of the treatment-free period. This is best demonstrated in prostate cancer with lower responses by skeletal metastases from breast and lung cancers. However, the treatment is yet to produce any improvement in patient survival. Experimental approaches to improve treatment efficacy include combination with cytotoxic therapy, and administration earlier in the course of the disease. Bone seeking radiopharmaceuticals have been used in treatment of advanced osteosarcoma in humans and canines and achieved effective palliation. The myelosuppressive effects of these agents have been exploited in patients with multiple myeloma to assist in attaining myeloablation prior to stem cell transplantation. Development of more potent non-radiolabelled bisphosphonates and recognition of their antitumour effect against several tumours has sparked a recrudescence of interest in their use for bone metastases. Set against these developments, the role of bone-seeking radiopharmaceuticals in skeletal metastases may need to be redefined

  4. Export of radiopharmaceuticals and establishment of export base of cyclotron

    International Nuclear Information System (INIS)

    Jung, Kyungil; Kim, Youngsik

    2006-01-01

    Sam young Unit ech has seized an opportunity to advance into the radiopharmaceuticals market through successful transfer of radiopharmaceuticals manufacturing technology and medical cyclotron, an original technology in nuclear medicine that is the core of less developed areas in nuclear-related fields. The company has continued to push for research development and establishment of market base through industry-academia-research center cooperation with an aim to complement relatively less developed domestic technology and market than in advanced countries, and is making efforts to establish export base in the overseas market based on stabilized supply in the domestic market. As for radiopharmaceuticals, the company is exporting Tc-99m generator to Vietnam, Thailand and the Philippines and preparing itself to export manufacture facilities for Tc-99m generator to Syria and Kazakhstan. In addition, it plans to export 13Mev Cyclotron that has been commercialized after being developed in the domestic market to the U. S. The company plans to grow up to play a pivotal role in the domestic RT area by conducting proactive business activities with an aim to revitalize the domestic market and further domestic original technologies and products in the global market

  5. Annual report on operation, utilization and technical development of Research Reactors and Hot Laboratory, from April 1, 1983 to March 31, 1984

    International Nuclear Information System (INIS)

    1984-11-01

    Activities of the Department of Research Reactor Operation in fiscal year 1983 are described. The department is responsible for operation and maintenance of JRR-2, JRR-3, JRR-4 and Hot Laboratory. In the above connection, various other work has also been performed, such as technical management of fuel and coolant, radiation control, irradiation technique, etc. In Hot Laboratory, we have performed post-irradiation examinations of fuels and materials, and also development of examination procedures, too. (author)

  6. Eleventh annual U.S. DOE low-level radioactive waste management conference: Executive summary, opening plenary, technical session summaries, and attendees

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    1990-01-01

    The conference consisted of ten technical sessions, with three sessions running simultaneously each day. Session topics included: regulatory updates; performance assessment;understanding remedial action efforts; low-level waste strategy and planning (Nuclear Energy); low-level waste strategy and planning (Defense); compliance monitoring; decontamination and decommissioning; waste characterization; waste reduction and minimization; and prototype licensing application workshop. Summaries are presented for each of these sessions.

  7. Biomass as Feedstock for a Bioenergy and Bioproducts Industry: The Technical Feasibility of a Billion-Ton Annual Supply, April 2005

    Energy Technology Data Exchange (ETDEWEB)

    None

    2005-04-01

    The purpose of this report is to determine whether the land resources of the United States are capable of producing a sustainable supply of biomass sufficient to displace 30 percent or more of the country’s present petroleum consumption – the goal set by the Biomass R&D Technical Advisory Committee in their vision for biomass technologies. Accomplishing this goal would require approximately 1 billion dry tons of biomass feedstock per year.

  8. Short-lived radiopharmaceutical development at E.R. Squibb and Sons, Inc

    International Nuclear Information System (INIS)

    Loberg, M.D.

    1985-01-01

    This paper describes the present status and future plans of E.R. Squibb and Sons, Inc. as they relate to the development of short-lived radiopharmaceuticals. The advantages of short-lived radiopharmaceuticals are summarized as are the problems inherent in their manufacture, quality control, and distribution. The nuclear generator is advocated as the best means of distributing short-lived radiopharmaceuticals. The E.R. Squibb and Sons work with the 82 Sr → 82 Rb generator is summarized

  9. Legislative situation of EEC member states and european provisions concerning preparation and use of radiopharmaceuticals

    International Nuclear Information System (INIS)

    Lalanne, P.

    1977-01-01

    Radiopharmaceuticals are excluded from the directives on pharmaceutical products and considerable gaps exist in the legislation of many countries. The pharmacopoeia provides standards and methods for the quality control of the final product. According to the same principles, it is proposed that special provisions, taking into consideration the very special nature of radiopharmaceuticals, might be introduced in the european economic community legislation, to secure that all radiopharmaceuticals used are safe and of an uniform quality

  10. Detection of endotoxins in radiopharmaceutical preparations. III. Limulus test assessment using radiopharmaceutical preparations; correlation with the rabbit pyrogen test

    Energy Technology Data Exchange (ETDEWEB)

    Cohen, Y; Bahri, F; Bruneau, J; Dubuis, M; Dubuis, N; Merlin, L; Michaud, T; Peysson, S

    1986-01-01

    Experiments using 17 radiopharmaceuticals containing known amounts of added endotoxin show that none of them inhibits the pyrogenic reaction of the rabbit. Gelation of the Limulus amoebocyte lysate (LAL) is inhibited by 4 of them: colloidal erbium 169Er citrate, colloidal rhenium 186Re sulfide, colloidal technetium /sup 99m/Tc (Re) sulfide for liver scintigraphy and the colloidal technetium /sup 99m/Tc (Re) sulfide for lymphography. This inhibition is cancelled, either by dilution or after neutral pH adjustment. Both controls were performed on 313 batches of various radiopharmaceuticals, 95% of results were identical (93% negative, 2% positive). The remaining 5% correspond to positive LAL tests vs negative rabbit tests on the same batches. No negative LAL test vs positive rabbit test was observed.

  11. The role of high performance liquid chromatography in radiochemical/radiopharmaceutical synthesis and quality assurance

    International Nuclear Information System (INIS)

    Boothe, T.E.; Emran, A.M.

    1990-01-01

    The usefulness of HPLC in all areas of radiopharmaceutics has been demonstrated in numerous laboratories, particularly in the development of in-house radiopharmaceuticals for SPECT and PET. HPLC continues to be a powerful tool in preparation and quality assurance (QA) as illustrated in such areas as chemical and radiochemical identification; product separation and isolation; preparative scale purification; and specific activity determination. A review of established HPLC techniques in radiopharmaceutics will be presented. Examples from the literature as well as newer applications will be used in an attempt to assess and define the present-day role of HPLC in the preparation of radiochemicals and radiopharmaceuticals with emphasis on QA

  12. 99m Tc-labeled dendrimers as a potential radiopharmaceutical for tumor diagnosis process

    International Nuclear Information System (INIS)

    Tassano Hartwich, M.

    2008-01-01

    The present thesis to access the Bachelor of Biological Sciences studies the following: biology, molecular biology, pathology, radiotherapy, radiopharmaceuticals, research techniques and malignant neoplasms

  13. 1993 Annual progress report for subsidiary agreement No. 2 (1991--1996) between AECL and US/DOE for a radioactive waste management technical co-operative program

    International Nuclear Information System (INIS)

    1993-01-01

    A coordinated research program on radioactive waste disposal is being carried out by the Atomic Energy of Canada Limited and the US Department of Energy. This annual report describes progress in the following eight studies: Fundamental materials investigations; In-situ stress determination; Development of a spent fuel dissolution model; Large block tracer test--Experimental testing of retardation models; Laboratory and field tests of in-situ hydrochemical tools; Cigar Lake--Analogue study, actinide and fission product geochemistry; Performance assessment technology exchange; and Development of multiple-well hydraulic test and field tracer test methods

  14. 1993 Annual progress report for subsidiary agreement No. 2 (1991--1996) between AECL and US/DOE for a radioactive waste management technical co-operative program

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    1993-12-31

    A coordinated research program on radioactive waste disposal is being carried out by the Atomic Energy of Canada Limited and the US Department of Energy. This annual report describes progress in the following eight studies: Fundamental materials investigations; In-situ stress determination; Development of a spent fuel dissolution model; Large block tracer test--Experimental testing of retardation models; Laboratory and field tests of in-situ hydrochemical tools; Cigar Lake--Analogue study, actinide and fission product geochemistry; Performance assessment technology exchange; and Development of multiple-well hydraulic test and field tracer test methods.

  15. Preparation of sup(113m)In-labelled compounds of radiopharmaceutical interest. Part of a coordinated programme on radiopharmaceuticals

    International Nuclear Information System (INIS)

    Servian, J.; Robles, A.

    1975-06-01

    Techniques for the preparation and control of already known and new sup(113m)In-radiopharmaceuticals were investigated. New rapid procedures for the control and preparation of a number of radiopharmaceuticals were developed and standardized. After biological distribution studies and clinical tests, new techniques for the preparation of the following indium-113 radiopharmaceuticals were adopted: a) Indium - labelled colloids of: S, Al(OH) 3 , Fe(OH) 3 and AlPO 4 for liver and spleen scintigraphy. b) Indium labelled chelates using the ligands EDTA, DTPA, TTHA (Triethylene-tetramine-hexaacetic acid) and DHPTA (Diamino-hydroxy-propane-tetraacetic acid) for brain scintigraphy. c) Indium labelled Fe(OH) 3 macroaggregates and microspheres for lung scintigraphy. d) Several complexes of sup(113m)In with different ligands (fluoride, tartrate, pyrophosphate, tripolyphosphate, trimetaphosphate, EHDP (or ethane-1-hydroxy-1, 1-diphosphonate), ethylendiamine-pyrophosphate were synthesized and its potential use as bone-scanning agents were evaluated. It was found that the complexes with tartrate, tripolyphosphate and EHDP show appreciable skeletal uptake (bone/muscle ratio are 9.0, 5.5, and 4.7 respectively), although they are inferior to the sup(99m)Tc bone-scanning agents. e) A new simple technique is proposed for the preparation of highly concentrated sup(113m)In solutions. The technique is based on the precipitation of In(OH) 3 , millipore filtration and redissolution in a small volume of 0.05 N HCl

  16. Development of radiopharmaceutical for radiosinovectomy; Desenvolvimento de radiofarmaco para radiosinovectomia

    Energy Technology Data Exchange (ETDEWEB)

    Couto, Renata Martinussi

    2009-07-01

    Radiopharmaceuticals prepared with different radionuclides have been used in diagnostic and therapeutic procedures in Nuclear Medicine. The interest in radionuclidic therapy has been increased in last years, with the introduction of new radiopharmaceuticals applied in the destruction of specific cells or to prevent its undesired proliferation. Radiosinovectomy (RSV) is a therapeutic modality that uses radiopharmaceuticals administered in the intra-articular cavity and represents an alternative to the treatment of different arthropaties and, in particular, the arthropaties derived from rheumatoid arthritis and haemophilic. The objective of the present work was to study the labeling of compounds with {sup 90}Y and {sup 177}Lu in order to improve the production conditions and quality control procedures, study the stability of the labeled compounds and preliminary biodistribution studies of the radiopharmaceuticals with potential for RSV applications. The study of the production of {sup 90}Y citrate colloid ({sup 90}Y-Cit) was based in a labeling procedure using {sup 90}Y Cl{sub 3} solution (37 - 54 MBq) that was previously dried, followed by the addition of yttrium nitrate and sodium citrate in p H 7 at 37 deg C for 30 minutes. The production of hydroxyapatite (HA) labeled with {sup 90}Y was based in a labeling procedure using mono hydrated citric acid, yttrium nitrate and {sup 90}Y Cl{sub 3} solution (37 - 370 MBq). The reaction mixture was incubated for 30 minutes at room temperature and the HA was introduced in aqueous medium and the reaction proceed for 30 minutes under strong stirring. {sup 177}Lu-HA was produced using {sup 177}Lu Cl{sub 3} solution (296 MBq), in presence of lutetium oxide in NaCl medium, p H 7, under continuous stirring for 30 minutes at room temperature. Several reaction parameters were studied for the three radiopharmaceuticals. Labeling yield was determined after particles were centrifuged and washed with NaCl 0,9%. Radiochemical purity was

  17. GPHS-RTGs in support of the Cassini Mission. Semi annual technical progress report, 1 April 1996--29 September 1996

    International Nuclear Information System (INIS)

    1996-01-01

    This technical progress report discusses work on the Radioisotope Generators and Ancillary Activities for the Cassini spacecraft. The Cassini spacecraft is expected to launch in October 1997, and will explore Saturn and its moons. This progress report discusses issues in: spacecraft integration and liason, engineering support, safety, qualified unicouple fabrication, ETG fabrication and testing, ground support equipment, RTG shipping and launch support, designs, reviews and mission application. Safety analysis of the RTGs during reentry and launch accidents are covered. This report covers the period of April 1 to September 29, 1996

  18. Annual report on operation, utilization and technical development of research reactors and hot laboratory, from April 1, 1987 to March 31, 1988

    International Nuclear Information System (INIS)

    1988-10-01

    Activities of the Department of Research Reactor Operation in fiscal year 1987 are described. The department is responsible for operation and maintenance of JRR-2, JRR-4, Research Reactor Development Division which performed upgraded JRR-3 and other R D, and Hot Laboratory. In the above connection various other work has also been performed, such as technical management of fuel and coolant, radiation control, irradiation technique, etc. In Hot Laboratory, we have performed post-irradiation examinations of fuels and materials, and also development of examination procedures, too. (author)

  19. GPHS-RTGs in support of the Cassini mission. Semi annual technical progress report, 2 October 1995--31 March 1996

    International Nuclear Information System (INIS)

    1996-01-01

    The technical progress achieved during the period 2 October 1995 through 31 March 1996 on Contract No. DE-AC03-91SF18852, Radioisotope Generators and Ancillary Activities is described herein. This report is organized by the program task structure as follows: spacecraft integration and liaison; engineering support; safety; qualified unicouple fabrication; ETG fabrication, assembly, and test; ground support equipment (GSE); RTG shipping and launch support; designs, reviews, and mission applications; project management, quality assurance and reliability, contract changes, non-capital CAGO acquisition, and CAGO maintenance; contract acquired government-owned property (CAGO) acquisition; and program calendars

  20. Bioremediation of mixed microbial mats: System development of mixed contaminants for application at the Savannah River Site. Annual technical progress report, October 1, 1995--September 30, 1996

    International Nuclear Information System (INIS)

    Bender, J.; Phillips, P.

    1996-01-01

    The fundamental objective of this project is to develop and field test the mixed microbial mat bioremediation system for decontamination of target sites at SRS. Although microbial mats have performed well in several pilot projects in the past, atypical problems and site characteristics at SRS demand special field designs. In the interest of designing a pilot and locating it at an appropriate site, the project investigators have worked closely with the technical staff at the SREL. We have concluded that the diverse characteristics of contaminations at SRS may dictate testing several pilot designs during the course of this project